var title_f9_39_9840="Dx esophageal chest pain";
var content_f9_39_9840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    Approach to the patient with unexplained chest pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 558px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    GERD: Gastroesophageal reflux disease; DES: diffuse esophageal spasm; LES: lower esophageal sphincter.",
"    <div class=\"footnotes\">",
"     * Combined impedance-pH monitoring, if available.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9840=[""].join("\n");
var outline_f9_39_9840=null;
var title_f9_39_9841="Fissured tongue";
var content_f9_39_9841=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fissured tongue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A fissured tongue with a focal area of inflammation in a 4-year-old child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Delaney JE, Keels MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125. Copyright &copy; 2000, W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9841=[""].join("\n");
var outline_f9_39_9841=null;
var title_f9_39_9842="Patient information: Keloids (The Basics)";
var content_f9_39_9842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83435\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/42/27296\">",
"         Keloids from acne",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/12/1218\">",
"         Patient information: Acne (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/11/43185\">",
"         Patient information: Taking care of cuts and scrapes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/40/20099\">",
"         Patient information: Acne (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/60/33729\">",
"         Patient information: Sunburn prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Keloids (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/keloids-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H98769101\">",
"      <span class=\"h1\">",
"       What is a keloid?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A keloid is a growth that happens where the skin has healed from a cut or other injury. It can be painful and itchy, and look different from a normal scar. A person can have just 1 keloid or many. If you have more than 1, they are called &ldquo;keloids.&rdquo; &nbsp;",
"     </p>",
"     <p>",
"      Keloids are more common in people with dark skin. They can also run in families. If someone in your family gets keloids, you might be more likely to get them.",
"     </p>",
"     <p>",
"      Keloids can form after any injury or procedure that breaks the skin. This can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Piercing &ndash; This can be of the ears or another body part. &nbsp;",
"       </li>",
"       <li>",
"        A cut that gets infected or leaves a scar",
"       </li>",
"       <li>",
"        Acne, after the pimples heal",
"       </li>",
"       <li>",
"        Surgery &ndash; A keloid can form in the scar.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98769116\">",
"      <span class=\"h1\">",
"       What are the symptoms of a keloid?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A keloid can look like a lumpy growth (",
"      <a class=\"graphic graphic_picture graphicRef83338 \" href=\"UTD.htm?26/42/27296\">",
"       picture 1",
"      </a>",
"      ). It can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Itch",
"       </li>",
"       <li>",
"        Hurt when you press on it",
"       </li>",
"       <li>",
"        Cause sharp, shooting pain",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Keloids are most common on certain body parts. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Ears",
"       </li>",
"       <li>",
"        Neck &ndash; One type of keloid happens after a pimple heals on the back of the neck. &nbsp;",
"       </li>",
"       <li>",
"        Jaw",
"       </li>",
"       <li>",
"        Chest, shoulders, and upper back",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98769131\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have a new growth on your skin, see your doctor or nurse. Keloids are not cancer. But some skin growths are cancer. Ask your doctor or nurse to check.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98769146\">",
"      <span class=\"h1\">",
"       Is there a test for keloids?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have a keloid by looking at it and learning about your symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98769161\">",
"      <span class=\"h1\">",
"       How are keloids treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors have several different treatments for keloids. Possible treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Giving an injection (shot) of medicine in the keloid - This can make it flatten out. Doctors can try different medicines to see which one works best. &nbsp;",
"       </li>",
"       <li>",
"        Doing surgery to take the keloid off &ndash; After surgery, the doctor usually gives a shot of medicine in the area. This can help keep the keloid from coming back.",
"       </li>",
"       <li>",
"        Putting a sheet of sticky material over the keloid &ndash; This might make the keloid hurt or itch less.",
"       </li>",
"       <li>",
"        Cryosurgery &ndash; In this procedure, the doctor uses a very cold liquid to freeze the keloid",
"       </li>",
"       <li>",
"        Pressure earrings &ndash; These are special earrings that press on the holes after you get your ears pierced. They could help stop keloids from forming when the holes heal.",
"       </li>",
"       <li>",
"        Radiation &ndash; This treatment uses high doses of X-rays to destroy keloids",
"       </li>",
"       <li>",
"        Laser treatment &ndash; This treatment uses strong light to destroy keloids",
"       </li>",
"       <li>",
"        Putting a prescription cream on the area &ndash; The doctor might prescribe this to use after surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Keloids can be hard to treat. They often come back after treatment. Giving more than 1 treatment at a time, such as a shot of medicine after surgery, can work better than just 1 treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98769176\">",
"      <span class=\"h1\">",
"       Can keloids be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can lower your chances of getting keloids by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Not having surgery or procedures that break the skin, if possible. For example, you can:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Avoid getting your ears or other body parts pierced",
"       </li>",
"       <li>",
"        Avoid having surgery to take off a mole (unless your doctor or nurse says you need surgery)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Treating acne or a cut right away",
"       </li>",
"       <li>",
"        NOT shaving your neck &ndash; This can irritate pimples and make them form keloids after they heal.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have a cut or scar, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Keep the cut or wound moist while it heals &ndash; You can put a thin layer of petroleum jelly on it. Cover it with a bandage or gauze. Keep the bandage clean and dry.",
"       </li>",
"       <li>",
"        Cover scars when you are in the sun &ndash; Do this for 3 months after the scar forms. You can also use sunscreen on the scar.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98769191\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/12/1218?source=see_link\">",
"       Patient information: Acne (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43185?source=see_link\">",
"       Patient information: Taking care of cuts and scrapes (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/40/20099?source=see_link\">",
"       Patient information: Acne (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"       Patient information: Sunburn prevention (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/39/9842?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83435 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-581423BC0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9842=[""].join("\n");
var outline_f9_39_9842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769101\">",
"      What is a keloid?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769116\">",
"      What are the symptoms of a keloid?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769131\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769146\">",
"      Is there a test for keloids?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769161\">",
"      How are keloids treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769176\">",
"      Can keloids be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769191\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83435\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/42/27296\">",
"      Keloids from acne",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/40/20099?source=related_link\">",
"      Patient information: Acne (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/12/1218?source=related_link\">",
"      Patient information: Acne (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=related_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43185?source=related_link\">",
"      Patient information: Taking care of cuts and scrapes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_39_9843="Odontoid fractures";
var content_f9_39_9843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Odontoid fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9843=[""].join("\n");
var outline_f9_39_9843=null;
var title_f9_39_9844="Mepenzolate: Drug information";
var content_f9_39_9844=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mepenzolate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/61/14292?source=see_link\">",
"    see \"Mepenzolate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cantil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cantil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F192710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent;",
"     </li>",
"     <li>",
"      Antispasmodic Agent, Gastrointestinal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F192697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Peptic ulcer disease:",
"     </b>",
"     Oral: 25-50 mg 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F192698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use caution or avoid; anticholinergics generally not tolerated in older adults.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F192681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as bromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cantil&reg;: 25 mg [contains tartrazine]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F192670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F192683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration with meals and at bedtime is preferred.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F192682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of peptic ulcer disease; has not been shown to be effective in contributing to the healing of peptic ulcer, preventing complications, or decreasing the rate of recurrence",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F192715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cantil&reg; may be confused with Bentyl&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F192708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, dizziness, drowsiness, headache, insomnia, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Bloating, constipation, delayed gastric emptying, loss of taste, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary hesitation, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Blurred vision, cycloplegia, ocular tension increased, pupil dilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis decreased, lactation suppressed",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F192686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Allergic or idiosyncratic reactions to mepenzolate or related compounds; glaucoma; obstructive uropathy (ie, bladder neck obstruction due to prostatic hyperplasia); obstructive gastrointestinal disease (ie, pyloroduodenal stenosis, achalasia); paralytic ileus; intestinal atony of the debilitated or elderly patient; unstable cardiovascular status in acute GI hemorrhage; toxic megacolon complicating ulcerative colitis; myasthenia gravis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F192674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: May be a sign of incomplete intestinal obstruction, treatment should be discontinued if this occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heat prostration: May occur in the presence of increased environmental temperature; use caution in hot weather and/or exercise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis: Has been reported in patients with an extreme sensitivity to anticholinergic effects; usually resolves with discontinuation of  treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with coronary artery disease, tachycardia, arrhythmias, heart failure, or hypertension; evaluate tachycardia prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric ulcer treatment: Use of anticholinergics in gastric ulcer treatment may cause a delay in gastric emptying due to antral stasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hiatal hernia: Use with caution in patients with hiatal hernia with reflux esophagitis; may aggravate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropathy: Use with caution in patients with autonomic neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia: Use with caution in patients with prostatic hyperplasia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ulcerative colitis: Use with caution in patients with ulcerative colitis; may precipitate/aggravate toxic megacolon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; increased risk for anticholinergic effects, confusion, and hallucinations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some products may contain tartrazine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F192679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F192687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F192700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F192688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticholinergic agents may suppress lactation.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F192689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cantil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $224.23",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F192690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cantil (GB, SE);",
"     </li>",
"     <li>",
"      Colibantil (IT);",
"     </li>",
"     <li>",
"      Eftoron (JP);",
"     </li>",
"     <li>",
"      Tralanta (JP);",
"     </li>",
"     <li>",
"      Trancolon P (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F192673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mepenzolate is a postganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F192685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Low",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (3% to 22%); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10134 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9844=[""].join("\n");
var outline_f9_39_9844=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192695\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192696\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192710\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192697\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192698\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192681\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192670\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192683\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192682\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192715\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192708\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192686\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192674\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299668\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221526\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192679\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192687\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192700\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192688\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192689\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323370\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192690\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192673\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192685\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10134\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10134|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/61/14292?source=related_link\">",
"      Mepenzolate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_39_9845="Sodium phenylbutyrate: Drug information";
var content_f9_39_9845=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium phenylbutyrate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/59/22452?source=see_link\">",
"    see \"Sodium phenylbutyrate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/20/11588?source=see_link\">",
"    see \"Sodium phenylbutyrate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Buphenyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Urea Cycle Disorder (UCD) Treatment Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Management of urea cycle disorders:",
"     </b>",
"     Powder or tablet: Oral: 9.9-13 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day, administered in equally divided amounts with each meal or feeding, 3-6 times daily (maximum dose: 20 g/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F221879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/20/11588?source=see_link\">",
"      see \"Sodium phenylbutyrate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Management of urea cycle disorders:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;20 kg: Powder: 450-600 mg/kg/day, administered in equally divided amounts with each meal or feeding, 3-6 times daily (maximum dose: 20 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;20 kg: Powder or tablet: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buphenyl&reg;:  (250 g) [contains sodium 125 mg/g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buphenyl&reg;: 500 mg [contains sodium 62 mg/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5674004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: One level teaspoon equals 3 g of sodium phenylbutyrate; 1 level tablespoon equals 8.6 g of sodium phenylbutyrate. Powder should be mixed with food (solid or liquid). When mixed with a liquid, shake lightly prior to use. Excipients may not dissolve. Powder may be given orally but very bitter and feeding avoidance may develop. Administration via nasogastric and gastrostomy tube may avoid the problems with oral administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in the chronic management of patients with urea cycle disorder involving deficiencies of carbamoylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Endocrine &amp; metabolic: Amenorrhea/menstrual dysfunction (23%), acidosis (14%), hypoalbuminemia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Syncope (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (&le;2%), headache (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Alkalosis (7%), hyperchloremia (7%), hypophosphatemia (6%), total protein decreased (3%), hyperuricemia (2%), hyperphosphatemia (2%), hypernatremia (1%), hypokalemia (1%), hyperbilirubinemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (4%), abnormal taste (3%), abdominal pain (&le;2%), gastritis (&le;2%), nausea (&le;2%), vomiting (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (9%), leukocytosis (4%), leukopenia (4%), thrombocytopenia (3%), thrombocytosis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (6%), transaminases increased (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal tubular acidosis (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Offensive body odor (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aplastic anemia, arrhythmia, bruising, constipation, edema, fatigue, lightheadedness, memory impairment, neuropathy (exacerbation), pancreatitis, peptic ulcer disease, rectal bleeding, somnolence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F221865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not be used in the treatment of acute hyperammonemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F221854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid retention: May cause sodium and fluid retention; use with caution in patients where fluid accumulation may be poorly tolerated, such as in HF, hypertension or renal/hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperammonemia: Hyperammonemia and hyperammonemic encephalopathy may still occur while on therapy; hyperammonemia should be managed as a medical emergency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Restricted sodium intake: Contains sodium 125 mg per gram of sodium phenylbutyrate; use with caution, if at all, in patients who must maintain a low sodium intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tablet formulation: The use of sodium phenylbutyrate tablets in children weighing &lt;20 kg is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5673907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5673904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F221875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5673943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A clinician with experience in inborn metabolism errors should manage the nutrition delivery. Medication must be used in conjunction with a protein-restricted diet and, if indicated, essential amino acid supplementation. Patients requiring calorie supplementation should receive protein-free caloric supplements.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Infants with neonatal-onset ornithine transcarbamylase and carbamoylphosphate synthetase deficiency: Initially limit to a protein intake of approximately 1.6 g/kg/day. May increase (after the first 4 months of life) to 1.9 g/kg/day if tolerated. Protein tolerance will decrease with decreasing growth rate. Infants from 4 months to 1 year should receive at least 1.4 g/kg/day protein, although 1.7 g/kg/day is advisable. From 1-3 years, protein intake should be at least 1.2 g/kg/day although 1.4 g/kg/day is advisable. Citrulline supplementation is recommended at 0.17 g/kg/day or 3.8 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day; free-base arginine may be used for mild disease.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Late-onset or infants with neonatal-onset argininosuccinic acid synthetase deficiency: May initially receive age-determined minimal protein allowance; increase as tolerated based on amino acid levels.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Argininosuccinic acid synthetase deficiency: Arginine (free base) supplementation is recommended at 0.4-0.7 g/kg/day or 8.8-15.4 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F221867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Buphenyl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (250): $2860.08",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5674006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood ammonia, serum proteins and plasma amino acid quantitation, serum electrolytes, CBC with differential, hepatic and renal function tests; urinalysis; monitor for physical signs/symptoms of hyperammonemia (eg, lethargy, ataxia, confusion, vomiting, seizures, and memory impairment); nutritional parameters (weight, height, head circumference, albumin, prealbumin)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F5674003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Target biochemical markers for control:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Plasma ammonia: &lt;40 micromol/L; Plasma glutamine &lt;1000 micromol/L; normal plasma levels of alanine, glycine, lysine, and arginine (except in arginase deficiency), no subnormal concentrations of essential amino acids (eg, leucine, isoleucine, valine)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ammonaps (AT, CZ, DE, DK, ES, FR, GB, IT, NL, PL, PT, SE);",
"     </li>",
"     <li>",
"      Buphenyl (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F221853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium phenylbutyrate is a prodrug which is rapidly converted to phenylacetate, followed by conjugation with glutamine to form phenylacetylglutamine; phenylacetylglutamine serves as a substitute for urea as it is clears nitrogenous waste from the body when excreted in the urine.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5673910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic and renal: Phenylbutyrate, a prodrug, is metabolized to phenylacetate followed by conjugation with glutamine to phenylacetylglutamine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Phenylbutyrate: 0.8 hours; Phenylacetate: 1.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Phenylbutyrate: ~1.4 hour; Phenylacetate: ~ 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (primarily as phenylacetylglutamine)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berry GT and Steiner RD, &ldquo;Long-Term Management of Patients With Urea Cycle Disorders,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):56-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/39/9845/abstract-text/11148550/pubmed\" id=\"11148550\" target=\"_blank\">",
"        11148550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brusilow SW, &ldquo;Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion,&rdquo;",
"      <i>",
"       Pediatr Res",
"      </i>",
"      , 1991, 29(2):147-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/39/9845/abstract-text/2014149/pubmed\" id=\"2014149\" target=\"_blank\">",
"        2014149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maestri NE, Brusilow SW, Clissold DB, et al, &ldquo;Long-Term Treatment of Girls With Ornithine Transcarbamylase Deficiency,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(12):855-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/39/9845/abstract-text/8778603/pubmed\" id=\"8778603\" target=\"_blank\">",
"        8778603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scaglia F, Carter S, O&rsquo;Brien WE, et al, &ldquo;Effect of Alternative Pathway Therapy on Branched Chain Amino Acid Metabolism in Urea Cycle Disorder Patients,&rdquo;",
"      <i>",
"       Mol Genet Metab",
"      </i>",
"      , 2004, 81(Suppl 1):79-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/39/9845/abstract-text/15050979/pubmed\" id=\"15050979\" target=\"_blank\">",
"        15050979",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Summar M, &ldquo;Current Strategies for the Management of Neonatal Urea Cycle Disorders,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):30-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/39/9845/abstract-text/11148547/pubmed\" id=\"11148547\" target=\"_blank\">",
"        11148547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9934 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9845=[""].join("\n");
var outline_f9_39_9845=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221871\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221884\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221872\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221879\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221873\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221862\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221850\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5674004\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221863\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221882\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221865\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221854\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300066\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5673907\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221859\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5673904\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221875\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5673943\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221867\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5674006\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5674003\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539930\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221853\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5673910\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9934\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9934|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/59/22452?source=related_link\">",
"      Sodium phenylbutyrate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/20/11588?source=related_link\">",
"      Sodium phenylbutyrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_39_9846="Thyroid extract (desiccated thyroid): Drug information";
var content_f9_39_9846=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Thyroid extract (desiccated thyroid): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/28/32197?source=see_link\">",
"    see \"Thyroid extract (desiccated thyroid): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/57/22422?source=see_link\">",
"    see \"Thyroid extract (desiccated thyroid): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F227348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Armour&reg; Thyroid;",
"     </li>",
"     <li>",
"      Nature-Throid&trade;;",
"     </li>",
"     <li>",
"      Westhroid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F227363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Thyroid Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F227351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The American Association of Clinical Endocrinologists does not recommend the use of desiccated thyroid for thyroid replacement therapy for hypothyroidism (Baskin, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypothyroidism:",
"     </b>",
"     Oral: Initial: 15-30 mg; increase with 15 mg increments every 2-3 weeks; use 15 mg in patients with cardiovascular disease or long-standing myxedema. Maintenance dose: Usually 60-120 mg/day; monitor TSH and clinical symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F227359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/57/22422?source=see_link\">",
"      see \"Thyroid extract (desiccated thyroid): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypothyroidism:",
"     </b>",
"     Oral: See table.",
"     <b>",
"      Note:",
"     </b>",
"     The American Association of Clinical Endocrinologists does not recommend the use of desiccated thyroid for thyroid replacement therapy for hypothyroidism (Baskin, 2002).",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Recommended Pediatric Dosage for Congenital Hypothyroidism",
"     </caption>",
"     <col align=\"left\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"132\">",
"     </col>",
"     <col align=\"center\" width=\"133\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Daily Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Daily Dose/kg",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         0-6 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15-30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.8-6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         6-12 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-45",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.6-4.8",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1-5 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45-60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-3.6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         6-12 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60-90",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.4-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;12 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;90",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.2-1.8",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F227352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in the elderly.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F227333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 30 mg [DSC], 60 mg [DSC], 120 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Armour&reg; Thyroid: 15 mg, 30 mg, 60 mg, 90 mg, 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Armour&reg; Thyroid: 180 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Armour&reg; Thyroid: 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Armour&reg; Thyroid: 300 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nature-Throid&trade;: 16.25 mg, 32.5 mg, 65 mg, 130 mg, 195 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Westhroid&trade;: 32.5 mg, 65 mg, 130 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9626657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer on an empty stomach. Take in the morning before breakfast.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F227335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement or supplemental therapy in hypothyroidism; pituitary TSH suppressants (thyroid nodules, thyroiditis, multinodular goiter, thyroid cancer)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9954591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F227362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions often indicative of excess thyroid replacement and/or hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, cardiac arrhythmia, chest pain, dyspnea, excessive bone loss with overtreatment (excess thyroid replacement), hand tremor, myalgia, palpitation, tachycardia, tremor",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F227338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to beef or pork or any component of the formulation; untreated thyrotoxicosis; uncorrected adrenal insufficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F227324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated; contraindicated in patients with uncorrected adrenal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution and reduce dosage in patients with angina pectoris or other cardiovascular disease; chronic hypothyroidism predisposes patients to coronary artery disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus and insipidus; symptoms may be exaggerated or aggravated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myxedema: Use with caution in patients with myxedema; symptoms may be exaggerated or aggravated; initial dosage reduction is recommended in patients with long-standing myxedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in this age group due to risk of cardiac effects and the availability of  safer  alternatives (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Desiccated thyroid: Contains variable amounts of T",
"     <sub>",
"      3",
"     </sub>",
"     , T",
"     <sub>",
"      4",
"     </sub>",
"     , and other triiodothyronine compounds which are more likely to cause cardiac signs or symptoms due to fluctuating levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infertility (unapproved use): Thyroid supplements are not recommended for the treatment of female or male infertility, unless associated with hypothyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight reduction (unapproved use):",
"     <b>",
"      [U.S. Boxed Warning]: In euthyroid patients, thyroid supplements are ineffective and potentially toxic for weight reduction.",
"     </b>",
"     <b>",
"      High doses may produce serious or even life-threatening toxic effects particularly when used with some anorectic drugs.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13851598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Management: Take in the morning before breakfast on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F227330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12966353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Endogenous thyroid hormones minimally cross the placenta; the fetal thyroid becomes active around the end of the first trimester. Liothyronine has not been found to increase the risk of teratogenic or adverse effects following maternal use during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Uncontrolled maternal hypothyroidism may result in adverse neonatal and maternal outcomes. To prevent adverse events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Levothyroxine is considered the treatment of choice for the control of hypothyroidism during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F227355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12966354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endogenous thyroid hormones are minimally found in breast milk and are not associated with adverse events.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F227341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Armour Thyroid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $12.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $14.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $16.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (100): $25.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $29.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (100): $47.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (100): $70.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $87.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nature-Throid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16.25 mg (100): $17.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32.5 mg (100): $20.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     65 mg (100): $24.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     130 mg (100): $36.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     195 mg (100): $52.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Westhroid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16.25 mg (100): $17.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32.5 mg (100): $20.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     48.75 mg (100): $22.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     65 mg (100): $24.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81.25 mg (100): $27.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     97.5 mg (100): $30.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     113.75 mg (100): $33.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     130 mg (100): $36.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     146.25 mg (100): $40.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     162.5 mg (100): $45.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     195 mg (100): $52.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     260 mg (100): $66.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (100): $79.22",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13361514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     T",
"     <sub>",
"      4",
"     </sub>",
"     , TSH; heart rate, blood pressure; clinical signs of hypo- and hyperthyroidism;  TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T",
"     <sub>",
"      4",
"     </sub>",
"     remains low and TSH is within normal limits, an evaluation of &ldquo;free&rdquo; (unbound) T",
"     <sub>",
"      4",
"     </sub>",
"     is needed to evaluate further increase in dosage.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F227323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The primary active compound is T",
"     <sub>",
"      3",
"     </sub>",
"     (triiodothyronine), which may be converted from T",
"     <sub>",
"      4",
"     </sub>",
"     (thyroxine) and then circulates throughout the body to influence growth and maturation of various tissues; exact mechanism of action is unknown; however, it is believed the thyroid hormone exerts its many metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores and stimulates protein synthesis, increases basal metabolic rate",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F227337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Liothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ): ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Thyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ): 40% to 80%; T",
"     <sub>",
"      3",
"     </sub>",
"     : 95%; desiccated thyroid contains T",
"     <sub>",
"      4",
"     </sub>",
"     , T",
"     <sub>",
"      3",
"     </sub>",
"     , and iodine (primarily bound)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: T",
"     <sub>",
"      4",
"     </sub>",
"     : &gt;99% bound to plasma proteins including thyroxine-binding globulin, thyroxine-binding prealbumin, and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to triiodothyronine (active); ~80% T",
"     <sub>",
"      4",
"     </sub>",
"     deiodinated in kidney and periphery; glucuronidation/conjugation also occurs; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     T",
"     <sub>",
"      4",
"     </sub>",
"     : Euthyroid: 6-7 days; Hyperthyroid: 3-4 days; Hypothyroid: 9-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     T",
"     <sub>",
"      3",
"     </sub>",
"     : 2.5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Serum: T",
"     <sub>",
"      4",
"     </sub>",
"     : 2-4 hours; T",
"     <sub>",
"      3",
"     </sub>",
"     : 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (major route of elimination); partially feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/39/9846/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baskin HJ, Cobin RH, Duick DS, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hyperthyroidism and Hypothyroidism,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      ,  2002, 9(6):457-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/39/9846/abstract-text/15260011/pubmed\" id=\"15260011\" target=\"_blank\">",
"        15260011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhasin S, Wallace W, Lawrence JB, et al, &ldquo;Sudden Death Associated With Thyroid Hormone Abuse,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1981, 71(5):887-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/39/9846/abstract-text/7304660/pubmed\" id=\"7304660\" target=\"_blank\">",
"        7304660",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Helfand M and Crapo LM, &ldquo;Monitoring Therapy in Patients Taking Levothyroxine,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1990, 113(6):450-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/39/9846/abstract-text/2143640/pubmed\" id=\"2143640\" target=\"_blank\">",
"        2143640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson DG and Campbell S, &ldquo;Hormonal and Metabolic Agents,&rdquo;",
"      <i>",
"       Geriatric Pharmacology",
"      </i>",
"      , Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 427-50.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanders LR, &ldquo;Pituitary, Thyroid, Adrenal and Parathyroid Diseases in the Elderly,&rdquo;",
"      <i>",
"       Geriatric Medicine",
"      </i>",
"      , 1990, 475-87.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sawin CT, Geller A, Hershman JM, et al, &ldquo;The Aging Thyroid. The Use of Thyroid Hormone in Older Persons,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1989, 261(18):2653-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/39/9846/abstract-text/2709545/pubmed\" id=\"2709545\" target=\"_blank\">",
"        2709545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watts NB, &ldquo;Use of a Sensitive Thyrotropin Assay for Monitoring Treatment With Levothyroxine,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1989, 149(2):309-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/39/9846/abstract-text/2644903/pubmed\" id=\"2644903\" target=\"_blank\">",
"        2644903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10075 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9846=[""].join("\n");
var outline_f9_39_9846=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708983\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227348\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227363\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227351\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227359\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227352\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227333\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227320\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9626657\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227335\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9954591\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227362\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227338\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227324\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300136\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227329\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13851598\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227330\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12966353\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227355\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12966354\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227341\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422282\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13361514\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227323\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227337\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10075\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10075|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/28/32197?source=related_link\">",
"      Thyroid extract (desiccated thyroid): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/57/22422?source=related_link\">",
"      Thyroid extract (desiccated thyroid): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_39_9847="Folate pathway MTX";
var content_f9_39_9847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Folate pathway with sites of action of methotrexate (MTX) and leucovorin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 572px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAI8AhoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyf9oq/vNP8ADGmyWF3cWsjXm0tDIUJGxuCQawNI+I11p/wu1GxvpJT4ms5Tp8QZi0jM+dr+pKgN/wB8j1rf/aKsLzUPDGmx2FpcXUi3m4rDGXIGxuSAK1W+GenXnjSw8TyzOrxrHI9p5fyvKq4DZzxyFOMdR715lSFV15On2S+/r8j7fB4jAU8roxxiv70pK27cWrRflJNo4T4KrquvR+LNJ1LVtQSXyo4hL57O8LbnBKkng8dqzfFWhanovxF0Tw3F4o1qWC/SJmma4YMm+Rl4Gcfw11fwM02+svE/i2S9s7m3jlkUxtLEyB/nfoSOeoo+Iem31x8b/Cl3BZ3MtrFHbiSZImZExNITlgMDgisvZ3w8W972+Vz0ZY3kzevCLSg4c2ytzci/U1Nb+HWpQ+Dbu20vxDq1zqschuIJZLhlLfKAYjg9DjjPQ/jXDReO/EfjDR9I8JaYtxb648nlXt4CUOxP4iRyvq3+7gdcV658TfEN9oHh2Q6NZXN3qlzmKBYIWk8v1dsDt29TjtmvIbzwD4i8G6do3irTGuLrXEk8y+t1BkI3npgcsMEq3Xk8cc1eJi4StSva3vW7f5/ocuS1o4ihz45xc3J+y5rfFZ72+ze3lzHvmgaYuj6Pa2Czz3JhTDTTuWeRu7En1P5dK0KzvD+prrOjWt+IJrYzJloZ0KPG3dSD6Hv361o16cbWXLsfDV+f2kva/Fd39eoUUUVRkFFV729tbKMyXlxFAnrI4Fc1f+PtHtgRbtNdN/0zTA/NsVcac5/ChOSW51tFeZXvxHu2OLGwhjHrMxc/pisS78Za9ck/6Z5Kn+GJAv69f1rojg6j30IdWJ7RTXdU++yr9TivBrjVtTuf9fqF249GmbH5ZqkysxyxJPqTmtVgX1kR7byPoJru3X71xEPq4pPtlr/z8w/9/BXz75dL5dP6iv5g9t5H0Is8LfdljP0YVJXzsY6lhuLm3OYLiaI/7Dlf5UngO0g9t5H0JRXhcHiXW7cgx6ncnH9994/XNbFp8QtZhAE6W1wO5ZCp/QgfpWcsFNbO5SrI9corgbH4k2jlRe2M0R7tGwcfrium03xNo+osFtb6LzD/AAPlG/ANjP4VhOhUhui1OL2ZsUUDkZFFZFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVy0/jjSoPGkfhd1uv7SkxghB5fKb+uc9PauprwjVv+TmbP8A4B/6TmufEVZU1Hl6tI9jJsDSxkqyq39ynKSt3VrHu9FFV728t7GAzXc0cMY7ucfl610JX0R45Ypk0scMZkmdI416s5wB+NcLrXxAjTdHpEHmHp50oIX8F6/niuG1PU7/AFWTffXMkvOQpOFX6DoK66eEnLWWhlKqlsekav480uzJS033so/ufKg/4Ef6A1xmqeNtZvsrFKtpGT0hGD/30efyxXPrCfSp0g9q7YYenDpcyc5MrSeZPIZJneSRuSznJP40qwH0q+kHtUyw+1a8xNjPW39qeLf2rREPtTvJ9qXOOxmeR7Uoh9q0vJz2pfIpcwWMzyfajyvatLyKQwe1HMFjMMXtTTFWmYKa0HtT5gsZTRUxovatRofaomh9qakKxmNHUZStNofaomhqlIViTTNe1XSyos7yVEX/AJZk7k/75PFdlpHxI+6mr2nf/Wwf1U/41wbRVE0dROjTqfEilKUdj3nStZ0/VY99hdRzeqg4YfVTzWhXzrG0kEqyQu0cinKspwQfY12Gg+P7+yKxamv2yAcb+kg/Hv8Aj+dcVTAtawdzWNZdT1qisvRNe07WY91jcKzgfNE3yuv1H9RxWpXC4uLszVO+wUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4LrkscP7SlrLM6xxqELMxwAPs5r13xJ4msdDTbKfNuiMrAh5+pPYV84eItSm1f4qi8uFRZJNvyoOABHgCsMVSk1Tb2ckj6LhuS58Sv+nM/0Pcde8eRxlodGQSt089wQo+g6n8f1rhL68utRnM17O80nqx6fQdvwqCNKsIlfQU6UKXwo+TcnLchWKpUi9qnSOrCRVbkKxXSGp0i9qsJFU6Re1ZuRVissVSLFVpYqlEVS5DsVBFTxF7VbEVPEdTzDsUvK9qXyvarwjo8ulzBYpeT7Uhi9qv8Al0eVRzBYzzCPSo2h9q0zFTGi9qOYLGY0NRND7VqmKo2i9qpSFYyHh9qieH2rXaL2qF4vaqUxWMd4faoXhrXeH2qu8VaKRNjKeKoHirVeOoHjq1IVjPieW3mWWB3jkU5V0OCD7Gu78NfEGWHZb62plj4AuEHzL/vDv9Rz9a414vaq7x0p04VVaSBScdj6Bs7uC9t0ntJUmhcZDKcip68E0LW77Q7nzbKUhT9+JuUf6j+teveGPE1nr8H7o+VdKMvAx5HuPUV5dfDSparVHRCopG7RRRXMaBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU2WRIo2kldURRlmY4AHqaAHE4GT0rgfF3jhYDJZaKweYfK9x1VfZfU+/T61j+M/GUmol7LSnaOz6PIOGl/wX+dcfElejh8Jb3qn3GE6nSI8mSeVpJnaSRzlmY5JPqTXGzr/AMXJgH+7/wCi66ePWtJHXULX/v4K5Oe+sz8Q4boXMRtRjMu75R8mOv1rkzOvTlGlyyWk49T6zhrBYinPE89OSvRmtU99ND0dEqwkdZia/ow/5idp/wB/BW7AodFdCCrDII7ivRjWhP4WmfL1cLWo29rBxv3TQ2OOrMcVSRRVZjjqXIySIkiqdY6mSOpljFQ5FWIFi9qkEdThfaggKpZiAAMkntUOVhpEQSnBKQXVt/z8Q/8AfYpftVt/z8Q/99isfrNL+dfejT2FT+V/cKEpRHSfa7b/AJ+If++xR9rtv+fiH/vsUvrNL+dfeg9hU/lf3C7KNlAu7YnAuYf++xU+2rjVjP4XcmUJR+JWK5SkKVY20hWruSVSntTGjq2UppWncCk0dQvHWiUBqJ46pMVjNeOq8kdabx1BJHVpk2MqSKqzx4rVkjqtJHWikJozHSoJI60XjqB0rRMmxmSR0yCaa0uEntpHimQ5V1OCDV9481Vljq076Mmx6p4K8Xx6wq2l8Vj1ADjssvuPQ+35e3X186qWikV42KOpDKynBB9Qa9Z8CeK11aJbK+YLfoOGPSUDv9fX8687E4Xl9+GxvTqX0Z2NFFFcJsFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUjEKpLEAAZJPagBs0iQxPJK6pGgLMzHAA9a8i8a+LJNZla0smZNOU/Qykdz7eg/yJfHniptVmaxsHIsEPzMP+WxHf/d9Pz9K5rSrM3t/BbA48xwpPoO5r0KVKNCDr1tLK/okYTm5PliWdF0W71STFumI1+9I3CiuzsPCNnAAbp3nfuM7V/Tn9at6/eR+F/B+q39pbq66bZTXKw7tocxoWwT74615rpnxf1WDStF1zxP4YSy8N6q6xx6hbXomMJbODJHtBxx1B4x3OBX5rj+I80zRyeCfJTTskmlJ9d73vbpH8Tup4enT+LVm7/wAKd8Nf89NR/wC/y/8AxNH/AAp3w1/z01H/AL/L/wDE1PbfEmyX4k+IfC+rNY6dBpcUMkd1cXSp5xdFYjDYHG71PSuWPxpuf+FT2vjBdEh86fUfsP2U3JCjr82/b7eleBClmc7Wb15bar7Suvw+7qe//rBj/wDn/L7zov8AhTvhr/npqP8A3+X/AOJrpz4fFtCiWjlkRQoV+uAPWuL1T4ja5ovgXxB4h1XR9JLad9nEMNnqYuBL5koRtzBflxkEdc80/wAM/EnV7jxpo/h3xL4eh0+XWLRruzmtrwTrtClsONoI4U8+uPw7MFi82wTlWpSTSvdNxadkm+t3ZPWxw43HVseoxxM3K21+lzqBEUYqykMOoNTRpWvqMAePzAPmXv6iqCLX6Pk+bRzTDKvFWezXZni1Kfs5WEVfSkt5Ypw5gljkCOY2KMG2sDgqcdCD1FSOyRRl5XVEXksxwB+NfNnxw11/CfjS28SeBvEVotxer5d/aW9wkoZ0GFd48nIK8ZI4K9cmvSlLl1JSPpULUN+v+g3P/XNv5Gvn3wh+0lCyxw+LNIdH6G5sDkH3MbHj8GP0r2zQ/E2leLPDc+o6FPJPaFHXe0Lx/MAcj5gM49s1hXmnSlbs/wAjWirVI+qMCVxHE8jfdUFj9BXJ6D8QNJ124t4tOttUdJ22LMbNxFn3foK6i+BayuAASTGwAH0rzL4MeGLq28O6dfXeoa3ayJJITpzybIPvMOYyueevXrX5xQp0nRnUqbqyXzT/AMj7itUqKrCENne/4f5nYW3jPSLnQdT1iJ5vsWnSvDOTH8wZcZwO/wB4VtaZew6lptrfWxYwXMSTRlhg7WAIyPoa8LsfCd5P4D8W3UkmuQXIvp/KsYpHSKcfIQxix82cnn2HpXbX3iI+Gvh74ZsjPHY6neWEUMclz8qwbYl3uwPdcgBe7Ee9dNfA078tF3d7fK1zCjjJ25qqsrX/ABselR/6xfqK7sivEfg/rk2v+C7C6vrwXeoK7pcNxuU+Y20EDp8u38K9L8X+O/DXhBG/t7VreCcDcLZTvmb0wi5OD6nj3r3eHaboyr05bppfmeRndRVY0px2ab/I6PbVeG7tpru4tYZ43uLfaZo1bJj3ZK7vTIFfL3xD/aH1PVEls/CFs2l2rZU3cuGuGH+yPup+p9CK9J+BOt+F9E8C2kF74n0ptZvma9vfPvUEhkfsdxySFCg+4NfSqabsjwbHrxFNIpbeeG6iEttNHNGejxsGB/EU8iruIhK1GRU5FMK1VxFd0qB0q4VqJlqkxFCRKrSJWlIlVpEq0xNGZIlV3StNoi33VJ+gqB7aX/nk/wD3yaftYRdmxWZmOlQSJmtCSMqeQR9RUDpW8ZX2JaMuaOoYpJLeZJYXZJEYMrKcEEd60ZI8iqcseK0TuQ0ew+C/ESa7p+JCq30IAlQd/wDaHsf0roq8C0fUZ9I1KG8tj86HlezL3B+te5aTfwapp8N3bNmOQZx3B7g/SvKxVD2bvHZnTTnzKzLdFFVNU1Ky0q0a61K6gtbdeskzhR9Oe9cjaWrNoxlNqMVdst0VzvhLxjo/ixr4aLO8ws3VHZkK7sg4YA84OD1A6V5X8fLK61Hxr4btdOYi9eCQw7eDvB3AD3yKwq4hQp+0jqergMonicZ9Trv2bs27rayvqtOh7tRXyt8TPE15410ux1TY0djYCK1kUjAa5kRmcj2Hlgf/AK67/wCPfhHR7fQrzxFFbuNVmuI1eXzWIIPH3c46AVj9d5lKUI3UfPffyPTfDSpVKFLE1eWVVtWUb8rTVk/eW6d/LazPaqK80svhf4bl8Fz28FuYJL+2ikad5Gfy5AuVcZPGCxzjGQSK808EXFz471zR/C2v6jDJpWkB5FRWObzYcKM98L0/2QfrVTxMoOMZR1e2v/AOfD5JRxMKtWlWfLT+K8bO1nqkpO+qatddz6WopEVURVRQqqMAAYAFLXYfOhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnHxG8T8yaRYP7XEin/wAcH9fy9a3/AB34iGi2Hk2zj7fOMJ/sL3b+g9/pXj/LsWYkknJJ7134Shf95L5GNWf2UIi5rU0aX7FqFvcYJEbAke3f9KqxR1dhjrsrwjVpypz2kmn6Myjo7o7bxlZS674H12w04o89/p08EGThSzxsq5PYZIryGz+HvjPXvB+geDPENtpem+H9OeN7qeK5M09yqEkKoAAXOeST6H2PoekalcWHyod8PUoen4eldPa6xazgbiYm9GHH51+S4zJcxyi8cPD2kL3UkrtPa9u69Gup6kK0Km7szz2z+HCXnxf8V6/4j0nS9Q0i/gt1tBdRpOVdI0VjtYHb9081xifCfxIfgjYeFpIbQ6lFq4vJEMw2eV82efXnpX0Ek0bjKSIw9jT9y+o/OvCjmeMpNJrblsmn9lWX56m3JFnmnxG+HFpc/DPXtC8FaTp9jeagYDtiVYVcpMjfMR6ANWF4P+GmpeBfiDY6toVpa3WkXlklvfxzS7prSQAbmidskqSM4zzyOy17FPd29vE8k80ccaKWZmYAKB1J9BXgniz4la/8QNbm8LfCkNFap8t5rbZVVHT5G/hXrgj5m/hAxk92W0c0xUXh4RfJK93JO2qS362srW1+RM3COp33xL+K/hnwVG9re3Ru9UPSxtcPIP8Ae5wn4nPoDXnEWt/Fvx4N2habbeFtKk+7cXf+sZfqwLHjuEH1rs/h38JdB8IBbyWP+09bY75L66XcQ3UlAc7fryfevR1FfoeT5THLMP7GMr3d2/M4qlTndzw+H4CHVnSfxr4u1nV5gd21H2qPYF95x9AK4r45/Dbw94X07QNM8JaVcza9qd0yo3mvLI8aLyoXO3qynOO31r6pAqodJsn1hNUe3Rr+OEwJK3JRCckL6ZOMkdcD0r03FWIueHfCv9n6y0xIdS8bLHfX2Ay2AOYYj/tn/lofb7vX73WvdJ7YLp0tvbRqqiIpGigKBxgAdhV4LShaUoJxcO5UZOMlLscR/Ymo/wDPv/4+v+NH9iaj/wA+/wD4+v8AjXcbaQivB/1bwv8ANL71/kex/b2I/lj9z/zOH/sTUP8An3/8fX/Gornw3d3MZSezSRSCPmZTjPXvXJ/DHxBq/jP4veLNSg1G4HhfTgLOC2DZikfOAwHvtdsjn5lHSvZ6S4cwu6lL71/kDz3EdYx+5/5nnPhzwY3h7TbfT9MsjDaQklVMoY8sWOSTk8k10fi3wb4f8XWvkeINMgu8DCSEbZE/3XGGH0ziuiIpMV6mCy+ng+ZxbblvfX9PM4MVjZ4lRUkko7WPkv4mfs+anosc2oeEZJNVsVyzWrD/AEmMe2OJPwwfY123wq+GvgTxr8O9Mv73Q/L1JFa3unjuJUYSodrEgNjJwGxj+LtXv5qpZ6daWU93NaQJDJdSCWcoMeY+ANxHTOAAT1OBnpXYoJM5LnjN3+z5p9lM1z4Q8S6zol51DCTeB6AbdjfqaoTav8Wvh38+tWkHi3RI/vTwA+cijuSAGHuWVgPWvWfiJ4usfBPhW71i/ZSyDZBDnBmlI+VB/X0AJ7Vp+GLyXUvDWk31zt8+5tIZpNowNzICcD6miy6Acr8PfiZ4c8dRBNLuTDqAXL2NxhZR6kDOGHuM++K7RhXmvxL+D+leJ5G1XRH/ALF8SRnzI7u3GxZHHI3he+f4hz9cYrB+H3xN1PStdTwb8TYTZ6ypCW1+2BHcjou49MnHDDg9Dg9WpNaMLdj2UikWB5ThBn3qaOPzJAvbvWgihFAUYFfN8QcRLK7UaSvUavrsl5/5GtGj7TV7HHeMPEeh+Dre1k1yeZ7i7fy7a0tozJNO3cIg5PUc8Dkeoqbwb4q0nxJcXdta6fqOn31oqvLbalZNBKqsSFb5uoO09DXE/Fm0v9H+JfhXxmNPvNQ0ixgmtblbOLzZLUurAShO4+fk/wCz9KwfC3izxZb6X49v3m1zWrG1to00ae504wySytlTtUICcMQSOcAZr5SvWxWYYZVJVW20vtWV3K3LypW0Vnq09brRHSoxg7JHqfhPx/4f8U67q2j6NcPJeaYxWZWj2qcMVJU9xkdfcVh3/wAZvCthf6lbXI1UJpty1pd3CWLvDC6sVOWGeMj8a8p8E+FvFPw/8W+B9Uu9FhWzmjOm3j2LPNIyysz+ZONvy7WcHPIwgGeBWfrHhjxlLbfEqfTPt40qXX5Xu9LS2CvfW5lYl4pCpbpjhcgjnnoc45TgnWfv3g0rPmW/NyvVJ+q9dWP2krbHvHib4k+HtDuNKtrgXl7JqkH2m0WytmuPNjxncAOenP0rH134h+FbLTIb/U9H1uC2lQyGQ6ZInlgOV+c8bTkcZ6gj1rjde0I+JfiD8Mhoseu6PpEelzQi4tkaGayCxOFjZmUhT8oU5HIJx1Brs/ivoN1afA7WtItLjVNZuViAWW5bz7mbM6tyVUZwDgYHQCsqMaOEnQjTnKMptXtKzXvNdFbSy6g7yTuiTw5Np/i+0nutAj1GCKPaQNQtWhEgYEgoT94cdfcVyfjK61Dw/rVgLlBHYyHZKCvOfXPpzkY9DXrngiJ4fBegRTI0cqafbqyOMFSI1BBHY1W8f+H08SeGLyy2KbkL5lux6rIOR+fT8a9HD8YYqlUdGq7xvo+qs+r0un1ur+Z15bRw0cTF4iKcHo/Rq112a3XoeeSL3Fb/AIO8Y2XhiaWLWbpYbCUbsnLFXHcKOTnpwPSvLNM1PXdSs47GwiSNrdRHLO55HpnPQ4HoTxV+08KwpJ5+pzPe3B6lydv+J/Gv0hYyeNp2w8Lp9Xol+rt5F1ckw+WVGsxrJWfww96TX5RutVd38j0q6+Jeu+KLh7P4eaHNKoO1r+6XCJ74ztHr8xJ/2an0v4Tz6rdrqPj/AFi41a7/AOfeNysS+2eDj2ULXb+AtQgv/DlusEcUT248l4o1ChSOhAHTI5/OuirzZYR83798zX3fcU879jHky6CpJ9d5v1k9vlYp6VpljpNotrplpBaW69EhQKPqcdT7msHX/B8eseL9E15rx4n0zOIRHkSZPc54rqqK1lTjJcrWh5dLF1qVR1YS95ppvfdWe/dHGeOPAGn+JdBTS7Uw6VGLsXjtb26/O+1lJIGOTu6+1aHj7wuni/w8+lSXTWqtIsnmKm8/KemMiujoqXRg76b7mscxxMHTan/DbcdtG7XfnstznfEfh2fVvCf9h2upPYq0awyTpHuZkAwVAyMZxz7ZFc5qHwr05rbQv7Fu5dLvtJwI7uOMM0nOTuGRk7iT+JGMV6LRRKhTnrJF0M0xWHXLSnZXb2Wras76a6d7oagYIochnwMkDAJ+lOoorU88KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqnq2oQ6Xp815cnEcYzgdWPYD6mrleTfEPXf7S1H7Hbtm0tiQSOjv3P0HT862oUvayt0JnLlRzerX8+q6jLd3TZkkOQOyjsB7Co4kpsac1chSvY0Ssjl3Hwx1cjSmRJVqNazbKSHxpVyJKjiSrca1lJlJD41qwi02Na80+PXi240Tw/b6Fou59e1x/s0Cxn5lQkBiPc5Cj6k9qxlKyuWkct411rU/iv4rk8F+EZzDoNq2dT1FclXwfujHUZBAGfmIz0Ga9o8H+GNM8J6JBpei24it4x8zHl5W7s57k/wD1hgVlfCzwXbeB/CdtpsIVrtgJbuYf8tZSOefQdB7D1zXZAVml1e5QqipVFNUVIBQ2IVVp4FAFPAqRiAU7FAFL2pAJiuJ+M3iX/hE/hvrOoxvsumi+z2xBwfNk+UEfTJb/AIDXbV4L8e3/AOEr+IfgnwFExaGacX16qn+AZH5hFlP4ik9ECOw/Z/8ADI8M/C/So5E23d8Pt8/HO6QAqD9ECD6g16LilRFRFRFCoowFAwAPSlprRAMNNp5FNNUgCszxLruneGtFudV1m5S2srdcs7dSeygdyegArTrC8UeEtD8VRwx+INOivkhz5ayM2Ez1IwRg+9D8gPin4tfEK++IPiE3cweDTYMpZ2pOfLXuTjqxxkn8Ogr1r4fah8VfHfhi1/4R3XNE0nSrRFs/lA80bFAGRtdgcAHquc+lelah8CPh/eKdmjyWrn+OC6lB/JmI/SofBnwhHgPxENS8J69draS4S7sL5FkWZPZl27WGcg4PoeCayUXfUdzC/wCFX/EaX55/ifeLIeqxo+0fT5h/KuI+KHw++Jj6GV1W5tPFVnBl0eOMG6g9SvyhyD02gsPbgEfVBphFXyJiufPf7NHxUku5ofCHiSYm6VSlhcyHlwP+WLE9wB8vqBjrjPq3xp8T3XhfwJcT6VJs1e8ljsbE8f62Q9RnjhQx/CvE/wBpvwMuj3dr410BDbSNOovPJ+XbLnKTDHQkjBPrtPUmu/8ADEOl/Gzw54X1vX5i66W0sd5pwUeVNcbQCW9BjawA7Nivic+yhyxkca05QXxJK70206p7Pt6HVSqe7ymn8Idf1jxT4P13RtY1Vk8S6VdzWE19EqFhydkqjG09wOOdtcP4X8feJtM+DnijxdqWszanfQ3X2C0inhQJEwZV8z5QM/fzg8fKK9K0X4X2Ph3Wtbv/AArfTaPHqdoLb7PBGrJA4xtlXdn5hzwePmNU/DPwhstJ8Ka14b1DV73U9H1T52hkRIzFJkEyKQPvZCnnI+UcV859awKlOWnLKUHbl1t9tLTT0vaxtyy0L3gjw54psZ9K1LVPGF1qiTwl7+znhjEZZkJBiKjK7WI47j06V53oHxO1u5+LcFxcXqt4M1TUp9Is4cJhXjVAkmcZw7EY57t6V32i/DvWLCBLa58c6vd2dtay21nCYY0EW6MoGcjmQqDkZ6ECsqf4DeFT4Zs9Osg9nqdsyONWiX9+zKc5POOf049KVLEYJTm8RJS5lZNQsknfXZarTVJvpsDUtLHJfEfxzf6b8VPEOl3fjW58PaZa2Mc1osVqk2+Yop2Y2k85J60zxN448aW3w6+H17qV7d6Zqeq3xhvHtbVWmkhLYVhEQRuK4IUAZJHTOK9PvvhlpepeJ9f1fVZpLtNZsEsLi2KhVUKFw6nqGygI9DWda/ChE0zwtY3ev3t3F4d1BL60aSNdxVSCImP90Y47gHHQCtaeOwChSTirxtf3Vr7rTtp/Nve/RoTjLUyIBr2o/D7VNV0/xj4kgm0/7RNuv9Mit5JNsSsE2sv3M/xDuT6Vr/Apte1bwpYeI9e8R3epfb4G/wBElhjVImEhG4FQCeF7+td/r1lHqWiahYzy+TFdW8kDSD+EOpUnn61xvh+3h8J+ELHw3pNzJcRWiMn2lwFZgWLcAfXGaMBhq2b05UMPBJuS15VZRs7+8kuttN+wTkqerZwmu+XofxKuXhATTtTc4x90Pnk/99c/Rq3Jkq5d2kFw8bTwxyNGcoXUHafUVHKtfreXYT6lT9jF3itu+2v46meZ4+OP9nNxtNR5ZPvbZ+trJ+hs/DvVDp2vLbyNiC7xGR23/wAJ/p+NevV8+ktHIHQlWU5BHY17noN+NT0e0vF6yoC3sw4YfmDRjadmprqcNJ9C/RRRXCbBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUyWRIYnklYLGgLMx6ADqaAOe8da3/AGRpRSFsXdxlI8dVHdv89zXkAGTWp4l1Z9Z1ea6ORF9yJT/Cg6f4/jWfGuTXsYel7KFupyzlzMkiSrsSVHElW41q2xIfGtWolqONatxrWTZaJIlq3GtRRrViMVm2UiVBXhvw7QfEL40a34unxJpWjf6Jp+ehbkBh+G9vYuvpXf8Axk18+G/hvrN7E+y5ki+zQEHkPJ8uR7gEt+FR/Avw8PDnw00mB023N0n22f1LSYIz7hdg/CsJaysUtj0BakFMWnimBItSCoxUi1LGSAU4Ui06pAKSnUhoGJmvBPhJ/wAVd8cfG/iyT57axP8AZ9oe2M7Qy/8AAYyf+2les/ETW/8AhHPA2uasHCSWtpI0RP8Az0Iwg/76K1w/7Muif2R8KbKd1xPqUsl4+Rzgnav/AI6gP40t2B6tXi3x4Z5PG/w9tDa39/bXD3olsbK4MD3GEiIG4MvQ89R3r2k1UudNsbu8tLu6s7aa7tCxt5pIlZ4Sww2xiMrkAZx1xTauhI8Y8P6l4o8Cab4SsfEN0LeHVNamjMV7OJ3tbQoDHE0pOMgg857ge1NT4ieJL7TLB9NutP8APvPFUujxyvBvj8gD5DgEZ7HIPNeya3oul67aLa63p9rf2yuJFjuYlkUMOhAPfkj8TWbbaf4Wi1FNItbHR0vbVv7RS0jgjDRMTt88KBw2eN3X3pWaA8s13xBq3hvX/GtwTYS6zp2gW0xvVttplk3YORk/L6DtSSfEHxX4ffxENUnstWeDQYdYtljtfJWJncLsIDEso3ZJJzhe1eoaMfDHjDSTren2ljqFnqUZhe4ktADcIjldrh1DFQyngjHHFayaRpq3DTrp1mJ3gFq0ggXc0I6Rk4zs/wBnpTswPN/hT4n8T6rr8lprrrc6dPYC8t7iWO3hkDhlDKqRSvujw4O44I6HqM+r1z1n4f8ADXhOO+1XTtHsdOKwu881paAOYx8zABBuI4ztA5wOOlbNjdQ39jb3dszNBcRrLGWQoSrDIyrAEHB6EAihATGm4p9BHFUBxnxd05NU+GPia2dd3+gSzKPVoxvX9VFfP/7KeuzaZ4ruNEuSRa6xbGeAHvJEWHH1USZ/3RX0L8V71dO+Gvie4ZtuNPmRT/tMhVf1YV82WNi3hjR/g94mwEdriWK4bPWNrgsv5o71EviTBbH1wsjoflY/SpBdsPvKD9OKiNMYVxYrJ8Di3etSTffZ/erMcak47Ms/bkHVG/CkOpQj+GT8h/jVFxULivNfCGWN35WvmzT6zUL0mrov3YmP1OKpz6zOciNET36mqziq7iuuhwvldF3VK7823+F7fgRLEVH1Iruea4OZpGf2J4/KqTirjjiq0gr6ClThSioU0kl0WiMG29WVJBVWQVdkFVJRW8SWUJR1r0T4U35ks7uxduYmEiD2br+o/WvPZhW58PbwWniiBScLOrQn8eR+oFKvDnptBB2kexUUUV4x1BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVw3xM1ryLVdLgb95MA0uOydh+JH6e9dpd3EdpbS3E7bYo1LMfYV4Xqt7LqWoz3c/35W3Y9B2H4DiuvCUueXM9kZVZWViqoyatwpUMS81ehSvTkzBEsS1ajWo41qzGOaxbLRJGtWYxUSCrCCs2ykMN5bxuVeTDDr8pqVdStB/y1/8AHT/hWFff8fcv1rzGbx7qsviTWdL07TNOZdNlWNpLq/EJfIOCAV9jXxks8xsqs4U4xtFve+17fzH0qyrCxpwnOUrytt6X7Hc/FLwzZ+PdM0+xk1c2dvbXQuZEFuz+bgEY6jHBbnnrXcJqlgihVlCqBgAIwAH5V5JH42gj8bX+g6l9lso7a2SYXEtwF3swU7cHA/iPftVr4feJ28WaJNfvbJb7Ll4AqvvBCgc5wOuaxlnmPhH2jhG2nfrt9o0jlODlLkU5X17dN+h6qNYsP+e//jjf4VetZ47mISQtuQ9Dgj+dcHXXeHf+QXH9W/nXblOcV8dXdKokla+l/LzZzZlllLCUlUg3e9tbf5GsKetMFPHWvojwiRafTFpwpDFoJpKKQHiv7VmpSw/D+00i1y1xq1/HDsH8Srl//QhH+desaDpsej6Fp2mQY8qzt47dceiKF/pXjXxXB174/wDw80EAPHZA6i47cMXOfwgH5+9e6Ulu2M8V/aBtL641DR5LVL26jgikYWJsrme0uHOMBmgYMrjHGeOeo5rlvFsfiXTJPDtppkNzp1z4w0qPSZLN7l3NlMjpmT5iW4iYg85HUnNfSlUrnSbC51O01G4s4Jb60DLbzugLxBhhtp7ZHBocQueF+OvBd7d6v4sgitdcns7DQIBpZikn2yXEYIGNpxI/HIOTz61PpOjG3+L+h6r4h0vWnkvdEsttyizlVvVKqwl2nC4A5Vvl7kZOT71Sd6OULnzd8L/COq6H/wAKxv007WrW8kkv4dVWQTbYotz+WHjb5Ywc5HAyTnk81U8Iab4ktvFunXGtPrNv4hjv5Ptjw6dcym5iZiDmYyGDytuMYUYwOpHP04aaaFELny94W0/XoB4hgt9L1TUJ5NIv86pLbXltdiZom2JIjsUdyxAAQEg9DTvF2n64I/DUr6fq2qXcWiWUJ0y7s7wJ5vlrvMcsLDbLnht+CCO/FfT4oo5QuQWW82duZYzFJ5a7kLbipxyM98etTUvWkNWIxPGPhyx8WeHrrRtV877Hc7d/kvsb5WDDB+oFeP8A7S2iwaT8H9FtLASLDpV3bxQt/EFWJ0BJHfpz617ya8n/AGl7K81D4Yy2+nWV1eTtdwnZbxGRgBk5IHOO2fcVMloCPS7KcXVlb3A2kSxrJ8vTkZ4p7VV0KF7fQtOhlG2SO2jRh6EKAauEVomIhYVC4qwwqJxVIRWcVXkFXGFVpBVoRVcVWkFXHFVpBVokpyCqkoq9IOtVJRWsSWZ8wpllcmzv7e5X70MiyD8DmpZhVKTrWq1ViT6GRg6KynKsMg+1LWd4cuPtWgafNnloEz9QMH9RWjXhSVm0da1CiiikMKKKKACiiigAooooAKKKKACiiigDN8S38mleHNV1GFFeW0tJbhVfoxRCwBx24rzzwV8V01bwvrmo6xBBb3WmJ5wiiJAlQ8LjOTkv8v4iu78bQy3HgzX4LeN5ZpNPuESNFLM7GNgAAOSSe1eU+D/hedW8P+FbzUjPp8tqJEvrOaFla4jFy7orA4x+IPBHoK4q8qyqJU+x9LldHL5YKc8bo+dJNb2s21bztbybTNrwd478VeLfD15daTpmlnULe7SIxyO6J5ZRiT1znO0fnUXhPxv428Raje29rpOjbbC4EF0TI4K8kHb83P3TV34Jabfad/wk39oWV1a+dqBePz4mj3rzyMjke9Hwd02/0/WvGb39ldWyXGob4WmiZBIu6TlSRyORyPWs6ftJezvJ63v8juxf1Ki8X7OlB8nK47v4rX662G3HxMm8PeJNX0rxlaw26wQmezmtlbFyvOBgk8t0HYEEGuo+Hmsaxr+gJqmt2lvZ/aTvt4Yg27y+zMSe/bpxz34818b+Hdd+JfiDUXjsrjTtP0mBksTdQNE13ITk43AHBx17cepr0b4aazqWr+GoRrunXlhqVtiGUXEDRCXA4dcgZz3x0Oe2KuhObquMm+XW3n/w3Q5szwuGp4GNSlGKqvl50nfl00sv732t7PQ6yivI9Y8M+OfDGq3ereE9XfVraeVp5bC76kk5OBwD/wAB2noMVoeGPi5pd7c/2f4kgl0LVFO10uQRHu/3iAV/4EB9TWqxMU+WouV+e33nnzyWrOn7bCSVWPXl+JesXr89UbHxO1L7PpkVjG2HuG3OP9gf4nH5GvMlHNbXjPUl1TxBcSxOskEeIo2U5BUdwe+Tk/jWRGMmvosPDkpo+bm7yJ4Vq7EtQQrVyMVUmCJUFWIxUSCp0FZMpEqCp4xUSCpkqGMwb/8A4/Jf96vNNH8BQy+LvFGo+ItNsru2vZo3szKBIVADbuO3Vfyr1q50uaa4kkRowGORkn/CmDRLk/xw/mf8K/PKuBx8K1V04O0m9fK9z7KnisHKnTVSa91L8rHlw8GC8+JWraxrGn2N5pc9rHHCJ0WUhwFBO0g46HmqnhHwxq3h7wRdWU+qRaI4vZLl7mMJIFh2jj5uF6de2K9Xs9ON4Jja3VrL5UjQybXJ2OvVTxwRWf4q+H8fijSxYanJ/owkEhWKZkLEAgA4HI5zj1AojhcfK0J03y6dL7eTdhSr4ON5wmubXrbfzWpx/wALdQ1bU9AuJ9Xma6i+1SLZXTxCJriAY2uVHTPP+eT7B4d/5Bcf1b+dch4b+H50CKaO0vJ5ll2/8fV08u3GcbcjjrXbaTbPaWSQyFSwJOV6da9PKsHWpY2dWUOWLTtpbscOYYmnUwkaaneSfr3L4pwpopwr6c8AeDT6jFOB4oAfmkpM0ZpAeFeGB/bX7VHia8PzQ6VYLDGcdGKxqR/49JXuorwv9nn/AImPjr4m603Kz6l5cZ9F8yU4/Ip+Ve6CpjsMWijNGaoQhpDSmkNAGR4mmkh04NDI8beYBlWIPQ1yF1q81pbSXF1qEsUESlnkeYhVA6knNdX4r/5Bg/66D+Rrx/4sppLeB9R/tk2/EUhtPObH+keU+zb/ALXXFfG5zKbx6pqTSaWx9RlaisG5tJtX3OuTxGr6Z/aK6sTYFPM+0eedm313Zxiq2ieMLTXfN/sjWxdmL76xzklfqM5xXi+q3aX/AOz1DDps6TParCt2kZyUG/OGA6djWtp1zbX/AMWDceC2spIY9C2sycQ+Zk7Fcr/2zB7gD2rkeHmozbnK6cuumlt/W+h0LEQcopQWqX4329LHsc2qXEETyzX0scSAszvMQFA6kkngVj6Z470zVJpYtP8AEMVxJEpd1S5OQo6nryB6ivPfiXH4sn+HOtDVo9MG0wsBprSMTGGy+7cBwPlPHYNmtWLVfB15pcMOiSWD3i6fN9nSEDzIo/L+YNj7vbg96yjTqez53OT1a0eisk9fv/A1lOHtOVRS0vqtXq9vuO0fxfZppCaq+uINNc7VuTcfuyckYznHUEfhS654ttdCRH1jWhaCQ4QSzkFvoM5NfOd7ZaqPgbp92+ro2lNOQlh9lUFT5zjPm5yecnp3x2r0PUp7HTvjTNdeJ3gis5dNC2E11gRKwI3DJ4B+/wDn7iuieGlBu1Ru3Ns3f3baeuuu67GEMSpJXglfl3tbW+vpppsepabro1SzS607UzdWz/dkimLKfxBqHWPE1vo0ccmrauLNJDtRpp9oY+gya8s+Hf8AaLzeMLvwfHY/2fPqCmyF1vSBsbvMK7Rn+5iovifFrNyngyHVjp0WpyauqKbdWkhXJUKSHwT7islRn9Y9k6jt667X/DZmjrR9h7RU1f003t/wT02Pxtpctib2PX4GtBKITMLn5Q5GQuc9cdqvS67HHqUOny6ltvpkMkcBmO9lGckDPTg/lXkXxT02+034eww39zZy3L6rEyyWtqIFA2kDKg8nIPNSx2eqWXxq0BNZ1VdTmaxlKyLarBtXD8YBOec8+9NUnKHPGq/tdXrZLy/yE6vLPklTX2ei6v1/zPY/tVx/z3l/77NXdKlkkmcSSOwC5+Yk968zvPHDr460zRLK0SWxuZZbd7wt/wAtY13OqjvtyoJ9SR2Nej6VJFC80s7lI0jyxCM569goJNXlsq1LF0nVk7PXfpqTj3Rlharglp5ehpvRFbxNcQR3U625mDGNTy8gAJJVfQAEk9K4rW/iDHGGi0K1Ifp9qulBI91TkD8c/QVleEPEFnbalqOoa/c3ct7PH5ccgTzTyfmJyRjgAD2Jr6ern1H2ipUnpfVvZI+BljKfMox+/odxIKqSiqTeLPD5/wCXm+/8BR/8XUL+JvD7f8vV6P8At1H/AMXXpLN8F/z8Rft6f8yJphVGXrSya/oDf8vl6P8At0H/AMXVdtY0Fv8Al+vP/AQf/F1qs5wK/wCXqJdan/Mj2n4ePv8ACNjzkrvU/wDfbV0deQeGviV4f0HSlsyupXRDs25IEXGe3L1qf8Lk8Pf8+eq/9+o//i68qrmOFc21NG8cVRSSckel0VwnjPUFt/GXgqV7n7PayNctIXfYpGxMbucd6h8W+Kr/APty103w/OpjltWuBcQJFN5jBiuwb3VcDGTgk+1TLFwhzX6NL1uk/wBS5V4xvfp/wD0GivPLfxhqC3llHqT2dt5mky3Mi7lK+ejleGyR26ZNQaf4m1jWJNDskv7XTZLrTjey3Twht7byuxFJA7ZPtS+u03or3/4b/MX1mHT+v6uelUV5tqniXWFn1dbfVbCBdIsYbjcYQy37NHuJXnhSRgY9RzTdX8a6rYsUMKCbU7G3n0yMp92ZyqvGT3ILZ+gpPHU43vfT/g/qrA8TBbnpdFeZ6z4n1q1bXZk1Czg/sXykNtJCCbosoJYnOVBJOMVqWWsazqfifW7VJbeDT7BLeRoZId0hEkJYrnIxzntVLGQb5Une9vz/AMmNYiLdkv61/wAmdxRXlfh/V9Wm03wlpukTWen/AG+2uXZvs+9UKMcbVyK7P4f6vc674Q07Ub3b9pmDhyowCVdlzj/gNOji41mopa2v+X+aCnXVR2X9bf5nQ0UUV1G4UUUUAFFFFABRRRQAVzHj/RNF1TQbqXWrCG58mMmNyMOrdsMORziunrjvifdmDQ4rdTg3EoBHqq8/z21UKaqyUJK6ZUK06D9pTk4yWzWjPATo+q6Mxk0S5M8A5NvL/Tt+WDV/SfFlq832fVI2sLkHBEg+XP17fj+dbyjJpL3SbPVIfLvYEkHZujL9D1FdcsHUoa4WVl/K9V8uqPTjm9DG+7mdPmf88bKfz+zL52fmatsVdFdGDKRkEHIIq7GK8/Ph7WtAczeHLs3FvnJtZv8AOD+GDWno3je1kmFrrML6beDgiUEJn6nkfj+dSsck+SuuR+ez9GKrkU5wdbATVaC7aSXrHf5q6O0QVMgqGFlkRXjZWRhkMpyCKsLXU2eJa2jJFqePrUKCp4xUMZOlM1C9g03Trq9u32W9tE00jeiqCSfyFPUV5V+0LrN5/wAI5B4W0KCa71jWW2+TApZ1gU5ZuOgJwuTxgt6VnJ2Vxo8o+C3xTk0jx5qA12bbpeu3TTTMx+WCdmyH9hztPtg9q+uAQcY6V8OaV8LNevfGreFbl7Sx1YWv2oLO5KYwDt3IDzg9sjg19N/CKHxlodimgeMbNbiC3XbaalBMsi7AP9W4JDcdjt6cHtnCm3sy2elinCkFKK1JHinioxThSsA6nA0ylBpDH5pk0qwwySvnYiljj0Apc1j+MZ/s/hHXJgM+XYzv1x0jY0MDyn9kmJm8B6vfSgCW61SQkjuBHH/UtXuIryP9lyERfCOycYzNczueMfx7fx+7XrYqY7DY4mkpKKYhaaaKKAMbxX/yDB/10H8jXFXNtBdIEuYYpkB3BZFDAH1wa9NFKK8PMcl+uVvbKpy6W2v+qPXwWa/VaXsuS/z/AOAeXwWdrbxvHBbQxI/3lSMKG+oHWksrCzsEZbG0t7ZWOWEMYQE++BXqDUCuH/Vlv/l9+H/BOv8At5f8+vx/4B5ueetVLXTLC0aRrWytYGlyHMcSqXz64HNepE80ULhhrRVv/Jf+CDz9PX2X4/8AAPMDY2hthbm2gNuDkReWNo79OlLe2VrfxCK+toLmMHISaMOM+uDXpprl5/GemJ46tfCcLGbVJIXuJQh+WBAMjd/tHsPTk9sn+rLWvtvw/wCCH9vLb2X4/wDAOehijgiWKCNI4kGFRBgAewFJNbwzNG00UcjRtuQuoO0+o9DXpFNaj/Vh3v7b/wAl/wCCH9vrb2f4/wDAPOZ7eG4QJcRRyoDkK6hhn15oa3hadZ2ijMyjCyFRuA9AetehEUx6a4Xf/P7/AMl/4If6wL/n3+P/AADwe6+F+jNrekX1i0trDZSSSSW/myv5xbBGGL/Jg5PA5zzXp2i/6+T/AHf610T1Xkr0MNklSnWhWqVubk8v1ucdbNKc6U6cKXLzef8AwDA1zw7p+qqWnhCTH/ltHw34+v41zGjaTd+HNdUSHzrG4HleaowAf4dw7HPH4130lVpO9etUy+jUqRrRVpp3uv17nz86EXJTWjK71Tmq5JVOevSiaMoTnrVCXrV6eqEnWt4kM9T+FBz4euR6XTf+gJXa1xXwnGPD1yfW6b/0BK7WvGxH8WR0w+FFLUdK0/U/L/tKwtLvy87PtEKybc4zjIOM4H5Vh66PCenwpYarY2aQxRPcpD9iLKqAjcy7VIzyCQOe54rqaqXunWl88b3dvHM0auqlhnAddrD6EcGuOpT5k+VK/mhThdaJXKp0TRbu3s86bYywQLm3BgUqinn5RjjNOu9B0i7tYba50yykt4P9VG0K7Y/90Y4/CuabQ2n+IGx0votJttPh8ny3dIi6ScKSOGwMcGuU0my1ePxRbS6i1/Fqa6jmR0tJpPOiL4I8zf5Yj2/7Ixj8+SdZRdnT3dvu+X3IwlUto4eX9foeoXWgaRdtbm50uylNuoSLfAp2KOijjgD0q1cWNpczwTXNrBLNbndC8kYZoz6qT06Dp6V4/odrraahdrY2t5c3clvcN9vuYp7eeKQodofc3lsSSAMZx1zxV4Wcb+DNRj0jT9ci1z7Cv2l5klBdw6FvvHBbhiNvbP0qY4tNN8n/AAbfLV/kKNdNX5f6XyPS7vRdLvL2O7u9OtJ7qPG2WSFWYY6ckUXzadpUF9qd1HBAjIGupxH8zqowN2BlsDgDmvOLuTXdVPiC50e11W2aXTYEt/OjaIlgw37c/wAW3d05q34C0tZ72/guY7ltPngQy2ktnNDEsisMHMrsS3qBwcVSxPNPlhDe+v3r5+fkxqteVox36nY6K+h3kuNLtrcPp/7tdtr5fkbxuKqSoxkHkD15rVs7W3srdLezgit4EztiiQIq5OTgDgckmktLO3tBN9miWPzpGmk2/wATt1Y+9T12wjZa2v5HTGNlruFFFFaFBRRRQAUUUUAFFFFABXlvxRu/N1uC3ByIIuR6Mxz/ACxXqVeIeK7gXXiTUJQcjzSoPsvy/wBK7MFG879jKq9LGfGOavQiqcIq/COlejIwRZjFQ6npFjq0HlahbJMo6EjDL9D1FWIxVhKwnGM1yyV0b0qs6M1Upyaa2a0Zwr+Gdb8PO03he+ae3zk2c5Bz9Ox/Q1f0bx7bNP8AY9ft5NMvF4O8HYT/ADX8ePeuxQVV1TRrDWIPJ1G1jmXsxGGX6HqK894SdHXDSt5PVf5o96Ob0cZ7uZ0+Z/zxsp/PpL56+ZpWzpNGskLq8bDKspyCPY1yljrmoat8RH07S3H9mWMZW5+Xdvb2PruwPwNct4j0u/8AAdv9s0TWHW0mfy/s0vJyQeQOh6dcCu78IWFx4F8CJeDSL3VNUu3WW4t7QKZfm6D5iPujrz1JrwM5z2eDUIOHv32ulf59u53xyzC4PCzxkZqoprlhdNNP7TafWK2tdXZ162sxGRGfx4pi2KxXElx9mRZ3UK8oQbmAzgE9wMn864zwp8XLXxCLu4Xw9rNnpVkZlvNQnWMw2xijMjhtrE5xgcA9RVjw18TJ9flsJ7Xwfry6LfyiKDUSsbLgnaHdA2VXPevIfE2Zwk/aUY2W+tvle++m1r+R897CHRnn/j0/2B+0V4N1d/kttSgNkx6bn+ZOv/bSP8q9zWvMP2nfDkuo+A01rTgV1DQ51vFZByI+j4+nyt/wCux8C+IYfFPhLS9Zg2gXcIZ1Xokg4dfwYEfhX1GUZpSzOi61NW7rszCpTcHZnQCnUzNLXqGY+lBpoNKKQDwaM03NFAx4Ncv8UpFi+GnitnOAdKul/ExMB+prphXJfF7/AJJf4p/7B03/AKCaT2Axv2ckaP4M+HQy4JE7fgbiQj9MV6UK88/Z/wD+SP8Ahv8A64yf+jXr0MdKS2QC5opKKYBRRQKAA0Cg0UAB6UgpTSChABpKdVa+tIL60ltbuJZbeVdrxt0Yeh9qBHiXxo+ONnoENxo/hGaO81kgpJdLhorX1wejP7dB3zjFeO/s86rM3xp0y4vp5JZr3z0llkYszs0bNkk8klgK9b/aC0Lwh4U8BONM8OaXFq+oSra2rRWy715yzDAz90Y+rCuYuvg3qvgabwz4s0V5b2TTzBcanZqMyIVwZDHj7y43Ajr3Gc4GTvco+n8UhpI3WWNZI2DIwDKwOQQehoNbEjTUT1K1QPVIRE9VpDU7mqz1aEQv3qvJU7mq8laIkryVTmq3IapzVpETKE/eqMnWr09UZOtbxM2es/C5Nnhgn+/O7foB/Suvrm/h2mzwjYnGCxkJ/wC+2rpK8Wu71Jep1w+FBRRRWRQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEdxKsFvLK/3Y1Ln6AZr5/LF3ZmOWJyTXtnjCbyPDGouDjMRTP8Avcf1rxNOtejgV7rZhWeqRagFX4hVOAdKvRCuuRmixHU6VClTpWTLRKlTxioEqzHUMZwdrF/wmHxNSO4UnSNGbkEcPJnofqw/EL717TXJwS25vJoY2j+0qqvKq43AHIUn/vk4+lbNvesgCyDcB3718BxLw7icXJYmg+aWt1t93y0+R7lfNI4hQpqPLCEUkt/Vvzb1PMvhLoGraH4A8a22qaI81xc6lezwWExCfa0aJAq5PADkFcmuG8NeEtTtfGWhz+AtE8YeGo1u1fVIdTlUWQgB+ZU5JkJ5HOex4617f4h+IPhXw4Sut65Z2ko5MLPuk/74XLfpXDX/AO0V4DtnKwTajdjON0NqQD/32VP6V4EFmaqVP9nd573Tttbro/mc3uWWp63fwQ3NlcW91GslvNG0ciN0ZSMEH6g188/CG6l+H3xF1f4e6rI32K5c3WlSycb8jpn/AGlH03IR1Nbq/tFeC7qQLKdTgT1e2BH6MT+lc18VNY8JfEPR7bUfCniG0i8UaU3n2YkY28kmDkxjeBlsgFevI9ya+v4cyieWUJOq/flZtdrdPU5q1Tnemx9BUoNcB8HviDbeO/DweUrFrVoAl7b9MN03gf3Tj8DkfXvq+nTvqYDqXNNpwoAdmlFNpRQMivI5ZrSaO2nNvMyEJMFDbGxwcHg/Svmn4ifFzxBptl4h8F+MtEtjey28lul7aOyKwZTsk2NnIPsRjnjjFfTteOftL+BV8S+ETrVjEDqmkI0nA5kg6uvvj7w+jetRO9tAR5V8Pviv4mfQ/DvgXwbp9tDqBJg+2TfvTy7MWC4AUKDk53cA19Y6PZyWGl21rPdzXk0SAPcTH55W7sewyc8DgdBXzn+yN4SUjUvFd3HlgfsdmT26GRh/46oP+8K+ls1ME7XY2FLSUZqxBR3ozSUAONJR3pKAHGkFJSigApDgDnpSmvEfjP47vNRv1+H/AIFJudevj5N3LEeLZCPmXd2OM7j/AAjPfom7AZVhJ/wtn46C+j/e+F/Cv+qccpNNnII+rjPoVjHrXv5rmfhv4Ps/A3hO10eyIeRf3lxPjBmlP3m+nYDsAK6U0RVtwFprUpphqhCNUDmpWqCQ1SEQyGq7mpXNQSGtEJkL1XkNTSGqzmtESQyGqcpqzIapzGtESypMetUZOtW5j1qqqNLKqIMsxCge5reJDPc/CsH2bw3pseMHyFY/UjP9a1ajt4hDBHEDkIoUfgMVJXgSd22diVkFFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHKfEyfyvDDJn/AFsqJ/Nv/Za8ni616V8V3xpVlH3act+Sn/GvN4RzXq4RWpHNV+IuwDpV2MVUhFXIxW0hInSpkqJKmWs2USpVmOq8dVfEOrwaD4f1DVbr/U2kLTEf3iBwo9ycD8azY0eHaj8TIfDv7QGrT3kj/wBjCJdPn2gsV2LncAOpEm4fRjWoNa8dfFyeRPDbP4b8KbihvGyJZgOuCOT9FIHYsa8K0nwx4n8aX891pmlXd9LcStJJOE2xl2JJy7YUc5719AfC3wT8TfDKwxy63p0WmL/y4XLNcBR3xgDb/wABbGe1ccXKT8jV6HR+Gfgh4P0dRJfWsusXnVpr1yQT3wgwuPrk+9d9Y6Bo9ggSx0nT7ZcYxDbIgx+ArQj3+Wvmbd+Bu29M98U8VsopbE3Kk+kaZdR7LnTrOZP7skCsPyIrkdf+EXgjW1fztCt7WU9JbLMBB9cLhT+INd4KcKGk9wPmnW/g54m8AaiviL4danLetb5Jt2UCfZ3XH3ZBjqMA+gJr1L4V/FbS/G8Qs7kLp3iCMES2UhxvI6mMnqPUdR+tejCvCP2hvhp9qtpPGHhmNoNWtP3t0kHymVRz5oxzvXqT3A9Rzm1y6xHe+57yBSivmf4d/HHW9K0e1k8a6dc6ho7uYY9WgUF1YdVf+FiBg9mxz82a948LeNPDviqIPoOrWt05GTCG2yr9UOGH5U1JMLWOiqhcava287RSl969cLV+uE8XXa2EmpXkilkt42lYDqQq5/pXlZxjauDpRlStdu2voz0cswtPE1JRqbJXOp/t6y/vSf8AfNI2uWDqVfeykYIKZBFeD+DD4t8R6TaeIm8QJbi5m3rp4tkMQhD4K7sbskA4P0rNT4g31nqPja1vWvbhrSWRLBoLMOsGA+NxVemQv3s9K8n+1Mc5SjBxbjvZPvY9H6hg1FSkpJPbVdrnu/hb+w/DGh2+k6SskdnAXKKVyRuYsf1Y1q/2/Zf3pP8AvmvKvhtqd5rPgjStQ1KbzrudGMkm0LuIdh0AAHAHaiTxho14l/a6VqlvLqMMMriNOWUqpzwRjg1zvO8cpygknyuzsnY3WVYNwU22r6rVHq39v2P96T/vmk/t+x/vSf8AfNfOPwv8T6rrtzpbal4kvJZ5jIZLL+ykWJgu7A84KAOAD9eKx7b4nasfhjd3Ek162vCUCO9FivkqvmKMFtuzO3I5HUjvXY8dmPO4LlbTS2fW669NNzkWFwPIpvms03uulvx1Pqb+37L+9J/3zT4dbs5ZUjRn3OwUZXua4DTLkyaPZ3FzIoaSFHd2woJKjNaum86ha4/56p/MVw08/wAW6ig0t7bf8E7J5NhlByV9u53tFIKbLIkSM8jKiKMszHAA9Sa+1PlR2eaSSRIYnkldUjQFmZjgKB1JPpXmHjT42eE/DjG3s7hta1InYttYEON3YM/3Rzxxk+1cYPDnxC+LcqyeLpn8M+FywZdPiGJZR2yp5z7vwDyFpOXRBYveNvipqfivVW8J/CeJru8k+W41ZeI4V7lG6Af7Z/4CCSDXbfCj4a6d4B0933/bNbuRm7vnHLHqVTuFzz6k8nsB0XhHwro3hHSl0/QLKO1gGC7Dl5W/vOx5Y/5GBW3mhR6sLisab3oNJVCFNMbilJpjU0AxzVeQ1LIaruatCInNV3NTOaryGrQiGU1Xc1M5qtIa0RLIJTVKY1ZlaqcprVEMqzHrV3wlb/avE+mx4z++Dkey/Mf5VQmNdZ8K7Uy6/NcEfLBCefRmIA/TNOrLlptiirySPV6KKK8M7AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzz4tP/AMgxP+ujf+g1wcI5rt/iuf8ATdPHpGx/UVxMPWvXw38JHNU+IvQjiriVVhq3HVsSGXV/Z2IjN7dW9sJG2p50gTcfQZPJrh7f4qWbeF7bXn0HW3sZVkZ3tokkWEI5X52LDGcZrL8Waay/FGPUNa8O3mv6RLYC3tUht1uEhl3ZO5WIVc8/MfUenFXw/oWqw/s+3uky6fcpqbxzBbUxkSHMhI+Xr0rmlOV2kaJI60fE3T4vC114gutF12106EQsjT26KZ1lOFMfz4YDgnkdR1pPF3xB8JReHdEn1i1l1Gx1nbJBbLEkn3Spy6swHysQCOeR7VieNtF1O8+Aun6Xa2NzLqKWdkjWyITIGUJuBHXjBz9K53x18K73T7K4udME+pBtQjFjawoWNnbl5JJFx6bmHPtWcpTGkj07WPiTpug6/eaDDoeuXtxYQLNKNPtUkSOMqDn74OACO1dd4X16w8TaHa6tpEpls7gEqWG1gQSCCOxBBFeU3/g/WtY+MXiK4gvdR0fTrjT4o/ttvECJvlQNGGYYHfpzxXqfhHw9Y+FvD1no+lK4tbZSAXOWYkklmPqSSf5YFCcr6jNkU4Ugp+KbEAp9NpwoGKKVgGUhgCp4IPekpRSA8B8H20XgD40ar4NuYY28N+Io/tFnFKA0YbBIXB4xw6Y74Sur8TfAnwdrExuLKG40a6zuD2D7U3euwggf8BxVj4x+B9U8UXfhrU/DbW0er6TeCVXuHKLs4bkgEnDIvGO5r02oUejHc8X034X+OtDvrY6T8RLu4sI5VZoLtXPybhlRlmHTPpXa+Ioknv7uKVQ8bjaynoQVwRXaA1iahokl1eSzLKihznBHtXi55hKuIoRhRV2nf8GerlGIp0KspVXZW/VHj2jeBNR0UR2Wm+KLuHQo5/OWy+zoXA3binm5ztJ6gDufU1o6d4Njsn8UsL1n/t1mZsxgeTuDDjnn73t0r0j/AIR2X/nvH+RoHh2X/nvH+Rr56WBzOV7w33+HXrqe1HFYCNrS29fQ8M8U6HY+GfB1hpz63qpv4YXg0+3spzCbiZmLBii9cEgEk4A9zXbeH9Mnfwja22pyRSajJaeVPcIAxLFcE5HU+p74rpNb+Gmk67cRz6va2l3LGuxWkU5C5zj9TV/SvBcOk2EVlp3kW9rFnZEinC5JJ/Uk1pVy/GzpJcj5r3e34a/oRTxmFhUb5ly2st/x0OS8F6Cvhjw1Z6RHcNcLbb8Sldpbc7N0yf72K523+HUUPw6ufCY1FzHPIJPtPlDI+dXxtz/s46969a/4RyX/AJ+I/wAjR/wjkv8Az3j/ACNYrL8yUnJQd20+m66/iaPGYBxUXLRK3XZnzv8AGmHU10Ge0lsro6Np9vAsFyjKI3lLIpdxuzwMqAAeWJ9K9l8IzPcW+kyywSW7t5ZMUhBZeR1wSK6CTw08iFZJYmU9Qy5FTWugyQ3MMhmQhHDYAPY1usDjZxpwdK3K73uvLz8rmP1vCxlOaqX5la1vXy8zifGVr8W73xHexeF9Q0iw0UsPs80wUuBtGc5Rj1z2rEHwT1zxC6v4/wDHGo6jFnJtbbIQH2LfKPwSvcqK+15U9z5W5yng74eeF/CCq2iaTDHcgYN1L+8mPr87cj6DA9q62kpCaaQC0lJSE0xC5oJpKQmgAJqNjTiaidqaQEchqBzUjmoJDxWiJInNV3NSuarua0QiNzVaQ1NIarSnirRLK0pqnKasymqcxrWJLK8pr0/4VWZh0a4umHNxLhfdV4/mTXlr8mvd/DtiNN0OytMYMcY3f7x5b9SawxsrU1HuVSV3c0aKKK8o6QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzf4rj/AE3Tz/0zb+Yrioetd18WU+bTH9pB/wCg1wkPWvYw38JHLU+JmjD0FWkqrD0q0lNgidah1O+h0zTLu/um2wW0TTSH0VQSf5VMlef/AB81E6f8MtQVG2vdvHbA/Vsn/wAdVhWc3ypstK7Oi+Gvil/GPheLV5LBrHfI0YQybw23gsDgcZyPwrr0rmvAGlro3gvRLBVwYbSMPxj5yMsf++iTXSJUK9lcZYSplNQKalU1LAmFP71EpqQVIx1ZPi3xDY+FfD15rOqs4tLZQWCDLMSQAqj1JIH861ga5/x/4Xg8ZeE77Q7mZ7dbkKVmRdxjZWDKcdxkcjjI9OtJ3toNHnR8e+IL34gW1u9hf6JaNolxdizuxG3mOoYpJxkjoBg46dKhuPiB4hT9nW28WLdx/wBuPIVabyU24+0tH93GPugDpXUaT8P9UfxVaa94n8Qx6pPDYyWDQpZCFXR885DdeTnjv2rDHwf1NvD8XhWXxWX8Ix3HnC1FionK7y/l+bu9STux17Y4rO0h6FbXvibqugfFizsNQmj/AOEX+zQNdkxL+5Mq4EhbGQu/bntg1W8CfErxF4gv/HMl0wgtbLTnv9OhaFQ0aMpeIscfNlSp545rvLz4c6dqPi7VdV1R0u9P1CwjsH09oiAAjqwbeGz1UcYH1qGD4bxW/iDxXqNtfrFBrenpp8dstvxaqsKxAg7vm4XOMD0zRaQaHmvhX4meJpJfB07+I9N1yfWboW91o0VqiTWq7iC5ZDkYA3fMB9CMmvo2uR+Hngmw8G6BY2MUdrcX1ujI9+tqsUkuWJ55J746npXW04prcGLQKTNc9r3iyw0lmiB+03Q/5ZxngfU9v51pGEpu0US2lqzo6inuYLcZnmiiHq7hf515Tqfi/Vr8kJL9li7LD8p/7661hsZJnLyMzuerMck11Rwb+0zJ1l0PYpfEmkRHDahAf907v5UxfE+jscC/j/EEf0ryJYm9KeIjWn1OHcn2rPZbfVLC4/1N7bufQSDP5VcrwxojVqz1LULAj7LdzRgc7QxK/keKh4P+VlKt3R7TmjNeeaZ46njIXUrdZV/vxfK35dD+ldlper2WqJus51dh1Q8MPwrnnRnDdGkZqWxo5pCaTNITWRQuaQmkzSE80ALk0hNGaaxpgIxqJjTmNROapCGOaruakc1A5q0hMjc1Xc1K5qCQ1aJInPNVpjUzmqkzda0SJZXlaqcrVPM3WqjnJrWKJZreD7A6j4js4iMoriV89Nq8/r0/Gvb68/8AhTp22C71GReXPkxn2HLfrj8q9ArzMZPmqW7HRSVohRRRXIaBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHDfFZM6dYyf3ZSv5j/wCtXnUXWvUPidD5nh1HH/LKdW/Agj+ory2LrXrYR3pHNU+I0oOlW0qnAatpWjEiwleSftH/AOkaN4dsD9y51Nc5PHClf/ZzXrSV5L+0MdkHhSZ+I01NdzenAP8AQ1z1vgZcdz2VcDgVKpqEV5z+0N/ySvUv+usP/oxaJOybGj1FDUqmvDbHwz4n8P2XizWdAt4/Dga2R7TTIZVugzx4Z2IIK5ZQyjHPzfnFd/EDxJqfhHX/ABTpN6bHTxcWlpp8TQRvtYlBOx3LluWwOcdfrWbnbdDse7m4iSeOF5Y1mkBKIWAZsdcDvVhTzXkHiK61fRfGXhu3vNQg1C7NhqUxu2sYUcFY9yBTglQOBwecc5rC8Oaz4z1W+8IwyeLZE/4SLT55XYWEP+jtGMgoMAEnvn39sS59LDse+PcQxzRQvLGssufLRmAZ8cnA74pz3EMUsUcssaSSkiNWYAuR1wO9eEeGvF2rar/wqrUb5be8vbuHVzKxtozJI0SMF2Nt3ITtGdhGe+RxWZ4b1q78QeK/hrqmp+I49Tvrq5u5JbFFiQWX7sgKFUbhwMfMTnH5zzjsfRVvcQ3MCzW0sc0TfdeNgynBxwR71KDXz54M17xBf+HvhhpemarFpA1oaqLl7WwgVf3TMyFUCBVPX7oGScnNNf4g+J28EeD/ADNQ8uXULu7trvUl8mFv3TEIu6QeWhb1I/h45o51YLH0NSiuJ+EurarqvhZm167tby9t7mSAz28scgdRgqWMZK7sNg49K7SrWqEPpSQASTgDuabmuH8ea8QG0yzfBI/fup/8d/x/L1q6dN1JWRMpcquVPF3i6S4kez0mQpCPledTy/8Au+g9+9cdHCWNTQwFj0rWs7InHFenFRpRtE5nebuyhDaZ7Vehsc9q14LHGOK0rezA6ispVSlAwl00kdKY9jt7V1ohRV6VRulXtWaqtlOJzMlrjtUElvx0rbmC+1VGUEGtlJktGJJDjtUcbyQSLJC7RyKchlOCPxrSlTLEVC9qSua0Uu5Njq/DXi/zGS11ZgGPCz9Af97/ABrtc5HFeIzRlK6/wR4kKumm37kqeIZGPQ/3T/T8q5a+HVuaBpCp0kd8TSUmaQmuM2FzTWNITUbNRYAY1EzUrNULmqQhrmoXNOc1C5q0JjHNV5DUjmq8hq0hEcjYFU5WqaVqpzNWsUQyCVqhjR5pUjjUs7kKqjqSegpZGya6n4baV9u1v7VKuYbQB+e7n7v9T+FVOapxcmJK7sem6HYLpmk2tmn/ACyQAn1Y8k/mTV6iivDbbd2di0CiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBh+NoRN4W1BcZ2oH/ACIP9K8aj6171fQC6sri3bpLGyH8RivBlBDYIwRXpYKXutGFZapl+A8VcQ1Rgq4h4rokQiyleYftH2TXPw8W5QHdZ3kUxYdQCGT+bivTUNY/jnSDr/g7WNMVd0lxbsIx/wBNB8yf+PAVlUjzRaKi7M19Dvl1PRrC/TGy6t45xj0ZQ39auTwQ3MRiuYo5oj1SRQwP4GvN/gBrQ1X4dWkDtm4052tJAeuAcr/46wH4GvS1NTF80UxvRkd4sdzBNZtO0TzxsmY2AcAgjcvuPWqnh7w5pmh+HrXRbO3V7C3GFSYB8nJYseOTk5rx+98P6qPikb6z0a5vxLqiSyPqFkuyGNSD5kVyHyAAAQmPbB7v8DaDcP8AEufw+5V9B8K3ct9bhTuAecK0UZ9CmXb65rLm12Kse5vFbS3CGaOF5wpCllBYKeDjvj1rnrnxV4ZsPD/9uRmKSwtJvsayQQcxuXCFVGARyeccV5V4T8B32nv4Nv20eeHUY9SuRfy5O5bdi4G7nG0g/qfU1Rg8FXUPgXxDott4WvotYOoKfPEWEntxcKVCPnnC5P4VLk+w7H0TbWlivk/Z7e2H2cssexF/dE/eAx0z3xTbPT9Kjdrm0s7FG3mQyxRIDvPVsgdfU14tqvgfWbS2+Jem+FbGW0srz7A9hGshVZgFzcKhJ4J5B556VkQeEbp9A8QwW2n+JrS1vVtzLbw6VHCodG6rD5pEnH3gCAfek5PsFj3m4m06wbSxBpzTK8xhgeztfMWAtncxKj5F65bp61bey02a3fT3tbN4D8z2xjUr1zkr06+1eFeHPDfiBrbw4ZPDyWcVt4kiui0NqLZnhEeDLJEGITnA4xn07mX4eeHNX074k21wuiXUtqZria5vdUsVintyysBtnVz52S2OnQ9B1C5n2HY93srO1sLdYLG3htoF5EcKBFH4DirANMpc1oIzfEeqjStNeUYM7/LEp7n1/DrXljFpZWdyWdiSWPJJ9a2vGGoNfavInIigJiUZ7g8n8/6VlWybmFejQhyRv1ZzTlzMu6fb7iOK6WztgFHFU9JgAwSK6CCMAVlVmVFDUhVRnFNeRUouptgIBrLkny1ZqLZTZbmufes+5myDg1BcSnPBqOH5jzWijYlshkZiabk45q1MqqeKrM2TgVomIruCW4FPjPGGq3BED1qG5UK3FO99AsZ93EDnFY8yFWyK6KRQY6zLiLOeK1hIiSO/8G63/amn+XO2buAYfPVx2b/H/wCvXQE15Bo19JpWpxXMedoOHUfxKeor1eOZZYkkjIZHAZSO4NcVelySutmbU5XWpIzVGzUjNUTNWKRYrNUbNSM1RM1UkAO1QOaV2qF2qkiRHaq0jU92qtI1aJCZFK1U5mqaZ6pSNk1rFEMack4HJr2vwbpH9j6HDC4AuJP3kpx/Ee34DArzz4eaMdT1kXEq5trQh2z3b+Ef1/D3r1+uDG1dqaNqUeoUUUVwGwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeJ+JrX7H4hv4QMKJSyj2PI/nXtleafE+z8rVLa7VcLNHtJ9WU/4EflXXg5WnbuZ1Vpc5WA1dQ8Vnwnmr0Zr0JGCLCmpVNQKakU1DKPHvDzf8IH8bL/SpP3ekeIgJrY9FEpJIHt8xdce617aDXnHxl8KS+JfDAuNODDWNNb7Tasn32x95AfU4BHuorU+FXjCPxj4Vgu2ZRqEGIbyMcbZAPvY9G6j8R2rCPuycfuLequdspplraW1tLNJb28MUk7b5WjQKZG9WI6n3NKpqRTVsROhqVTVdTUqtUsZMpqQHioAacDUgTZzS5qIGlzmkMlBqC/uBa2U85P8Aq0LfkKfmsbxhN5egTjOC5VR+YP8ASqjG8khN2VzztiXcsxyxOST61dsk+YGqKda1bAZYV6UtjmR0VgAkW5iAAMkmrf2uPyy0Tq69MqciuDtIX8UazM080g0i0basaMQJW98fn9MVoX+jxabK13psxtVAzIhbKEfjUvDxUuScrSO72MY+7J2Zc1jXLW0kWOeYCR/uoOWb8KpWusWtzL5aSFZc42OCpqCDRLm21KXU9QUO03ELAcBcdv8AP86nvbS3ugPNQbx0cdRV8lKPuvXzRMo04S5JX9SyxyazrvW7WzuVt/3k1yf+WcSFj+NX76wvofDkl5p6/amTjg5ZPcjvis/Q9MFhAXm+e7l+aRzyfpRGEFFyk79EheyjBOU3ft5k9rqkN4zoA8cqfejkGGFQTatZW9wYpZh5g5KqCxH1xUd+LU6jaJIxjuJnCI69R9fbt+NW7Xw//YcskdwN1w53NI3VgelW40kuZ316f8Ep06aj7R3s+n/B7Fq3uo5YhJDIroehFNn+c5qhHpxjvt+njAf70Q6H6VJqt7FpsJa4JDdFT+Jj6Vm6acl7PW/3mcqV2vZ6pknPSopo+KzLeTWrgPcFYIY8ZSFlO4/Wr9veJc2hlceWy8OGP3TVSpSjruTOi4q+/oULlME123gi+M+ltbufntzgf7p5H9a4o3VvclhBNG5B5CtmtXwfP5GshCfllQp+PUfy/WorQbg0zJJwlqegM1Rs1NZqjZq4EjYczVC7UjNULtVpCFdqhZqHaoHeqSFcHaq0rU92qrM9aJEshlaoYo3nnSKFS8kjBVUdST0FDtk133wy0HfIdXul+Rcrbg9z0Lfh0H40VKipQcmEVzOx2XhjSE0XR4bUYMn35WH8Tnr/AIfhWtRRXiSk5O7OpK2gUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzPxCsftfh2SRRl7ZhKPp0P6HP4V01MljSaJ45FDI4KsD3B61UJcklITV1Y8HiPNXYjxUepWb6dqVxaSctE5XPqOx/LBoiNe09VdHKi4pp6moVPFSKagonU14x410q/8Ah14tPjTw3C0uk3LY1SzXoMnlsdgTyD2b2OK9jBp0iJNE8cqK8bqVZGGQwPUEdxWc4cyGnYreGtd0/wAR6RBqWkzia2lHHqh7qw7Eela6mvDNa8L678NtXn1/wIrXeiyHdeaUSTtHcqO4HYjlfcZr0PwH4+0XxlaBtOn8u8UZls5SBInrgfxD3H6dKiM+ktyrdUdopqQGq6tTwadhFgNTw1Vw1PDUrATA07NQhqdupWGSg1zvjtsaPH7zKP8Ax1q3gawPGy79FB/uyq36Ef1q6XxomWzOFi5at610ubUNJuxY3EK3ewhEkbbn6fhWDBw1WfJkur+yKOyRwv5jMpwfpXpLfewsO1ze9sb3h7T20jSYbaQbZvvSc/xHr+XT8KwvFt419cx6PaHMshDSnsi9ef5//rrevYGmG+K6kiJHOOc1mWGl2ummRoAzTSHLyyNuZvxqYVIqbrN3f6nR7SMZOpe7/U0oL5rfSl09gZLaNQqA9RisG/1aOAYSC5mmP3USM9fc1rHbQsq5xURlFbq5iqifxq5U8MpqVrNPeXUzI06hfIB+VR2z70mp6k9uHP2OeSQH5UjXIb8avtOAOKYJsmqdTmlzSX6FOtzfEtDH0TTLiWdtR1JdtzJ9yM/8s1/xrd1nUdsMQvWO1BgSYJ/A0JL3ps8yOhVgGB6g0pVHOd5oXtuaV5bHPjxHGsqrpKvdXWcptUgA+prZ1WG31S9ttTuoVS/8pVkiByoYdxUcPlRE+TGiA9dqgVHdqJ8fMyMOjKeRWnPFO0Vbz6lxrQiuWKsn16j7qeK1gMs7hEHc1UtdNi8Q6Fc3iiS3EMoLJnHmp6/nn8qqpokTTia7uLi7I+6srZUfhWpHdPapIIwSjLtZR3FVGSgrU373cdOcKekHq+vYyriyg8gRxosYU5UqMYNS6WzW+q2ZcgkSLkj3OKqyapaM7RmXbIDgqwINFu2byAg/xrj86cufl5ZHPUc0uWaPTWaomams9RO9eYkUOd6hZ6a71Cz1aRNxzvULNTWaonerSEEj1VkbNOkfNFrby3l1Hb26F5pGCqo7mqWgjQ8MaLJrmqpAuRAvzTOP4V/xPQV7ZbQx21vHBAgSKNQqqOwFZfhfRYtD0xIEw0zfNNJ/eb/Adq2K8nE1vay02R0whyoKKKK5ywooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDz74m6Ztkg1OIcH91Lgd+x/p+Ario2r2zU7KLUbCe0n/wBXKu3I6g9j+BrxS7t5bG9mtrgYliYqw/rXp4SpzR5X0MKis7lhGqUGqkb1YU1u0QTA1IDUIOacDSGTqa898bfCzTNeuzqmjzPouuKd63NtwrN6soxz/tDB9c13wanq1RKCkrMadjxyHxt438BEQeONIbVdMU7RqVpgkD1JHB+jBSfWvQfC3xH8L+JAi2GqwpcN/wAu9wfKkz6AH73/AAEmulyCCDgg1xHiX4V+EvEBeSXThZ3LdZrI+Uc+u37pP1FZcs47O/qVdM9CDU4NXiS/Dbxj4eJPg7xpN5K/ctr0HYo9MfMp/wC+RT18TfFfRABqnhm01aJePNtSN7fgjH/0EUudr4kFux7Xu4pwevFR8bvsPHiHwlrOnEfe43Y/77CVp2Xxz8G3GPOnvrX/AK62xOP++S1HtIdwsz1kNWd4iQz6LdIOoXd+RB/pXIW3xa8ETkeXr8Iz/wA9IpE/9CUVdX4ieD7iEj/hItN2sCp3TBT+tVGcU07iaZzsMkbSuiOrPGQHUHlcjIzWlbttIrxb4ma8mleJLHV/DOrWc84VrecW8yyK6qcruAPIOTz7DFdV4L+JGl62I4L1lsNQPHlyN8jn/Zb+h5+tdX1iDk4Pcy5Glc9RSUlMVC6sx4qrJcGK3kcDJVSwB9hXnmnfEDW4/Dtj4h1Ox09tHuJPLlFu7iWEbym7ByCMjoKJTUHqNK56JJuU4JpgJrzx/iHPHr2tWV/awxQQNPFZzjO2SWNd2x+epBHp6d6s6542u9P8IaJqNpZwz6nqMXneQc7Qixl5COc8DFHt4WfkHIzvATnmplxVHTtSt9T0a01KDiGeFZuf4QRnB+nSuf03x1Y6hb3Fza2GpyWcMbyfaBCpRwmc4+bIPBwCBmqc46CszsGyF4qBiScVhP450dYVZPtEqnTzqZMaA7IenPPDZ4xWZN4+s5LTU3tLDUVurWwN/FHcwbBNH0DDnO3JGT6ZxnFT7WC6j5WdtHFxk9ahkB3Vwk3ju8/s/wANXkenXKLfzCOeEwFnkHlhsxDPIJPBrXj8daTJpEF+sN8ZJ7hrVLPyh55lX7ykZwMDkknFCrRvuHKzp0GF5qOQcGuWl+IOkfYrWaKK9knuJ5LdbRY1EyyIAXVssFGAy9+4pJvFcUWqRi6M1pa/2fJeyQT25EihXwSSG9umDnrmmqse4uVmzdBSclVLDocVFpq+Zqdsv/TRT+tZGkeIoddVpLezvYIiodJJ0UK4PoVY/kcGuh8OR79SDnpGpb8en9a6FJOF0Q73szsmeoneo2eo2auRI1uPZqiZqazVC71SQhXeoHekdqjzmrSEOGWYBQSScADvXq/gTw1/ZVuLy8T/AE6VeFP/ACyX0+vr+VZ/gHwr5Ij1PUo/3p+aGJh93/aPv6en8u+rz8ViL+5E2pwtqwooorgNgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4f4j6IZoBqlsv7yIbZgO69m/D+X0ruKR1DqVcAqRgg9xV06jpyUkKS5lY8Fiercb1oeMtBbRNQ3wqTYzHMZ/unup/z0rGievYTU1zROXZ2ZeBp4NV0apQaQyUGnA1EDSg0hk4anBqgDU4NSsBOGpQ1QhqXdSsBNurPu9E0i8z9s0uwuM9fNt0bP5irYNKDQ0hnPXHgHwjcZ3+HNKGeuy2VP8A0ECqUnwu8FSNubQLYH/Zd1H5Bq7DNLmo9nHsO7Plj4v+F9JsfGFvoXgzS3E6QiS4VJHkwzcgHcxxgYOf9oVN4Y+Er3BWTXrzyV6mC3wW/FjwPwB+tfRF1oNl9lvfsdtHFc3MhneTGWkk9yeT6AdAOBXIxFopSrAgg4IParo4WnK8pb9iJ1JLRE+k6Pa6ZpP9n2RmEAUqPMlaQjI7bjx9BgVzGl/Dpo9PsdLv9ZnutHtZPNW0WBYw53FsM3JIyTxXaQyArU8chFbypRfQlSZy9/8AD6yvtL1yzup2caldtepJsGbdyMDHPP6ZBIqunw8sZZdO/tS5mu7ewsRZxQqWh5zy5KsDkjjHSu4WUsKNu4VHso9UPmZzfhXQf+Ee0MaXHePPEjuYnZMFFY529TnBJ5rI8N/D8aVrw1We9imkWNo/Lt7RbdX3dS4UkN+AHNdqyFDk1JHJniqdOOnkF2eeeCPAEtv4c8QWuoq9lNqZe3iVmWVoLfnYODjPzE4B9K3pvBED3LSyXr7W0P8AsQqEA+XOfMznr7V1YcAdahlct0qI0YpWG5M5LT/B08VvoEV9q/2o6PMHgZbYR5jCBFQ/MemM7veq158OrW408xfbQbhdQmv4pJbZZUBkxlGjbhl4Hp0rsSSvNBkOKfsYvoLmZw154Ckm0qOyN9poAmeZlXSIliO5UUYQEFSNn3t2Tu54AwW3gaPTorbyNSlLW+nSWCtLEr53uWLEHjAzjaRjHFdqTnkmql3LxjNVGhC+wnNnEeG/Ci6BfXV0bpJJJ0CFIIBBGADnO0E8+9ej+H4DDZmRvvSnP4dqxLO3N3dKn8I5Y+grqchVCjgAYA9K0lFQjyRJTbd2PLUxnqNnqNnrNIoc71CzUjNmkVWdgqglicAAZJqrCE616J4G8IEeXqOrR+jQwMPyZh/IVP4L8Gi28u+1ZA0/DRwHonu3v7dv5d5XBicVf3IG9On1YUUUV55sFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAVdTsINSspLW7TdE4/EHsR7145r2j3Gh37QTgtGcmOQDhx/j7V7bVHWNMttWsmtrtNynlWHVD6g10UK7pOz2InDmPFI5KnV6n8Q6HdaFdeXON8LH93Mo+Vh/Q+1ZqyV6itJXRz7aMvhqcGqmslSq+aVgLGaduqAPTg1KwyYNTg1QBqcGosFyYNTg1QBqUNSsMsBqN1Q7qXdRYCbdXNeJdN+Y3kC8H/WAfzrf3UhIIIIyKqEnF3QmrnDQzFeKvwShutT6tpBjYzWgynUoOo+ntWTG5U106SV0Zarc3EKgdaer4asuGXPU1Y83HQ1DiVcvykMtQLHzwaiE24YzTgxHelawXJDx3pQRVdpRnk03zwop2C5PLzUMjACoHuaryT571SiJsklmwODVJi80gRASzHAFOAeZwkYLE1rWNotqu5sNKep9PYVTaiTuT2FutpBtHLnlj6mpmeomemFiay31ZexIz1GWzTetdB4a8LXutuHUeTaZ+aZxwf90dzUylGCvIaTexkWFncahdJb2kTSzN0Vf5+wr1bwl4Rg0dVuLrbPfkfe/hj9l9/etfQ9FstFtvKs48Mcb5G5Zz7n+nStOvMr4p1PdjojeFO2rCiiiuQ1CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAgvbSC+tnt7uJZYX6q1eYeJ/Blzpxe408Nc2nUgcun1Hce4r1aitqVaVJ6Eygpbnz6GqRZK9Z1/whp+qlpYx9lujz5kY4Y+47/pXnuteGNT0nc80PmwD/ltF8y/j3H416VPEQqeTOeUHEzVkqRXqluIpwetrE3LoenBqqLJTxJSsO5aDUu6qwenB6VgLAajdUG+l3UrATbqN9Q76TfRYCfdWffadBc5Yfu5P7y9/qKsl6aXpq62B6nPz6fc25yF3r6pz+lVxIQcHNdOXqGVY5P8AWIrfUVqqncjl7GEspFOM59a02s7Y9Ex9CahbT4T0Zx+IquZBZmc8tQtKTWodOh7s5/EU5bK3X+DP1NPnQrMxwWc4UEk9hVuCwkfmU7F/WtJQqDCKFHsKXNJzfQOUZDHHAu2Ncep7mnEmkqzY2NzfziGzgkmkPZBnH19KhvqyvQrc1Z0/T7rUbgQWUDzSHso6fX0rudD+Hzttl1iYKOvkxHJ/Fv8AD8673T7C10+AQ2UCQxjso6/U9646uMjHSGrNY0m9zj/DngOC2KT6uVuJRyIV+4Pr6/y+tdwiqihUUKoGAAMAClorzqlSVR3kzeMVHYKKKKgYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGDq/hTStT3NJb+TM3/AC0h+U/iOh/KuP1T4f3sJZtPnjuEHIV/kf8AwP5ivTqK2hiKkNmQ4JnhF/pd/pxxe2s0I7Fl4P49Kphq+gyAQQRkGse+8NaPesWnsIt56sgKH9MV1Rxy+0jN0ex4sHpwevSbv4eWEmTa3VxCT0DYcD+R/Wsa4+HmoJn7PdW0o7bsqT+hreOJpS6kOnJHIeZS+ZW1ceD9cgPNkXHrG6t/XNUJ9F1SDPm6fdKPXyiR+daqcHsxWaKu+gvTJIpIziSN0P8AtDFMqxEpeml6jNNNFgHl6aXphp0cUkhxGjufRQTTEG6jdV6DQ9VuP9Vp12w9fKYD860bbwXrs5/48/KX1kdR+mc1DqQW7Gk30OfLUma7q0+HF4xH2u+gjXv5alz+uK3rHwBpNuwa4ae6Po7bV/Tn9ayli6UetylTkzycAswCgkngAVv6X4Q1jUCCtqYIz/HP8g/Lr+leuafpdjpy4srWGH1KLyfqepq5XNPHP7KNFR7nE6R8P7KDa+ozPdOOqL8if4n9K6+ztLeyhEVpDHDGP4UXFT0VyTqzn8TNFFLYKKKKzKCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAx9c8UaBoEsUWu65pemSSqWjS8u44S4HGQGIyKzf+Fj+B/8AocvDf/g0g/8AiqP+ap/9wb/2vXVUAcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFV1VFAHK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVdVRQByv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVXVUUAcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFV1VFAHK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVdVRQByv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVXUeYnm+VvXzdu7ZnnHTOPSnUAcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFV1VFAHK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVdVRQByv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVXVUUAcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFV1VFAHK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVdVRQByv8AwsfwP/0OXhv/AMGkH/xVMf4heBH+/wCLvDDfXU4D/wCzV1tFAHGnx18PT18U+FD9dQt//iqB45+Ho6eKPCg/7iFv/wDFV2VFO7CxyKfEHwGn3PF3hhfpqUA/9mqT/hY/gf8A6HLw3/4NIP8A4quqopAcr/wsfwP/ANDl4b/8GkH/AMVR/wALH8D/APQ5eG//AAaQf/FV1VFAHK/8LH8D/wDQ5eG//BpB/wDFUf8ACx/A/wD0OXhv/wAGkH/xVdVRQByv/Cx/A/8A0OXhv/waQf8AxVH/AAsfwP8A9Dl4b/8ABpB/8VXVVRuNX022uvs1zqFnFccDypJ1V+enBOaAMP8A4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIqug/tKx8vf9sttnm+Ru81ceZ/czn73t1q1QByv/Cx/A/8A0OXhv/waQf8AxVH/AAsfwP8A9Dl4b/8ABpB/8VXVUUAcr/wsfwP/ANDl4b/8GkH/AMVR/wALH8D/APQ5eG//AAaQf/FV1VFAHK/8LH8D/wDQ5eG//BpB/wDFUf8ACx/A/wD0OXhv/wAGkH/xVdVRQByv/Cx/A/8A0OXhv/waQf8AxVH/AAsfwP8A9Dl4b/8ABpB/8VXVUUAcr/wsfwP/ANDl4b/8GkH/AMVR/wALH8D/APQ5eG//AAaQf/FV1HmIZTEHXzQoYpnkA9Dj04P5U6gDlf8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+Krp1kRpHRXUumNyg8rnpkdqfQByv/Cx/A/8A0OXhv/waQf8AxVH/AAsfwP8A9Dl4b/8ABpB/8VXS29zBcq7W00UyoxRjGwbaw6g47j0p8cqSbvLdX2sVbac4I7H3oA5f/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4quqooA5X/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4quqooA5X/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4quqooA5X/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4quqooA5X/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4quqooA5X/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4quqooA5X/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4quqooAw9G8XeG9cvDaaL4h0fUboKXMNpexTPtGMnarE45HPvW5XK61/yUfwv/wBeV/8Azt66qgDlf+ap/wDcG/8Aa9Z3xg0qfWtD0qxtxNmbVbdXeJSxiUkgvx0AznNaP/NU/wDuDf8AteuqqKkFUi4vqdODxMsJXjXjvHU8g8L+GNQu/HmrDxnard/b9MRrn5SYN4mG1FbpwEQ49c1k6T4YtbT4XmUaJdDxHPdMlo0MTLMkolPlPnHyqo5JOBj6ivdaK5/qkfz/ABPX/wBYa7e1leDsm0vdTVrdnpfySOF+FVrNaWmqJq9vOniE3TG/uJVOLg5Ox42wAU24AA6c8Cu6ooropw5IqJ5GLxDxVaVZq1+nb08uy6LQKKKKs5gooooA8J13wjq9x4c8YPCJBpl3e315PZbG8yaeOZ/JZBjlWBjYn/pgmAdxrauZfFF/rGs2dzcXUDyPfwLbLBKyyW/lyC3MbeX5an/VNv3n5iyHkgD1yigDxO4t9UTRm1LSbnW/tth4VkkgZoWV3uoyWWJlKAthhjZjnvmuogu9bl8XrA82qLM2ozxTweQRapYeU5jkV9m3du8s53FtxZTwCB6JRQB4/wCBYfEA0bwrYW19rMRs9D33ME8IQNeRCBRbuzx5CZ3jggkZ+am6RqfikaFdTNfag+qmCBo7R7OVm+2b8FGLxoqo2drBThVG8FQMn2KigDxrxFrXiT/hGrfy31eHWRa3dxJKtvJtS6VhiBYo0YMAfulm2lfmO/JIlu5NesrjxZNZNqi3V1qVpOyCFyi2jW1qskkeEJyGWRMLlgFJAyM17BRQBzvgKW9l0HOoXT3TrNII5HikQ+XnKgl1UvgHG7HOO5yT0VFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4fdfD6/1348eItXuYbeDTY47F4ZrzSortLgqvzrG8g+QjGCV55HoK9wooA+XP+EI8Y/YPM2332H/AITn7Z/Zf2EZ8vzc/afM+9sx+Fe92fit5PHEnhq70q4tpmtpLu3n81JFkiRwhZgpymSw25689CMV1Fczo/g2w0nxRqWvW91qD3uoMWuBNPvRh/CoBGQq5wq5wKAOmooooAKKKKACiiigArx3w7p9stvpyaTpU1v4oTW5ZZ7pLJoiLf7Y7S+bKVAZWhyApJyShA4yPYqKAPEYLXW4bO81O1W/tL610RHhjt4BGskq3VwwQoF54Iyo6hsnsa3b7VPFpvfEum6c0sk+iQXNxFMEVzdNMu61jC9ygMgI7mOPP3ufUaht7S3t5biSCFI5LiTzZmUYMj7Qu4+p2qo+gFAHk1rHqP8AampHQr3XI4L3UbCI3s1ufOMXlsJCPNj6A9yuB+lXmn18as9p9r1l7sXVxBMjQkQiyEEnlSq4QLvLiI5ByWZlxgYHqNFAHiujxa3oegaXZ2b6xFOmkWMmnQR22Y5bptwmjmKx4AAEYIfG1SWByCRLrlzrNhHrFvYRalaSS39/cxXUMcrKXAj8tdkaEuWySNxC/Kc7ug9looA8Znn8RW0+uXdu2qLe3r2E0kYgfy1tzDAs0ibUJ3BgykLlgNxAyM16J4ClvZdBzqF0906zSCOR4pEPl5yoJdVL4Bxuxzjuck9FRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByutf8lH8L/wDXlf8A87euqrlda/5KP4X/AOvK/wD529dVQByv/NU/+4N/7XrI+MniLV/D9l4Wj0C5htbnVtftdKkmlhEoSOUPkhSRkggH8K1/+ap/9wb/ANr1o+KfDGj+KrK3tNfsxdwW863MSmR0KSqCAwKkHIDH86APHNc+KfiXRbHUbO4W3vNR0jxHaaXNc2ltxeQSqWwsZY4lwMEA4yRVXX/i74kXQ/iBf2EEli+k31hb2UF7ZgTRLNgOHTPJPUc9xXsEXgPwxFpNtpkWj26WVtdrfxxqWH+kKciVmzlm92JzS6h4F8N6h/av2zSopf7Vminvcu4854seWxweMYHTFAHj3if4i+LPDul+HW1LU7u1+33d2tzcXXh7ypooYoUYEW4kbcM7iW3DgnoFzXrXwo1vVPEfw70LWNejto9RvYPOkFscoQWOwjk4JXaSM8Ekdq2NV8P6Xq2oadfalZx3F1p7O1q7k/uy67W4zg5HHOaTw14f0vwxpS6boVqLSwR2dIVdmVCxydu4nAzzgccmgDVooooAKKKKAPN7XW9Zg0ptdl1R7mP+3p9ObT5IYghiGoPaoIyqhw4UK3zFskEYGcjOl8daxa/bdUjijubGx0y9vbi3mmCMVgupEJQrHyxSPABwOmSeTXf2nhbRbTUPt0GnxC586S4VmJYJJIWLuoJIVmLNkgD7x9ae3hnRmtrm3bToDDcwS20qYOHikZmkU+zMzE/WgDn9Q8fR2Go3thPp7G8spLh7iJZclbSKHzRcDjkNujTb/eYjPymso+MddsdU1Wa/sbaT/RNG+y2EN0diveXk8BYyGMHP3M8EHYMYycdrDoNsviLUNZmCzXN3bRWeGQYSFC7bPfLSMTn2HaobLwjoNkjpa6ZBGrm3LYzz5Ehkh7/wMcr6dOgAoAxI/GOpLeMt1pVnHbw38OlXBjvGdluJEjYFAYxujBlVcnacZOOADznhnxtr8Phpr+/tYL25XTjrd1vvNqrAd2EiAhGG+R/lOQNq5Y7iR6Q+g6VJrA1V7CA6gCGExXncF2hvTcF+UN1A4ziq8/hTQri2s7ebS7V4bRPKhRlyFTj5D6qcDKnIOBxxQByD+Nr6zk1lYFjvrgX8v2a2cSbxAlvA5wI42wA0oyzYALgckgUyP4h36R6vqb6fFJpCQae9oglczeZdCMIrKsbZG+QZIJIA4VicV2d94W0S+keS702CR3laZmIILMyqrZI6ghEBHQ7RkcUf8Itoe1lOmWxRrVbJkK5VoVGFRl6HA4BPIoAb4R1i71mxuZb7T5bKSGcwjfHJGsy7VYSKJERwPmK8r1VsZGCeNt/iRqdxpWh3C+H41udXsDqdvBFNPdYgCxHDeVASrFpQBwVAGSQSFr0HSdLstJt3g0+ERRu/mN8xYs2AMkkkk4AHPYAVTn8MaNPp9hYyafF9msIxFaquVMCBQu1WByBtABGeQOaAOSu/F+rahfaf9hsxYWKata2Nz58hE5Z4VlZCm3AA8xVPzZyD2xmdviMF0nTr06Yd17pv29IxcdHM0USxk7ehaYZfsAeDXS/8Irof2+G8GmWy3MJjaN1XG1kXajYHGQuFB64AHSo7fwf4etzP5WkWgWeJ7eRWTcrROwZkweNpIzt6UAZE+u+ILTxfpGn39tpMVnNY3l1cut2+FWKS2AcEx9QJm+U8HruGMHKtviJqM8V4sehNPNHDbXMbQLcFDDK7KX2mESMF2ZyqHdnoOtdhH4W0WP7Pt0+ItbszxuxZmywUNlicsCFXIOQdq+gqCDwX4et43SDS4Yw6ohZSwYKmdgDZyAuTjBGAcdKAOZh+JE13eQwaZpR1EIkLXLWi3Eg/eOVIQiHA2hSSJCnIK8YJr0esM+EtBP2bGl2y/Z0ESbF2/ICWCtj7wyScNnkk9Sa3KACiiigAooooAKKKKACiiigAr528MeMPHepXHi/UJtS1V9M0ubVIoWWzsvsqeTG/lKzY83cDtPQg4Gcgmvoms210LSrSxvbK10+2itL15JLmFIwFmaT75Ydy3f1oA8W+H3xH8U654q+HNhqcN3aWupaZPPdyzxwbdQdYgyyJsyUAPOPl69K9x0/UrHUftH9n3ttd/Zpmt5/IlWTypVxujbB+VhkZB5GaxNW8HabdaVFbaZFFpV3a2r2lhe20K+ZZI67W8rP3eOKx/hJ4Iu/A1rr1pcXVtNa3eom6tUgj2bE8qNPmGOGOzkcjgHJJNAHe0UUUAFFFFABRRRQAV5drWq6h4c1jxDcf2lqV/DYR2H2e1ldNhkuZXiJchQSoO1uo4U816jVaWws5TcmW0t3N1GIpy0YPmoM4VuPmA3NwfU+tAHBW3iDxTceINBs7iK3sRJdXMU4lhx9qjSKN1dVDsYz8zjG48rnocVBH431+fw7pt7HbaeuoajbSXtvZwxvOTBGF3szM8SpgumSScbgAGrt4fDWhQW0VtBoumR28M32mOJLSMIkuMeYABgNj+LrT7rw/o13aWtrdaRp89ra8wQyWyMkPGPkUjC8elAHn9h4x1aTUJtVj8k6XcPo6taSlmeP7YY4/kYEBdplDHIO7GOOtWpfiFegT28dhb/b7FktdQDMwSC4lukt4P+AMC8pPUIF/vcd2mj6YkXlpp1mseYjtECgZiIMXGP4Cqlf7uBjGKr2vh+wh/tfzYhd/2rMZrsXKq4k+RUCEYxtCIqgH05ySSQDh9O8Q+IrfUbrTkewv9Quddms1kmMkUMSJZpL8qguQMg/LnqTzVfxL451qLwpq1/araQ+fpuqXFkY1Yy2r2oIzJk4YnHPA2thTuzmvRrLRNKsRGLLTLG2EUhlTybdE2OV2FhgcEr8ueuOKYfD+jGW+kOkaf5l+jR3bfZkzcI33lkOPnB7g5zQBx1jruqaPJLZSC3ntdO1K10ucSSTSXE73JiIlR3Ynavnrwc5CPgqFArFXx3qml+H3mgxqM1kbm6vYpIizCD7ZPGh80yKEGImAwHPy/dxXqEukabNqceozafZyahENsd00CmVBzwHxkdT37mq114Y0G78v7Vomlz+VvCebaRts3sWbGRxkkk+pOaAOHbxhr9pPeQMLe7e512fTbLbBuMCJG0nzLvUOdqYA3KeScnGK7zw3e3moaJa3Op2f2K9YESwbg21gxXsTwcZxnjODzRdeH9Gu2u2utJ0+ZrsqbgyWyMZiv3d+R82MDGelXLGztrC0jtbG3htraMYSKFAiIPQKOBQBPRRRQAUUUUAFFFFABRRRQAUUUUAcrrX/ACUfwv8A9eV//O3rqq5XWv8Ako/hf/ryv/529dVQByv/ADVP/uDf+16rfEbxjceGZdE07SrKG81nWbhre1S4m8qGMKu55JGAJ2qOcAZNWf8Amqf/AHBv/a9WPGnhDT/FttZpfSXVtdWUwuLS8s5BHNbyYxlSQRyDgggg+lAHI3fxLurLwJcaukOh61qjajHplhBouo/aIbyaTZtXft+RsMxKnsuc4IrO1X4yiLwb4M1uwtNOT/hIJGgkOoXpt4LORQd4eTYeAysucelalp8FvDMa20d7PqWoQx6hcapLDdSpsuLmZFRncIi/dC5ULtAJPWltvgt4Xt47a2DX76db6jNqUVjI6PArSpseLBTPlY/hzn3oA5/V/jZc2XgTwp4gOiW1q+uXEkBS+u2jihCZxJvCElGAyDtHB79asah8TvFUB8Lmz0HQLyHxDJ5NnNDqshQvgk5Pk/d46/pXSaV8K9I0218OW0eo6xNB4fvHvLBJ5kbZuBHlE7MlBk4Gcj1xgV0HiTwpY+INW0HUL2W5SbRbo3dusTKFZyu3D5ByMehFAG1ZtO9nA13GkdyY1MqRtuVXxyAcDIBzzgVNRRQAUUUUAcXpniy51B9NuvM0W1sdRlxaW11dlLmeLdgSLxgsRgiMA9QCwJ4TRPHtpPohutTRobuOFJmiiQkSCSd4YxHz8xLptx6sPUVcTwVaxtbxR6jqK6bb3a3kWnhojCkiyeYACU8wKG5Ch8DoOOKp/wDCCWyax4YkjO6y0VbhwZHJlkd2VkUgAKUDAvzyGRMDqaALU/jOA2c11a2d0bNJkhS8lQCCYmdYWCkEtwzHBKgHGQSOaks/Glhd3720VrfY3XcUUrRqEmktpCkqJ82cgqcEgA4ODkEBg8E2ospbAalqX9mNMJ47PdF5cLCdZ/lOzfjcuMMxwpIGOMR3vgHSb3TjZXEt4YC9/IQJFBJvHd5Rnb0BkO32Azu5yAR2XxD0m8hY28N1JdLeLY/ZYjFK/mtG0ijcjmPkKed3BHOKiufiLp66Re3kdrdwiHT7u+ia6j2JIbYYmT5SWBRiAeMHnaWxT9M8LaQutu39tXN9qlrcQ3cqPJAHjKRPHGGSNFCrtc8YGcD3zJffD/SrzSX0+W4vhC1rf2hZXTdsvG3Sn7uMg/d4475oATUvGqQ+INLsbW2kayl1CWyur+QKIUMdrPMyqd24sDEATt2/eGcji54V8Z6V4muZYNPaRZUiW4VZNuZImJCuNrHHI+621hxkDIqKTwRYS6nHcvdXrWyXkt+LEtH5HmywyRSH7m/DCZzjdjJ4wOKsaBoNr4Wtmb+07l7GGERot35KrCi9PnVFZsAAZdmPHXJJIBWn8aWf2yW2toLomC/i0+WaWB0i8xpFQqr4+Y/ODxx6kVn6J8Q7abSorjWrW4s5pIZZoise5LgJKIysWCWLbnjGGAJ3cZGSNxvCli0MkRludsmppqp+Zc+arq4Xp93Kjjr15rKg+Hempa/Z7m/1K7ijikhthM0Q+yh5FlLRlEX5t6IQW3Ebfc5ALZ8a2YKQf2fqR1JrlrP7B5aecJRF52Cd+zHlkNu3Y7ZzkU618caNc2BvIpJjCIrSY5iIIW5fZFx67hgjtT7HwhaW2oW9/LeXt3fxXTXj3ExjDTO0HkYYKiqAEwAFA5GecnOYnw406OC3t4NR1SG3jhtYZIleIicW8hkiLkxkggk52lcigCXxB41Fpo2uXml2FzOmnLMounQfZ3mi4dMht/DAqTgDIIByKLn4j+HrXUbq1uLh0S3aeMz/ACsrSQozyoFBL5UI/VQCVIBJ4qxdeCbWez1Sx/tLUo9M1Fpnks0aLy0eZi0jKShYEszNgsRljxUc3gLTZX1FDdXi6ffmd57FfK8stMG8xg+zzVJZ2bh8BjkDtQBHqXjuO0jhVdH1Fr1r2G0ls3CLLGsoYpJwSrA7TjDdcg4INVtY8fpZ6Nqs1nZS3mo2iXsiwRAEItuxUvIWK4G7AIBJPO3OCa0JPBVvNFK9xqmpTai88Nx/aDGETK0WfLAAjEe0bm4KH7x781XvPh7p9xFdrHqGp2z3i3UdzJE0W6WO4cu6HdGQAGJ2kAEZ60ASx+PdIGsW+lzOwuXeK3kkUrsSeRA6x4LbySGXkKVBIBIPFddXM23g+0tNYa/sr28t/MkjlmgURMkroqoGJaMuuVRQQjKDjOMk56agAooooAKKKKACiiigAriLT4gwTePda8NT6XeWg0uwN/Jdz4AlQPtyijJK9wxIJweK7euCX4fTN8QrzxRca7PMLu2NjNYtbRhGtskiPcOeCfvdTQBl+Bvi0niLVbC21PR/7ItdTsJNSsLl7tZBJEj7W8wbR5bY+bGWGO+a1/FfxAGn6tpGj+GNPTxDrGpiWSKKK8SKGOOMDe7y4YDrgAA55/Gh4P8AhJpnh/ULee61C61e3s7GTTrK1vY4zHBA77mU4Ubz2ye3GKv+JPhvp9/eaTf+Hrl/DWqaYZBb3GmwRBdsmN6vGylWBxnkcGgChd/FO20bxBYaR4tsrfQbm50yS/drrUI/LR1kKCINwGLY3Ag9O1UtJ+Lc2v2XhpPDvh83es61azXws5r0Qx28EblCzy7DklhgAL9cVrj4Z2s/iCx1jWNSudXurfTJNOY3sUb+ZvkLmQ4AAIJwABgDFUNN+Elvo+l+HU0TXL6w1fRLeW1h1GOKNzLDI5ZkkjYFSMnI9DzQBv8Agrx7pfiXQ472Z49MuhPJaTWd1MgeOeNtroDnDckcjsR06VyemfGQah4q1rR4dHtFGl3d5aO0mrwrPJ9nVmLJbkb2UheoBA55+U11vhn4e+HtC0i2sTYw6jJDLJcG7v4kmmeZ23PIWI4JIHTHQelV/D/w60zRovEwVhPc63f3d+1zJCvmQG4XDIjdcDn8zQBheF/jLpHiPVfBenafHBJd+IY7l5oorxJH08xR7wsigZy2CBnHQ9a9Try+x+F+m+F08KapYfaLm68JWt35cUECCXUDJEVwx4+b+7z1NL8HvFHiHXtb8W2nihJY5rKe3MVu1uIlthJCrmIHq2CfvNyRg8ZwAD0+uSm8ZCCz8Tzz6ZcwvokohEUkiZuGaNWQgqSFDF1AycjqQOldbXIv4Oe5bxIt/qbSwa1hmWOAI0DKiojK2TkqEU8jqM+1AGhoWvtdtqUGrQ29heafcrbyqlz5sbFokkVlcqpIIfGCoOVPbBOQnjuD+39Xsrh9ItbXS5HW4abUcXOxIVlaRYBGcqA397sa1tL8M20Md82rGLVLm+uRdTPPAu3esaxrtTkABUHryWPemy+FbS40zxHYXEszQa3LJJMVwrR74kjO0+oCAgnvQBFL440OC2825lvIH89bb7PJYz+eZGUugEQTedyqSMDkgjrxTW8daKLoW6HUJJWla3ULp8/zzKpcxD5OXChmI7BWJxg1HD4ODalBqV/qU11qEd1FctL5SoGEcckaIFHQfvXYnk5J6DAE8XhOCO/tboXMpa31abVgu0YLyQSwlPoBKTn1AoAfD400Gaxlu1viIYraK6fdDIGEcrMifLtySWRl2gEhhggGiy8SiXQNa1Se2ZU02e7jMceXZ1gdlyBjOSF6e9Yn/CBomr+Ftru9lpKzvLIzY88mRJIkZR1CyASA9jGBzuNdHYeH4LXSdT09pZJIb+e5mkPAI852ZgPpuIFAGfb+PNGksrW5lN5CJoI7iQPZyj7OjkqrSkr8ikhgGOAQpI4BNR2/xA0c211Ndrf2wh1CTTVU2M7maVWcAR7UO8ny2OFzjgHkjOc3w2tpLi1up7qC4vIrWKzeW50+GbdHET5ZUODscBiCRwe68DGrB4QWK8ST7fK1vFqj6rFCY1ysjrIHXd3UmUkemMc0AN1jxxp9jb6iqR3QvbeynvIYbq2kgE4iTcwUso/zkjIBqxpfjLSb54IXkntrqWSOEQ3FtJGd7xs6feUfKwR8McAlcdeKwpfhlaS3V5K1++Lhb1d32ePzT9pDBi8mNz7d2Fz0AA5xmrXinwbJeaXrA02eQahewWcEMm4J9meCQlJwe5Utvx32Y70AP8R/ELS9N0W8vNO83UJ4YZJRHFDIVwkjR7nYLhVLowDHg7SRkAmtG58aaJBeX1o01089nIsMyx2UzqJGKBYwwTaznzEwoJOCTjAJGZqnw+tbiyks9Nvp9PtZtMi0maNEWTdBEXMeC3QjzHye4b1wav3PhGGaHUAl3NFPc6kmqRTKoJhlRY1AweCuI8EHqGPTg0AZ2p/EGyh1HSre0jcwXMdzcXVxPDMgtY7d40lDgRkqwMn8W1QBkkblzdm8aWjvZpZRTtNLeQW0kVzDJbvGku7bJtdQSDtOPcEcEEVXPgCxmEovrqe5NzZ6haXZIVTN9saJpG4Hy4EIVR6dcnkvPgkXF2L3UdVubq/8y2Yz7FjJSDzCiYUcHM0hLercYGAAA1T4gaTYW147RX7T2rQb7ZrSVJSksojV1UrkjJ6Yz045GdIeLNJOoRWnmXCyO8cRd7WRUjldQ6ROxUBHKsp2tg/MoOCQDzFj8LrS0tZYl1FwxtoraOSO2jjIMUqypI+B87llBYn73PTNaUHgO1i8SNrXm2z3U0sdzcPJYQvI0qIqlo5CC0YYIMgE452kE5oA7OiiigAooooA5XWv+Sj+F/8Aryv/AOdvXVVyutf8lH8L/wDXlf8A87euqoA5X/mqf/cG/wDa9dVXK/8ANU/+4N/7XrqqACiiigAooooAKKKKACiiigCrqsDXOmXkCbt8sLoNpwclSOD2ry/wxaavFpfhuC1PiJLew0N5ZrRw0Bmu4/JCwM0icA/OBggEZwSK9aooA8b0iTxNM13bxya2tlNJpTBmt7uN4vMnlW6UPPlzhFjLMNoAOQFzky3r+I7Q24H9uXa215dQwWYF0jSxi5xE5uEVgcR4AE3yMDknqa9fooA8ks9NvdMlmku/+Egj0u61fUZLoWYnaXPmsYGVYwXEZGSSvBwmcrU9tH4um03VLvULnV49QtPD0LwW8SgJLeNDMH4C/NIG2fKpwGxx0r1SigDy26sdetLi9ktbnXpfs50ye3DSSOrvJNtuQR/EuxRlPupkkBc5qhqg8Q6to3jDSZTdXUejWs9ihj+dr+WXbLGSByWSExg+rSNxwK9hqK3toLYSC2hihEjtI4jULucnJY46k9zQB5RqN14kl8UXZsm1jTkka/t5ALS5uViRYpPInUsfJOWVGVI1z821mzkVWW48Syabaw+Tq9vpi3siz3H+nSySjyUMbBSFuUj3+YCORuA5KmvZaKAMzwx9q/4R3Tf7QuJLm7FuglnkgMDStgZYxnlSeuCBj0HStOiigAooooAKKKKACiiigAooooAKKKKACiiigArjNU+JGgaf4hm0b/iYXd1bMi3b2VjLPFaF/u+a6qQuc/h3rs68w0/wl4v8NeLvEFz4YudCm0bXL1b+b+0PNE9s5AEgQINrggcZK49+4B0EvxG8Nxaff3z3kgt7HVTos7eQ/wAt0CAUxjkZYfMOK6+vAdR+Bl5drrl4ZrP+2bzxS+r28v2y4ES2jSK+xowNnmcNztPb5vTpZrmbxX8Tr3w+/iGWfSrGGSWb+zLmWxktp94CQb4pAZTs3FwR8pA6E4oA6h/iNoA8WT+HI/7Rn1OCeO3mEFhNJHE8mCu+RVKqMEHJOBz6U6z+I3hu807Rr6C8ka21a+Om2jeQ43zgsCpGOBlTyeKwPD/wvht/iT4j8UawRMbm5t59O8m9nVo/LjCt5qAqrEkDrurj/DnwMvNJi8JXRmszrGm62b+9lF5cNFJb72YLGhG0Pgr/AAr0PPqAe/UV5Z4C8f6t4i+JeqaVf2N1p+nDT1u7S1udPmgmjHnPHmRnUDLBQwx8vO0ElWr1OgAooooAK5YePvDx083ovH8kal/ZJHkvu+07tu3bjOO+emOeldTXmf8AwrT/AIlvmeZH/a/2jf8A61vI2fbvtG7G3/WbPkzj26c0Adzfa/pNiuoG61G1RtPgNzdRiQNJDGBksyDLYx7c1Ui8X6HJqUVmuoW4aaCOeGRpVCSh3dFVCTy2Y24rjD8Or1zqdtO0E0U51AwXj3spZDdCTrb7NuR5mCd/O0HAPAtaj4K1PUrHUvNi0u2urnRI9NjWKVnSOVZZG3bvLB2kMh4Gcg8cAkA7bVdZstM0m51G4mRre3SVzsYEt5aszKvPLAI3HsfSnwatYTXUNqt5bi8liE62xlUSlD/FsznHvXn194OvNU1/xbDCTHpv2acWCTxlI1vbqHbM4OOVAAO4A/NPMOowLOmeB76z8SC7n8m7tjepfLKb+WNoXESxkeUEKvgAgEsvykAjjkA7eDWdLuI7l4NSspUtVDzsk6sIlIyC5B+UEc89qrnxLov2rTrcanaNJqKu1oUkDLOFKhtrDg8soxnntnBrz8fDXUh4c0WwjuLKKaw0exs5BG7qs09vMkpG4LkIxVsNjILZ2nodPT/Bl/a6npt+ltZJLHNdG4R7+WdgJhFmVJGiBLjys7dqgk/eHJIB1l74n0SytLq5uNVsxDaSpBcMkofyZHcIquFyVO4gc/j0NWZtZ0uCEyzalZRxBPMLvOoAXAO7OemCDn0IrzSx+G2owaCLCRLGS5trWC2guXv5pFmEM8coDRGPEQby+xfaWOM852rrwhqTSa7qFnHplrqt/NaPGyMcpFHHEskIm8vcgOxwrBTjIOAegB0d34t0S0l08TajbC3vopZYbvzk8grGUB+fOOrgD8a1/tdttdvtEO1HWNjvGFZsYU+53Lge49a870LwHf2t3FNefYiitqL+WbmW5KG58rb88i7mI2Pknnn3OINN8G3sXiPRbKWR1sLbTLWfUWjQ+XLewIYoWRyBuPVz3HkQ5AzyAdvb+KNIuNbuNLt72CW5t4vOmZJFZIvn27WIPDZ7Gri6vprXFvbrqFmZ7kFoYxOu6UDqVGcnGD0rzf8A4V9rE+i/2ddpo6xxaPDpKFJXYT+XKrF3UxjaGAPy5bk9T1rZ1LwZdNqt0mnRabFpl3dWV00mSktr9ndW2RIEKkHZwdy7S7HB6UAbWneM9FvjfuLuKC1tLk2hubiaNI5JQzIyr827IZCPmAz1XI5q1L4l0q3utQhvbuKzWxMQlmuZFjjzIu5QGJx0FcpbeDNS06S3u7SDSbu4jn1Yvb3LskTx3l0ZkbcI2O9UAQjGMO4zjk1rbwNrumQQQ2F9BcQxpZwyh7mS2kuUhtmiJMqIzRkuVbK8kAjIzQB3Uev6VJq66XHf27X7263SRBuXibdhlPQj5GPHYZ6VZ07UbLU7cz6beW13AGKGS3lWRdw6jIJGfavM7P4capFo76c81goudEfSZbhZHZ7c7pmVkyuZARKFILIcA8mut8EaDc6RJfz31vDDcXIiVmj1CW737AQOXRNuM4AAPHfgUAdTRRRQAUUUUAcrrX/JR/C//Xlf/wA7euqrlda/5KP4X/68r/8Anb11VAHK/wDNU/8AuDf+166quV/5qn/3Bv8A2vXO/HldT1Pw7p3hrRtOur6TWrxIrlYDs22sf7yXMh+VCwUKMkZ3GgD0ymSSxxsiyOqlzhQxA3H0FfKOtWd3N8HtK8N+JfD2oy61oGtLaQ5sZLgtaK6sWDxqV27CF4POzjNdRqul6Knj/X5/GfhLWNa0i6s7RPDv2XTppkhgEWGhRRgwybsHnaRzyO4B9E0V8y+KW8Ut8VZfiHbaBqsunaRqcWmxFcZaxUNHMVh+++55C6sBjHPbNZa+HtUtfi3Prt1otzFpCeMnlk1K1tZDdqm3KA462zE/MQD0PqAQD6uor53+HHwxOseOPGWr6/pmnNp7eItSjMV7YyfaJonBw0cu8Dyzv/unPzc88dD8APBOnaHqPjS//sQWN5F4hvrSyleJkb7FmMoqZ6pwcH9aAPZ6KKKACivJNKu9Zh8a3XiB7K9jsdYe6so3ZgyKsS/6M2zOVB8mY5I5NwB6CoTf+KotEmvP7Y1WW5j0G01UI1vDhrli++MgRD5cKo2jB59eaAPYaK8u8/XJ9aurK3vLywtnudTkZ7W3jDN5Yh8rJZD/AHn56nuTiorfxB4iuJNOlnnvYdQlXTWt7GO1Hk3SSiM3LMdhIK7pM/MNgRT3+YA9Worxq41LxJFoGqy2V1eWj2GmajqEMUFrGFmuI7qby1YFCSCFXgY3Zz1Oa1tUutestcNlFLc6mtvqcLwPdQoWIazmYruVFAG9V5ABG4jOMCgD07cu8ruG4DOM84pa8VstVvoLjUNUF1q17dTaRp8U0zxCA28rXEgkGfJOxU3Et8jFRnvyJF8S6zJpNnaT+IbzT76XUJ4UvRbxeWLVGU+Yxlh+Y4YKgAXdkE5AY0AeykhQSSABySaAQwBBBB5BFeVT6nrd0+pW8s99NPIupRXti9uBFbQqJBbujBAcsBHjLHeHY44+WDw9qviRNc06ymnWytoTZxQ28u/E9sYI95CCA7m3l/m81dpUZAGdwB67RXF+KdQuYfFFvbXOo32l6X9k8yGa0gEnn3G/BRiUfkKAQmBu3N128cTL4r8TNLq8lhNeIG0m+uY4Z4hLJa3EU0Kxqw8lVDbZHzGC/QcnqQD2ncu8ruG4DOM84pa8h8Wf2poviLUHtdX1S41hdEi+xN9njJvrgTzskThItu3lVwNp2nJJI3Vdj1vWPt9yLnVNRtZA9+t9H9kVksIEL/Z5Y8x/MxAjwCW372OOMKAeo0V5JF4l8RyaEDrbXljq017HDLCkYgiso/JLq7OI5GYSEZ46ORHldrFqya54su/Dsl41/fwXVnokd4qR2qKJ7gTTKd4aPPKomVG3r0HGAD2Sk3KXKhhuABIzyAen8jXlmrXviGx1b7LbNcarJZ6w/wBla6gQs4OkzyBdyqoA87AyMH5tucHFYy6jrFvea1qOj3eoahLPp+jx3F3cw+U0Sme787aFhONu7n5GKbjxxwAe20VzngK5vbrQN+pXcV5IJpFSaMswMeflBYxpvIBxuCgHHrmujoAKKKKACiiigAprSIjKrOqsxwoJwT9KdXzW15r/AIg+Ivh/+2bjVX1O31q/ibTmsvLtbKEQyLCyyeX824YO4uc56cZoA+lKpw6XYQXb3cFjax3TklpkhUOSeuWAzzXzt8ORqd1dfCbR/smqLqGgyX7awk1vKgtwQwTe7AKckjGCa4mbw342X4VwTGS9OiHUDqAiBbz/ALQbsweUV+95YjXzPTLUAfZdFfOOm+D9f174ueIb2xjFhFY+I4bptTkuZUkMCploI4wu11fuS2PY19HUARiCIXBnESeeVCGTaNxUHIGeuMk8e9SUUUAFFFFABRRXjsENoTqI023ZfGB1+doZYIWEoj+1HmVwP9T5echjgjgc7aAPYqK8dj8QeMT/AGtL5u2+jjuw2nhGlkj2ufLeOPyABhRkZdxJkdSRVy81/wAQ29ldP4curzWHS9RNPjubZf8ATlMIMqs21MKhywcY+YbCTwKAPVqK8zfWteTUNC02x1G4vo9ct4Xgv5LWONrcxNuui6bRtLRlQqkfK2R7VUTxZr0lm0Mc1wdQttE1ea5H2QDbdxSwrB/BjcFaTCjgggkHg0Aer0isrZ2kHBwcHoa8r1i51/SryFvt95dNJY27XN8bSLzIEe6QSlAkYGFjLEAhsfeO7FZMFzqWnWV7caVJdTuLjWJ4bma2VpGIgBiblB1IGOPm96APa6K8l1jVfFGmPPbQXd3dWpkspJ7udVjaCOSOcyYZIWCrvjhB/dttEjHKjlegm1TWoPg/q+px3a3GtQafey21xDGW3Ogk8kgMi7zgJzsCseQMEUAd1RXml/N4g07Vr8RavqdzDZ6npkcaSxRFZY7iaKOfdtjGQFZyMY2n2GKypfEPiZNLv5re71B9SXTLua8ge0XbYXKugiWP93zkGTAO7cFDepIB7BRXmF5qOs2Gr3WnXuq6mmjRaiEfUhAjSojWiyBSRHtCGUn5tvBwueQKytQ8TeIxbrFJf3tvrI0KG8tLKO1XddXZklCiRTGWXcETco27QW6YyAD2NWVgdrAgHBwe9LXk2nvr2kXE82lPdzNd6rq6ixljXycgTSRMDtDDLovJbBDEemIpNb1xrGc2OtXcloqWjyXN/B9nYTMZfPgDrARHwsZOUO0nbkFhtAPXqRWVgdrAgHBwe9eO3HinWp5/Jt77Vbe/XR9Ou7LT5beNpLi4kmuVcS4iBwViTONgAy2FPSxaXGr6DJc3lq2qXEE+qax5lhDEjZVRPKhjymd7MigEkg7sY6YAPW6K8QOqa3fxutzq96lhaajp9wL23AkMaOJVkG9oFDKCEJOzAJ544HSeHdY8RXPjk2+oXSwwi9uYmtJNxL2yh/JdEEAC5AjYuZSMsy4BwqgHpdFFFAHK61/yUfwv/wBeV/8Azt66quV1r/ko/hf/AK8r/wDnb11VAHK/81T/AO4N/wC166quV/5qn/3Bv/a9dVQAUUUUAFFFFABRRRQAUUUUAFcHqfxK0xfDlzq+iq97CumXWpQGaGa3E6wxLJ8heMBlIdQWB4PHJBA7yuIu/h5a3PhXTtDa+nWKy0OfQ1lCDcySwpEXI9QIwcdOaANQ+M9IUSKTei5SdbcWps5RO7shddsZXcQVVmzjACtnGDiO48d6BAkTm6neN4FuWeO0lZYomcpvkO3CAMrAhsEYOQMGq0ngt5L4arJq0511Z0mS78lAihY5IxH5fQrtlcnnO45yMAVEfh7Zf2dqFml7c7bzT/sEjsFLEmWSVpOABuLSscAAelAG9/wkekiaONrsK0l5JYLuRgPPSN5XUnGBhI3OTxx1zgVkv43spTpT2MNw1te3aQefcQSQJ5bRSyCVGdQHH7rt2IJxkZjn8CxXGsLczahM1gL6bUPsXlrgyS20kDgv97GJGI9CT14wq+CzNp+nWGpatcXtnp7oYUeJEJRYpIsMygZYrJyRgfKMAc5ALUXjfRJIJJfOuVwsbxo9pKrzrI22NolK5cM3HAPqcDmmweNtNuNc0vTbeK9ka/iuXDi1l/ctDJHGySDblDmTktgDAyfmXOTpvw1s9Oskt7S5ige3aF7aeCxgilVomBVpGVf3h4wegIJ6Hkaen+DlsNUsNSh1GY30LXRuJHjUi4Fw8byDAxt5hjCkdAMHJOaAKM/xEsTpOj3NlE91PqDaduWJJGihW7liRS0hQAHbIWAYKTgZA3Ct/T/E+l3+p/YbaWUyt5gjdoXWOYxna4jcja209cH6ZANc3YfDiGw06wsLXVblbSD+zWljMSHzpLJoijZ6ruEKBgPQEY5zf8M+BbHw7qzXdgbcRb5XUfYohMPMYsVMwG5lBJx36ZJoAmvPHOlafqus2eoi6tk0sQGW4NtK8Tebt2gMqkZyyjGc9fQ4snxdpa3NjDML+3+2sscL3NjNCpdvuoS6jDHpg45IHUiquseEE1HUNQnF/LFDfG1kmhEan54JFdSG6gELgj8arap4Ct7/AMTNrDXjKzXdteFWgR3VodgCLIRuWM7M7R/EzHPzEUAWV8f+H2jkkNzcLEsTTI72kyiZVkWNvLyvzkO6Lhc8uvrVTWPHcNlqek2qWlxFFdRXF1cTXltPELeGB41kJAjOP9YDuOFwMlvmXLv+EDtxaWMC3hYWtldWIEsCSpIs80Mrb0YEEfuQuO4Y9Dg1DZ/DjT4rIWlxczS2zWN/YSRKojTy7t4mcIo+4q+UAoGfvHrQBpv440OK2ea5lu4CkkUfky2M4mJlz5eI9m87trAYHUEdQRTX8daItyIAdQaQyiDA064/1xj8wRcp9/Yc7e3fBqFPBgkv47/UNUuLu/Wa1czNGiZS3MhjTAHrNISe5bjAwBZ/4ROD7f8AavtMu7+1v7W27Rjf5Hk7PpjmgB8XjXQZLG4u/tpSK3tftkoeGRWWPe6H5duSweNlKjLAgAjkZpr44s7fTLu+1WC5gt7e7urd5IYJJkRIJChdyq/LkYOOvXGcGqFz4DRtR8NIju9pp11dXdxIW2mUPKJkhKjqPOEb5/6Y4/iqPWvhlaamtyrX7qLj7YGElvHKEFzIXYxhgdjjONw5I/AgA6IeLtIM98vnTeRZBzcXfkP9njKKHYGXG3IUg9fbqCKuaLrlnrDXCWv2iOe3K+bDcQPDIgYZUlXAOCM4PsR1BA5bUPhrp+pX9zNf3BaK4tZLSQQQRwySI8ezEkijLhRyoYcHHJxW54R8NReHYrhImtD523P2exitQdoPLCMDcxzyenoBzQB0FFFFABRRRQAUUV4R8QviBrtxr1xYaXNa6bYaZ4g0/TpMTMLu4LsrMQBwIyGxjnPJ9qAPd6K8R0z/AISZPizr+izeM9Xn0/SrCLUEjeK3/elicoxEf3eO2D7159pHxJ+Isvh/waL2aeOKXVLb7TqhhXbewXDr5cQO3GRiYNgDGxPWgD6vor580TxL451T4n6jbaTeardWll4nazuYXtovsMWngZfMm3cJRkbQG5/n9B0AFFFFABRRRQAUUV5vputa1DpNhrc+qPdx3WsHT5LGWGIKEa8aBTEVVWDKMOdxbKq3TqAD0iivM9N+Jl1qFlb3kGhTfZr9YTZSyLNFHulmjijWV3iC5IlDfuy4wrjn5S1vU/iHPpFrv1DSUaVb19LYQXYwbvaGiVSyr8jg8sfuHqCAWAB3LWVu2oJfNCpu0iaFZT1VGILKPQEqpPrtHpViuPfxjNFry6FNpsY1lriJEhW5yjQPEXafdsB2qY5UwRyyDpuFcpp3jLxVNZ+HL+W2055LjQr/AFCa3+0sscvlNabXz5WVb95Iu0ZADZycYoA9bori7Xx0t1q1tpkensL65mgaGJphlrWSEym4PHAXZKm3uyAZ+YVjL8Q9Yk0pb9NE08RyaTLrMaG/ckRRY3qT5X3juXHbk56DIB6bRXCW/jC8uvEF9pWm2iT3RvSkP2qby40hWztZmOVQnO64AAOerHOAFrF8N+OtTGg6M08Q1C+udG0OYmaYRI8148sbOSsZI5QE9QeMBeSQD1WivNZ/iPeqVtINFNxqsZuvPhhE8qHyJjFhDHExy5GQWChe5NdX4h16407TdMntLES3N/cxWyQ3Mph8syAnLEKx4xyMUAb9V1srddQe+ESi7eJYWl7lFJIX6Asx/GvP3+I13ZWL32qaTbraqmop/o90zuZrN2RxhkACMUfBzkDaT1O2/ceMNUtb9dJn0qyOrvdw242Xj+QFlildX3eXuyPJYFdvocjOAAdzRXnP/CxLptMvLyPSoCul2LX+oq1ywIRZp4mEPyfOf9GlIzt/gHG7I1P+Evuxr72zadANOTVRpJmFwTKZDCJA+zZjbyARuJ79sUAdUllbpqE18kSi7mijhkl7siFyin2Bkc/8CNWK8q8K+PtXj8K6ANXs7e51G/0rTp7eZbggTSXDpETL+7Gz5nVjtDdSB0G7R1Dx/fWAIudKghW1nmgvrtpJmtYmTyyPnSJioZZN25wqrtIJNAHolFcJceM70X0sR0+COya/uNLjmW4LS+akLyhymwDadhGNxI4PTNZug+OtSh0C0TWILM6i+mWF3BIJZJPtJnJQgqkRbf8AIW2qpBzjIA3UAem0V5rp3jzVL7VtMP8AZ0EFn9k1OS/iklYOrWtxBGWQGPJ4ckIdud2CRtBbc8DeLLvxIzNcaTPaW728dzDOY5lQhv4CZI0ywGDldwOevHIBJrX/ACUfwv8A9eV//O3rqq5XWv8Ako/hf/ryv/529dVQByv/ADVP/uDf+166quV/5qn/ANwb/wBr1mfFHx3qPgaK1uYfDjapp80kcBnW9SErM7bVTaQSe3PTmgDvaK8i1b4v3eneIl0C58P2VnrCW6XE0Go6zFbKxcnakLlSsrYHqozxnivW4mLxozKUYgEqeo9qAHUUUUAFFFFABRRUdw7x28rxRGaRVLLGCAXIHAyeBn3oAkoriH8ePFpmpX91otzbW1hdLaSvJPGR5hljjONpJwPM3Zx/Dit/T/Eukag6R214vmsJT5cqNE48oqJAVcAqRvQkEA4YHpQBsUVzZ8ceHAYwNSVhIqMrLE7L86B4wSFwC6kFQeWzgAnipF8X6Q3kyC6VbWS3ubhppP3fliCSOORWRsMCGkAIxwRg8kZAOgormvD/AIw0/Wb++tUElu8N6bKFbiN4nnYW0U7EI6gqQJSMH+6T0pLfxlp0+oXkUPmTWkFna3iXFvG83nCeSeMBURSxwYCcjOd3tQB01Fc1F410WbVrGwimldru3kuY5REwjURuI3VyeUYNkEMBjaQcHitHRde03WjKNNuDK0aq7K0bRko2drgMBuRtrYYZU4OCcUAalFYcHizRZ3cR3vyLKsAlaJ1jd2k8sBHI2v8AOQuVJGSBSX/i3RLBnW4vh5iPJGUijeVt0YUuAqgk7Q6k46Z56GgDdorjdU+IWk2a6uIBLcSabFDO5AxFIkoUqyycjGGB/lWoPF2im0+0C6lI842/ki2lM3mBQxXytu/IUhvu/dIPTmgDeorm7bxro11qd3ZQTTSm3tYr3zooWkjkikDFSjKDu4Xp3yMZ5w9/GWhrbrKbqXcZGiMAtZjOrKoZg0W3euFZWJKgAMp6EZAOhorIHiPSTqq6aLwG6ZggARtm8rvCb8bd+35tmd2OcYrXoAKKKKACiiigAooooAKKKKACse+8L+H7/UxqV9oelXOoqVIuprSN5QVOV+cjPBAI54rYooAprpdgt/PfLY2ovbiMRTXAhXzJEHRWbGSB6HioToGjnT7SwOk6ebG0dZLa3+zJ5cLqcqyLjCkZOCOlaVFAFWx02xsJLp7GztrZ7qUzztDEqGaQ9XcgfMx9TzVqiigAooooAKKKKACsWw8LaLYXwvLXT4luFd5EdiW8tnJLsgJIQncclcZya2qKAMJfCOgL9pxpVttuARIhXK8sHO1ei5YBsrj5gD1GaePC2hi3WA6XbNCsUsOx13ArL/rcg9S+PmJ5Pc1tUUAY1v4ftYfEQ1jJaeOxWwgDDJjjDFm+Y8ksdmcn+AepyWvhjRbXIt9PhjBjmiCjOAkpQyKBnAVvLTgcfKK2aKAMa18PWdv4hXVkUCWKxXT7dAoAhiDFmAPU7iE69Ngx1OXr4d0hbZLdbCEQJaPYqmOBA+N0f0OB+Va1FAGPP4Z0admM2nQMzTi5LY58wRrFuz/1zRVI6EDBzRB4Z0aBIEh06BFgitoYgAfkS3ZmhUeyFmI+tbFFAGLdeF9FugBPp8JKySyhlyrBpDuk+YHOGPJGcHvWhNp1pNFaxSW8ZjtXWSFcYEbL90ge1WqKAMs+H9JKKjafbvGGnfY6blzOzNNkHg7yzEg9cmmWXhvR7FIltdPhj8qcXKnBLeYFKBiTySFJUZ6DiteigDEl8KaFN5Pm6Xav5LMy5X+85kIP94byWwcjPNQ6Z4S02x1y/wBXaIT31zdG6WSQZ8ljEsZ2joDtUjd1wxHSuhooAx/+EY0X7HFaHTbY20VqllHGVyFhQgog9NpAIPUEA1DL4Q0CW2ht5NKt2hi3YTBw245YPz8+4jJ3ZyeTW9RQBzml+D9LsdSvr94VuLu6uJbjzJBny/MG1go6DjjI5IOOlWp/C+izwJDLp0JjSGK3TqCiREtGFI5G0kkEcitmigDFtvC2iWv2T7Np0EX2SR5YCgIKM5DPyOzEAkdCQPQVNpHh/StHkd9MsorYsuzCZwq5ztUdFXPYYFalFAHK61/yUfwv/wBeV/8Azt66quV1r/ko/hf/AK8r/wDnb11VAHK/81T/AO4N/wC16l8f+E4PGWiwadc3MtskV3Ddh41BJMbbgOexrP1y5uNJ8fRaj/ZWpXto+mfZ99nD5m1/N3YPIxxVv/hMv+pc8Sf+AP8A9lQBkeP/AIap42nnj1PW7pdKn2b7P7LbyeXjGTDI6F4ycc4J74xXeWsEdraw28C7YokEaDOcKBgVzX/CZf8AUueJP/AH/wCyo/4TL/qXPEn/AIA//ZUAdVRXK/8ACZf9S54k/wDAH/7Kj/hMv+pc8Sf+AP8A9lQB1VFcr/wmX/UueJP/AAB/+yo/4TL/AKlzxJ/4A/8A2VAHVUVyv/CZf9S54k/8Af8A7Kj/AITL/qXPEn/gD/8AZUAFx4R87SNTsftuPtuprqO/yvuYljk2Y3c/6vGeOucVjeLPA02oQTQ2s8pk1DWRdSzxERm2t3gEM6E5y26NWUY5DOhx8ma2f+Ey/wCpc8Sf+AP/ANlR/wAJl/1LniT/AMAf/sqAG3Pg5Jbu8lju1iSfUrPUFjWHiMW6xARjnv5XXjGehxWZffDoXUryHVCjZvnTFvna9xdQXKE/NyEa3AI/iDHla1f+Ey/6lzxJ/wCAP/2VH/CZf9S54k/8Af8A7KgDE8QeC9UuNG1VYb7zdZ1LVre+S7tIxb/YsQw28jqGdif3UcnGSTv2+9XdW8BLcXLvpt7HZ2/2WxtEtGgMkJjtmnISRQ6l0YTgbcjBjBOQSKvf8Jl/1LniT/wB/wDsqP8AhMv+pc8Sf+AP/wBlQBkaZ8OfsNpBbLqMH2cwaja3McVn5atDd3BmKxAP+7KZ2g/MMdhWv4K8KHw40rSSadM7QxwiW2sTBI4XODIxkYMeewUZJ454P+Ey/wCpc8Sf+AP/ANlR/wAJl/1LniT/AMAf/sqAMW88Cz2+neJGjmFwL2zlSHT7BDaoZiS6yfPKyLKGxh1CDOSQeMael+DGtINGMt9vubS0uorl/Lz9onuSjSy5yMfOrHGP4u2Kn/4TL/qXPEn/AIA//ZUf8Jl/1LniT/wB/wDsqAMqL4fTQ6XcadFq8f2a4sbO1l3WhL77cKodTvAAIXlSDz/F2p+s/D1NQ1m71RbyA3M1812kdzamWJVa2ggZGUOpY/6Orhgy4zjBGc6X/CZf9S54k/8AAH/7Kj/hMv8AqXPEn/gD/wDZUAZ0ngS5S3vIbDVYLGK7sLezkS3s2RUaFnKlMSArGd5VkySV4Dg81nt8MZBY38MF9pltLd3j3ayW+mvD9mLW8MP7nZOrIf3O4ncQS3IOM10P/CZf9S54k/8AAH/7Kj/hMv8AqXPEn/gD/wDZUAUbDwClj4hbUUubS5R7lbtjd2ZkuBIFCkpKHCjJXPKEjc2D0x3Fcr/wmX/UueJP/AH/AOyo/wCEy/6lzxJ/4A//AGVAHVUVyv8AwmX/AFLniT/wB/8AsqP+Ey/6lzxJ/wCAP/2VAHVUVyv/AAmX/UueJP8AwB/+yo/4TL/qXPEn/gD/APZUAdVRXK/8Jl/1LniT/wAAf/sqP+Ey/wCpc8Sf+AP/ANlQB1VFcr/wmX/UueJP/AH/AOyo/wCEy/6lzxJ/4A//AGVAHVUVyv8AwmX/AFLniT/wB/8AsqP+Ey/6lzxJ/wCAP/2VAHVUVyv/AAmX/UueJP8AwB/+yo/4TL/qXPEn/gD/APZUAdVRXK/8Jl/1LniT/wAAf/sqP+Ey/wCpc8Sf+AP/ANlQB1VFcr/wmX/UueJP/AH/AOyo/wCEy/6lzxJ/4A//AGVAHVUVyv8AwmX/AFLniT/wB/8AsqP+Ey/6lzxJ/wCAP/2VAHVUVyv/AAmX/UueJP8AwB/+yo/4TL/qXPEn/gD/APZUAdVRXK/8Jl/1LniT/wAAf/sqP+Ey/wCpc8Sf+AP/ANlQB1VFcr/wmX/UueJP/AH/AOyo/wCEy/6lzxJ/4A//AGVAHVUVyv8AwmX/AFLniT/wB/8AsqP+Ey/6lzxJ/wCAP/2VAHVUVyv/AAmX/UueJP8AwB/+yo/4TL/qXPEn/gD/APZUAdVRXK/8Jl/1LniT/wAAf/sqP+Ey/wCpc8Sf+AP/ANlQB1VFcr/wmX/UueJP/AH/AOyo/wCEy/6lzxJ/4A//AGVAHVUVyv8AwmX/AFLniT/wB/8AsqP+Ey/6lzxJ/wCAP/2VAHVUVyv/AAmX/UueJP8AwB/+yo/4TL/qXPEn/gD/APZUAdVRXK/8Jl/1LniT/wAAf/sqP+Ey/wCpc8Sf+AP/ANlQB1VFcr/wmX/UueJP/AH/AOyo/wCEy/6lzxJ/4A//AGVABrX/ACUfwv8A9eV//O3rqq4a3vrjW/Hmi3Uej6tZ21naXayy3lv5a7nMO0Dk5PyN+VdzQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9847=[""].join("\n");
var outline_f9_39_9847=null;
var title_f9_39_9848="Acute phosphate nephropathy";
var content_f9_39_9848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light microscopy demonstrating acute phosphate nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 521px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIJAVMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5l0LSLrXNTisLAI1xICVDttHAz1rsovhF4pljkZI7MlG2lftA3flVH4Py2kPjyye/lSKAJLyzYBOw4Gfc19RfCnRLnxgPEFxc6pqujG1vFtltbZLVsDykbJMkLnJLE8HvUu/Q2gqfLedz5Xk+HuuRXy2c620Nw/3UklA3fSob/wACa9ZSwpLaBvNYKGRtwGfX0r6u0rwv4R8c+J9W0W38YeI7nU9ClAmDRWSbWDFSUItuQCMH6ivOfH2gappXxDvdMsdbuZNN04xsZboRmV90SNtIRFBHzHtUyco6s3o06NZ8kU7/ACPIbT4b+I7q9a2itotwGd5kAU+wPrTNT+HuuaZHJJeC1jSMEs3nDHHb619DeBftxMCsFa4DH94F457j8K0tZ8MafrlpJaXu64ljch1U7dx9c9ualVG1c6pYGnF212PlPwx4X1PxLPcRaXEjNBCZ3LttG0eh7mujk+FHiSHRm1S6Fjb2S4JkmuAuM19FeDvCtvpHhu1W9t4IrqFWibyBksm4nBPc1uSaNBfxLb3ghuLCRPltZhlT/wDXqnPXQhYFezu/iPlLSPhh4l1WWZbO3gaOPBExlAjkB6FG71pt8FvF6s48mxO3ri5GPrXuumXOt6N8RltDpwt/C0Nr8uyMFFIHY9ua6mC6u/7c1ODVLW1SwkUNaPCPmkB4KsPxodQI4FNbNny5H8HvFc1uJ4IrKWIkgNHchs47ippPgt4sikgjlGnJJPnyka6AL464r3PStY8NeFL+7sUt7uxiSXaxkJ2s3bbntXZalaaPrQ066mHmG2lE8Do3KH14odRXGsAmtvxPlXw78HPFfiC8ntdOjsjcQu0ciSXAUqy9eop1x8GfFtp4hfRr2KxtbkLvV57pUjcf7LdzX1D4wa20jTJfE1pc/YdRtyMMHCpcsoO1WHc4OPpil1v4U2vi1dN8Ra/q063j2yGYI+IwSARj6HitE0zkqUIwerPmG1+Cviq6vp7K3k0mS7iAYwi8XcwPdRjkVi+NPhxr/g6ZYtbjtkZhlfLmDg19qX/w2trq9i1O0vALmERASoPmdY/+WZI/hPevMP2h/Cs2pXdpcxTtiX/VwkhRuPOMmlJ2sVQoQqtpPU8L0X4QeKNZ0uO/sVsGgfGA1yA3PtVyT4H+MY5CjRWGf+voV6N4M+H3jfSbebUtMlARsebE8u5U9/f8K7Wwmu7JxqGu30Cx7hAYwfvMf/r1m5tHfTy+jNNtvQ8If4E+NFtHuTDYGJPvEXQ49/pVa5+CnjO21tdLls7cTNGJRIJwYyp6fNX1tLby2DSFx/oxT7p5znoKdYxmWeG6mBBEapuP3QozgH86fO9jP6hTtzX0PjfVvhV4q0u/+yXNnG0nkPcbo5Ny7VGTz6+1aNh8EfHGoW8FzZabHNaTwCdLhZRsKntn19q9w+MsUVvr3ha8u9VurC0+0+U4tl3bgTySPTj9a6nxF4w8V+DvCOrzf2HELG3Kw6a0fzF0PRmA9c5q07o554WKdonzmvwB8cOF229gdy7v+Pof4Vk6f8I/E1/q2oaZbiwN9YDdPE1yAVXH3vpz1r6t0fUrnUPA0d/qMq6XJc24j81iB5bMCA3tzXJS3ps/iTpM11p3mXN9ZtZ3l7CCVdcL83HHOetKLuVLCRTsjw+x+BfjO/CNZw2EqM2wOt0CufrUbfBDxik00UkFkjxYDbrkDGen8q+o7Rbiy0RdMtpikEEpZFQenQA+nSuJ13VdS1rXZNFggktLkCG5W7lbakpRsshPv0ovfYf1OEbufyR86S/DrxClrHcJbxTQvcG1VopN2XH9PerGh/DDxHrN1cWtpHaLd2/+tglnCun1FfUd3p3h2wsUstQbAtHFy4WTY0eZCQc/jj3ra1Tw/b6MTeaTp+Td/PJPKPmfPbPpik52RccFTclFvc+V7j4I+Mbe3kmkgstiDJxcA1n6R8J/FWqWCXcVrBDG/KrPMEcj1C9cV9O+FNSt7i51XTra8a6XTZz5jEZKq2SE98cjNIPCiaNqOo+IrZZ7+/axkktLe4cmIyFemO3pTu9ifqlO3Mrs+bG+DnixVLGKzCDOX+0DAA6nNUND+GWv65bzzaWbG4SByj7ZxkEfhX1Z4f1abUND0tddsora7vImUxQp+7iyOpz3xTvJ0TwtpS/ZJILeESBBjje5PQmlzfeH1SF72dj5b0D4ReKdbuJoLaOyhliOGW5uBHn6ZrfP7PHjgI7n+x9qDLH7evA96998RaQl7xayJFeEBy6jB+p9cV5ld6R4p0Kymt/3l9cX8uTPuLIi+mPfNTzsqWAptXjJnJWn7OXj67t0ngt9NaJ+Vb7YvI9elUtc+AfjrRbU3N3ZWphUgM0VwGx7njpXuFjf6vo3h6xXUL77HDb9ERzwev8AjxXqurapaa/4DEtlqSsJlVDIn8TcZUgetNTuYTwns5Ru7ps+H7D4WeJL+R0to7RmQ4IM4GfpVjUfhB4psIpJJlsTHGAWZLkEc9vrXt0Xh/WvCHi4Xd6fN0q5VliYHnH0qD4j2zatcQ2sFzPDbtGJEWMYOc88d6l1Lbm6wMJv3L2PCP8AhWniQorC1jKHuHyB9ajvPh34itImkltUIHZXyT9BX3h8NPDH/CP+F4be5bz5Zgsj+YvI+UcH3ql8TNM0aDwtfzXSRWrylcSovzM+eAKOeSOZRoufIk/v/wCAfCVn4J1q7mjiigQSP0VnANP1nwNq+k6TPqVz9le1gcRyNFMGIYnGMfWvWdNsdQ0fxcb6WeOex24WMnlf/r1e+MWm2dj8Nr77FEsBaeOR4x/EWcEk++adKbluGKw6otWTt5nzfRRRWpxm94H0iXXPEtpYwOiSPlg79FwCc/pX2z8JUvbXSPGq6aUu9SjmTyDIQqySi0j27j2BOM18m/AC2e6+J+nRRJvcxTEL64javojT9RNr4nv9K0XxVfaFq14yyy2QgtnQsqBd372Jj91R0bFS5WdjohS56d1vcs/DX4UeLPBXinwxrcmpWV8WgmttXhWERSIspMpzJuPnESnrgcLXPfGFL1vHXisaU6pdyPboC/3cfZ463tb17xZZNKtp4z1W42LncLaxwT+Fv0rgILjV7i41nU/FtzNPcOys82xCZVChFIWNVAwFHasqklJWR3YLDzpVVOe2p1Gha1dabp1ra3DRo+FMjIn8QHPPpXSxlta8P3sWlOkOtTxsqqOmf734da8/0RZprb7RLcia3YgxqUw2ztitXVG1rQlg1nwzZf2jdwuGaME8IfWsIyaZ69elCdJyRv6Pq914D0e11T4h3tlHbYaGW3jXzHml/gZPQ4zn1qrqPxP0zxVBLb+GNIuRcgGSJ3gZQ2Ohz0xW74aGm/EuLRx4o0gRz2lxJJLZy8qrheCfrmvWbW1tow0MWnQwwoRGm1FAK464HQV12Ulc+fnVlRqHzboOu+Jrm01LRr+zB1Z4XubSSPJhfH8BPY8V0Xgl9Y1iawufEFube4gUGVVU9c/dP5Ct7xJMNF+KkOk2xWGy1GxkuEiA6TKckj0yO1cjrnj+107xJbw3d9qNrJb/AL6WKNA0Uyd1Pt7iolCN7JHoUMROUHO/l23Ivjj4Wk1GGOa0gNwLc5lAODg8ik8FabJ4bsJ7yS6lk0ydUURS/wDLI49a6jxFZx+JtNa8024eOxvArsYX+Ze+MUmkeGZrvwXJpkFyZBbXMcrPI2SVGetTfodMbKKnLy1Mf4q+H28TaP4W0yGQqj3bvI+QByvB5+orr9Ah8RN8LLnSYLWOe5tI3toJ2kHzlSece1a+kT6XPPa2t/bpOWYQoeq7sZGPyrpLSG08MwSQlhHYzSlo167WY8qPbvW0btWPKxLUJNW13OO+C2t2194Pnt7y+jGoRTSLcxF8GNuhx7VmeOPDtv4r0zRnkaQraTeZGWPEgUkDJ7gisePwlbweMtSl060l+wAtdyzCTaCCc429+c/hXUaLq1nquhzz2cp8m2laNkI/1LKMYPt3ol2RrRjaftH1exhaR42XVry88Gz2zaTPax5LN/y0jXocjsa5nXdNurnTLhrS3YXUeGRpFzGzg5U+3atTwheWkHiaS51eFLjVJITm4VPkaMk7dp78V1t5qf2u9aBFHkTp5ccfAV8dCT6isZJPU9OlzUrxitHr/n8/wDwvqtzrHhuGXWo4ob+L5ZkByuBwcfzqe5LyS+XC8cduAcZOW3dsjpisOz0/V4Y7zTYXto5E+aOWQbgc9Qw9MVPrIlltbyHQXgGrxxjyhMfkJHY/rVJ6amMqSjJqO25FqOlPqGm6ZLrSW93qFod7Hb8jMCeQO3Fej3ttB4n8LmG3cpHIoAOOVI7YrlLa2M+lRNOUgvSgM0SsSN+PmCn0zVTw5eanoMq21rP9rtGLny5iBsJ9DVXs9ephUpOpCLpv3olPRJtH8RaXqfhy823L2imC6iIwDzwf0rdsdLtrbT4rSD91DGqxRKeSFx61wPhLWL/xNr3iVpNNj0vVYgqSME27ypPfv0q98Q7rVr280bw7o11FaT627RTSEbmiQD7w9OaEug5PXnvqzuI7f7LC4h8qR4mIeRh0BHT3riPGVvpGu3MuiTXcVvfXC+bDEuQwI6MPTkVV0C38VeBrm6h8R3LappWVWKRfnLqeufTBrsIpfD1lf/2zPZMxMQjaUJvfk5xVdeUi3LF1Fqmed2uky+ILaU6pY2n2h5/J1sI5DMYwDEyn06HFXLnWtf0TRdNstauotRghMuVhJaZotuIjjuecGvRdWs7KCyF9p6iPTbvDSsV6HoCe/PSsfVmh02K51G2tklnS02AqBuZByFz2FEnbfYmio1EpQ3R594YhvLe48SWpuZUMECQWxMPlFt/z7i38Tcge1ekaDeTrosEGsR4BT92yndsIHc9wa5aO0h1+9sL6We6e5hUP5CHCKcd/XFX9HtntNc1PUReX09rOig2RG5YnHUr6ZA6Vm5KTujqdGUI2aKGqeIILPxRp3h+WCVZroGSCfbmN+vy59qzNb0g+Kr298ORw3Ntb2/lT3F2y4jJJDbU7k4713EaWCTCS5tyXRS0LEZaLI5x/KrIvYreJZWYyZ5Bx90dMYoVlqKfPNcvQ5SPUtP1PUrF7a4i+yW1vIjTJLtfKkL8ynqMj860NStLmO/0+7tLxhFGSTEwBSRT6/wBK5rWtH0vSJby90qyilnk3S3FzfSFYlRzkxgDjqal17WZtKE2r392P7MiUQW1tbJuUkgfOT6elU7LYyhzN6rY5v4jC+vvE6aVHBvtpFBmck/KOp/Suz8FakvhCXSdBW1+0NqS5Emc+Q5JVDgdjxk1R+GHhXxBrmp33ii81HzrCZM2sZXDOcYwR2GOK9P8AF11b+G9Ihm0y0tZNXiVUTcoyABzz9AamK6smvVUn7KOr/L/gdTzXXz4ga60mDxlcwfa/tDbYo12oEzxz71yHxDuNR/4SiE6e0UMsRUBXP8OecVpav4svPG/jWC1m054FgVSHJ4I6k1Q+LV3o2mazpVxNLILkR4CYzgVnJN3N6clHlT0/Q9a+EWv6trurag2oXzT20UCqImXG189R+FXPjXZ6pd+HIhpkKTQRv5k6n72B0I9qf8GV0z+xZ5dNlmeSbY0yyLgKcfw+3Nd3f28dzbSRzHCEH5s4xSSvE82rUVLE80VazPkVLqG1s/tN7Ky3k8oghOwssbHo7AdveqPxJtrnT/hPJZ6nem8vI3QGbH3/AN6DzXT+PfDer6PfTpocaXsb/NFIGDBhn+Yrz/4i6jqx8ES2molSGaPeDHgqQw4z+FVSny2jY6MXRdZuqpXVrnjFFFFdJ5B33wQu57L4h2U1oUW58mZY2forGNgDX17pPhyw8U6eJdftIpNVt7cxSXq/JKCR8xUjpXxr8Jgx8c2OwgNtfBP+6a+4fB6C+0l2nuli85dsgTGc9BWcnqd1KCdFy8/8jk08N6boVmYbNJDa42hnfcdvvXH6lHBeaaX0y8URMpEVzEdwPoD616NrPh19KMsttqU93biMIYpsbYyAcnPfPevny68VR6NcOmkp58cczBreH7q888Vz1Ja9z1sLyuF27K3zPQPCN1aSQiBpYL27j+W4VDgDnpjsa9n8LQaS1spsQuyaMwyK7jKe2O9fMuk2E1k99qvhsRNcahIjNBIcbB1OK3dZ8URaFqWmSyPdxSCQbhHHlSfQ1MZWemtzetQ9rStN8rX3eR0X23xL4N+Jt5C+mRro7RgfaG+7IB91s+vavdPDOu2et27SW/7u5AHmwsfmX0P09DWOs1l458MSxRbfP2Dl15VuxrwqbWEg8V6hoZe+t9Z08FVuocqCnUxMe6ntXRF8u2x5VSk8QrS0qJ2t3PWviJ4LufEni/R77TzEqRRSw3M4b54uMqV9815joupwTRajbapYC91PR5ntZXMY3MM43j1BHUV7r4EtILfwzZ+VbGFrhDJKGcsQST1J5NeXXoh09NTmtY7ee7NzMY4lG3zNny/MfT5hVy2uRg5PmdNvRFqS4sdLt7N4JvL0rVEUQlY8ABuNpHbBrqPDd3baTqVzYy7RFMA8jSjAHY8+lcZ4ksNSvfh/FY6YYItRlYyKfvRwMByPYGo/C9p4iXQYpNdurW9u1hYPCo5DBuOfTbmot1O5rnj7OWz6lvSLqVNd1y0u7QafDaXPnW8ivnqfldfYiun1C4v9VjePWyi2FpLDMklu2Hlwfm3DsOg49atXfhyDxH4ahu9KWC01No1TzGBIAB5Uj+VY1mJ9Jkk07UZY5HRQQ4OQwJ6U78u2xklDEKz+KP3h4l8SeHo9RRDP5KKwWYltokHUr+VQ6eltrWn6tb6YsdrHeQygGDnGeAeO+K8p+LHgXV9Z1nbpVtvinj3mTfgBgcbSK6LwF4Z8Z+ErXTzLbx28QfFyJOSV6fKR7etXbTmQ1Zfu7W7PuWfFfw7v5P7Ml8Oaq1hFZRiNo5F3BgOv581YfVtJ0q3ittQvD/aQJMKZwGb09u1dF4v8Rpo1peT28QvrxLcSLZK3zMC2M4HOAaisINP1m3gv205TI6q48yLlW7jPsaiUb6nTSqtJxfkcp8J9R1+81fVbnXrd4P3n7pWXsDWf8cI7mObSZrCaexs9RmEM11CCTGQeAceteraVqdjbay8BjxeCPesfUFTxmtvxVBaXHh9ontIzOg86GJwMNIBkAU+U56tdxmlrrpc8z0SfXNDvo9J8RTee7gNBeDlpEPr6Gt/VY0WEtFMDk+XuHY/5NM02X/hLvB1hrZgNpfWbGK5gb7w2nAH5VnRaY9nZ6uumzK/22X7QFmyRE2ADj8s1Lja51U6nOk0tVozD+H413w9qus6j4kvfM0mFWdWI3M/PH6Vb8eRQ6jqcHiLRdQQ3nh2UvPFbncWUjdt4796xvDOq3t/4mm0DVLj7barbtHOnlYGcdz3GK3fhzpSWNhqNzfQm3v7y5eR42G0NHGCqEL6bcVephUiudPodz4K1e18e6Bb31ntETbluYZByjdwR+tcNdy6r4A8YzSa0sE/ha4kCxzBuIWPQOK5i1tb/AFWC3udDupdNMNxKt1DBlC0u75cgdsGm+J5r6G11vSru5S9uLzyY7a1mOS5wCZj6EHIFVa5z8soOyfus9Xn1ybU9XEE1sp06G2+0W1zHgwyN02exHUVzOr+IZBq9pp0dm80V5ExMy8BGAPyk/Sr2kWM+ieDLOzlaNTbxDexPyg/5NYPiS91G20m5u9Ps1mljlXaAPlZc/Nj8KynJt2R2YehCEXJnRS2lzpMccEdsx+0RKwkUjcSeSAOwAqjq+vQW66pZxS3NtLHaeeJvKOMdCQem4dcVh6Z4m1O8FgmpwyrLPKxidOiLwACfSrnirU9SsfEWnWphjbTb6zcFnXcgkB4DHtkUoR1siq0nGMeZ6tnK+BvEerWs+l2Wqahbana6lKyQ3JYqygfzya39U119Q1nU9C01ZI720i3RSOMRl/8ACtLxDPoFhp2kahdaev8AobMuYICxU7vlIAqh4m1i20y20/VjbXH2e8AdikfzLjk5Pb6VU1fVImi+V8sn/W3/AASx4V0+41XRZbHxZbxtcyyfPEzZV1GCCR9RT/EyzNo08OiWkU0xAQI4BQ844FQy3Gk6v4R1vxPo93eXVzIhtcuhja3JXliO+M8Gs74J3TXnhdGuPPkWBzGXlGGfHdalqwQnz3t/X9XPcvh+jp4T05ZeJREA64AAbv0rwTxraa7rXizXrDWftFvayXmIGhYqCm3AIP0r0zwp8Qk1K9m0LSrIm7tiUDE8HB5JFReMvD9/da1NMxumEqrIqxrlI2C8nP4Yqp35bI4MKlCu3UtZ3PN/h3LFYQapptvYSx3FhMUie4k3NIMH5iOwyP1rI8QH/hIWF9arb3Bsj5V0gXLRODnv/OtfSNJs/wDhKL2ZNSuYdTlhbC54Pbv79qTwnp9rp2v69YnzPtH2aN7mSThZCf4/8aJRjOOhcZToTvI2Phr4+i0m7Mchj/s3bh0QZKt6g9/pXtFjq2leLNJuItPuw6SxlHUHDpnjkdRXzLqS6dpuif2jpUM1xbyN8vlpt3c4zzWh4Vt/EGiStq0N/HJJKBIka/fUddrevbisVeOnYvEUadeSnF2k9fI9SfwBpaaW2nafdvLqVpukEpcg7z0BHSvnf4yvrX9hTw+IrdYL2MoCAoUsu/gn1+te0eBviQ6XOqrq0B88t5ypHgb34BXnp0zVP9po6ZqfwnvtQ8uD+1ENuOGBeMNIvy5FOCTsYV51KfNGet1v5tHxhRRRXUeUdz8F4jP8QrCNVDEpL16fcNfU3wzS71DxdeW7rJDBDGHLn7kuTjC+4r5b+CgJ+IFpglf3M5JHYeW2a9jj8ZXMej6ifC7SjVYm8tIpOPNGcFl9QOtYVItzTsevhJpYaUb2bfqem/EvV28J6PeRW0yXd1LnyoN2c+xr5ZsbmS21NJ7mCSzN47BYwmQOe5+tepeMI9Vm8OWN+rF9SeQRuW5AJxkEfXNdf4f0my1aK2iWe3t7yJBKxmQGMkDB/GueW9u56lKleKqX+HW9tDzfTdC1OK/GqR3nmKq/LCvGDXbfbrLV7aOO5Cm6hTc6MnIPb613T6X4bs9MdheNc37kjEI2qh/3fSuIuNNifUbadU8tYpCpAP3sjkH2rOzg7SZ6FOUasW6MWmn1697XPSPhGhhubnLBQIwW7A+mKs/Ee401b2K2bT0W9lxIbnaARjsT39K5dols7zNhO5Vowz44waPFniW+bw3LMbP7fqEBBjQLgkD1/rW8Z+7yHBVwt8SsTuvusN8I+NptT1DU7Qyy25sUZwfLKgKOo9xUPhPVdJ1XQ5rvRoyjSB/JeVeWO/LdfU8/hT/Bul6jrLSzSWpVZ4ws0WMBcjlc03RvC+l+H9TtlxcWiW0rCO3MmUfd/CB9ea2i/d1OepCMalo2fV23Nvw1f3EWhNDrkqfap/kllEeAwyccfSm2uj2VnrM+oxXSGTIi2hyMgjjC9KfO8cibFkhBO5i7N0A7AdziuO1zVNOVrfQtSm8g3konjuYyQcqeF3e9JN3NfZRSbjp5fgdV4Z1zU9H+Ko0HyHk0m+j3h88IwB5A/CtnXdMC+I5JQI/s7ybNq/eXIGSfzrm3tdT1Hx9pEsMixWMA2uejsTxwf1rtfHEdxb3scir/AKPLGVDL94Pj/Cq0cTladPEJrdowbC+k/tyxsLZFnuyxkVW6FFPJJrtdQOr6jbXEH2SC3iA+9I+4t9MVyWkWuNas7mykIv1jEXmlcgqxG7Ira8SSajpMOow6bO15fXkZkSN1z5Z4BxjoMVpBaHLjW5VUkjjIdEeTVdH1bVrqGPWbdXiYwnC3KHJAxWldalLb7BGxCE5C9MVS+JPh06unh/UNNuvss9kqSxtg4YAYZSKntJfs23z186Bx164OKzm+h34aKlDmauaWmzrcqXiEXnleNy5PrwazL+8uH1LM250Oc5PQ11mi6SJY7ZrN1gWSMyu+0M/JwAPSuE+IEN/p+r22nabqUM84dZylxgMUJwV/LpRKL5SaOIpuu4JFPwfqknhjx3qlhqls6aLqaCU38z/Ju6Aeg5OKmu9R1HTPFdzp8lqGs02qkgXAIbod3SrninTpdS0LYtkLpFK74Q2Cy9yp/vc1wXivU/Fuj6RF5JXUbBmJiUxHfGirhVb3AHWna8UVC0aspPbqd34iuLfR4JNajtRJJHHtk8tQDt9Se4FZ/wDwlMJv9Jgt5BNPqimSHbEWMcRXDNu6AZ9fSqngTVk8TeEIhqq7bi6Vo5In43Y4OB6VY1HxBo3hq7stDyILuS322/7rcqKO2760l+Jc1dJJq2h1dhpWnaVZymyG6W4YSTzNwWbAGfyFYd94I0bV7uHVpJJXMcgzKj4bg52mptGWWeMxRCRznBPYe9atvp88FvM0G4qRlk7NSUm3cJUY01y8xU8R20Ws6c2nyyOtpJhSEbk4PHNY2uW91L4ZvdDtnkthIu0ysM4Hop/DFdJassKlHjwjcjP8JrPv7mEXEFrJIqS3ORCrn75AzgfhS1e25ajH4ZL3SjYaGD4LtdFspD9pk2oZVHzgdePTNafhKKPSrufSNQaa5WNAhMnOWbOFGfTFZVlrui2+lX76peG0WNmhDo2GD9sHsRWGthrms3hv7XxBLObe1ZrbaQpaQg7WNVHbUxqp3klsb1vf2+nrdy6xaXFlE96IEjQ+YJjngqPyrOu4nsk12HUruZ4buYT20Zi+W3AByo9zWb4h1UJ4ftBrmpRWV5ZNbzyz5By68tgepNddda/ZXfhyO9W3P8ExfZxICOD+OelNuNjOKmppoxPDssEOi+I0s3BlMCGaEjgRA8t+tU/hjrltqslxFZiQwDKh9m0EqMgVf+HsGn2WsSSlj/xNVkSQk5CpjOMemRUek3dsk4bRGhktIZGjKqMBuecj+tc/Kkk+x6Dm5SnDvr69P0NbSHn8P649zawxMLtcNIV+aNj0Oe9esaRq0Wou8KgiWJQXB968L8cx6r/ZIi0pmSYqWDHgA56fhXUfDHVLiw8G32oatcBtRtYSsg65x0JP14rWMrOx5mMoKpT9paz2/E5LxlZm28cSxWtu+WudrvuwFVucj8aytTOoad46m1OWy2aZa6e1v58jYNw55AA/i5ArSu9RuLzxMuoys8qSuCY2ONv4Vh/FfxDcaVr1nbpazXFuiiQEDI+YAjj1qVPdo2qUX7kZ/M52Nda8WWt0NcYW1pgeV5TbFA+lNXwZfaHPA8mpziS1GQMnacn9a9J8C3Vg9xONUNvDBNBuU3CjIJH8I9a3fCOh6Z4h8LXU+otPJBZzyeTdSS4WVc5K+3T9azi+YdflpP3ltb8TxzWLOG9i8+WTCxnJcNjJHrXKfEG4lPhaeIyl1JjJIbII3DFd18Q9VtXilzFDDp6bQIo14VRwBnvXmvivTbQ+FrzUrOSeZZfLI3H5IxvAwBSpr3lr1Hipfu5aatHmlFFFdx80ehfAaQx/EvTyqhsxzKQehBjavZVstHt9StLO40G6s1ur47J0BeMMOhyOgOTxXhvwcikl+Iuk+VMYgrM7kDO5ApLL+IyK+qV8R2hL6bdQtB5cu+1acgLJ6Fazk7M9TBxcqencwrjT7y51PVdNa1ZbIBTFcs3ys3t6EGqUGi3ml3iRXZXdI2IstkHFdbfa7Em5ry0VbZBl33YUAdTmj+yP+ErlsbrS9Q2w28m8xhdyzr/dz2+tc0oKpqj2aVeWGVpbHM3mp3Fpcz2qyR+flSYlZRIy5681JModpobfced7PnIB+ta2tfDPS/8AhIJtYltpDqscRMCtMfLkIHANcr4S1nW5bvUodR0hLK0iBVGVSF3A4wCeual4duPodFLMY86SW+3b1bOkspn03ToTqsqfawn76RT8ijccfpiqHi3xDLpugrqOm2zX3mTxw4QHCqTy3HbtWhqsVlc2cC3MWVuV5Z3wuPeoby2lstGhtNKuIo0BUttG8BM8498VStfVDnF8lovX8T0HwtFd6l4FvLfRb9NP1IzlvOZd2wcdvcDFYfi+z1bUNW0yCztPtc+mSqZdQlYAMpHzHb3IBIFYnhLxLbagbxrW2uVt4nMRZ8xsSOmRTbTTPEdz4httRm1FYNNhPmGzRyC5wevqM4rphLTlZ49XCuNV1ou6e3zMXV4tNsfiZY3Oo6hK0mcWVkBuRD03MB2JrqtS8P2+pLDdXcKSPE4lQquAv0/wq1bWDal9jvZtPt4L7a6+YFy6gHg59xVX4n67qGgeEZLqxZWnQqBvUlcY5Y+p9qVrnR7Rxbff9Df8tFiguY2JZQNw6YIrYk8R2N5CLLWStvNs3RzFvkJ6A57GuD8E65LqvhSxvb6ZHJUtPIq7V96g8Y6RY3ej3gv7nyLA4YTgkgDII/ChXTsgnRjVV5PVao2/Al9qVlam41KHddQXckfHIeE9Dmumt79vtc1zeQyyXd2B5SQDOFVjgfTvmuf8D6bHZaFCkd+NQtXTdFMzdj0x7CrvhGfxPFdznULGw8uLAja2n3eaOc8HkcYrSKscddRk79SyuiX0emWmn3kU88hLyJIG5DEkkMfTnpWNc2phu3sJw0Uy4OOoGfSu5bVr/bN5sKwK4whJHyH1965DUHCatDPNOJSfvu55Zvb2qKltzXBTqXcWlby7l3w3LfweLbW23OLQwlCByOOce3Peu31PRdO1Ro3vbSGWSM7kcr8yn2PWvGPG2tar4XuIdb02RZLeKYJ5JHBRwQc+vUflWkPinb6fpNtqOqD+z7lnaKSz8zerMDglTWkVocmKpSnV5o6OyOj1S6I1+TRrW2MNnDEri7DghnzyhHqBg1k69eixtDd3lxbx2MYCzeYnysDx17GuMuNTv9V8Rp4g8M3MWoWSofPsVfbuZjz9DjHWuj1TV49asbKylsY/7OuwUuI5z82ecrjvgg1LaWp10qcrKK1Oc8LxS/8ACRaiuo29vHLbRiWxuEGFaFifw4zzVHTrHSQl7J4kvo5723aWZZFziNJOAQf7o9u9dbqcsWkQ61cXcYm0ywsUljij++EAwU+hwK5jV59IXR5kmtZYofLit8RxZ3JKMhfpk0dfU1jJNWvqjQvdM1V9Htm8PaqV1CL97GT92c44Vj6Hip/DPizUZ9Tn0fXY1h1JLZLryY+VUkkOAe/OD+NXPD2kwaBYR2NhOZFtMDY8m6RAfmAI/GtvVbqxtbNr67W0hJYJ5sgCsAeoDd+nSoWzRVRXlGp95Eo+2YQHb2FYXjbw/d65oNjPbS/ZLuzu0lhmbpkZBGfpWbd+IbjVNKkvfCDrcRwTNHMCvzHHpmtzStRvdR8LT2zFBfsu8I33UkHTIpR916mlRc8fd20Kd94f02+sL9ZoY0DL5kzquQGA5bFafgHRLbw9owWKVrmGQb1mkPIUjjHtWZ4S8c2Mvhu7utaRbGSG4+xXKDkFycD866VLuIWu2GMxtGdgUnjjj/69O1tzNy9o7RR88a7oM0Xj61Xxo8gWe4naFAMxNGGymT716NoE0fjPw1qkWjG5to45FhgeYbVGP4h7e1dD8RfCkHinSLRspDcWuWV+/r/hmn/D65nay+y3jW4ubUlXVdoxjoSBVSSauY03KDa6dznLzwlf3unxjSr6S41SNPszTxEBYz3GO1P0XwtLoerIZ5VilaLE6kY3yY59sd66vSY9B0LXbnVL2R7S9vj5ZAkIjc+u31963/GNg/ijwfdxaJNDJqe0taTpjBI7Z7YrPlb2ZpLEqnNKcdO5zetC51DSpwMRSryuTwQP/wBVc74F0rXtVm16C+lB8JlA/mRDLtKuOBjqai8GyahbeGdS07WrqK61a1VlnWN97RjsCfWus/Zu1OyuNE1Oy04TpbwyBwk45BP3ufTpQo3ZGIrclK8empw+qW39i3StcyvJulUINuH2n1FJ45lvJNf02XTrM3VtJCEmY/8ALMg4zXT/ABO0228P+N7nxFczSuk9urLCV3RgqecVT0u4TWPDlveRFlQMWPy7SwJrOcLXRvSxHtOWpsZkHhr+1pI5xIBFGxyznCkiqninxLqGlaFDo2m2Uj2olKTEDG/BzuH41bv7iGPz47a4KxwsGdAcANjNZl14ksJIbK1nuI/38xa2JH97g5PpkVnHTRI1re8+aT0OetNDutevXErW40ojEqscsD6fWofi1ZR6H4GvNJjs0t7aMQ+Qc/MzF1JJ/D+deg21vYQR3F61xBbQACRkc4aRj6flXnPxn1I6t4Qe4hXESvGrAntnjHr2ranZWPNxfNPmfY8DooorpPEPSf2ekhk+KWnJc7vKaKcHacH/AFbV7N4uitm1Pzo4Ibm7siRBHL1BOOR+leI/Aq3uLn4kWCWaPJOIpmCocHiNjXsXiHwvP4h1W3nWK7S/hk2vLB0Hs1ctZvnR9BlaToSvrrt92psC4nvdIU6pCyM6FZrcjIYe3rXU+DdK1Pw74YvLHQb6KyO4yQPcJvCbucfQVm2WnSl8TPFiBMqpPzA966y5vtKXT42uml87Zj5TkZ6AmopuzbO7F0+dKDV/Tc5bxKPHl9eWwtNS0+a2S32u7R4Pm/3gPTpxXMyeLbuxuDpniOICdId93KmdgA6MgP612On37TxQp54FyXK4gzgDscGtPxFoya/pl/ZyNComtDD9pCgyBjW0Jpt3OWpQdOKcdPI5K/Sw1uC2WR1lspYd0DjKggjrXBWUviLRrG4icW88dtdqqrDIDiHByc+3Fdt4nsZNAOiaDpVpJcvaRKhmY7UVO7H6+lZcXgzTZYNTjmWfF/gyBJMcjuPzrJuzaezPRjF1acakd0gudZ1eG7sk0bTYb5J/nmIlG4D1OP51q+ItW1yTVLS00FCbhCJLoHjCdAMn8a47RtD0bSfGVjZW19ew6jap84ZsrImeh/Cuu1bxht1mPR9Gsl1a5Qn7fhtrW8fGOe/BrSnBJpLU58RVcoOU3a7tp+n6nbXLkt5kdyYIwMjHY46ZqO5jF7pkllOVurab5svzjrmsC/EpV1t3naQSrtUcxNEODUSeKdKstcg0uV5FnlwSiLuVSR0z2pat2RpaKhdkPhrUtOi1F/CP/Hu3lsipt+UhhnrVvwexuvD934d1qMu9iTbyrJyJYznafy/lXMCTUta8WR614ajEUNpL9muFu4trNz1z3GPyrt/E8Et1ZXcuizxR3bqVEg5ww7GtHojJWm9duhuWdhaaZo9hZ2kR8q3ULEoPUDkfzq5fXv2eJGt5fLYHcR6D0rkNNl1650Ow8y6ggv4/9bxuQkf0q7PeTWenPca5JbJPbIdxjPyMe2M+vHFNttaGapKDSlsams6iPsaiCTzJXXPJ6VxV9cX8D287MmxT84fnPpipdPuZdTuNTsZ0EVzZSI3JxuiYZ3AfXNS6RoMn9qSXIuxdWLEnyn52n1zWMk5PU7qMoUY+7qams3tq/huSa+sWvLVFUuqdUyQC2PYEmu88DeHdEtdHlMVnFMZZ2nfzkDkMwHTI6YANcvZWSWlolvI5ZC7AvMc7gWOAfUcgVy+oeJvEuneNbjStDQu8YSUK/wAscibfmXPYjtXTBO1jxsZTVT4dDq/iLo+h6ZrularHcwaXdXYa0+zooT7Ux5XIHcEfrXFeM9bstE/s651CCX93cmKAx9Pu8sfzNdxrEK67LZXWowwvNbKJI5GGTCxHOPeq0thpV94cuotTljaZGJWNsZbNRJpyNsLTlRoqLet+19ymty3iDwuiWDwzWV+TDKxH3oTw2D61zXiW5vNIudEsrGF7gfaUhIK7vMRFwCf0NdB4YsrPw/JaaPYeYROHmjjJ3BQoy2T26gVNHd/2T4num1WWGLTp7dXt3k4CS7gCM9sjFOKbsVOUYuTW73KmiaTb6N4t1fWdc1S336iAI45XCnr6fpWh460Oy1jw3cfaLEXcVuRMItxGGXoRWrfaHoGoatDd39hBNfwDbG8q5wOvy9jzWzCqJPJDNjyrhPLYHvnpVvuc3Po9NOx5v4WuVvNCknjtYYS/RYRtVs9/6VyGhf8ACSp48+1aj5q6ZDIV8qNc7xyBx3wO9do+ky6X4f1GytLiOVGZp7ZkIIVSclcj0Oa4tPiHp2nzXxKXMj2u1CcY3Z4OPbIrF3u0lc9G8ZQTlK3/AAx3V/4O0q8a6d7XMN7PHcSruwN6HPSulubKG5QtbHy1VhgZz8uOprH8La7DrvhmK8gVozKdyb+qkdqls7h4tWIdMCRSdueGUjp9c0r30ZmoSXvR0sOivJI5jH9lScbjCZM8KG4JrnfDngy28NeNL++spWD3SlZAZC3JPoelZnhHUtSPiDxXLPp88bBI5rSwlbGUG5N6n0yAfxrC0S6vLX4yahEPN1C0uwJZXdyPs/GRx61pytK1zm9rCUlLl0Z2XjHQNP8AE0yM+oeWbEmGdI+ShIyB7EjmuS+Gfja68N+MYfD84ePT5LgqrzjBcnjNdvqc+n6hctb2d5FYXkkp8xWTic4wMnsQOleYeKfDV54V0+K41EvqiPdjbtf95HjJBzQndWJlHdta9T0H/hD28JeNNWn8zzRqrFpOwAJz+ea5zwTY6xomu6nPc30h0d5iIol6rz39q9O8faVrHivwHpGq6Api1i38uYRuf9aMcqa5G803+09KnNx5ts+VeRIz91x1A9Rmoknf1KoVYyhtrH8zX8ZazL4m0a30+7sw8kUhfMYwrpgqB656Vl6eg03QUtkYRCPOAegp+lG6sdAR5Ln7VdsFRX24LjPv04xWRbC6vHuo5G8vnAjf+L1/AVlKTUtTop0YeztHRIfizmV0vEWSOQEZTgk//XrH1rTtDgjtI2gieaNcwRMcEYqS51O3srpLe4tMYdURQdoBHRsntWf4ls1n1eO8jhMzKnl7kbBQHvinGziY1bqpZvQx4tXi1nUbnTrqKSN4wwRs/KAPauB8Um507w1PptwZbhGKuk38Kjf0rq9Pjltp7rSPs9w0MwIN4eGAx2NYPj1JtP0GfTg8LWcax+WzvmVjuBPFONuYwrXdJt+f/Df8E8uooorpPEO5+DHiEeF/iBY6oz7PLjlTdjpuQr/Wvq7VfESx2K3chtIUu1BMkTYEhNfJHwphtZ/GlrHfoj25jl3K/T7hr6FtdB0vWL6KzcosFm6lIVkOcgdSOwrGom3Y9vLXGNNyaV7nWaXpy3loAsii4kG8ZOCFz2rldfs7nT9QurlbmS4RIjGtqv3c9c1pfEDVtbtbyK08L6XBc3SKF88OCYx6AVxniLQPFN9Ewu9WiEM6BwwH7yOQYyBj+HNZSpK17npU8XNztytrpY2NK1B7XTra+uIWtfO+ZRIQrI2a6vSr+VjIBdRzXj5lKDjbGc8kd/r7VgWWhaf4osbbStWumupV2K752fOB1z710N4tp4fk+xLYbvJjEPmdSU6YB7iojaKvc66rlUmo2u7f8PoMl1q11vTTdJdwXTQnyxNGcgkfwmoLaKae5h2RYjZgAcdKwZo7W11D+zvDNhaxyTQ+dBngM6sdykevPFdFo7SrqNn8mZY2EjJn5fX+dE1qn0Kw87U5RfxLoUvENhbWnjSASKVn8tgzmPO7AzgntXM38nh+11m5jl3QahfjyZ3tjiR0PUewPevWdUEN/fTzQrnzG/eiVf4u2O+K8a8Z+F7my1uPWdJsZbm7D42k5VMd8Vd5KXusxi4VKVpxvtf9beZ1+m6lb6Zrz6bFBL9ltreNo8ZcBGO3mta5bTbTVGml02CWcnaJTgbfTJrAk8NNrOli9E09tqoMUxWN8AlAflPqOT+lbmnXIubGW21GBRtGN5ILMPXHpWkndJrczhDlbUtrnOaZfajc+K7u6ttSgutJVtggQYMZxxx9R1rStdMvtK0/xXrOmmQXFxKnlQEbkXoSwHcnJrO8FaLLa6hqo0+2Q2U6h4LgMTkZ6gfhVbRfFlzoWp2ukGb+0xLdMryRN8seD0Oe461pF2dzCpFSio9b/wBf8A6/WL620eCNtQn+ytJhWlZDsLY5yO1c/wCNzc3kWmXMMEepaSXU3MIXekg/hbj0rvL2S08R6ZcJdRQXMUg2n+IE/wBKxPCGnWegyy6RB58YlO/Y7Fo/+AE9PpSSSd0E5ynHlmtC5b2UZu/tpWE3E8HkyyoP4RyBU2hXFtbQyokSIhyFy2MN61IYm2yJGCJEcjPbFZb6XDe7I5XjLRyebgP0IPGRWTTTOhcsoNNluZ4tU1RtAug/zW6ykhsFlLEcH1BxUtzYRQCKGEGNkXoX3Pt9T3xV24tI47i11IbRcRo0Rx/d4IH+fSuU8Uw6hatJrWgQefrGFhYE5Hl55bHfFab+6cyk4v2i6G5o00dzdz29vOshiIV0zyPrXIfE3+27G805vDturzXLGMuy5MPPf9ea6Kwk04alvhuIx4gdE+0xRHhh1Jx9c1v6jaxz3ZW5CqjfMpBzx7fjS26FublLe1+25Ws4ZNOsrVLyWJ2S2CyXLkBi7EZwfQ1zl6Tqsl1e3heaxmuU0uPTpQGUSpIpEin3BFUPi24udBZozdbLZ0by4RywBFdHez2dl4Bs/EFnbzSeRJ9tkt2IyXZVTnPTGAc+1a09TixSlC1zZ1DXJdAlX+25rdbZgsbySJgxFjwoNQ6zJqD6bqNzBKtq32V1sHkG4Fyp/et7DtU+ueF4vFtm0GtQeXDKoh3F+I+M78d2yMA+lYXiDVVu/CGpeHlubNNX0+1aArGfM/ddFcAd8AcetU+5zxafuJeplfDyOwX4d2q6OJZo45SszsSSXbAc8/w55qre6fb31tqQhsLVpJAq4KAbsHvUHwcEEHh6401kuYLzduaO4fmbA5ZF6gVsXd6+jXNybmImzjj8wuuM9K56z5ZaHrYJKVJxf3GhYRLYaNDbIkcOEAAQYUNjtWQ811dpdRTPLbgnCTx4LKfUVla54xs449Oe3FzKkxSV0SIlQjcbie22tSzvoNVfUYZIgjWLDlG4YHoaTi0rmkJxbcDc0JDp+mWs1/drdSohQ3TKF8xCcgH6Vn/2Zptlr2oa9532d7qIRzIWwjFT8rfXoKedOW80R9KuPMW3mjaLzF6rnofqK5f4m6taaIunaDJbSXaNGvmyk4O0EAN9Sa0inJ6HHUcaekt0UvGfim60WWyh0y2sb3T719s1xIQHikJ7+lbuu6Q+reGrhlm/0qAZ3K2c45qCy+D3h/U/EFxJql/M1pfIs6W/m7Wi4zmuvPgG08G2qTabqMsmnzvsljlfdnPQ5PpVPuuhyxqKM3CX2i7+zlqkV14Nnsmu5J7m2uGLJISSit0Az24NYes6jbWfjfU7BLgGdm837I38IweR9etcz8MPEEvh/wCKl7pt4LG2sLqXZH821pM9GH+Feq/FHwVYaokutpi3v4IGTzo1+ZuOMn2pOzRzwfsa1n9o8km1LV21bV5r6BYdGtQpt2VfvHjI4/GopNWOu6VBJodz5FxAzbwesnchvTJ6U/wjZ/2f4XntZ7qS9iZ28w4JK46gZ61j+G/ANktzDrOmam6WinzXhJwzn0INRJc2p2wm6aUXsNur661fQJZX08R6tAxijt5OQSP4gTV/QkuLeCL+1DCt3IgSQDu3YA03xFptjca9p8seoTwygnZGPuvxzmtCCzUzN9oZcKAQXOMEdPxrO+qNGvdd2ct4ivr2z1OGO2tjPC5zIV/grzv4jOG+0LdQr5iKoglU53fMN2f1r2LxBbB9NlcExTdOB/CPevKPFENtD4BmW1/0hlmAe4PUZcHH6VUbJnPXblSaPLqKKK6DxDo/AenpqniFbWSR4w0ErAqcHIQkD9K9f8AJeDW7TV7CGc6dHAbS6aSTLyTE9GHYDjBryL4fRW8/ii3jvUka3KSbxHnONp54r6M8O6tpujX6aXaYhiZFaCSYcXIxz+I6etS52fKejhaLlDnXcm13SJ9H1DVp9H1CN9Y1Bgod1ytugHAxWz8KPDmoXVxDbeJb4XDoGZmXgMM9BWTqlhY2eoXN6twqXWoEbzLLjeQMAKDVmz1i6ZZ4WYw7DghD3HvXDUmlK8tj6TDYeU6TjTlaWvXa/W3c96XQdHt4VX7FbKiEEEqOv1rmfGF94Z+ztbTSQmdVOzy13EN9a8f8UX2o67pNvaazrtxaWscwAKSeW0noue9TeKPD9rP4dhU3s1nbAALcknIdf7x/rWjrRlHRaHDSyupSqXq1G2trPqQi80+HxPptleqPPnbdA6cGNvXPv6VreKZNV07V4LjSreKWGWQGbcdpAPUj6VzEOp6Wsdld2hk1gCZIVaBNzRnuxPYVrXEPiG70PU4L+4jE3nE286Y4jONo/LvTjFqF2tjtqVIyr2g737f5naWdxFfNM08pgkIUByPkJHY+5qxGyRafdIMPOgY+x7k15ZYaK+o+FzY32rXE81vP57vC3K4/hrZ0Lx9ZyeGmv7TTrmZoJxbskjbmxwMn3qopNaGdVOLs1529Cf8A4SUjxrptlbQrJp09sS1xH0Vs8qfy/Wl1/wAIvJPI+l6vd2iEnzCzA7ySDlR2HbFSalf6a97qUOnxrayxhbgIFAzux0p/iQX6GG5t5cMYVJI5PucVcJW0IqU+dKV77/8ADGxbRx6dpsZsOIYY/LZR1C55NZ0Gi6cNL+0WkNvbWsrNKWjGSSep9RVq3vpGkic2/wAkwxKWbZsQqct7njpWT4e0afQ3uZk1Jr2zu2E0DtyFB7fTBqd07mi0mkireeGda0nw258KPc73kDSE9dntVnwVrd3qbz6fr9lOJoAAt3t2rIQf0NepaB4usb2b7OxCmONS2Bwp9vaqnijTEvD9ptCkJb+JRgN9fetHtpqcMKr9ryVVy/kVLxvKlZEkDF18xN5xnjv7VH4M8F2VpcalqSw/6beod8krlwc8gqOwrB03wvcSeL21y41J5YFsXtfshGRuYYyPbnP4V29hoF3o3hG2t4b17wxLwXHzshPAGOwBxj2rRWtc5sRUcbU9tdzldXuDBoV1cq6O1srlsN97YcGobm/mYQtBNDDZzWpkV8gSbmXt68VkeINAay1CzhtoJoLGHc8hDEh0kbEyEevKsPxrRtfDsMejWUF+onltCyo+TgIG+XJ+mPyqHFLU6oVHP3Xsct8Ko7GLTZhYakl/c+YUluXjKvHnopJ57V6BOire2aiRBAsRUuT/AB5ya4nU9G1XRdahextbWLRZszXEiDDdMkmrNgIfFej3lhvfy/ODRyq3Lrwc+1Q227s6IxioLle1y89zZm8FytwjkyG2ZS3G8Hpj1rU8Nrf376tpWuWMUlq0mYYxjDockYx+FcxL4atdRvmW3kMSxXQuWweCwXB/PaK2PCutXNrDE/iCSOC5mu2S2Y4UtzwAO/IpwsldEYhSl7rR1o1LXby+azhi05bMR586R8Shwfl+TuK8/wDDXh7RdD8S3tu15FN4nu90s6/dMgZs4VfQVe1bSNKvvHsF7eXtzbalDGZz5c2yMovI3qeo9657Xra28NeIZPEal9U1y+DLpxkYBYQR97d2UCtfi0OGEPZNtJHUWGnWVn48eZYc6oLNjIZHIMaZ/hX3J61mfE/WLDRjaxX+5pLghRHGuQSRzn25ql4MlvtV8az6vf3dvMjwLYxeSScy7gz5P4VK93Z+Lta8R6PazR3jWUyiKZkx5B+4y/gwqJxTXob0azhU10bvYqLr1lo+hTrK0Yhths+UZDei1d8CfadQ09LySxMFxckRu4HEi9VNYmhfB68aw1iDXb7cHfzohG2d2zv+NXvDHim1h8Wv4UtBMFtIgscz9CQORWfIoqy1Oj6w6kuZ2Xl5nZJqNpAkS6i3k7ZfKbd/C/b86r+OfDel688N3fWslxJHjZHEcM4GDzjtVu+0mG+UtqcG2MyLICejMOhq98OfD90Lq98Q6jqT31+DJFFbqf3cK7jwB3OAK1i9DhxMuR3epzNxoHiuG+XxPp2mNNLbRrHHpjuAGjHv1zisvxL4h/4T+3NncNLpt7YlHlt0/wCXaQNnDEcHP9a9uW+bWrW/tGRrVTGY/MJwyk8fhXzG8em+FvHcml6bfiDazG8dR5plfIxn65x+NUtdjkjNuTc0v+H8yv478F3N54kttc010jWMq0pc/dKnqor6mkaXWvB8clowMl1bKQT7jmvF9A0TWvFfjmaNpxDoEYzIygEkf3R6c967n4l+MbnwZHomjaFprTtc4jLjOIIxxnjvUq7DEW50or3r3PJdFu9a03xBqmn6zDa+TCzfZwpC+a+fu596tTPDrWkyG3hFndqzpJEjAmJ+cqccZqfW9JstU8VLrepJtZGDKuThmwOSPqK5TVPEOq3uuz6d4c0tILeJi8kuB87f3j9az5lujtlCTa5v8zorXRBb21m8juWt4lLcj5v/AK+a4a5vdL36np0kN7PIlz9sMIkIMj5yAG9B6VvT63gxxaoBZysdhXf8pb1Fc54p02S9uHlkb7M9ufNM0ZxuTtWKaTbRtUi5RUXrYu6hrGp6leWEpjFvaYLXEB6j0rmPGkNtD4Huzaf6p5lK46H5xk1q3hXW7SxvtLuiyQ7tyYI8zHY1D8QdMe3+GiXxg8qOeYKFTlVYFSefxqoPVHPXilCT8vv0PFaKKK6jwz0D4GT2dv8AEexk1JA9qIpg4Jxx5bV7Za6h4M1Xxnb26ukkccgmt0dtxVvUfl0r5o8NJby6skd5dNaQOjq0qjJGVPH41754R0HSbOWxewt1cIo2XDfeOfeuWu1F3PfymEqlNxVrdbv06fqeu6toVrfQqupwWk4WQtDNCuQvcZB6HFZF34YluJmmsDtLjeUc9foax/Ci+KbXxHdXWtW05sbphDFGXASBf75HfGB+ddifF3h6OddNuL+MahFnZHH1x61VSEWrM3w1arTfNTvfY80+IenLJorW17bySXKFWiEZ+YPnqK0fCdxrdjpt5F4rWLUbWbalrFjPUc7scfjXZ3M9pqsdxHNEtwskZjUjhlyMZHvXM6Rph8OaRZ6aLya5S3J/ev8AfIJzg1hpCNrnpcrr1U5Rtoc5beKrbw69za2vht7KG0YshgTKsCQCa3tT1fUb/QU1Hww0U7FcNAybQVPXj2qLSdWvJtdvre+sEWxQFoZgPvD0NR+IJpLWFr7TlkUW/IjTgHPritFUakjOWGi6cmlZLys0UrPS5dK0S+1LR45FvL5fNjjf7qt3GD75rf8AC0At9JVr2CGG7kTfOIgADIe/1rkPEfibxO9/YLYQwLYXLJBH5mPmkPJ611epXkNvJHZyyxC5lACp1LDvgVN7q8dmbQSu4z0cdPLXt6lSzs/D0HiqK/Mkk97dgqGVy0ZCjn6Va0fxHaa1rqXbRs2lrf8A2ZQoxuVVyfw4rMl8MCDRLyz0O4W3eUNskc5MbN6HtVC/sJ4ZvCejyanbQXdu/nzrGCBMoGCfcnmtaTvdHJiY8tnb/h3+vU7Lxxe6J4w1htP8NXXlzWse2UAFVO7pj1xU+mS2mjaYNDWK4eLSLNHMuNxfJwR78mvQbXwfayxsbWG2txtAE6Jh2PX8BXn19a6xFd+JdIFzHFflVNtdKvTIzz9CB+dXyKMnLvucdLExqQjSi7uF7d7Edo91Z31x9mssWBtfNiIGHd+oBz069Kw/Aut+I9Y1G5PiO3ktoVbEMfK49fr9a24Y5Rq+mQ6prMA1s2uJ7ffgTY/iA9f8K0Li7e3vC6YLADAI5GamfunXRTqa9UdBp6G3Ajdty7crnqRjiuotrnRtNj0+e8vFhuJF2xpJL1YjkAfnXh1r44uP+E5TQryCbzrkZhnHIXP9K3tIivhqepal4mgsRLYR7LG7AJzlTlgp6YJrSDstTgxlD2nXXrY7TVJ4fFEur2emwTiHJtnvSdkZJTDbT6jjn1qhpV5Bp2mpCJobs28QgdlOclQB+fQ1R8N6lBrPw1FjJbTw3c+8SyQnIaUMQWB98Z/GuR+FV889o+jtaos4M11OXGHjIdY0UDuMZOfarkrptdDno+41GotD0HRpNPvYLk3kiqWVolhc9j1Nc7p+mXll4mu9vlppTRFIUjABDdcn361n6bqFxd65qemT2DQi1iH+lucCTOOR+f6Vd0WHVE8VJFM0H9kKnMoOXZ+mKx12Z6iUVecW/Qw/Emi39zbTLo909pJHKsjO7Yyo61Z8Y+G/+EiOix+TcPc6RGkpuVcKkjHkg++a6x3tl1D7NfRu9uz4Kj+JT1FWfEJ0rShZaNYOSHP2lmL5yhJ/rRH3VcVaXtKkYtPX7tDkfiPo8PirRL2O0sJJNYs7dRFKrGMSb+qZ/i4BGK6TS/8AiV6Jptmmn2NxfW9tGhguWGANoDDPsc1UtPEemy6rJpcFx/pNuoZ4ieee9T+HN09/qVvqYiaV7xRA0PzPDAwAw3pkg1tGV1bscNekoNuXUTxF4f1uDR59U0e907TQ5WRFjjARDvBzn35BPvT0sdP0ePVpLLT0E9whlm8kbTI/XP55rvDpMGmaPeWhYXIuXJSOXkEkcKB+FcPnVW1u5SW2iWzwggYN87Hb824fWiXkYYSam/e6Gf8ACXxTL4n0m9e9hmhWwLRiPHzoO6n1HSuQv/CGoXHjSfVoZktrZ8MGiPzNjqpFeoeDbaK28SzN8qLNCwYdAWz39TXJ/FrXbbQWku7EMXLBACDhGzycVkvI7NI1XFronc6jVNbsLfStPttR2xmWcW8RbqWPbNdLpeqWFjpaI0ckSAkEAZPHf8a8ln0t9dtdGuJZ3R7SdLtQejAjOD+db+oanCGaGO5LAbQ8eeYyeQT7U0+plWw6l7r9f8zf1PxZJdz28EejyPpV7kfaZAVAx3bHQDmvJ9S0jw2fEJ1Ow8m8k1dlnieNWCJHGMNgnrk7a2rS41rRPtCW0N7fWMlyJVuElDRohxlHXt3HvXFa3c23haaE3V7PNG8zm3tzjNrG5+6B/d64q76OxyxpqMlbY9H+Hc9t4Ohv7zWtUEY1GZZUWXjcuSAqj8ag+PdkdVk0LVdP1kWturlGCHhm4xkjv25ptpF/bWn2N5cWz6jIj/umRc/Zo+m7646e5rZ8RafYraXmii1keO+sHnhWUZKyAZAP+1xSW1xytGtdnHyxImnvcNuL7xISWyOmOnbtVW7Gm2Gk/wBsWkRjlmb/AEhU5YN7egrI0mTX203TfMhgEasU1BJB82zopFWfAzWVx4vufD99qP7+/wDmtlZPljcc7fxFYSTueiqkVF30t+pyGv2lvr/iuzuLiMi3jUMhPBP4Vqa8Yi0ls6ukATKSnGNuOhr127+GQv4bpgyRTRDbGcfebsK8z8U6OwU6ZrNpJCWBXcOpA64NJp9SIVIP4Hr1OU8OiEzyRi7jtrBlG3YmdrdCeOor0H4zWto/7PSyW19FdNbtCN0A2qcygZZexxXlfiDS4NC0g2QS4W2lI2yLkkZ96PFWrJZfDvUtFtjujnW3Mm4/NlXBB/z60Q0ZzYtOpDR7anjtFFFdR451nwvsLXUvGNpbX4Bt2SQsD7ISK98urbUxeafYeHtlrAuJXndcgKDjYB6kV4L8LFtn8b2Avbg20OHy4OOdpwPxPFe5aw/iB4rWOzvILSaKcP5iH5XiHUEn2rlq/Gj6DLH/ALNJWe/Tfpodh4i1ia/jks4GCHBJUMOB296T4XeH9LvNLuYNWjhudTuN8X21UxJCDwAD7V5r4mtbiHxC/iPRpnnMcYBgGSrjOM5r1j4NPLqsUN9LZPZyA+ZKJOOAeSPaohfR9ztxDg4Sjs46r/M5SHwdrPgnWbyGfVWvLUnK9dyjru/pWvZX66xbyYkJMTbSx4JNbc+uab4p1nUXiuoyBIYzsO47V4H515vJILGPxDLqMVxFpIbykKff543DFE48zZrh6vsqUb9v61OruHRLhYkaN4T/AHWzz6VjeJ/GNt4fvILGS1b/AEhf9Zj5V/Gsqe4/s34d2d34cihgRLlWle6O4mInBYn1JxW9rdjpmtWgS8iWeM4cegHY5qeXklrsdKqyrQcY/ErPy1MzQ9Xi8S2VhfXcAhGnzs6NJgL0Iz7cHrXUW1rYy3Y1IRxyXCDYsmMkfSsmCCwksvsCQBrdgA0ZGBwen6VX8S3mt21xaQ6DYC5hBHmbRwORwfbFCfNKyKcVSp3kr7fNjH1ex0jUI7BpJN91csAwO4Bj/ePauiubmKz8W6Ol3pqPDDbPcG/kkULEwJ429e361iXbaPoEt/qWpWpVpGjaZWXIR8YBA7VqXHhO28Vww69azG4eOMRPFn5WgbO9s+oGa2ppcxw4ycvZ9LJrTy2PbdJkE3h9X8P3UFzJK2/zmbem5uT0/lXCt4e1HTPEl3c6vdx3b6nIZkWNSojKLjH0Ix+VbnhC0sT4MtJvBO2MwosfzEgSFcZDe9UfE+oa9aapY3Gr2lqNOUKITAxLGZuMNnoOa6ZLQ+fw0nGt7vW5w3jfSv8AiY2esWNil5qlmQqZOG2N/hk03xrrA0LRppoHifUdgkSHOWI4z+AzRrx8QLJfNYIjXIYBVdcjbnt+FZ2r6BdXs+n3k0MS3kCruIPHP3kPsa57p25j6HlcU1B6szPhv4kstZ8y61CGOO8tiB52P4Seme1eg6haXbXM17CsN0qKPsls7FFbI+YNXnXjTS9U0O3MXhXTQ3mvuleOMMqL716Fo1tf3Vh4evLuTEsAJuARjBI54FaRS3XU5qs5P3ZatdfU9C8IaJNFoAi1e3t4rqU728gYC56AfSvL73SLbwf47vdSn1BTZMSpLDmAuOAcdiwH4kV1V3r88urpcxa2xjtSEawQA+Yx9cc965/WoFtNR8TW4tf7Q1i4uILiKCc4QxjAUr67SCT9K0VjzFCom3J7mzr1g8ls5VmjWTA3pjKk1zPibU7PT/DN1az3vkXZgZoWzh3ZBnI+ld5PD9qs0xPtKqXYKOoU9K5bVNO0u/S0uL+0guAjHymkXJjZhjIrGyUk2enCcp03FboyNB8Qpq2qNb3aZuLa0iuBPGflmDL8xH4mtXUVhura0uIkXzIyYzK/BCk5ArG0TSdP8MXEZiSRlRDbqznohOce2Ko/EPXbPSr220I2jXUF+Q+6J8FVyMEEdTzTaUnaJcZunZz3W39fMzfGuhCXV5L7R7uO01+FAd4P+sUev4CvU/AzRGIavapEuqvEsd0zNhZAo6n6ZJrl/Dt9oOva43hudRFrXlZhuCuDhe2e/Fc7DBe+EPGk8eu6qraVqDNbJakHqf6e9EL6PoZYpU5c1Jr3r/L1PYvEOj6zqemCW81P7O8ILKbJQCp5w249sdq43RYNet4hdatcSS3U+VKBwYkwMBlHXnAJHvWtol7Lotnc2Dedd2USMil23Oy9QoPsOKf8IZL/AFq71DV7yIx6aCYbOOUHcMHk8/lmt907Hla4de9v0M25v7O0u/tmq3RtIIseaVOAOOCPXNN12zN9olrq4jWaxkbIaTGQpOAWz+dQ/FHR2kmv9PnBNvcxloZNvAySSv1B/nVbw5d2mv8Awg1nRorqSRbfEDEH5h6iue2rTPTdVuMKsOttPwZoxSSGEyWUYncQBkX1wccfpXA6f4b1SDxI2t3l7bwT3StDf2DS/wCrjPCMG6ZHpXT+BWXR7K0sVu2mWGJ4PNc84J4z9K2PBXio6t4yHhS+06DzbSDNzPIoIuVwcHGOvT9adOzujPGSlC07HK6NpU2gMkVvcS3NtJveWd58qq+mKwvHWkWGv6e2raTbrcXjL5YKscHy84/mfrXtfxB8KBtOS90KNYp4OGtVX93Ov90j1968p0i1Nnpl7qmnqBaTo04tjwYLhch1+mRWjVtUctOtGokZvw08a6xoa28j26LbyRFWRjjBB7Cux8LX3iDxJ4pl1i5gRLPT4nZh1Lkqdor59v8AV7zUJLN78TWcjs2MA7ME9a+r/g/BLD4AeVV86eaRgeeSAAP/AK9Ry2Kq1Y8raWu1zzSx89BeG7nWaWZiQUXjYTnb+FZXhnw7bP8AE/SdUnkYNHOJAOg45B/StfWoX0fWbiyuZCEZjMM9lJ/pXO6xqX2HVLWCFXZ5Rutrpfus2fuH0NZyTex0RcVFqWzPfdSn/fsUkbdvOVz0/wDr1ja/Z2+upCuoIsjqcHnDbfUH1qt4S1U+JNDS8kVY9SgAjuoQe46OPqKvzROu1XXCnPOKrc437unVHnuv+BtRga4fS3i1XTyu5beQ5dQOcEeteM/EyCxGhXlwsDwXzmNWXtww4r6gCyLKCoMTBgQw4NeWftD6dYTfD6+v/IWK/jmi+dBgSBnAORQlZkTqXi1I+U6KKK2PPOs+F2kw6341sbK4DGNtzEL1O1ScfpXt9xpGvQeI721njabQJF8vaf4UI7d815L8CjCvxIsPtEnloYphu9D5bYr6H8T6x/ZtjNcafE96sW0qpID8dfwrnqq7se5lrjGk2+juWfCmjaVpnhvyLESh422yCY7gwJ/TFWLzVGj0y60y3uuDiNo0PKj0JHTNZOlXVxcaSmqoywJONzwSEfIfQ02HSxfXZ123lhWeWIJNHCdysQeCfX61nyyd+56SnCPLpeLf3HMeF4tLZ9Sbw751vdqfLnDZBQ+oB7VL4eS5sX1C31K/t7yNsEqzAkDuWHat6OCC3e5uEhjjuXGXc8Fsd65n/hFtNvJ797Wc/aLtSkjxvkLuPNRzXudfs3BRat18vwOqWKy1GyaziWGbT5U2SKuNrKeCBV2KC3tNLtrKK3CR26CNH65Xtn3rP0/Ql8P+GpLPSFLTwoX3TH7zev0rK8P69dWlzNZeKDC88x/0aGHP5k+/anZtPsJVIqcXb3rdNvS5Gvi3TLXxA2m3UE1u5Plxz7coW960vC+vX+harKniQWZt0l/cOx5kGe4+neobiDS57WcwacbmXO8xu38Xse1WNLtRr9n5upWSpqVrIV2FeAvVfrxTvG14kuNS/JV67dvR2PYBD4d8d6Zc219YoysF85cAHHUEGsbVvCEHhSFW0NZY7KOIgIrH93j1PcGsXwz4kTw5FcGS08wyDB3HAGOf8/SoIPiVceKra7e2ZBp5zBsVep/GtlNSjdnmPCVqOI5aXwPu911PRPhZbadY+FUstKGEidmkH+253Hn8a4/xnPr2m+XYaiIr63WWS9iaPIkChxtHvt3V0Pw41OO30Qafa2D+XathpFYEMSf1NZHie7i1PxetwVKy6eht413/AN/BYkfhiteb3bnnU6EliXFLZnI6fcXtvZW12ELNLh8zPhvnOcH6ZxU/j3XbTw1At5LA959qYII4s/I+OcmtPxHKUhVLVI5JQ4IR+FU565rodW01P7Btp5jG8zThQdoZRnH3vy61mrPU9epUceXW19Dy+z0+58Y+FoZZvtFhOJsoCxB2e/qMV3Xhu72WtzbWsyyz2y+Ugb5huxgbhVbxDqLWFtq7hY2uLaEyhYxhWAHH9K4TRPFEOgWWkRzLbSajeT79RigyGjLnhj7jIzTim9iak4uNp9VqzpfAvhy50rxHqOtXt3bPefYHXUGhTCCfd8hQHuF4/CoT4iHidrcaPNFJr+iP5/mMAEuYicOhb+9nnHetfQ4LvxF4uk8N6laqLSxkkvppVYjdkhUQ44OeTg11fh74beGvDN3f38cKGWXqucKijGAF/CtbX3PNlWhTfLu/6/M5Pw1ql359rJqgdNVSKdxGOI3QOOCP+BCoX1W7udC+13VpBby5ZikJyFZSRgflUNzdfYW8U6pcQvCbW3ZbZZEIDo5BOB9VFZvi+31CTwLp0emuLS5ljTcOhVsAkfnWc9T0MO0pN2OU03xVJr1nc6b4gL2cmqM9vAyLhsev4V2nhXwq1h4bt0vru2v7qy3CK5K/MkWfu+uRzWFfQWkumaPJqsf27UIGVFlhH3ZOueO3TNdX4fvZbhpbuS2FjaqfLktpyFeVycblHfNK91oU/dkpN6mGxt7L4g2MljYSPcld0dz0xng/h1/Ou9+L1laP4ftNZv7CKVLdBIxYZMbAZBH8q4/x7rj+E00+aCz+1zPP5cZPHHXmtm88Z3uq/ELS/D15YhvDup6X5ku5cqjkN39ioHNEFoYYubVSM1r/AMEwPh/r1n/aFvqGntd3KXlyrypjd5LMQGQg9u9e8Xkk1hDEtjam5DTAOAwHlqTyfw9K8Q8F2c2k32rwIkaYmzD5Q5wOmfwr0j4YeI5vEHh+Q3LD7Yskig45wDgbvcdK1i7o4MfTaamVvivbaxdRaVLolgt0kMrSTsXClUxyAD3NeWeG0mtfGsltbw/Y9PmCzFU/5bMeTn/CveLeW/FrMdfitY4FAXKSZDjuTnp9K8W8cakbJBrugWYntoZ2WONMgYVtp469QamcexWAr2vTltuZXhiR9W8S67Zx2sloIJ/kabhWXPb3rrDo1n/wmdhq0VzMmpMsQWKCQIzLkgknuOOlZ+i6/puv3SCylMN1+7e6Xb9wH7w/AmtRfCmhTawBaPPPr4uiYnWQ7YQnzckdBgfjmlBWkzbFVG4JXJPjh4+vvDF9pmm2gdYbpgjzpycggkfXFKJ7G6jlkjVXtjITlRgFwcE1hfE2eLxJot3Jf2qm50y+tokljbAcyNtI/wB4fyNZ/hW80jT9IvNGinmVLZ35uCfldmycE9RWk1paxx4f3XvoUfHNnb6xpdwYrSIXEJ22xZcYx/SvSf2dJbqPwKLbVLiKS8+1SMEBG4Lx2rhbO9t7xHwhJUlPxH+Iqlplu+la3DePezQC0ZmjZDjKkc59RWXWzOmtBVIaHoXxU+GEvinxBaajp+oNZSKuJQVLK4HP4GvIpnl8P6vLpurwmQCQmJkXIUZ4avqzR72HUdLtrq3kE0UiAhwetY2t+ENK1W1u0eBUlnQqJgPmQ+opM5aWJcNJHh+iX40rVE1Oy2yxyDMkOcZFdV4Y8bWl/rF5YahdiOGYA2xl+Uq3oa5Txl4RvvBaXGo3MsDWKcJMGw0gPbb61wviCwj8SWFrf6Vc+QyNvZCMb19vfipSZ0zcKiutT6GvYJI7gLJgFhwScgivL/2hRn4YaiemJIPx/eCn/DnxXPPPJoF/MxkK77N5T0YdUJ96f+0RAU+FV+00iCUyQfuxyf8AWLVRdzkrJw91nyFRRRWpyncfBnZ/wn9l5gBXy5ev+4a9j8VXFibyHTNSmMKzp8joDnOeDn+lfPfhYXJ1iMWTSJPsfBj6/dOa93vLO/s/C2lXclgL28jIaQzKSyjPUe/Ssai95M9jAS/dSjbz/ILOS6uFuNDuo5zGI2T7aOMr2P1rV8KS2nhS2W3lu5mknkCIHGdxP8qdPd2f2JxB5kVyQGUY4J9DVuyRZZlWeJS+3chI746iueVR30PZpYePLq9fPsS6fBJZNfNfXk19DK5dY7gDEQP8K45qa0DW0iHTYbaKBhmRFj+Ye+au2eiTu4nuRIlu7YVsZBGKvCKGC0kl2yMmeGxjr2qbyerNowpp2jt/XUIbmQyuLg5GwrwOtY89rHJcCSWKMyKflOORWvHdwSzRo6hSxwOPvdq5rVbybRtUuIZPOuVllBG4YWBehBP1qbc2p0RmqT5WtxdR0hrm+sbm1v3s1hb97Gq/f5rcfWIdKt/tVy4iQELk9/SuV17VdUs0ifT7E3xdvmA/hHtiujs/A2p+N9MtvtVtLaQ7hKd4249verjzSt2Mq1SlRU7vXz2Nhr211KKXybQfaGQlMHCyHHQjtXNx6mmjWReLSbI+VCk7RQygbmJOQvY9K0J4JNCvbi0liZHaMrhv4T0BFXfg38MYoVhn8TSLdNFB+7s3begJd/n/ACI/Ot6UVJNSPPx1b6vaVP4bdzO+GnxBt76x1C3tLCOxu/NeVUlf5sE9VB981Boum6za62by8u2uUmkaa5yc5bJ2gegANW/Fvg1dR8bSRWmg3EmmW5BjvbJtvk+qk9wTnit9XK2bLYBroQgHYCNzZ9aud9kY4ZwfvvVr+tTG8SNPcz+VCygSMFkdz8qjjP44rr/CmrzWi3FqF863itmdY35yVHH48V5n8SrbxBGtvLoih4zLvbGMgn+lcx4a1bWND8Sw2kurRHZuEwlk+Xe4wFOfSlCPW5ripRlHka/yOqXxXqT6hrd3rGkuLaJBIPKTO/LABQO/WrMcPh2y14a7Np0kl39oTeF+UAHALMvcjNdHoFtc6bMxmkW5EgVCSvyhe+BWV4y1KPTta0pWt5GS/YwI0aZKk9OO/OKab5vdCcYuDVTbp5HrXhUWFrc6hLG5lurlzM8gGcr25+ueK4PS/FX2nxTrNjfw/ZW83ED3h2rOM8Kp7muo+HtneRaReR28iK/mtu3jO1j1A9s5/OuP8Sx6FrvjvSNF1awvrq702FpklViIlk3cbj3rZWZ49uSpJbs7fxTHcPBa3t19ne2K+WURehbpnNcX4igttfhOneeIbvYZlUHDgA4LD+VdtqmmzwPZTT6l5in79sQNjMOdw/KuI1nQ7q21q81iC5VruJJJbWPGQyOn+rP44NZyWp1YWpywslf/ACPMdHg0/Qb+48M3Fxey3VxIJFcEqFYchc+/FdH4ltLfWrqwtri++yaisiyxRrnL7e1Zdxqnh24v49f1QNbXkMnkyxyna0T44OP5Vc06GW/8YC6ks1aK1i863uQ3VCBj86nW9zs93l5Vqv0Or1t5E0Se6uwJrm2Jk2lQSR2wPpWn4A8RC4sdNk+yR2hm/dukvJZATyCeRkk8Vylzq+u2nxATS7izhk0e+XdbzKPmBC5bJ/pXN+KtdS48eQ5Nxa2OkkO06ghWAGdpH6UctmZzlGpGz22t5nStb6ppHxI1Sa4vILjQ7mQxRlJBlG4IHsRW5a6zqunatf29lE9tbxKkiTIBtn3fe49RiuLsLXStItm1W51SO5g168a8jST/AJZOGIAH5nn2r0FpHi0qMId7s/APUj2qou7sZVI/u1KWvRo6Hxv4p0W98JxMly0q3DqAISC8ZHJ3Dt05rFu9B1kaFDqttLBFFvNw9pIBh42HIz2OOfrXDQafb22s7zHOkEySGSOFPlkbvux3wa9T8LWr6P4QbUtbfLPhkhnJ2wxg/KMeuOa20cTy5r2EuWO551oOj6JB4ht7XS/NjutWdy0ud2OQePTHpVvxbpt54V0+LV7zUbCG+trkvCUYr55HTzMdvatbx7rml6beWeuaXJaoQGeMqB823qwplr4l8OeJJNM1DXLWKSyZc7Cm6MSH+Iisk+V2OmfNVipRWnY830HWta8e6vpv9sW9vpdpbGa+kNuuFvplAwxX8FFelaPod/B4Z+0appttfkpm4ubw7JZTnJ2qOFAzx9KyvG2paZH4j0+38HW8TOEZpTCmQFPCgDsC2Mn2rZ+Kn/CbWfhdLmJba8EMTebFApyWI4P0FW22cyUY26HLaNFay6tc2tkhWGJuo5CL/wDWrI8R2dr4luNR0nTdTWO7tZMSbc/d9CPQil/Z+8F67PqV7ca99v0yOWLcIZhu8/J5YZ6V0vjb4aanp+uRa3o8c90Ylw4tcLJImRlSO9TZX0KdfuP8A+JH8DWNtpEyvdWZdV8wnlPXivbWnS5t90DBgyggg9jXzxNaebNJujkgduSkvDp36VTl+I3iLwjrFjaiNb+xbIcFcZQn19azaYVaan70T1H436NHrHw+vX2SyT2aebGkZ5JFfPnhISpYQQXSLGrnaiE8j3r0rxz8X7O/0uHStNt7iK4uwFkZudi+gPevKV0DWTrj6mpnbT7dd2EUngDkAUtbWKoXhFuRJNFrGpTLJZ2iRXllOYzED80yH+JT6iuW+J8HiG0gmi1C5maxO3dE7E4OQR+uK6GHUdRvNdW+t7aSG0dcO20q5cdOKyvidf3k2hyxXO4jcuS3X7wp/C0Ntzg7s8kooorU4DrPhhfWuneMrS4v5PLgCSDdjPJUgfrX0hJqM2pWtqIJUWDBZf8AaHrXy54SiaXXIQlp9rKqz+VnAOATk+wr6S8NOl7pCazNYNbRtCIolHAXHcH0NY1YJrmPWy6s4+5a+pgfESymfSbeSzmaCRZlB4xuBNLq+r614bmtJmthNa7FVWH8T455rbOvW0t/HbXjKZ5V3xQuOTSeIJlt9Mnup4nnt9gZQOcEnr+FYxdtLXPUqJu807FT4f69qmpXuovcM81ruAMZPC85wPwruNQS4bToXeA26SPny1PAA6ZrgfBett5v9jxWK2yXCm5WTJYsBxye1bzeIZ9Wi22ANybaYxOJD5aqRwT706kW32Hh6sVFdWYtgdZsNdvtRv5Gn0uAGQRxjcSOwUDvWh4huNaudTspobVZNLuArurpyM8/N3H/ANao49W0l9enWymuJ7+BMeQHxGpHXA7n61JJ44jtIoE8S2DW127FUZSSWHqR+NO2mi1BVLP3pNL/AIP9aHoPhjWdF0VZLl9O33TcBzzx9O1a0HxIuJLqKCOzXdMwSKPPJPoK8P1fTbuMTXuo+Ib028jZjjt4MsB6cdqTUbDVdJfw7qGgie4ubAJNC03RsnPzinG6S97QitTpTc26bcvN/oj3L4j6LqGq6X9rji8uUKyz+X1UY4+uK47wNZapd2ljp897JJeQTkQ3AJBEZ+8reo4zXtvhu/bWfD1neXEQR7iIGRByAehFePeNYrjwB4gi1VzLHo/nbxcJkhCeNjD3ycVbi+ZNHHh8SpU5UKiSlHb+vI9Zs0t/DeirDe3fmnLHcwALk84AFeHeINLTw1q9jrs2sW8Ek948UunmUj5WZiCPcAj2rtdD1jTvE1qdQ167dlLf6MkecBeob6msrVvDGkXWoNrWsXEWoCGT909yv+qJ5/p3rW6ZzUqcqUm3v17E93Bb6tZgMN4QhlwSvzA5Brx3WvBK6l4kkikJtwZjMWByZSe31rvZdTvH1y4vJZ0u9PMjy27J8ryKoxtwOmMVuvp0V/5V+ih5I4xMAfvAEA/ng1k7weh60OSslzodYyRW9oFhEki24VWJ5KnHr34rK8YaxfQWkOoeHore9urS5AkyAQgK5Y89K0LOK21vTLu3tLySMzFo5AvBUjjP1p0ej6dp2jyaccQwSSYnycl/lx1/X8aI2WrFVk5aIv8AhfVbe08SaRqZ1QQx6zGsX2dm/dTMQTlf9oEEe9dl430S61OHy9JQW9067ftaABkyef0zXj/ii5svC8ngXRWtDLCy4iZxkxjeSG+oyK1rPxt4lu/FK6bp2qwTx3G+KOCS3KugVc+YH6HntW0X0PKrU5X9tH0fqdBrmjJLNcuL57W/jjNokoYv5ZI5cL0z0/OuG8nxna+LdNfULyG90tIBDNNENu7GRkj1xivWPAvhe40p3k1uf7dqE8fmTSSD+PgHA9OgrkPF13NYalLbW1vEYk3SO0r7UDbgqjPvn9KmV9ka0KsJS32tscb4r0fRtc1hw0Uc0O8PNInB3qMYasjxdbXVppMg0GVbe9kKJ5rMQEjH8I9KPFFvqF58QzZ2G6xskC3EhRceYc45Peu/8caLJYaP5EK2097LGpRJBwfqfWs9VY9G8JXTVn/kcH4912/0u38IXFufOvIQd+08P8oyPxrevriDVdDs5dTsBbS3abnibkAd8461zX/CLeIvEXijQ5o4DCiW7uInIwrocY+nSuivNVgvZ1tbmN4NR09QlxGR97HVh7E0pt8qfYmi4urKPRnG6bor6h4dudVvy0mkWUjGxEIA+TksMfh+dem+CdctfEPhZJoI8gEKiy9VZTjGfyrlfh7rD+ILPxBY2umrBa6fIWQJ/wAtSc5X610HhKdrvRQ8dgulxxyFSq8BgD1+ua0b6nKoq1rm5aG90/xDBKVXypCIp488qM8OvuD+YrR8Sy6hq17H50sb2cOVIB+VvVvrXD+IfG2naJOLK/njDhT5u4/vAuOorB03X5PD8ul2ujhr3wzqLs8d0WZ3Dt1DZ96blfYxdFKScjLvdFuviD4pnijd7S2ty9pbLjCOSMZFb+heHJ9B/wBCnuUMlipMkJP+sXODxU48Qw6R4usrK0jzduTcqzjCD0H1ODXV+LLC11a0g1e2mS3nnYs4PRiBkj1pO+w1JRd0Zfw0lGn/ABR1SK1eKS3u4YjHv6w88x49Dyfwr3VlWF5HuJv3chx8+APYV4bpSG2cSu6rdYDRyxrtI7gc9cVleIPHF7q0DWly80lpPbNLbtvMcshU4YY/hIqkubQ4a8E5cyPoa5jd7m28tiiJy2Djj0xUkjqkfJwc9ucGvntPGPjDS5bV9Kt/t0KW8aiOc5eQEAnJPcetXtZ+Jmq2eqWU91dCyd0EYt1i8yJmODlz2o5GzncWi38fPEen6HqmgRzRtFPeO5ebZ8u0DA3H1ya4iLxMjSrHcWIezMZdLhxuVvYdxXI/EyTxX4015bnxBBbx29ujR2yLLhcdS2O/QVzmh+K7rS4XttZj+07WGGXsh44ocehtSlJKzPT4rjQtRtRLBaRxkk4l3d/as3xfr2oW+mrZaLctCI16Rty3uaw9JcPbagsEIhgVhLA+MqVPfFRaDpV7PHuuGDTsx+7zgYrGTa0R204xlrIxvDeua3cXs9teW5HAIlPGMfzzUvxGa8fwvM90QysydR8w+YVur4l0zR786XrlhKuFDrdJ1OD/AIVo/Fa60jxD8K7jWdIHmJE8UIkYbWB3qDkd6cYu92c9SolFx3PnSiiitjiOv+FluLrxjBA08kAkhlUvH1HyGvotNXubPT0s540eFF2glQN2OnAr5w+GJI8Y2hDbflkyf+AmvfNPjs9Us1aG5afDYyrcVzV3K9ke3lsI+zc3vf8AyMjU9Pj1DU7W/mHk3FuDs2nr3Gan0TWruXVbuyurcHS8hY2Yfe496S2af+3pNLaxZIlX5J2bIz2z+dJpXhfUbKzuA0pu5DKXx2GPeoSsdt1J6bdTsRF9jdFggjWOU7IzgDr1C1VuYBbm4XMUUByWxwAe5JrI1jVtT059JijsVuk8zM6K3MOcYYelamszWUttItzJHBFKuCZHwrH6+tXJOUUzGlNUpyTOQ8B4uNd1S+SxtcZ8uK5JJ39s/lU1zqkOpXtyNX0p4pbHLQTMm5MA8n+tbvhzT49J0gWqEeVvMgGM/e/p0rZsIftEkkcsa7ApBGeCDUOd5Oy0OqFNqCu9dzktP8QjWrOV9LbZsyoLeuOuKu/D6XxFqkN7BqST3DxHIby+QK5/xp4e1eXXbHTtBKw6fcMMTQjbsbvux2r6U+Gfhm60DTYVurhpH8sBiRyxxyaqFNWsupniMdKn78t4/K50nhWEweHdPiKlSsQyCMYq5qVha6lZyWuoW8VxbOPmjkXKmrOQMVR1i/gsbKV55ljJUhQTyTjsK6dkfNNupNtbtnhd1rOnRePtUsbCKOC1sx+8AGI0UDnn8KhuLwahPf2v2d7ixdVlj8sZAHXaR3YZBqO8tp9M0rVL2806XUJWRpGgjGGlTqQT9KseA7ttPgvtWGjz2UkX+kYuGykquo6emAAPrUQSep71Wbp2gneyNLwZ4astZ0zUL+ySQ67ZSloIpGKR9Pl/A85pun+ZexXWrRRyW19aI8FzYhsgsuMkeo9DXrmh2FnpVqxDQrPIPMncMOe/5DPFcn4lv7U6m8ml26MvkMs0kYA8zdjH1HerklY4aWJqVKr5dmcR4a1e31jQotcs7I2lw5bzFVerIcEHt2qbUNDs9V0m7itleOa5lEzgyHL5Xhge3biuM8WeMZtL1WLQ/DcKRxID5ojTO2QnJIH48/Wur8Malc3/AIZuprvZ9rt8pIY12jggVErrU9GFn7r3X3FLx34eRvAXhZpL3Z9kkeL7TIfmUbuFz68VtfCS7jtPFdxY30KuERfslw/J+YDdj6kVqXmgw6j8LbsXB+0xxSm7gHUqQeh/WuPze2lsupacyzXduGG3O3oMjn0461E3Zxl/WoqMI1KVWk3bf8LtHv2qz29lbyXcwAYIUB7nPYV5fPp9lqEN5p1yqSiMJK8Yf5wWOVYn2P8AKsDQ/EOqS+HZfEnji6aCxnmSO1iQ7xGM4zj3Pf0qXwq+n3EuoeIWhuvtN+TbRJITyqE847LwCK2kedh6fJHzZyeuy69D4zuFEXmWEkAcOR9xgf8AP513FzrKa/ostzNCUvrGJQInHMrYwSPapvE8cMcMN7DCtzI8OBlsbXHc1z/h5dTutW06S5jDCV9rrEu5dp6g/hzWOx6V+Zc3YpeDtdvdR0K4ubqA219avIsQ3FASQOOegzxVbQNHvNP067vvEMkU+puDK6RENsRjnaPUe9WfGGha3pXiLbaeWbI7vMRzgNGT/D71yWnW9zG6TQJdHU7Ofy1V5gwkhGP3bL3J3LitEua5jKoqbUr3NltXl0Lxboi6QPLsL8GVvLT5ZGII+b3GRxXTeE01CPw19l1aUNeK7yFwcgZPTNU9Wu20KK6DafItxZgSLAyc5I/h9qtN4lgjksLe4gkguL6EMU2HAPvSd2rWHC0Jc97nD/EW10GfWbK71Mx/2hzEu88Mg9vxrt/Dtpp9hoiw2ixtbncdoHAJ/lXmXxjtrVPEWhaleW0pt1JglKj5QM9TXdXeq2eha1pVhYgSRalbDac5AIGP1pRV9TOU7XVrajPFOi2GtraXVz5hFmC6JE20uT2J/CsvxJ4j1C28NR3mm6eDNEceVJ84QdCce9bd4kV9b+VzEDztBw2RWVqUVxb2hW33EzKVZD/C3Y0SbjYcYRmn0LFjqf8AazW29ZUkEKSxENkbiP8APFSeNteSKbw7ffZoV33QtrqQjoCMZHpnvXnnh7Wrjw9pqR6hHIb6OVwocclQfX05rS8cXiz+H/34UWd7IhlK9YjjIYenOapXRzzcWvM19c1W8u/Gv2aOdYdMtrUyySq3DEkgDNc7c/8ACUWUsuUiuLaaZfLfg7UPR/w4rM0G5S2a90XUnE9sHRFuCdpdH6An+tbvh3xDctfnRLWwm8uziLQPM2d4HbJrVPqcb7GnqOj2scWk3HiK5a8ltDtN6rbc5PQj055rjtYjsrbxO9obPzICN8c0f3Nh54PfmtDxTBZ6ZYXkespfTwXMqykCTBjOP4cdhmrOpWFvqpttFs7No2sYUmt5jIV3oRkfrwRUt3CKcHYbaaLfaJez+fMHsLuPciA5A7gj0rlzBr+gakNQtrtriDduYg5AFdSx1qbwpcW91AIrtsxQpvyVHc1BY+BvE+heHDqFzIiwykfunO/aD3NZtX6miqctkzZs/HHhzVdNgvdT0JEv1k2h5DlSemQKwfiLa6afAmp3dhqICu8YSwxt2EyLnA6EVRPk3DvDJYos8fQBvkPp9K53xjJdJos6X1skXmbPL8tt2MEZJNCTvqRKULWTPPKKKK0OY6T4fu6eKLZkTeNj7x/sbTu/TNexeEzdR3hj0i2hh05mOJ1yPzB715V8Jomm8b2aIdrbJCD77DXtlt4khj1CXS57mOG6cbQgjGM9fwrCpvY9XBO1O9+v+Ro2ei63H4mkv766t5tN2lRAG5d+n5e9dprNqumaSjFWVVO9dpG0k44J746VgXPimwstBS21C0Ki2Td9oRevPUfjVGfXBqWh2UFi7PbTlpGLdQSevt0rN3SOyPvSs/U5+DSTH4nn1AXUrQ3wZWiJyoB64PtVeLwjE2gPpV/NLPFHcmeNjyUHYVeecaPpc0kYY28JaQoDksfr2rO/tzVINBWa0kF3Nf3BcDyy3lRnon4etXByfUmrGnHdHXIGt9PEDMuIYNoZjy+BxXLaSb7VPCuq296bk7ZwEaI7X25zwfStfW4bm80eeOLasy7RxwTwMgVN4Ptp9J8LZ1aba5kLICedp4waSSVzWUnJpdLFpPtlxor3GgoJ72zMe+3Y/MEyM/iBXqHg7xJf2aynX72BdPj+7LM4BAxXB6BNHZXThC0KTks2By3uTTfE+k6LrdqINTuphEGDDy26kUoSS2Lr0nVTUtX0O98QfFe1t9VttO0Oze/muPuzdEX39xXM319fz63a6jfarAEiy00LLkMf4VX0ArnLizudRtH0vwuzRTCLy45FTLAYx17VsfDD4T6hp+sM3i68Nyvk+YsAJZQSR1b1rRSc9TllSpYR2a/zIrvWbu6uhBotpcXUZDzzTk/KAB/jTfDN1e3XhJdU8X2ctrYTMYJ93yjGeDg9jxXd/EG8g8L6Zb6fottDGbk7ZfLHzKn/ANesDxDdad4s0a203xBLLY6PbxiSRUf/AF7D7q46n1pq17MPaScPaQXuvp/X4EUdvNqerwwW8IuNGESi1hIYNI+7nfIDyMdvTNaeuw29vrEnmjydQt0WSYQSZRo8HClew7VycOv3WladpuqeHrkDT7PMMdgqblCZI3nPJYjrVaTxRa3YstSt7hbm/wBdYxmXb0x/Dj0X+tXK9jGjG1S9tBvhvwgmr/E/TtQXb9jlDyynPLFRwAPSuovzZP401zQtOfbLEqyPH0ABGSP5Vx6/EHUvDXiCQafpMElugFv58x2kf/rNT6HfrF41vdS1CMfbNTG+eRT8qADAUfkKTtazN1zqq5r4f1O38G+KZbnxDdeFdQtRFp+z7PC/Qs23J571yyXNuuu674SvIJYW8t4o5SOqkcMPwNZnjm/k8Oaxo+rKkk+LkSJj/llznn88V2XjrUNGeW08XR6gmxVEUkYAynHQ+9G62Fy8lSyekt/U841u1udG0y50CaO9utE06xV28kHzZ3LDbtP4jPtXePfWosNPjvW/suSe1Xyrdn5UhQSM+vc1m6j4nsHl0tDOWW+HlxOONwP8OfWn+KdB0/W7e2065ube01aYMljJOT98D5gPqBiqvzWTM2nTbkn/AF/WxX0+e4tNM1GG6vmuzMHZVI+4p52j2x3rZ+HXiow+GLu6j0945meIiOQdB90kVzXhXw9faPr0kN5crdx3ECwBD/DIAMn6Vz1zf+ING1m6sp7FTYLhlbPO361k92dFo1IqLW57vqNtp+uWcWpvdYt42BmDDpjsK5N9G0XVdWuJElOlwXiBoZ3wrGReFIz06Z/AVxV411q9lBZW93NDpszrI5jnAb1ZT6ViPrsF2mq+GrQ3c7WcLP58vzY2+h9R604y1MqlFqDV9Oh1XjXWrmwvdJt7pn1C8uZVSS66ZUfxDHauw+INhFZ+DrXWW2Obdd3mYyzZOMCvna519SmkppzzrcWKvIIncyCQHkYb09q9+8MWmo+KPh7DLfRyy27ja9puxgY6qTVyjbcw9pZLldkjjvFMUfiLwRNc6ZKqsY8pJKvTHXIryfwY11d6lEbq++1HTwNm4ZAO7qpr2bRorOC1uNJVZRbxq6FXUjIPBPPWuK0nwPNo+uSqJlGklQ8ZLYJbP8qjuka7OMmet+A9OsvFt7fSiWP7NZu1vIqj94XxyB6YrQ1H4dX0eq7NGuE/s9k+dbs7juHpWr8IbfRF0ae60qMJfNK6XSvwwlBOcj8qqeKfEt/4FvbvWte8yfSJmjQiI58jJxwO/b860PLdWalozyfxx4Ul+0qJ4VhvLN/mQchx6/Q1z+jmLxJPfaXJH5VuV8ot1wBxXe6j4ji8S6/fagoaOFoUWPPTbnjPv/jXOPYjT9Qa7t4/KaQkuQOGPas5e6d1KXtFrucx438K29l4ZSyNyqTI6kXEnAKjhcmtO1mWK0gZJ43WONU3KM9ufwpfFkc174flhVY5Hk4VXbk4NZFg0MNtEjKIN3yFCeAcdKznPaJtSpW5p+hmeIPE9y2pta28Ftd24G+QSNuIA7gVYvvFF1b3mn6nZWq3WmPHslZRlkPqPpVazg0dfEN4ixM16ow245UgjnH4Gor9rbTm/s2O3ljtXUsvlnJbPUVaaWhzSUpXbZ1GtQTXVm0mjSl5XCsMdSB1H1rC1j4m6lJpwspRNBDC4jeKZeSPQVoWN/Y2QRLF5kYAbFkPzDjuKzNe06LXIRJLIfNWUF8DhqqLRzV9LMgl0l9UQPaMymQiQbP4vaue8aQRtoPmQymUQYjLE843Dg/jW5pWtm3ultmkNpLBMiLIozsUnG7HpzXYfGPwjpukfDS4uLRT58c0bNKTzJucA5/PNUkc8qq5tT5woooqgOg8C3kun+Jba6hyXjDNjGcjaciveoLSzvp7bVZ7aNLqeMBnxyhNeC+BvtA8RQmzGbhUcoPUhTXtXhvVblLHZrSRw3MrYVM4B9Me9ZVFc9HBOyudDcx2xhe3vI0JILZY5Vh/TFc1ZR3tzr8NxYTp/YrRBREvRcZHFdBvtr62ea7V0+Vkbd1ArI0u80+C0+y6ERIqNtKjOV571k4tLY74VISktSVdU0e1nl0S0iuHuIeJPPGQ248nPpk0yHVZfJ1KK0tGjuLMY2xfxD14qW9gVXM8sS75RtZyOTjpzUXhbxPFFGplh2XU8hjUovzEA4Gc9apLm6Cb5LJsd4YkvrnRbrVJofNulJIjkYgED/61OuPO8Y2WnXbbrexVm3oRggr2X2PrXUa4+qaXo8GqppLS2txKqt5ZA4JxkCpfEV3aabZRvM4W3VN7sBgJnsKpaK6WpN/aSSbuluc/4pvLg6dNDZq5lVOAvXA7Ctr4JeFrjW4s6mZY4EJZxL9457LVzwPo0/jPS5NR0hcWQYqrTDDEj09a2Ly4m0W8ks9LuyiW/wC5klHVmI5/nioV46NG9SaqN+zlrY6ew1Hw7oniW50TT9XsLaYpvIAzIpHYt0q74m8eQadYxx2GLu5ZtjswwAPXHevFPFXgRNVaKfT7kWl0ZN0rkHc+PU1suLWy077df3RuPJAiVVPLueMY7mq5rWjExWEjJOpW1t17+pp3VwmrX82r6xKI1YhIxuwGY4AWrGlXtnpviSwkvbMPBODBBDKwy8g/iArmdW8Q2KadbW9/HGkBlXczAEK+c4PuPWpH0P8At7VrZruSW4a1l863nB2+XxkYI6jjFVG17susvc5Udp4707w54WmtJ5FuUv7uXd5cSl1XJ/u9AATiuB1/wXdX/i3TL3T7wW2n26lnSLhkYHPC9MGur1DWV1fxPdWlxMJL+wt1MkB5WMHv9c4+lcr8QdLmvdLsNRsbyVJh+5nS0nAIA9RWt9TjjC0NdStd+G9L8V3zyx3tyUt5j5g6An0x7Vo+LIPsnhG5nijCXcLeZC20vuK4wMVH8Nbi3aK6s7a0uraMAubi4O4M3TII711GgWsEVklpFdRXrqXZiz7+T1BPahpJ+hpzNprvuPKTat4e0q41C3XzJ7WMyhVyC5XIb6g15/aaTbWXhu+0jWJvMsrq4WSSRmwwkBOMH3zXWXfiTWNT1608LWU9rpczvHJatKuRIqH5oj6cdPXpXK65oOqDxLe2+tzRy6IshY7m2tGw4Bz3qNioyUm4NXaNaC4gj8SjRNPt7ZUtrFJLSZlBkjlJIJGfbvWrpHwvub21tIG1DUt8c32lJJ3wysRyQT2+lUb22sF1HT76GeAap5Bht9rArOg5H4iuitZPF3jLxdpT2upW2mW+lr5skKqd0mRtwfUVUWYYi8dUiLxFNfaXqP2OG1juJ7RAbjax3hccMv8AWs3x7c7fCq67oMS3FwyJHIjruaNh3x6da7fx9okmkeDdSuraWSfWZzta8ZeQD14HYCudt7zT4dLj0u08qW4kCmLB5nQD5h7kdaHFboVOu5Lc4bRIZb3RVvbuNLKZULyRkbd2e36frVjwfq2k6i8/2RX+2ys0Tkx/Lj61bvp4r29vLYBkeJA2wnO4H096zrLVLTQbS6iso4pJNmZLaMDezY6fWsbK+x6DlLltcu3/AIVj0/wzfXVrFb25UbYyQMDnqD6V6J8P75NR+HUtgL+NbuFtiyIfvHseO1ef6XdS6v4EaAWdxbiSFh5E5+YHB7nqDmsnwCsWh+G9OeG4OmzFwfLuHG1nOQRk89qvW5xTSnFLZHaa9rc9743m0uSwYvHAUWZFwBxnPvzWXqUcOpaW1nOWTzFMJYHlPQ0z4jeEvF2panZanoGomLTnCySgNtK9yc+nFTSXlhqZSfT5kYxhRMV5+Ydc0n3QU2rOLKfhSLU9JiV7y5iuJYph88eUMqjjLepwOteiap4r0XW5TY6zZ28tqFwpZslc8cg+9ed3FxOtu6W5XL/Mm77pOemfesc6xHC+qRXFurXbRFLYdMybepPrWkXzbnNWoqL9ClJd2HhPV7zSLzU1FjcSt5KiPcnPQ7+2OKv6R4iinuptFu1V5ygkt5M5DrnnFbmn/CN/Fvwy0yDxMWsdahViZgoJkUksv0PNedaR4Wl0h9KvZzMs1i723mnO1jk8HPaplrqTSqr4Tcs7mzm1t7O6xEGyyoTya5e8sZdZvr2KQqum7t0MiH5kYcFT610VzZH7X9oYZlPIOOV/H0qrcWtvYyTXW7aHcNtQ8F8c8VntqdLfNp3Kz6bFDIGtUVpNip5oHJGO59awfE9xe6e9q0Fq1wGPzHFP07VPENpPqckUcMiFD9mjbBJbPUDvxVm41PVxpCvqFmzTNHu4Xoc84FHJZ3Ide65LWsZF9p8l663MT7bnbxubketT6Bb3Flo226lfzFYkAtnjtmqN42pXF/ZXUIZLZ12yRsMEVsPH9qgEasFkUZA/vVLvBWQWjVlzS0HTpZS3BM6Kk8sJAlB/Hms3xV4v1a78EajouqtHdw7ohBcowyoVwcEfQVYvIBb2CO1uSGGwyFTgk9q4/wAQ6ZHp+nXMnmtvmKjZ2HINaU27e8clanC/udDkKKKK1MS9o1xf21+kukGYXgB2mFdzYxzgfSti7uvFV6ALpdTlwdwzC3B9elbfwHz/AMLL07b18ub/ANFtX1FpcPiHV77VF0ex0g2+nyLFJJe6jJASTGsmcLA4wAw5zVqCa5mUpNLRnyR/afjLdu3atuwF/wBS3QfhSR6j4wjmMsY1NJD1ZYCCf/Ha+xbCx8TX0hSxi8IXUijcVh16VyB6kC1p+lyX73+qWGrWdrbXenypG32W5aeN90auCGaND0bGMdqapxlomL2klrc+OZ9T8ZSxbZm1Yxj1hb/CoIrzxV50M0Y1IyQjEbCFiV/Svt+8sjc6dPCrAO6kA1j6FayQyy+arIVG0A96v6ukaRm5Rbctj5Pn8W/EOWxS0mvdaa1T7sbRNgf+O1RutV8a3sTRXDatNG/VWgYg/pX2RrMEzwgxH6elHhqCaONzcMSxPT0o+rod5KHNzHybpfjX4maTYR2Wm3+uW1pGMJFHAQAP++aov4i8eZJe41jLNvOYW5b1+7X3AIiB3JIrI1DTp7iTOcY45o9gn1M6c3fex8cDxL8QHOftWtN/2xb/AAqt/aHjbz3nxq5kbBJNux6dDjbX2zpts1qp8w7mc8kdBWzGp3DbyKHh0tRyrTWnM7ep8BXcfiu8LNc2urS7m3HdA/J9elakGufEG3jjSGTXI0j+4BA4x/47X35bQFEwxqSWMFcms+RbGft533Pz6t9Y8dW1/d3sL6wl3djE8ogbdJ9TtqpbT+L7c3BgTV0Nwcy4hf5/rxX33IiZwAPXJqS3tlZsgVfs0luV7R9z4P03xF4+0mBILGfWbeJfuoIGwPzWo4NW8dw3E9zAdZSW4bdI6W7DcfX7tfel3p8Vy4LDlTnP9Kh+2rBqH2XYoi28H3o9nfZgqkns9T4OutQ8cXV6l5cDWHukUKspt23KAcjB2+tWtR8QfELUopY7+XW50kGHD27fN25+WvvEliC3HHYVA7BI2ZyQg5PtR7K/UFUl0Z8BbvFwWzXyNWAtDm3/AHD/ALvnPHFbVt4r+JNtdJc213r0c6KVDrAwOD2+7X2e19KZvNDAoDwp9K0zOqxq6fxdM03RKlzpWPiyT4g/FmRGSTU/ELIwwQYCQf8Ax2sFtU8ctJbyE6zvtnEkLC3YGNvUfLxX3ta3XmEhshvSpjDvbC8DHX1peztuZc7Wh8Cf2546MofzdY8wNkEQNnP/AHzVGM+LYr1rtINWW5YkmTyHyc/hX6CpYxI+4Ku48nApzIhbacbgMkHrS9lHoU68u7Pgtde+ICqFE2t7QMD9w3/xNY9/qXiW9nCXsmoSzQ5O14zlO+cY4r9Ab6ZYTHGoG9zivGviLJF4W+JNh4gmjY6NqNu1nfyBNyxt0Vj+f6U/Y2Vx+0nJangK+O/iLPbC3TVdZeExhAioSNuOBwOlY0OreK9FSSRJdRs0lbLM0RUMfxFe8eJbLVPA3g24vdD16zuNTupBumMgLtH1RYU7YBrg0vBeQKfGuratqvkfvzp8fdsd/QDuaiUEtAhOUupx66/43njXZPq0idRthJH8qpzP4smuRPLDqzTBg+4wvncOh6V9HfDT4iW95eW1pcaTc2NpPiC2mbmNiOik+te1OA65Vfmq40k9mFaTi97o+Jp/HnxMYSCbVddxINrAxsMj0+7Va68W/EK+sha3F5rM1sMYQwkjjp/DX2ld2UU+BIgYZzzTY7VIY8IoCjoKv2C7kc0beZ8RNqfjVgATq5A/6Yt/hUUt74wli8uRdVZM7sGBuv5V9yEBQAARmmsoz0pfV13F7ZrY+E/+KlW7S68nUxPH91/JfI/SrcuseL5gqyS6o4T7uYm4/SvtG9UltpHyms+PT1jkMrH5Bzj1o+rruaRnpds+N5LvxSSd41LJ45hbv+FQRr4hjuBOkGorKF2BvKb7vp0r7RjMV2N7RgMpwDTbhdwIXntxS9gu4nJ7M+OjqHiw25gP9pmE9V8lsfyrO1L+2JLcNqEd55KH70sZCj8cV9mRkRSbW+6e/oa4f49cfDPUOB/rIf8A0YKTopK5PNrY+VaKKKxKPRPgGVHxN04uwVRHNyf+ubV9beDMTaR8RRB+83Pgbecn7HHxXyB8E7drn4h2MSfeMcv/AKLNfTPhnxDq/gq81iKy0jT9RhvZ0n3S6g9u0ZESIVIELg/dznPetUm4aGkYcyutzhPgfYSweNfAE9tpsc9zbW9xDeLbaRNZPah0I8y4nYbZz1A+vHOK9qGf+E88X46fabf/ANJYqih+JPiSaHzU8L6PtHX/AIncvH/krVPRp9QutR1nV9UtrWzl1GaORILe4acKqxJHyzInJ2Z6d6dOLUrsznBpanTKox1pj2wkfcPxrD1HVmsnjBQtuPPPQVaXWIAY9z4VwCOK6Li9lO10jUaNCm0jIHrTYYxvz2+lMEgZNy/MG6YqlrerR6Lp4lfb5jnCqTQKMJSfLHdnQooCZbpSLhsgD61y6a3cPsuHjJiCg7E7jGa6OCa3dY2UlGkAdVPUik0KdKUNwnhA+6cZqeFcKF7+tQ6kkq2byQAmQDgVy+lXl+dRTCSSKWxJkHAFHxI0p0nOLd9ju7O4LyGOTqOhqzdDbC2TjiqcagjkY54Iq5cfPCpHI9awe5hbU5uO9hmdo3c5HBPYGtSCOT7F+7P7zB25qBNKhN2XBwM7mHbNbMcQ2ALjaP1q5yXQ1qOP2TlrCx1ZJ0lnnCnJLJnIIrVujatKPMUMwPp0rXeJTyBzXP6jaTRTlk/1bHOcURlzvUal7R66FiFoFJ8vGW/GmXYjFu5lwEPHWn2cSuFyuCvO496NUtftVq0WOTyDT0TCyUjnILZHfaLmMhm6EEYroJ7NJYgsRIIGFJ6VijT7hJtjA+ma1Z7xrYJgDcoA5q5Xb0Nql21ysW2tZI+XwMcYzmtCMFmyD9aqWWoi4l2PH8+Mhh0rQUBpOowBWcm76nNUvfURjt4AyPWsrXLpbG3Eqj97IwQNWr5eGPzE98Vja1bSXtxAgyI4zuJHT60Q3FTtzK+xnGYz31mHOZFjL4/A1yXiq7tbTwLq91rNmL2yXIaEjOSTwfwrqL3V41niOmW4uNreU7Y5WszUpYbe7l07XDbtpl6PmjnIUDNbPbsdfK+W1v6R4t8INM0PWvEt5aPoQmURCWKV5S3k+4HrVjR10z4b+OtcbxXaXc3nRGO1nSMyLLGx5Ujscd69o0DRvCvhbT77UNDmsordUJllSQNt+p7V5Vf/ABP1LxJrEOn+E/DQ1ieJmZbqdcqQDgMPb61hFJIwbU79EJD5fi7UdIjsdKk8P+E7C4+0rLINrzsOyJ6GveIJUniSa3bdG4yD7V886hP8UvE2sGxmsLOyjs3CNcGPy06cgHuPpXbfBbxPez3+q+Ftb2tfacSyyg/61c4Jx2q07PUJKDp+69V0PUJCAM4J+lZV/fpayKhVmdhkADrW067kwCfeqlzCskbKyjJGAccj6GtUYwavqQlgyg9M9qjk+WpYYRDEqgfdGBTJDkEAjI7UE9dDHuLxIpDuGT0qVttzBjPysODVLVbGV5dyLlXHTPSrHy2lqiO+AowSaGbuMbJx3IRGttGRnA7k1US6geXakilu4qzOPtMTqrcMMBhWJBpM/noCFAV928GkVGMWm5M1LmLz4WRTgnocV5f8bLO7t/hxf+e+5BLFyT1+cYr1xY9o55rzj4/f8kz1D/rpD/6MWom/dZlGbWiPlGiiiuM0PRvgBIkfxP05pGCqIpsk/wDXNq+ob6zsJJBLJciIyDIORzXy18B4zJ8S9OUYH7ubr/1zavqafwrZX1xHPctK7cHbu4GOwroo7GtNxi7ydjRs7KGKIQRH5Sck5zmtMWy7Qp7cipYkWKIKiAADAFWUUbeep7Vsc8qjbuYmrWto0QF1cJAWOFZiBmmDSkMUZt2VwoxknORTdb0O08QXMcd7G4W3OVcHGPatjRdOtdMgMNtu2E5+Zsmg251GmrSd+3QfZWxit0TGSP0pNU0i01SJYr2FZVVgwB46e9aajuCD7U4kgDaoP1pXMFOSfMtzlNT0vVf7UiNgii2BHIP3O3T6V16W0e5GcKWQYDY6VBLM4JCCmK8+MAD60ndlylKaSfQ1gilcCojbbEwoHqeKalwVIzg+pFXIJVkXaOorF3RlZoqLIdvpjjpVkfNHgkYNVruIxOWwxQnnFPju4wgzwaGrq6KtdXRDd253iSItgjDKOhrSt49saqew6VWiRppBksEHPFaAApSfQcuxieLb260/Q7mfToHnuhgIiDPJ71X8Ktq9zpzNr8Ko52lB/F05zXRZIoI/OlzaWsWppQ5La9+pVkjwiBRn29qjkOxPvAYPJIq24+THU1lS29zLGVaTJ3cDHanHXclK+5LDPBJOQQS3SnXGnxTEsgABHII6+9UrWwMMgkLOzA7sA4B9q1rdvvZGOfXOKbdn7oS0fusqwW8cICwoAB3PWhmMhAAxk4Jq44VwSpGfaqTO44VFA7DvQnci9x2DGQGJPpRIqsD5gADA5NJCrum+XG49h2pZSkSFnICqCSW6AUyHoc5p8NnZXc4gjZYyRvlkbr6AV4r4/trLxZ8UdSt9fluDoWiWqu0duSCztjGccnqK3fEnxdsbrUZrXRtCvNUtbSUK1xEcJvzj8ea5LxJ4ms57xvGHhq9gj1RwLO502ZC32j/Z2jnI9farlJM6rSa5r6mXf+H4/FlnfR/DbTri1liYW17aST7YnjIOGwf4uOa7TStT1bQvCum6Je6NDp1stsILi7RtjkktkR46nHOT3NcrH4n1DxHpsvhfwzoaaPezDOoXIYqynPLDuasSeLotK0218OfELTrzUTFc+XDqA4Aj6I2fUUJq9zKVObjd7FvXNQ1K4S10m31O6vFdfJW18zdKOmNx9Md62dDtI4viXqmp2Qf/AIlmmR2E78FZbg4HUdTjqax9auPBuh6Jd3nh/XZv7VjSS28lZtzzTEYA/AntXqvw48Px6T4K0iK6jBvPJWackcvIRnLepGcVWl7EwaT5mdShbyUBOJCoz+Vc9cveR32S7+XnLA/dArah8x7ku/QDAFLdWkc8kbvnaB07GrWgRkoPUgnlItQ6kcrnNYdzKA4B4IGQVOSTW7fMiRAFflPGPaqVpa2xl8yNevQntTKg1FXY6O3LuAM4xz7CqmsWZkjKqORyM9K3UjKE85BHWmyqCCCMj0pGKqNO5ylhE8SStcAqo5JqSG6ty+2N0LHtnmr2rwGSGSNBjIrFtdId3Es5CAEEKBzx6mnY6FyzTlJ2NKZlRQT0Nea/H8f8Wy1H/rpD/wCjFr0kxZOWPfgV5x+0GVT4ZX692lhx/wB/FqJ/CzJbo+TaKKK4jY9E+AcixfE3Tnf7ojm/9FtX13pl9HdsyoDlK+RfgDCJ/ifp0bZwYps/9+2r7A060jts+UgUHknua6aPwjfLy67mgBwMgipEBIz0ArOXV7P7WLYy5lJ2gY4z9a01ZfNMWRuI3Y9q1MnGUd0UdZFy9mwsXCy1m+HhqJaRLzcBySzDGPxrWv5o7aQCQkbulXdGlW6RkzkUN2VzWMnGnaxh216/210M5dc8ADr7U9b/AFmS5aOCzdRnA8wYH51rxeHY11P7Ux3KPup0Ga6GGEKckDIqZVEtipVYLZXMm1tLp4EaYL5xHzYPAqSKxmUEFM81tD26VW1G8WytzK4J9Ky55PRGKk27Ig+xtsxtxxzSW0KQyb48kng81Q0zW5Ly92hSYgPmIHArYh+bkJ36+tErx0ZUoyjoyeQhImJBbAJwO9VI1trtIpEjOHUMOMVbmRpIXRDtcqQG9DXG2N3e6DZJBd3X2puVVnXBJyeBShHm2Kp0+dOz1O1wETAGAKA2U3Y7Zplr5slpE1wuyV1BZfQ+lTKoGBWZFjPsbqea7ljmiZEAypIq+MHgde1Pz0wM0EcZ4FNu4PUYQSBkYpiqoc+vXFEU8c24o+4A4yKfzzkYwaQnoRMRuI+XdjjigxqF2jC57CuO+LPiyfwj4aM2mxCfWL6ZbTT4iMhpW/w5NeWR/CvX9ctYdZi8Y39t4mDF7iOSfKCXGQoVTwBVJXF6nvJieOVipJ9RnrUikGLcVOSfzrifg54o1TxJomoWniSFYtc0i5NndEDAfjhvxFd4yr8q5wB2ov3EzPdiu7A7cfWuf+KLXC/DfxDJagm4FlJtC9fu1000ZMiggZHevGP2mfFeqaDpmnadpUrW6X24STD0H8Oaq63CMeaSSMmw8OjWPgNotj4buWindVkcR4RrhwxLoW69+PpWbpngjRfD/wAS0ubHWkSaOPzhpcjqXzjlSx/n1rxvTZPE8ktk2gzam5t5QYWRWKCT27Yr1XQvgzrfiO4vdV8YXsUerXZ3KUf54icfMQOvpirjK6tYqUHFt3G+M21SLwwnifVrRbDW01DybSZJArvCzAYIH3+9eqf8Immu+Hltr+CN7aRBuEq4Y+/sa5u2+Edxc6xp0/inXZr3R9JQLa2pG3p647Z/lXr6SxTRZiK+WBgD0q03e5UarhDlieYaR8KvB3hi9hv4bFrm/Rt6NM+5Q3qF6V3iNevYTSoUE7qfJUj7px3qeeO1klUzlVK+tR3lykNszw/MBwKtJdETvbTUpeFTqyw3Ca6QZMgow7j0rbcYQn061zNhLeTakshbKHg88V1EJLcMOGUg0pKwsQvfu7fIxdVikl2+XnjrjrinafDIIlDqV2n8atuu1s9qz7jUoLebyvMzJ3x0HtVAryjyo2tvygVRunkVvlxtxU0Mw8lpHbPrXLXGssbmYgL5YYqMmkiKdKUm7dDWkcyE5wRXNahrUsWvQabbxB5HIyD6etdFb4kiVh0IyKUxReZ5xRPMAxvxz+dUXCUYN8yuRSrtwoHPevKv2hR5nw4vWH8EsX/oYr1if7vAryn9oEn/AIVnqPTHmw/+jFrOfwsUO58n0UUVxGp6X+zsu/4raYuf+Wc3/otq+uUeZb+VZXRIFGETufc18ifs9SrB8UtOkc4URT8/9s2r6iuXFxulTcdx/wBYD1FdNH4S4Q5n5BptlaRar5k04kYSEoo6ZPvXWxxbZ/PBJJG0j0Fc9pGnXGY/3aiJDkc5z71u/a47e4Ebsd/A6VsOu3KWjuWdQsI7622Pweqn0NVtFja0ZweByK2E5U84rA1u4AwuTkDJA7VMddDKk3L3DqrGcTqQeo71cAXpnNcT4UmuyZnl3CIjClu5rXSW4SUCR8jPGPSs5U9dAnR5ZNXNySdU+VetU5I3ul+cZHp2qS3hJwSTt9DVxVwMD9Kzvy7EJ8uxTgsljXhQAecAYzVxF2gBRUg5pwUH61LbY7tjQCAMjvjiqF/asbi3nEEc2xicMPu+4960gACec0joHQqTwaSlZlRdncd1waPwoQceo7U2dSYnCHDY4pBYUY6Zyfah1DI6noQRisOKWeK7QTDG087e+a3HZURnchVUZJPaqlHlKlGxV0q3+z2m0rtO41bJ5plvNHcxCWF98bdCKjgukmnlVMFY8DdnqaTu22J3bbPOPinLK2hWmt5Eb6HqAmYNF5gK4Kk4HOcNXk3im61TQPGVtpOg2d9dWd4yagoV28wDIPU9G9frXTfEbx1H4s8bWvgTw7b3dysd9E19NarwoRwzgnvjFYH7SU3jOHxfp9hpEhNpdKWt1tUxISpywLDn0/KtW9NBWXMeseBbk6Lr+qafrc6Lqers2pRpjlY1CqVZuhI4rv5k3BSDjFeIarpxOseALnVbq5TX7m2mt5bVTuHllMu5PbHFe2wHFnDt+f5F/HilJbSIsrXK6yqku0nKtzkms3xJ4b0rxNHAmr2iXC28gkj3jODTNXikW43M5z/D7VrWyn7Ogbglefam1ZJoJqyUkzPu7BYLIxaVbwRbV+SNECjPbpWEmmXtkr3k8qPdBSQi9Oa6+dgq8fhWHp15Jc3Mkc8JCDuT+lXCTsOnKSi7bDYj/aFg6uQHYbWA7GjSraOxtzC5yzckntVpyiSMsQAOecVGtpLcHzSyiM1V18hOWjWyM/UdHmnuN0MgKHnntVi109YYRE4BHfNXZLmGBMOwGOBzTo3SZcjJz2o5pWE6krWexWjt44hiNAMnORVnGUYDjtQsexdoyR2z6UgGQck4pN3Mm7mfKrEbT1B61z0GmOZHLgAFixb1rq54gyHAO72qCKBguHGTWilobQq8qdinsAQKAeOg9ay10KBJJLi4ZvLzu2V0XlKmXJ+Y8DPamTlfLPmcjFO/YlVZL4TlZ9SDyiAxPDBkAEDqK2mHyfLgD37U0eTcNhosFD8pNPm5VlYhQwpsc2nZJWIWz5ZxgnFeR/H25h/4VxqMEk8f2oyQt5YPzY8xa9atwqJsD7h2ryD9ojRLU+Cr/VlBW4V4VJ7HLgVE/hZVPlu1JnyzRRRXCWejfAC2F38T9OhLFQYpjkf9c2r7CtNPWODymw46njAr4+/Z+uVtfihp0r/dEU2f+/bV9o6Yy3Ko6MNvXPrXVR0iDlJR8gt1aOM46DtVKVLmScZTIyDjFblxFsTKL161DGpJyOMVon1JjPqVdV1T+yvs5kiLRtkMR2pdPudL1mQeWjebjOHGOK1fIS5h2yorg9iOK5jxDe3XhyWGWx0VrmN/ld4Tkp+FStdFuaUoqp7sfi9bHWC2URlY1xjt2qWC0VWDPjio9Gu/t9hDcGKSEyDJRxgitDywQcmsW2tDF3i7MVMdAQapavqUenJHu+/IcCrwCRkADk96ybyO3/tOE3qGZnOYxjhMUo2vqVTim9S7pE89zbmSeNo+fl3cZFXWB6A455qG6uorOFpbhwqgZ6c1U0TW7XWDMLRZP3J2sWXAzSab1S0K5W05JaGoD7VFcQeaMq7IwHBFTYHel9qi4IrG6it4l86dTk4B9abdNJLCHtm4Pcd6SS3tVlDyxpvzkDr+OKspIjFljIyPSnotUVpuir9n85Fe5AWZccr2pbr98Ut9paKUMGP93FYiLqdvfgje25uQxyCM10LxGSWF87QuSQD1NVJcttSpR5WtRkdt9nszDb7QcHGemaisbBILMQlRuckuQepPpTbrWLK2naGWdUdVLtuOAoHrXkHiT9oHwxpwngt70y3iybQEjLKg789zSXMyYpz0XUqeHfFum6X4rvvB/gbw6LHXvtsjXD35wZIhy0gfqc44FecfHvVPGep+P7K3srG9s1tvlsXjHzOW+8dw9cdK+ivD+j2XiLT9P8VTW9s2uTWjLBdbMYR+mR34r5u8SfEK88O+Np7DUNcbX1tWYSmRAscc2eQn91QeKcrNMIx5Z2etjrfhPda9qmu6bp/iDTpv7U0KwumNzO5D4l4Ax3r6H0WZJ9JtZY2BVkGcHOD3H514LpkWp+NvD8MPg7xQ0viWxC3NzfKAIpFY/wDHvnGSFPSvYPBGoH/hC7Ce9t4re6XdHcxQHKpKGIfp6nn8ap/CkjNvmVkjfu1AUyMu4AdMUibmRWYbcjpUqSrLGpXBVhwajmPloepAHQVPkZMax5PSqEhjdsCRd/VitZ3iG4mW3EtuzFU5YL1FZ2jXVy9yyxozoRyxXBBraMNLmkaT5ea5uupXJhxlhySKW0ZoAVZtyHpntTmJSeL7Sm0SHaoHrUd9dQW0bMq7ivBGaN9CLX0OZ1SGcPcHsx/d57CtbQcw2YMxO48LmlS/jumChcFu3XFPvIn32KICS0vUdq1burM2nJtKD0NC3mjuIvMR8gHBHfNSbcA8c0y1tVtI5DncWYn6U/h8Ec8/lWL8jlla+hHKpXoOlV7ueO2TMxwSOBVt27g81nXlmtyWaQbvTmqj5hFK+pWF0kkRk3EAdzVc3cFw5gjLbyCcGqeqW8iIqWzAjoVP86TQ9MuVKPK3yITjHXmttFqdPJBR5rk32X7PKAzEMwyAO9Z11BevLgE7SeMdhXUXEsUSM0xDCMdAORWV/altMCUPOcBR1NJO5EJyeqRUWN1UAdR2rzr9oTj4W6iBnHmw5/7+LXpepOUtS6nBGOa8i+PDyn4caiC5ZfMhyfX94KU/hZUYuS5j5ZooorgKPQPgWSPiRp+IxJ+7lyp7jy2r7Y0K3EdsgSPy1xnaf4a+M/2dAT8V9LwAf3c3X/rm1fbtmm2JfU810U3aBNSXu8pLcMBEV7kVmTtsUM1z5K+nrV+8xsOawIv7On1JUaTzZxyAWyBWkVoFKN9Tooy0lpiIncwyGx0p1sT5W0k7+hJqxZzRGJGiZSOmRVnaNzEYwetZOXQi/QZFHhFC4AqRpRGuZPlUdWNKDgUFY7iIxvh0IwQagSIW1G2B+WVX9dpqaCVZR5+wBcYDHvVaPR7FH3CBc1Qurua786GzTYIASFHBY5qlFPY3jBS+Es6lpsl5MZo5eGAABPAFaNnElrAsSKoAHJUYyfWsg6gLDRJp9Rnjj+zxNLO7H5Vxk8+1fMWp38upX9trjfE7T7TW4i08kDTu0KDPyRoF4Ix1zQ7tWYSk17rPonxF8TPCugLObzVYJJYXCSQQnfICTjpXY20yXNvFPESY5UDrkdiMivhrRvCOla3eT67f391qETyyTXC2UDAl+W2r7dea9H+CHxetbTTJtO8Q60LSC3nMdmbs7pGjPRWPtjr71ktXYtQT2Z9MSWMLO0nzKzdTmltrRYSpDsQB07VHpOow6lbLLC6uCAwKnIYHoR7VdI5FNtrRid1owPI69aiu5vs1rJLtLbFyFXqamqK6kSKB3lGUXkj1pLcm3Y+e9U0V/HPxag0i9NzbaZbWv2+9XeVa4YuVVD6LwOPeu51bwZ4D8OaQZ7zwvZ/ZreN52UR7iMDJ5rl/ihrt94b8e6d4u0rSJru0itmtr1I8/vlzxn0Kkg/jUPxu8WWOsfC2xtzLIl7qwHk2VnIJHZuuxsfw9M1vZpkVIShZSOo8A/GDwfrunXVvpDvZxafAZNk6bEjiUADn07Vyvh2/8CeOfB/iPUrDwrC1z5+2+jSPezk5O9SOQDgnNchD8KdO0r4T38xndNZuLYTz7yFUkHcI19uMc9a5Wy8R+LPC2g2dv4M0uLS7FhHJdT7AJpz1BkJ6A5IA9Kh+5qx+zex6Xa3+keBvg3eeIPBljPZSzkQRrLJnLOxQO3qR1xXq/wAMdGXSfh7p1hLJLLM8ZluJJfvNJJ8zH9a8/wDjLPow+Ahvr2zWQ3IikSO3cKI52PXjjAJPFdv8NdTu9a+GOkPdQ+Vetpy/IODxkKfxAB/GnulYlK7Ot021FlZLAC7BM4LdaZdOSp2AnPTmsfwre3E8VzJdO7BV7+x//XTrTVTMpUp5hZyDnjC5qnBqT6lTpSUnfWxZh05S7SuQwIxgHg+1aEEUcShY1UHvjrVC+uI7eWGGEqq7GY47AVV0q7klulZ1KA8getDi5K5DjKSuzSvb+ys3VbyVEc/MoPX61gXsardNOqNJHIcqR0FWdVsI9RlVpV/eAEKcdjV3TbBooo4rjcRH93nj2qklFXuP3YRutylY2g3mYjG7+DHStBI986sy8J0HpVwqucNtC9T2oCAtkcj1qHO5m5N6lK9uktVG/ktyFqOyuhcqwChSp6A54qHV7OV53mj+ZWA69BijRYoUt2MbfvM4bJ6mtLLluNxXLdbl90AyPTmq8i7R6+tTkhSwHXvTZBlWWpRkc/e22b9JIyPmHStXTkKQ4fArM5Sd45GJKnKkjtUf2weeYnJAzgHNbtNqxvKLkrFrVb22tXKupZn6heaqW8Vk8Sz2wTDDhsYIqrcWMl9fuvm+WFHXFFhpklpFMhO4H3oSsHLGMd9SvdubqR4lXMWOteb/ALQFokXwu1BwCD5kHBP/AE0XmvV4oPLQE9R0rzL9oz5vhZqBOciWE/8AkRamfwsObWyPkKiiiuE0PTf2cv8AkrGmc4/dT/8Aotq+2NOkMluu8nKnHPpXxR+zicfFnTD/ANMp/wD0U1faUV2sceNpzXRTV4kTVx2puoQknAUZJ9q5Lw+1k2sO8UnmSAFlUL0+tW9d1m28xrSTc0sgwVTjbVrwvoFtppkukZ2ecfx9h6VsvdWp0wXsqTctG9i74VVk89WDeWW3AH1rfubryYywHtis2KeJLkwxtmVvmwB0qHULyUSFI0BA4IIzmoceaRi06k7tE9pqrzSlZFxk4PHStm0Pzsfl2n7uD1rJtrZJgJQhjdkwVB4q1YI8UoExX5RhQKidugTS6FjV9Sh0uBJZklfc4RVjXJJNMkigs/NuFJEk6/KpPcjpWhhTyVB+tYPiOJpJ4s52AE5HXPapgruxVO0tDOvydL8N6pf3entehIGP2QcmbP8ADzxzXlN78KfB0OoaQV0r7HqN2DfPZzzB0RcZZCPQZr0n4q3T6N8PLi5nnvLeKIxPPNaIHdU3jcMHtjINfPHxT1e28ba/NrfhC/v7uMQpAttsMYjXHPPZen40Tn1Br2k7n0HY+K/AdhG3hu3urDTt0JjWOMqm7OQcEV57qngn4T/D/wAOg+IreLUbqdZJ4csTLIg7D6CvJ/h/8LrbxB4rjsb3XLa21O3k33NkWzJxztU9Ce3tmq3xp8QX0vju9t9U0mWz8uFbeCzzuIQZCu3ueuBWacrXBxinZM+j/gT4osdV8LT3NvbR6XpNrMbOwimmG50wDyT1OSa9YjlSRnVTyh5r4U8AeD9b1rXdHtdTtNSTQL65RfNAK7ME8gD7vfmvqD4X3+pWPiPUvCus6la6pcafArR3MKkN5ecKsh6b8UfErscvM9MRNru24ncc4PaqWvBzpkvlrk9T7D1rQqtqkbzaZdxQnEjwuq/Ug0ouzTEnZ3OA8C+MbXV9F1uX+yrs6TZB3+1yqCl3ydwQdxwRXE+AfFfhW68UCHR/h3e2N8WBkuTCGWFH5D57Ag54rg/iT4u1zwz8OPB+j6Y4sVntpra+t42BXcr4ZSOxPU/Wu08OeKI/EfwrsrhINR0K4tCqfbrHDBfKXG5h3XHGDWra5nEUuZ++zR+IGh61rWp6FpRgiXQLu/RJ8Eh2VMu2fRflrxzxr4f1DxFq+va1b3aXsMV2YX02zlLPHEhO0tjgDC8CvYdU+KOiap4P0dtcu7rT5bpvNhntztaTy32lj6K+OnvXjF94Z8Waj4waDw1o0uh6frc6shSQmFxzzvH8JBJxRUbnoaNvm5me6eDYND8ZeHx4M1HQ7i002yt7a8t47h/3k+7LFiR2yMe+a9NsI4LTV5LaGMRxCJUjQDAVQOAPwrI+Gngw+ENIZLy8N/qdxt8+4IwAFGFRAeigVp6gWh8QW8gzhsD69jTjrdLsZQV7l2wsltElQAHc5b8D2rKuPDoieSWzlZSSW29s10LLjJBwT+NIJFOVDAsOCB2qVOSd0SpyTuc9a26vuSUK93Gu1x6Kat6RBA0RkjD8MVy3Xii8tGe/aWEFWAHTgE+tXbaLy4wGP3uSKpybQpSujN146iBGmlxfP1aQ9APSpbC/DqsV0yLcjhgD1NaoOfunIr5++L/xWXwn4z/szStMhuZ7ZVkuHlYjJbnaAPbvS5o8tpDilNclj2bXLe7uI1+xbXA6pnBP409WbTdHeW4y7oCxUc/hWT4W8UDXfB1hrtvbGL7XGSsLdmBIPPpkVtJLPc6SZJ4PKuNrAxdQSKpNuK7Eu6ST2uc74f8AEx8RXF1YpaNCyxMyyk/L6VxsfgLxNf3Trc6gbSGK6EqOrk7hzyAK7rwRN5sV1utPs7q2D8uM+1XNb1SSwjcrHu28/hWl2pOMTrVedCo4UIpX76l2FP3KIzmRkG1mI5JHekuOFJXPA4qjouoy6ipOFAC5J9M9KsQzPLLPDIMPEQc+oNTZp6nBKDTaYwQxytufbvxwRWHeaYTdO6s3LZ6cU1zdWPiKMRBntZs7/b3rfddy4rRe6W26VmnuU40wm5h81Yf228vDKbWHZGhILNwePSuhleKHCNIiyNyqE8n8Kq3bi2tJJjgKBkmqTJi+6vc4621jVE02WTULdIpHl2wqTzt7k1xnx3nlufg9dSOpQiWIMD3/AHgr0vSy15FKbny5kQhkOOme1edftDLOPhjqm8xmHzYdoHX/AFi0qnws3m4t2SSZ8j0UUVwAel/s7uY/ippzAbsRTnH/AGyavqddZuLpLiKKEiRDxjqRXyz+zqyr8VdNLgkeVPwP+uTV9haPb22+SWGIK27DE11UfhLjKMU21co6TpbXIE+o267gQVL9QK6O7Lpbl4QWwAAB6VW1NX+zj5sR5yx6cVZsmjeyjaCRXQ8gqcg1b7mcpufvMo6Ckn2ue4mQqGGF3DnPetg2Uc92hI5x36U0FdvQitCxQNErsPmBODUTk9xSm2+YEt/KRj6U0MBJypPvVt2BjYqRwKxLy6wREQxwu44OAazinIUE5G8nK57ZpuFNwAQCfftTbSUTWqyKMKwzjrWaWePXww3BGAyM9alRvcqMd0aupWVtqen3FjfRLNa3CGORG6MpGCK8Jf4LS+FI9WTwx4he00++UiVbmMMtvFnJIPqMcZr3xiw5AB4PFYWvadL4g8OarptypgkuYHiVlP8AeBFKI+lz4z0vTdF0jxnaaj4Vl1/X5LS/QtdRwhUfDfMAe5NfRnxT/tCJINWTwpZahzHOYVX/AEtcYzk9OK85+Eeu634CivfA91oQk11ZHlsVcYSZsZDFvwH51yXxB+K3xIXVFg1yzOjQyDymhEJAYZ5+Y+tDfdDSd9DodP8AG+vwa7qHjfUdDudLtjbhYrVZGWKfLYDZ6cZGRXtnwi0FrRtV8Q6gP+JxrjrcXAUgpEMfKinuAO9eS/8AE70f4RazYeLlXUJp7Pdp9vDICUjcjn8Mg17Z8JZ1uvBGlyqc/wCjxow7q6rtI/MGmrcjsVbdvodDr2rLpNvHI0TSb228dvesXxt460vwp4Xk1e9fJKDyoF+/IzdFFdJqFjBfw+VcqWQHPBxXz7+0rqFxpE3hibTrGO5aG9ykJXdkqMDj8acVFx80WlCUbdTyPwd4b1D4navqGn2UKQTXFxJf3F1KxYQ5JO1R2yT+OK9s+Jmo6N4I8CxeD5poU1O7tRFAFjwpXAV2fHTPJzWZ8DD4gvfiPr/iC70aTRdKuY1VrdY8K7KQMD8ic1f+PGseBYfEFjLr+nC81mNVWNHcoNhOfm9hRF2d2YS952Rlnw94W+JH9kab4T1y2WfS7dYHjuINxaMDkqD/ADr3zQLWztdKtLG2ZJIrBFjUqMAEDHTtXhii6vPDel+KrHRoP7Ui1QS2r2C7AbQsEbf0yuAf0r221tNP0GG71BZHK3JDsS2dx7YH405K5V3OyNGWcSwLJbYkVs4Zak2h1jkdBvA9ORUMlzb2sEZRQqyfMFA9amglE8W5cg9/aos0Jqw/kcnpWNaafPHqZuvtIaFyS8eOnpitWbbFESzHaByetY1pDLJMxjuWUA5xVw2YR2ZsqOTk5z0qOZW+zyCIAuQdv1p0eAgXJbA5z1NSYAHoKgytYrWMUsNqiXDh5cfMRXzv8c/h7P4i8XT6vo9zZGJI0juwsg81Xz3H0/lX0DqN80FncTwxmQIvAB5Jr5HZL3RY9YvjeSRWN5fpdO7zL9pjbcwIMWclfm/lVpJ35tjWk0p3Z9CeBNKtNM8A2thZzXV1DbMTl+GBPUY7Cui07UY9iJIjKAMZY5NfPHgj45Q+HLr7P4ijjlgkz/pFr3GMglO1er+BPil4Q+IN7JY6c0trfr/q45l2Fx/snv8ASq5oWt0KqqKb7HoygEhlPGOlV7h7aV3tXaJ5AMlMjcAfasyDUxBra6dIjh+iuT1rL1Lwo9x4yh1e3ujHGQBOgPJwKFGz1ZlCkr++7aXR0dpYQWMBW1TYp5Pcmnbd025QA2386nlyFGDg5AqOeVIZUUkDJC0rtmF23cx76O9bVrXyJI1tgT5oK5Zh6CrcjcnHAHFWWCq25+3eoJMHkAYPatE7hKV0jmLjw6zeLH1Y3RdWjCLEf4CKv3Nl9oi2XDEgZGB0rScqPY1Vnd1ZQgBGeTWibLlVnO13sVLaBLSIRRIEj9B3rzH9o4AfCzUf+u0OMf8AXRa6Pxbe3kWoBQWWMAGMDgMc+tcJ8ddSe8+G+rw9omt8n38xaKnws29hKyqNnytRRRXAM9A+BZI+JGn4kER8uX5j2/dtX2lokcaWeYpRMXOSw9a+OP2doI7n4q6ZFMMoYp8j1/dtX2jAkUEaxxIqKOgFdVH4RTkuXlJLiJbi3eKXhXBU49Kr6FYwaZYmygl8zaxcknkZq8pDHkdKw5LKex1qG7h+a3kYrL6gH1/Gr30FT1TjexVbU7+G+kST5gCRtI4FdZZXn7hVJCuRkrnpXI65aamdRZrPeyN9wgjA+tXUsLqSS1lMoWVMFyP1FNxTR0TjCUU9EbZupAzDLLk4HvTLu1ildfMnCOQFYjqfwrn4rm6S6eJy6yyMRtPOB2IFbml6WyTF5pFcEjvk596TSjrclx9nrc6OziWC0WJB8oqnqVu7zW88DESqcHHTFaC8ce1Vb8yLZyNGMsOcVzxepjCTuXkbzIxIOpHQU9c5JrN0e8WaMxr95edprRBbjIz64qJJp2G1Z2Z4/wDtBeHYpvCF1rGnrPHrOmv9qgktyQ7EDkEjqMdqTUL2Dxb8H4rfxXHYaXrdxZiaKO7YZR8/I3PPOAce9d3JqT3F08ckasjP5ezGeK8H8S/BrS/EXi25ul8Ws2kQSf6XmXzXhkY5Ea9gK1lFpK5c48trnjus6RrNn4vkh1/XYYJnwjzG4LxqrL2wegHYV9lfBzQbbw78PtPtLDUl1KFwZ/tSnKuW5OPavIG+DXhzTrqwefV31rTlcwyWrhRI27gbCOcg4r1P4P8AiHRtS0q90bRdOk0hNJk8k2E/EqjJ+c+xrHkcdRyqc2iPRRXzV8eV1HVfi/4J0jTYWZhMZD82Fb51JzjsAOtfSgPTNeKfE7UoPCPjrSfFNzoi3++X+z5JhKQ9urHgqvQk5NXTV0xK9nY6j4l+NV8L6BcXdlCL29EnlR2yyeWzr3K+pFeMeDNe8L/F7xq1j4w0AW2qLbbLaX7QcvtOSOf4uprof2hfBU2sagmu3fiC30rTtNgVIBIp3B2PPT14/KvMtD0Sz8DeP/CusQazDrm+7SGZYvmKu4+bp6ZGKbutjOKXLdbntnxtU6FoPhqLT5ksvDS3yRXcSMVdwT8qj/Zz1FenX9jNfyaeJpoU01YwZI8YZnwNuD6VyHxlsLCbwBqxnt7e5ew23kSzgsEI7j3xnFdhpax3sGnSMSYxbRuiHjBKg8072SZpSk0tBNYtRcXCJHP5e1QAMfdFXtPjWBBBncxXcx71BdwyC+LpHuBwT6VoC3TzklwQ4UrweOaUpe6kVJ3ikLKo2YIyD1+lV1a2toMqAqdBnvVwnArJ10AWKqSFUtipgruxmld2Lse1gHHRh19qbdD/AEaQjPTPFZulB5tMMa5xkgNnpWqigRKudwAxk02uV2FJcrscj450wXvhaON4y0yzpMsfn+Tkg5ALenqK+R7zRvCU+u69N4s1mfTdXW8Y/Z4MSRtvJIw3XCnrX2HrWo6ReXNvBK9veCOUbhHMp2EnHIBr5N+LF5N4J+KOtufD2myxXLCW0a5i3qMgEuPXkGqk/d1HBc3w7no+h/s4eHdROm6vHq11cWMqpM0WAVlXH97qAa5HXvCmr2nj2K81VbDwf4a0e6P2a5jAUyAcjb3diB36VkfDvXvGXjDVRfXnim7sdP06RCVgTChSfuqo4/Cuw+OGp+F9R8dafpnibxBfnTlZbmSCGEFIwRjGRzuP6Zoik1foTKnONnLZnp/hHxnovxA1v7Z4euWdrMqJkcbWIPG4D0rb8N+EbrR/Et7ftq81xayklYHB4z6mvOoPDFrD4m8C6h8KLIx6K8jrf30XCyRAjIcnr3/KvdFmRpXj3YZTjB6mqc3aw/bzjFwjs1YCM8HkVheLCyQxSDIIfOR2rZjjKzOwfK+h7Vm666NbKj4cu4BAop/EjGnpNFfWL9rfSjMoLMVBOB3xWL4T12XU/tcdwiK0JyCp6g10GpWRuoUhWTZHkbsDt6VR0/RrPTJrmW2BzOec9PwrWLjaxopU1Taa16GTrGoyxebJZS5nbaFikGcepFXtNupLi1VpkEcmOR/OqFx4fZ7+GZLjbFGxb/a+n0rYCkKNxDHua00Cq4ciUdSrfC3dCbhFZF5ywzivH/jZbxRfCTWJYHWSOSeHD45/1q163qcfn2k0EbASsuBXjfxe02bR/gzqlrcyq8j3UUmAeADKvAqanwsdO3s3rrdaHy3RRRXAUemfs5kr8V9MI/55T/8Aotq+whdt5nJ69BXx1+zz/wAlT03r/qp+n/XNq+r727aCTCAE46muqj8I1Dmdjo4LoDHoe9XFddhLfcAye+a59iTDG6j7wDA1q2M29F4yfumtGjKUbajdK1Wy1dZTZSiTyz8wHUVNPIlsrySYCAZJrL0Pw9BpU+pPayNi7JPuuc9PzrF0LRdeSa8g1S48y2BPkktkkZosjoVOk3Jxlorb7mzfXLXlvFcWE5iCsVc459qml1b7DZQmbi4YbicdT61estMSDThbMBt6tjqTV6406zuYljliWRVGAfSk5RQvawWjWhd0+8+2WcUygkscMPer2ByOoNUbOKO0twsYwgPrUE0w1WFo9NvVRkfDunJHqK52rvTYwSTemxQuVbRpZ71iWhX7i/XtXzF8T/i14vsviLezafqMtlZ6c8apZDlJBgEk+uc19a3ltFe2Jtp+dy45659a8x1/4O6V4i1qyv8AUUAeGQGTyzxMg6K1U2prXc6IyhKN5bmJ4mk8T+K4dAt/C9vPZWeubJL29XraxlQWHtnJ5p/xK1Ow+F3w/uG8JaNCywXawSSXCkhpWXPmHP3j059a6P4q6RNpNjYeJdF1I6fLoSPK9qM+VcQAfMhUewwKydTutC8c/CrTH8Ui702y1CQTJaCYM7hTxz6E/wBKcnezMZyc3c8R+EPiTxV4l8Qh5bNNQC3UUsl5JFxAS2DkjpkZr2lrqO4+P6f2Xc5vntGhv4Y8GMRLyjEj+Ldjg07Tbe08M/B3xDq2jWsvh1RauYIGYFgyghJD/tNWt8BfD0GleFbHU5LRm1nVU+03d3NzI+ee/SpiuVXKjq79j0TVL6aHULO0s1DyyNukyPuoO9eQfHLxLY6aLVb/AFC2iv7XUoLmO2wHdoVYZJX9ea7f4y61qeieAdXvfDmwapFGBvON0anuPfGcV8e6X411rTL62WK3jvNRmmV7meePzHud3Owlhxj2oi+VbFJ3Vkj64+IfhHTviB4Ne1lMn+lgT204PKZ5U49OelfNemfBbx3oHje1Ol2SXAgkWW3vg2IQw5BbNfYVkh1TT4JbhHt3kgjLRIcCMlQSAfbpVyzhSJigufNJJYAsMj2/CpbTWpjFyWx4poNh8WNZ8X+R4qstMg8NTSj7ZEuGDxqMbQevNe7JGqABFACgAADoK5LxXr9t/bEPhn7XcWN5e27Txzxr95VI3BW6ZxXU2sSQWsMCMzKiBQXOWOB3PrSldpNlpWJSM9qaxOMDrTiKY6bkYA4J71AwcbYz1Oea5LWLebMm4M0bHKqW/WuksbR7bcGmaVT0DdqhvdJs72YS3KMzgYBDEYrWElBmkJKEjOsBPDo0a20bSl+rA4K1T8aNqlh8PtafRCsmrRWrvGDzhsZxXT28KQ2yxQnEYG0c81m29jd7L6C/mjntJY9iEDDkYIO4/SnzJkSfMmz5R8NeC7Px/wCGrHU9Dun8OzQqLWVt5druUnLMccgA+tXYPCPxL125/s7W9Jsb2HSo/ISe9Xi4UHKjf1P1rT+AMgsfEXivwpbx+S1rctNCx/1jorEAYPJ4INe/NfapHasxQEKyrwuWx3xT5b7mTqNbHznrOh+NofAtzpY0bR9Fs5Zd86W37uWFEYZfP8QP8q5iHxjofhNYItLnh8S3zB4Jp7y3BCfd2uueSByOa+mdZu7LWbS8sdXihWUq8XmBxkR+pPavK/DPgPwnpvxV0Ow8NWo1BY1e71CZ282OFdhCqT0yW5x7UNaAp30lqj0H9n/UPEGqeCGufEUccSmdhabYhHmP12jtmvQpbRJJxKztkHPFZ3iDxBp/huPTkvWSIXtzHZwIMKNzH+QHNbOMMQT0qFdakOV3daGfa3Aa6uYSpUI3DetUotNKTXCS5KFt65OefUVpXjRRgqzIu/5cn1qCOOVYwJWDcfeBrVPqhc1ldCMw2YyeBgk1h6pqirb6jHYOkuoW0JkEXUjjjIrVmYRttHU1wvie5Ph66k1TSdOa6vbvEc0mcqFHbHrWkEa4ekqkrden/BH+DtX1jUIo01vYs8qmVdse0qo9R707x3aX9zpCyaVNKtxA4fER5atPTbq3vx56RmO4kjDlW+8o9KfHCskiPvLNCxK4bHJGDmtDWVTlre0jG1unQ5y51C5bw8LeC6j/ALeMYyR1Vvf3ryH4vSXcnw5m/te4mOo+Ym+Jh23jBb8K9Xj8My23jR9VEiGzf52Q9QcYrj/2jLezTwFez4AuJJYlQ+uHGf0qZ/C0bupTiuSGt9dtn29D5RooorgOY9I/Z7JX4paaQORFMf8AyG1fWv2WG+uVaQlT/Ovk39nUZ+Kumgc/uZ//AEU1fW0LiBx5gztz17V1UfhC7W25uvHGtuRtBVVwKz9Eu7e580QEhkOCD/OqVxq5t2AkGVb8qi0BSt4XjGIiWbPsa1sJU2oNyOqVtpBPTrUilWbcB0qqr5XJ6CrSbGXI4OOtQzA5XxXd+LbXXtOfw7p1reaZyt0ssmxiT0IPbFdfbxusCmXAkIywB4FUpNRtbZGM9xEmODuao727e6sI5NPcSMW42HIIpcrehoot2NuPLgA9D/KsXSdVsU1k6Zp1uI1BYyOq4BfritHTftRhX7WqrIvoapDTYbfV5bq2AE7KSQemTUpLVMqHKuZSNW31CC9E32dsywnDqeopYr0Z2bMAcZFFlaRwFnCr5kvMhA61J9nVWAUY56+tQ+UV49DO8ZaVPrXhXU7C0MSXs9u8ULyLuVWYY5FeMfGPWr/4dfCTw7p92thdeIAq28dyEGItvOVU9eABn15r6CBOTnGO1Zeu6bpGpGD+17G2vDET5YmjDbSfTNJPoJa7Hgv7PPjHUvEej6pb+N4r7V7e4u4YYA9tvjUtuJJOOFGB9K+klRVUCNVVVG0BRjAHYVjxXVlZQiOzhiiQceXAgUfpWhbyi4ttyDYhHfqDSlF2Laa1sZnjHw9beJvDt5pcztD9pAxNH95GXlW/A14Uw0fw9bqvj6O+ttb0YvIL5bYPFfAkhWXAxnBAwenNfRLxRXVu0L5aJwVODjP41S8RT2Gn6HNLf28U1vGmBE6Bt2OgwetOL6CPnXW/2h0sYFu/Ddg88Un7sR3TFSu3HOPQjiuy+D3j3W/HjW1/b6PaW9rHNJHcFHPygrkdeuT6V4r45+LE0s1vb3Xhzw+9hLEXe1SDDxZYjax4IYYB/GvU/wBleLUNZtrjW7m5uodOtc21raCMJC+Ry3H3iOOaV2mynFcuh3HiPStc1P40+HnNgh8OafZyyG57iRwVK5/754r00qvBxyOaxtU0mXUNe0y9N46WlkHY26EgSSHhSfYc8VrxBljVXbc3c1MndIQ/tzSAgrkdDQTimvwPx6CpQXHU1QFycdeTS9R0/OkyKYhQABgYA60yRQ6Mh6Hg4p3U0jDimI+e/En9seEvivp50u20y60+S5Ekl3KFWeJGG10Lk8/KeK9k1a6mt7GSbz4bVlbG+RgsYVhwcnjvXF/GD4Yr44hBsnNteHlpGOVPbGOx759q43W9G+Jkfg+40DXtE03X9PjgEEU8VwUcqOASO5HFbbtENXPLtN8EXur/ABdutJvPEa32nsGvL64tZW8raSSY856np+NfT/w20TQdD06aDw/p5tFc7mZm3PJ7k1z/AMMvA8fgr4ewW0OnRz6pK/mXTsNxLE9B7AcV3vh8MLciWJIpu4UdB6UNe62zVq1PUtahp9nqSRJf20NwkTCRBIobaw6Ee9SS7m4UZ9TmpXyAduMioYyxQF8Bie1ZnMzK1OyaYJvYgq2TjoRVfTdWiv5pYUSSKWElSkgxkDjIrYuSQMgA+ua5nWtIuLm7NxYTiB2Qhx68VvF8yszWDjNcsnYvXySMWZMbtuFJ6Zrjre21JVuwzSKoPfuc9vatnwtbapY6Ds1mXzpl+6ScnH1q5Z3q3OFZQHA/CtVoaqTpc0VZruZGkXduxha5IjvsmNlJwWH0q0Io7W4muJZAlueuTgA+tYuo2IstYW/fzbqWQnyokXocdzWbr0dxq+kRG8LQSFyPLzgEe/0pmvslOSaejOxcq6/IwdCMhge1eHfH6WQ+ENSgZiyRyxEZHT5x0r1mwaLT9ItopJS6om0EDlj7V5j8f4IJ/AF/ewh1fzIQysMH74qJ/CzKmlBy7Hy1RRRXCB6X+zswT4q6YScDyp//AEW1fXF7JAlu00yl0HXaMmvkL9n/AJ+KGnf9cpv/AEW1fWkFwFuRE20hu1dVD4RW1uIjWOpRbEccdUbgir9skVrEI4mBQHoDmquo6XbXxUyIVdeQ6HBrD8VQ6hpOkW//AAjqkP5qiQj5iRWxpCKqtQUrX77fedOdTaORlEDGPtgZzV61umkHMbKBUdk8gtYPP2eeUBcDscc1dQq24qOe9JnPJraxiatoumSp5lxavLlskqxzUd1PY+GdHl1GyimaIY/cg/eP49K22jKrnOfapoxHcW+yaNHU9VYZFDehrGs9FK7Xa5TGuXMvhu31S1tWYzR7xEeqj3q54f1WLVrGC7aMxytwUYYINWtm0BFACdOOmKVbeMvG4GCjZ4+lZO1iHKDTSXX+kUrTU57fW5bG6R2Mh3RFRwq+59K0pdTSO/hth99vvE9FFSx7TMz7QTt27sdK53xXpD3dlqE0NwYZFt2Iw23oD37Uvdk9Q5oyeumn4lXxn8RbTQ9EuL7R7WTXfIz5v2M71iwRkMR0OM/lXmvw7+OUfi/xmNKvLH7JbzMwtZQ2TwP4x2+tc/4Q+Ltv4V0u1h0fwpHD4fUsmoCLczNN67j1yMHmvRfhheza5rF3dyfD+DSNFlQCCfy181y/JJ/2SD2pW5dhRfKTT/ELS4NSubeysNR1ZLVitxJZxbkhPU5b1rr/AAt478P+IrZDo1xv3LyjDBT2I7GvH/GuraP8OPGVzfeD0jvTeSfZ9R0lZDhZSQQ2wc9M9Ky/EsF/o/xO0jV9D0+5itNRtBNfKkZESL/CT6Gra5nqbU37WoovqfTdkFEZ2HK7uMVW1DT0uru3mu3TyIXDhWOATS6CANItWBJV0DjPvzXzB+1dB4ptdbguoNSlTQ5NkNtbQSncZDktkCsursQ5OMtD1fx/8JPD+veMYNfutLRwqgzKjYWdgeAyjr9a2dNu7DwQ1tFc7rG1vrmKztbHgBWPdQPrzXB/AF9e1zSrDVPEst6txpm60tIZiVDrj5nKnlm5xk1b/aG8G3uq2UXjHSLuW21PQofPMD52Mo+bK/7Qot0ZnezPcjhW4oJ4rwn9mf4n6r43j1TT/ED+fd2oEsdwFC5UnBXHtXumSWIzxWVi3oKvK9OtKOB70zAHIHIpc8EkHNOwDs9eaa3UHoKQHIBxilJyKLCEXgnng0Z7UmTgjvSHp70xC545pMjB9KrX95HZwhpPmY8KvrXPapreo2jxNFamVH6qgzg1cablsVGnKex07HK+/pTCVXHYnjpWR/aLLZia8BRiM7AeR9aSz1Pzl2zsIt/+rbrz2p+ze5Dps0bsvsXbkEenehJ42DYYEjjIOefSqGl3sj3FxZXZzcRchum5ah03So9K0w2tq0khEjzM7nLMzEk80+W2jJlFLR7i6rfXMNuDbwrJk4bPUVDNdxRW0c90WjyOR6U3Q555o5TeKdyudhPGRUGvWhuSWxvhIwUHWtUknYq0VLkZZSTzY+cEHke4qvLHEpZxhT1z0rG1ZdRtr2zn08KbdEEZVz1FWNSZ7rTW2IyyN/B71aQOnazT0ZZkljD/AHgGC7vwrl9Vv4b5m+ysD5YKuuOx/wAasWJfT7yGPUrlXkkUrGKxrK5ttHvZzNDKZbiXbwM45/8Ar0zppUkm2tX0LWuJcW/h+3ltlbfF2HJAPf8AKvOPiy13L8JNUlvs7zLCoJGMgSjH6V7MMhiCwIrzP9oTA+GOogf89Yf/AEYtZz+Fke2vHkt13PkuiiiuIR6N8AMj4n6cR2imP/kNq+n3ika9DKQAWDBu4r5g/Z/cJ8T9OJ/55Tf+i2r6njQyTK2DwetdNH4Soy5bm2r4TI+9igSjAJFRxMRgZ+tNvI0uIHiYkK3GVODW5zrcuRS7nZcYxzmsnxNcXdxY3Gn6bI8F5IvySj1qeNfsVmwiDylecE5JpbC4F4sjyKYipx81BrD3HzpXsWfCEOpW/h21TXJBLeqCHYHPGeMn1rUgUQyOVPDdAfWqas8K5V98XXFQ6dqdvqDSLaPu8tsPn1pWIleblO33G/E/vUiykRZAySeAKqROEbORxT5GEaHb19azaM0KLpo7mGPOEcE/jWH4n1S1sfEGlJf61HY2EqSi4glTi4GAAA3YgnNS7HuILWaNy4SVsnpxmvCPFfg3xD8SfipqtpDqluNO06ZEZHkI8oFQcKB360SVjVxit2dt8cvEz/DwaZD4a0uwuV1KTfdRSRq4cKAB8vqR39qu23x/8PyvpFuYxYyXK5nE7fLbY42kDue1YmnfBm91DxEX8RXFsmi2s3yBLh5J5EQfKC5+7kda0PFPwI8KeINNRfCrxWpkuxLNdpL5uFA5RfTrUNIz91Hr0Ph7RJb9tYt7C0N5dKGN2IwXcY4Ofp3rzL4v/FWy8A3S6BJpk97NPCrJvIKupyMk9eCKsfCfUr7w9rmteD9Zu7m+i0sRCC8uGC5UgYVV9B6+1ePfG/U4LD412XiC9nW709beOWGFBy6KxUoM9855pNOOpUFqj1f4NfF6LxPBcafqFg1pe2o3R+XkxyRAgZBPcZFP8b+GrnTPi1D4pkiik8OzWrC7mnYslnIqn97tPHIwMgVx3wcuU8TeNtDfT7BNNtLa2vZrq2BzxIVC/hnFfRl9HBc20lteRrJBKNjKwyGHpSUlui6n4nlWrfGDwTpyo1r4giu5I8ER28Rdm9h71m+IfihB4z8F+LtN0Wxv1ZbJsXFzF5S7WGMnPf0FeqR+F/DlncveJo2nJMeTJ5C8Y/Cvmr9pRNTu9R0vUtF067i0e+HlSFFI8yRCQoKjtjkeuafMt7bEwipOx6z+zn4D07wl4RXUbO9F/Nq0cczS7cBBj7o/EnP0r1znIx0rzj4Aabe6V8MNNt9RieG4LvIYnPKAngY7fSvRSTjisypaNodnimc5GOaM8c9aXNIQhHOfSlFApDigVw9KaWC8kgZOBzS59ayZLeRb2S5uZfNAGIkXgJ/iapK4lqcZ8WNfk8OaVJeQKk17Iyw2sUrbVMjH1/WvJ4vFfj7RtV1VfFVzHZXM+n/8S+zRRh5GbAZcfxDOTXr2t6LZXlrJeeNHt20yCbzlFwf3cYB4P1rxX4zfFa0vtUu7bwzpcN0NPhAi1qL52hVsZ29gD0rabskrm0pWtFalbUvFXjfxBo+jW+n6dqUmpQRNK+oRHEUiZxuIHB6d66z4L/EnU/E/jaTQWtFm0xYczTtGQ6Oq8sfTLcVzHgb4ueJvDXhO3XU/DP8AxKZ42TTns4dvz+47jJJrqfih45u/A/w60+ax05LbxFrdsskmo21uI1RjgkEY4bB/Os1drcmVR25bHsl3ZNFrkF+jEow8uQZ4A9a0fMBYBWPI4rkPhPrN14h+GehajqDtLdTRESyMMFiGIz+gp3ifUbu2ufsyhkjZBskXpnPIrSK5yIwlVko9UdOx2qVQAZPWos7UwaYrhrddhzgD5vWm3GQ3B4IqkjBlW+USmMOwCqwIHqaiuGAUnouM1X8QIrWDMZDF5Z8zcBk8UyzulvbWKcKyq64wwwRWhoovlUjg9b8Qab4gsvOtPPEtpOFYhcHH+HFb2n6lHfum23OwRh1mcdT3H6VbGgaZFbT28VqiRzyeZIRxk5zXH+H5NUhvNWhvwfs8TEQxjuAeMD0xQz0f3VWDVPRR2u+52DXEckNxMpP7jhlX1xmvH/i/4gj1n4Y6svktFKksOVJzx5i16gIV1HQpoVaW0NyuC4GHBHFePfE3SrfTPh1rZj1M3jvJCmxhgjEq1E/hZjCFPklzfErWPnmiiiuIzPRv2ftv/C0NN3DI8ub/ANFtX1uZFZNqDFfJX7Pgz8UdOB6eVN/6LavrYRr0xXVR+EznuYW7Wl15gzxNph+6RwQMf41WutQmGqOiyH72wJ+HWunEK5JFVzpcTTrNgbwc5I5rXU1jWje8l0Ma2vLi2kLTb/x6GruppLrejzW1lN9muyQcn61qXlhFdxFHUexqhbaPcWshaBwS3GWboKZSqwdpLRot6SX0yxt7PUJhLNtxvxwfatLTdPtrISG1QR723N7mqk9pcSWIVihnXkN2BHetGFiUXOCcDJHQmgxnK92nvuXQRuGMZxUrxlkAHQ9fWq+A6kqv7wds9anjl+Uk5BXsahmRU0DTJNPt5oZZhIjSFkz1Gea4n4k+Cteur5dY8A6lHpmrSRmC5Q4VJ1Jzkn+8PWvQbeYzR7sY+Y4pn2hVufs7Eb2G5Ae/0pNNvUtuUpNvc8ekh8Qt8JZdBTU4dM8V27uLhJ7keZMpP3txPAYd/QVwvw98c638K4ZNIvrM3/nzJJ5du/mBUIwWGO54r3fxN4P0TxPdCTXdHjmmxt87o2PqK5rWvhiLRbKfwXqq6He2sXkb3AdZI927DZ9CeKUo3GtNzC+J3hrTdc1Kx1XTpNTtvEmtTR/Yk3thioBYOn8KrjJNYPi7RfF+nXjt4w8Mx+IrkRsLe/tY9ypkjC4H3cc/nXsnh3w8una1Lruvax/amrvGIo3fCJbrj5hGvbNd5byxuuVkDcdjmpmTrE84+Bng+/8ADekX+r+IoETXdVkDPGnPkxAfKntjvXpskQkMZJOUbIo3ZzmnjlaxC5HOHMLLCiMxHR/u/jUd1YWt3FDHPErRxEMigYCkdMVYFIOBgDihME2tgRERdsahR7U+oTMgaNWOGkyFBHXFPJAoHcefrzTQGBOT8tVIb1pdTntPs8ypFGrmZh8jE/wj1NWyT2FFrA01uKOgpCaRmA5NN3jcvfJxQTccxwK82+Lc3jG8t4tN8BratM0b/aZnkG6EnGBjtkEnNdzruow6ZpV1eXMywQQxs7SN0Xivkz4feH/iefiPJrcUN1DFczl7mS6fEUkROTkdMY6VSVlcce4ap8OfiZqXg+LRtV1i0kt4ZjNDatdhmkX+Jy3dVPY+tYGjfCHxtFa3b6IbDUbSUeVMba6DKe4zj0Neh/G6OCLxha6tofi+w0tNOgNu1sCSUJ5ICjqGBrkPhn8b7TwF4am02HRRcXbTtK00b7Elz0yO2KTtcr3nG6PdvhPZ3PhX4MxtrenE3tksszQyjcSRnHXpwK8B8V/HHVvGmoW2nT6Tpq6Y8yD7PKm4k5H8R6V9GfDfx1a/FDwrNNAi20y7obu2fngjjB9K+fPiV8L/APhALS11uN7GG5N4yRWzuZRKCRsKg9wM5FXa8fdM4NKd5LU+rNMt/segW8KiOIhQAsagIuR2A7Vg20OuTak8Gomyu9LIJW4QbXU+mKofDp7nS9KsdB1G8m1DUUtxe3U8vO1n5Ce2B2rpZdRto9QFivDsueK1hexquaDatvr/AMEfaRrBE0RYkZyDQX243Nn0yKc7DAycGoZ2IwWAB7EVfmc7d3cp6rFHPA8c8hROrHOP1rM0mzls5Jna9N1BLzGvUIPrT/EsEN/o88M+5kcZGw85BrO8Im4i07y51CorkRgf3aZ1RVqLd+uxtXJLQMB+dcZIl7BNBcXQLypLhXHHyHqD7V1Opy+XAQp5x0FcLrusG0icPIvmFTsXrz2pCpSa92K3JNf8RX9nchLW1Min+PGRiuO+N2mWz/Du61XyjFdO0JZenJdQeK67wK+pS2cx1RQCX3Rc53Ka579oOLzfh9cS+YwEUsfyDocuBzUT2ZtOag/ZrRrdrqfLdFFFcZmejfs/HHxQ07/rlN/6LavrZW9a+Sf2f/8Akp+nf9cpv/RbV9Zq1dVH4TKe5Opx+NToeOarLU8Z4rYzJcA49qlU/rUKnipFPanYCwhNQF1WQqgIx61Kmc1Kqo/3gDQwTsNSXbtbgn0BqxHKJDnI9xTRFGeNnFSJEoB2jrUthcURrt/dkrUE/lIFmuYy7xHcm3qKkRJ4kJ2JIRzgHFULy51d5VS10ldpI/ePKOPwpGkE2y9JrllAxWaURFcBt4IHI9aGuNN1GBlZo5kkyMA1E0Ny6gXdpHKhGWA5wfxrG/sFBKZLCaa0JJOwrxk/yoUUawjDvZmpD4f0lWDCNmUchXYmugtWghiCwYCKMBVHSsPQrTUbd3+33aToeFAFWrO4jmv5rZD+8i5Yc1ElfqKo3Ju7vY3MllBXGSOpp8e7b94E1HGflGaeDzxxisGYXKepW2oXO0Wl4tooOSwTcx9q0YgRGoY5YDk+tMYE4w2PX3pVYjPPFDd1Ypy0sSHqOAT2pm4OOM1n3WoiwuIluFZoZSf3gH3T6VoKwZQVOVIyD60OLQNNaj1yB1zTXBKEZxQTwMGmOeAM0iQ2DHqBzzQvyqdoFRuzeYxPEaD8zTA7lcnA9hTsDMXx7q2naJ4P1PUtZjE1jbxFnhOD5novPrXgvh+41T40afrbaR4ju9HljOY9MjUrGExhcuOueM4r1D46eJPDujeCryw8SGOZ7xD5NqwJ81lwe3TnHNcz8CpYfFPgLVrfStLPhQFxFHNaqSzAjlgW6nirWiBaK544vwR8W6TfWtzqd3pSXLyN+7uboEMijJYk9RXneqeHLyK9mtdLMeowSzeXHJB829x1C969c8X+HtQ074laV4Tg1GPUbWdWiD3k26Vg5BYNj7ueMCuO11fE+hXEVhpWhTWVzpc7qby1hY+Yc8EcccVnKPZG0Xdas9p+D194c+FvhT7H4ivoLPX7tBcyQSAhiDwi15Dd/FbVbvx60/jC2TVNPgnYJp7AFYOeCmP4hxXU+C9XbxhGfEnivTzeXHh1QssJi4mUjg+zDHStPwl4a8FwfEeS3s5JLu41e2FzbK2D9jMhyV/3gM/lWiTaVhSgo+89bnumh28TJJqyxuJtRSOU7xhgpUbVI7UtvptrBqst40jSTyHIDdE+laRO1Qo6KMAn24rntYkltUluIZP3rZEYI4FdEU+ooSlN2vvoadzcpCCWkCIASSx4ArF03xRpGsO0Gn38FxIjldqtk5HXiuV8Y6ffaz4S1G2S8WC/uYtsKF9u455H49K5n4G/Da68NzXOra7EYtQdTHDEWzsU9SfeolKSkkkXKlGCbbPXY4kjQiL7pJ4PQGqzuwlGwgKM5A9aNTnntrItbRGZ84C5xWdp1rLDLcyTyFpJyHKdl9qtkJXTk2Ov2kYfKpYY7Vzc+g297OZXJVyPm3cAVu2YuvtNz9oKmLPyYqPWrGPUdMntWlaPzF++nUUiovkla9vMW0gisbNEQjaq9QeK85+Nl5FefDPU3hbJWaFSPT51ruLCxFnoqWKSu+xSN7dTmvMfjLHHpvgO6hkZzNdyRhV7AK4PPvUy+FlKMW3Z3Z87UUUVxgb3gjxJN4T8RW+r28EdxJCrqI3JAO5SO31r04ftA6p/0BLL/v61eJ0VSnKOiE0me4D9oXVR/wAwOx/7+vSj9ofVR/zA7H/v69eHUVXtZ9xcqPcx+0Tq3/QDsf8Av69OH7RmrD/mBWP/AH9evCqKPaz7hyI94H7SGrjpoNh/39enD9pLVx/zAbD/AL+vXgtFHtZ9w5Ee+j9pbWB/zALD/v8APTl/aX1hf+Zf0/8A7/PXgFFL2ku4ckT6CH7TesDp4e0//v8APT/+GntZ/wChe0/P/XZ6+eqKXPIOSJ9EL+1FrQ/5l3Tj/wBtnpH/AGoNYf73hzTj/wBtnr54oo5mHIj6FP7T2rkEHw5p3/f56ZB+03rERY/8I9pxZv4vNfNfPtFHOx8qPolf2o9aXn/hHdOP/bZ6d/w1Nrf/AELunf8Af56+dKKV2LlR9FN+1LrTAf8AFO6cCO/nPTYv2pNcQEP4f098nvK4r53oouw5UfRb/tS6w67W8NaaV9DM9Kv7U2tAAf8ACOadgdP3z1850UXYcqPoz/hqfWv+hc07/v8APTE/aj1lM48O6fyd3M7187UUXYciPot/2ptaYEHw5p2D/wBNnoH7Uusgg/8ACOadx/02evnSii7DkR6n43+MV94v13Sr/UdHsfs9jIJTabiyykHuTyPStZ/2gddGqPc2+n21vakKI7OORhHFjuox3rxainzyGopHsN/8ZbO91+HW5fBOlLqsUvnC4S4kViwGAT610cn7TutGJkTw9pqsQcN5jnB9fevnuijnkS4Re6Pbrj9oLUJ9KksW8N6QEmAFwVyPO9cgetYHhT4rnw34gm1e08O6eblofs8Sh2VYY8k4A9eeteYUU+eQ+RHvMP7SWtIHD6JYvlsjMr8e1Mm/aL1SYKJPD+nsAcgGV68Jop+1n3Hyrc9W174zX+s3VtPLpNrG0J4CStgjOcVtxftEayqYk0aykb+8ZGFeHUUvaS7lym5xUZbI9yP7RGqnj+w7HHf969Rn9oPVOMaHY5xj/WvXiNFHtJdzPlR7Yv7QGqKDjRLHk5P71qjf496m2f8AiS2Qz6StXi9FHtJdx8qPZF+O+rB3J0mzKHGF8xuK5/xr8ULvxZoj6ddabbQqzKwkRyWXBzxmvO6KHOT6hZbhRRRUDP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) A low power view shows abundant tubular and focal interstitial calcium phosphate deposits. The calcifications are confined to distal tubules, with sparing of proximal tubules. (Hematoxylin and eosin). B) The tubular calcifications exhibit a positive histochemical reaction with the von Kossa stain, diagnostic of calcium phosphate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glen S Markowitz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9848=[""].join("\n");
var outline_f9_39_9848=null;
var title_f9_39_9849="Acute procedure anxiety in adults: Epidemiology and clinical presentation";
var content_f9_39_9849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute procedure anxiety in adults: Epidemiology and clinical presentation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/39/9849/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/39/9849/contributors\">",
"     Yujuan Choy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/39/9849/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/39/9849/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/39/9849/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/39/9849/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/39/9849/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12823173\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute procedure anxiety is an excessive fear of medical, dental, or surgical procedures that results in acute distress or interference with completing necessary procedures. Patients may experience anxiety in anticipation of",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    during many types of procedures, including for screening (eg, mammography), diagnosis (eg, amniocentesis or endoscopy), and treatment (eg, angioplasty or open heart surgery).",
"   </p>",
"   <p>",
"    Specific phobias are a subset of the varied manifestations of acute procedure anxiety, diagnosed under DSM-IV-TR criteria only when the patient&rsquo;s fears are specific to the procedure and its immediate effects (eg, fear of suffocation during an MRI) rather than fears not specific to the procedure itself (eg, a fear of the underlying illness that might be diagnosed). Specific phobias related to clinical procedures include blood-injection-injury phobia, dental phobia, and MRI claustrophobia.",
"   </p>",
"   <p>",
"    This topic addresses the epidemiology and clinical manifestations of acute procedure anxiety in adults, related to common medical and surgical procedures. The topic includes specific phobias where the",
"    <span class=\"nowrap\">",
"     fear/anxiety",
"    </span>",
"    is related to clinical care. Specific phobias unrelated to clinical care are discussed separately. The course, screening, assessment, diagnosis, and treatment of acute procedure anxiety are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11782?source=see_link\">",
"     \"Acute procedure anxiety in adults: Course, screening, assessment, and differential diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9512?source=see_link\">",
"     \"Treatment of acute procedure anxiety in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=see_link\">",
"     \"Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25527?source=see_link\">",
"     \"Psychotherapy for specific phobia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6806?source=see_link\">",
"     \"Pharmacotherapy for specific phobia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12823180\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1235004\">",
"    <span class=\"h2\">",
"     Acute procedure anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute procedure anxiety, which is not a diagnosis found in DSM-IV-TR, is an excessive fear",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anxiety about a medical procedure that results in acute distress in anticipation of the procedure or during the procedure, or avoidance of the procedure. The fears experienced are often rational (eg, concern that a breast biopsy may find a malignancy), but in some cases can be irrational (eg, fear of suffocation during an MRI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2928505\">",
"    <span class=\"h3\">",
"     Specific phobias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presentations of acute procedure anxiety are diagnosed as a specific phobia under DSM-IV-TR criteria only when the focus of patients&rsquo; fear is specific to the procedure or its immediate effects (eg, a fear of seeing blood during venipuncture or suffocating during an MRI scan). A specific phobia would not be diagnosed when the patient&rsquo;s",
"    <span class=\"nowrap\">",
"     fear/anxiety",
"    </span>",
"    is about, for example, the implications or outcomes of the procedure (eg, the fear that a diagnostic procedure may detect an illness with a poor prognosis). Specific phobias related to clinical procedures include",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86700484\">",
"    <span class=\"h4\">",
"     Blood-injection-injury phobia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood-injection-injury phobia is characterized by the fear of seeing blood, receiving an injection, or of other invasive medical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/1\">",
"     1",
"    </a>",
"    ]. The phobic reaction to seeing blood may be accompanied by a vasovagal response. Individuals with blood-injection-injury phobia often avoid diagnostic and medical procedures, leading to a delay in the diagnosis and treatment of an illness, which may negatively impact health.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12823194\">",
"    <span class=\"h4\">",
"     Dental phobia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental phobia is the specific fear of going to the dentist and the fear may be triggered by multiple stimuli in the dental office, such as sound of the drill, receiving an intraoral injection or undergoing any dental treatment. Individuals with dental phobia may suffer significant distress, avoid going to the dentist, or require sedation to have necessary work completed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12823201\">",
"    <span class=\"h4\">",
"     MRI claustrophobia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Claustrophobia is the specific fear of enclosed spaces and is categorized under the situational subtype of specific phobia in DSM-IV-TR [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/1\">",
"     1",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) is the diagnostic procedure most impacted by claustrophobia, as presence of claustrophobia often leads to avoidance or premature termination of the procedure. The MRI scanner poses a phobic situation unlike being in other small spaces, because patients in MRI scanners are required to be in a very tight space without moving, and remain in an uncomfortable position for an extended period of time. There is significant noise interference and the room temperature in an MRI suite is often cold.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12823208\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the large number of diagnostic, medical, and surgical procedures in contemporary health care, there is surprisingly scant literature on rates of procedure-related anxiety. Rates of the prevalence of clinically significant anxiety in community based samples are limited to studies of blood-injection-injury phobia and dental phobia. Studies reporting prevalence rates of acute procedure anxiety in patients undergoing specific medical or surgical procedures are described below. Studies reporting mean anxiety levels among such patients are reported more briefly.",
"   </p>",
"   <p>",
"    Many of these studies have methodologic limitations. In studies of acute procedure anxiety unrelated to a diagnosis of specific phobia, data on anxiety levels have been limited to patient completion of self-assessment questionnaires. The instruments used vary widely, from one-item visual analog scales to instruments with established reliability and validity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2928841\">",
"    <span class=\"h2\">",
"     Specific phobias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-based studies have estimated that 2 to 5 percent of the general population in the United States (US) has experienced blood-injection-injury phobia, dental phobia, or MRI claustrophobia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2928848\">",
"    <span class=\"h3\">",
"     Blood-injection-injury phobia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community surveys estimated that 3.1 to 4.5 percent of the general population in the US suffers from blood-injection-injury phobia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. All of these surveys included dental phobia within the blood-injection-injury phobia subtype. Within this subtype, one study found that 23 percent had a fear of blood, 47 percent a fear of injections, and 78 percent a fear of dentists [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited data on the rates of blood-injection-injury phobia in the medical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 3315 adults undergoing venipuncture in a US outpatient hospital-based phlebotomy clinic reported that 7.5 percent of the participants reported significant anxiety symptoms during the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/5\">",
"       5",
"      </a>",
"      ]. Patients experiencing anxiety were more likely to report a history of vasovagal reactions and vasovagal syncope compared to patients who did not, and were also more likely to report significant fears of fainting, disgust, pain, and health concerns during injections. The study had multiple limitations, including the absence of a standardized instrument to assess anxiety.",
"     </li>",
"     <li>",
"      In a study of 1275 patients with insulin-dependent Type I or II diabetes in the Netherlands, 9.3 percent endorsed extreme fear of injecting themselves with insulin and testing their glucose levels [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 115 insulin-treated diabetic patients in the United Kingdom, 14 percent reported that they had avoided insulin injections secondary to anxiety. In a subgroup reporting the highest anxiety levels, 45 percent avoided injections [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 1529 pregnant women attending an antenatal clinic in Sweden, an estimated 7.2 percent met DSM-IV diagnostic criteria for blood-injection-injury phobia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A community-based study of 1920 individuals found that blood-injection-injury was more common in females, younger adults, and adults with less education compared to individuals in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2928855\">",
"    <span class=\"h3\">",
"     Dental phobia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on semi-structured diagnostic interviews, an estimated 2.4 percent of the general adult population in the US meets criteria for DSM-IV-TR dental phobia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/3\">",
"     3",
"    </a>",
"    ]. The prevalence of anxiety over dental procedures has been estimated at 10 percent, based on studies that have used self-report screening questionnaires [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/9\">",
"     9",
"    </a>",
"    ]. Rates of dental anxiety have been found to vary across population subgroups, with rates of 14 percent in adults over 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/10\">",
"     10",
"    </a>",
"    ] and as high as 19 percent in university students [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A higher prevalence of dental anxiety, compared to dental phobia, is expected as a phobia diagnosis requires additional functional impairment or distress criteria. In a study of 18-year-olds in New Zealand, only eight of 100 individuals who screened positive for dental anxiety met DSM-III-R criteria for dental phobia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dental anxiety tends to occur more commonly in females and those with less education [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Dental anxiety is also more common in patients in the lower income bracket, those without dental insurance, and those without a usual place for dental care [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/9\">",
"     9",
"    </a>",
"    ]. Studies have reported mixed results regarding the influence of age and race [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/9,10,13\">",
"     9,10,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2928862\">",
"    <span class=\"h3\">",
"     MRI claustrophobia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on naturalistic studies from 1984 to 2004 with a total of 17,961 patients, an estimated 2.3 percent of patients undergoing an MRI examination have claustrophobic reactions resulting in premature termination of scanning or medication to complete the scan [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/14\">",
"     14",
"    </a>",
"    ]. Claustrophobic reactions are less likely to occur in newer scanners with a wider magnetic bore compared to convention MRI machines (0.7 versus 2.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/14\">",
"     14",
"    </a>",
"    ]. MRI claustrophobia is more likely to occur in females, those in middle age (40 to 65 years of age), and during head-first examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of MRI claustrophobia in the general population may be higher than that estimated in the clinical sample above, as claustrophobia was stringently defined as requiring sedation or premature termination of scanning during an actual MRI examination. Patients who have claustrophobia would not have been included as a case of claustrophobia if they did not take medication but completed the MRI examination despite great distress. Other patients with claustrophobia may simply avoid MRI exams and would not be included in these studies. As an example, in a study of 1215 women with elevated risk of breast cancer who participated in a trial of supplemental MRI screening for the disease, 42.1 percent of participants declined further screening with breast MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/15\">",
"     15",
"    </a>",
"    ]. Of those who declined, 25.4 percent of them refused because of claustrophobia.",
"   </p>",
"   <p>",
"    A high rate of unexpected claustrophobic reactions during MRI scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/16\">",
"     16",
"    </a>",
"    ] suggests the possibility that patients can be anxious in an MRI scanner without having pre-existing claustrophobic reactions to other small spaces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1235078\">",
"    <span class=\"h2\">",
"     Screening procedures",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Transvaginal ultrasonography",
"      </strong>",
"      &mdash; A study of 145 women in the US, who had an elevated risk of ovarian cancer and were screened for the disease with transvaginal ultrasonography, found that 38 percent of premenopausal women and 27 percent of postmenopausal women experienced high levels of cancer risk-related anxiety prior to their first screening test [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/17\">",
"       17",
"      </a>",
"      ]",
"      <strong>",
"       .",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Colonoscopy",
"      </strong>",
"      &mdash; A study of 45 patients undergoing a screening colonoscopy because of a strong family history of colorectal cancer found that 65 percent reported moderate anxiety and 19 percent reported severe anxiety prior to the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Other screening procedures",
"      </strong>",
"      &mdash; Mild to moderate mean levels of anxiety have been found in women awaiting routine mammography screening for breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Moderate mean levels of acute anxiety were found in an observational study of 522 women undergoing gynecological exams in a private office setting in the US [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/21\">",
"       21",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"      Anxiety levels were comparable to those reported in patients undergoing invasive medical and surgical procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1235127\">",
"    <span class=\"h2\">",
"     Minimally invasive diagnostic procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;These procedures, which involve invasion of a body cavity or access to an internal organ, may include treatment of a positive finding.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Prostate biopsy",
"      </strong>",
"      &mdash; In a study of 1781 men in Sweden undergoing prostate biopsy, 49 percent reported intermediate levels of anxiety and 6 percent reported high levels of anxiety [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/22\">",
"       22",
"      </a>",
"      ]. Two smaller studies, conducted in India and the United Kingdom found similar results [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Amniocentesis",
"      </strong>",
"      &mdash; A study of 28 women in England undergoing early prenatal testing with amniocentesis at 13 weeks gestation was associated with clinical levels of anxiety in eight percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Two case controlled studies in England reported that women of advanced maternal age undergoing amniocentesis had significantly higher average levels of acute anxiety immediately prior to the procedure compared to women in the same gestational age who are undergoing routine ultrasound testing [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/26\">",
"       26",
"      </a>",
"      ], and compared to women of advanced maternal age who chose not to undergo amniocentesis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Having prenatal testing may ultimately decrease anxiety among pregnant women by providing reassurance of fetal health. A study of 179 women in England found that women who underwent amniocentesis had significantly lower anxiety in the third trimester compared to women who did not undergo amniocentesis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/28\">",
"       28",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Chorionic villus sampling",
"      </strong>",
"      &mdash; A study of 23 women in England undergoing prenatal testing with chorionic villus sampling to be associated with clinical levels of anxiety in 24 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       GI endoscopy",
"      </strong>",
"      &mdash;",
"      <strong>",
"      </strong>",
"      A study of 79 outpatients undergoing elective endoscopy without the use of conscious sedation found that 15 percent reported experiencing a panic attack during the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Other diagnostic procedures",
"      </strong>",
"      &mdash; Elevated levels of anxiety have been reported in samples of patients awaiting or undergoing GI endoscopy, bronchoscopy, breast biopsy, and colposcopy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/30-36\">",
"       30-36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1235157\">",
"    <span class=\"h2\">",
"     Minimally invasive treatment procedures",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Coronary procedures",
"      </strong>",
"      &mdash;Rates of anxiety tend to be higher in patients undergoing coronary angioplasty for the first time (26 percent in first timers versus 42 percent in repeaters) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/37\">",
"       37",
"      </a>",
"      ] and in women compared to men (24 percent versus 16 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/38\">",
"       38",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Anxiety levels have been found to be elevated in 16 to 49 percent of patients undergoing coronary angioplasty or stent placement, with some of the variation likely due to differences in anxiety measures and cut-off scores [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/37-39\">",
"       37-39",
"      </a>",
"      ]. A study of 88 patients in Turkey found that patients have moderate level of anxiety on the day of coronary angiography [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Laparoscopic surgery",
"      </strong>",
"      &mdash; A mean elevated level of anxiety was found in a sample of 57 women in the US undergoing bilateral laparoscopic tubal ligation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/41\">",
"       41",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"      Elevated baseline trait anxiety level was associated with increased amount of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      required to induce and maintain anesthesia. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1184805\">",
"    <span class=\"h2\">",
"     Major surgeries",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are typically the most invasive procedures posing the greatest risks to patients. They are usually performed under general anesthesia; thus, anticipatory anxiety is more typically of clinical concern rather than anxiety during the procedure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Open heart surgery &mdash;",
"      </strong>",
"      A study of 80 patients undergoing open heart surgery found that 32.5 percent reported clinically significant anxiety one day before surgery, 21.5 percent one week after surgery, and 18.7 percent at six months follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/42\">",
"       42",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"      Females reported a greater level of anxiety then males at all assessment points. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Neurosurgery",
"      </strong>",
"      &ndash; In a study of 109 patients undergoing brain tumor biopsy or craniotomy with resection of tumor, 30 percent of patients had clinical levels of anxiety prior to the procedure compared to 20 percent in a comparison group of patients undergoing elective spinal surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Other major surgeries",
"      </strong>",
"      &mdash; Other studies have found elevated levels of anxiety in samples of patients awaiting coronary artery bypass graft (CABG) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/44\">",
"       44",
"      </a>",
"      ] but not among patients undergoing cataract surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]",
"      <strong>",
"       . &nbsp;",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2929291\">",
"    <span class=\"h2\">",
"     Procedural risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;For some procedures, characteristics of the procedure, such as the degree of invasiveness, influence the level of acute procedure anxiety. As an example, in a naturalistic study of dental phobia, 987 patients rated invasive procedures as more anxiety provoking than non-invasive procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/47\">",
"     47",
"    </a>",
"    ]. The most anxiety provoking types of invasive dental procedures were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dental surgery",
"     </li>",
"     <li>",
"      Having some gum burned away",
"     </li>",
"     <li>",
"      Root canal treatment",
"     </li>",
"     <li>",
"      Extraction of a tooth or molar",
"     </li>",
"     <li>",
"      Cutting or tearing of soft tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The least anxiety provoking were non-invasive procedures (eg, dental x-ray, dental check-up, getting molds or imprints made, teeth cleaning) and stimuli related to personnel or setting (eg, the dentist as a person, white gown, waiting room).",
"   </p>",
"   <p>",
"    An uncertain diagnostic outcome can be a factor influencing the anxiety engendered by some procedures. Studies suggest that the possibility of a malignant diagnosis may contribute to the anxiety experienced by patients undergoing breast biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/36\">",
"     36",
"    </a>",
"    ]",
"    <strong>",
"    </strong>",
"    or prostate biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/24\">",
"     24",
"    </a>",
"    ]; the possibility of needing CABG can contribute to anxiety experienced by patients undergoing angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pre-procedure anxiety may also be influenced by the presence or absence of sedation during the procedure. As an example, the anticipation of pain and discomfort during a procedure is a common focus of fears, such as among patients undergoing colposcopy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/35,48\">",
"     35,48",
"    </a>",
"    ] which is not typically conducted under conscious sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521715683\">",
"    <span class=\"h2\">",
"     Comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a diagnosis of specific phobia (and possibly acute procedure anxiety) have been found to have a higher rate of comorbid anxiety disorders than patients without specific phobia, including [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Agoraphobia",
"     </li>",
"     <li>",
"      Generalized anxiety disorder",
"     </li>",
"     <li>",
"      Panic disorder",
"     </li>",
"     <li>",
"      Social anxiety disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A community-based study of 1920 individuals found that those with blood-injection-injury phobia were more likely to have had other psychiatric conditions, including marijuana abuse and dependence, major depression, obsessive compulsive disorder, panic disorder, agoraphobia, and other specific phobia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with high dental anxiety have been found to have higher rates of conduct disorder, agoraphobia, social phobia, alcohol dependence, or another specific phobia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=see_link\">",
"     \"Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/15/10488?source=see_link\">",
"     \"Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=see_link\">",
"     \"Overview of fears and specific phobias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12823250\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute procedure anxiety is the experience of a high level of anticipatory anxiety before a procedure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute anxiety at the time of the procedure. In severe cases, anxiety may be associated with avoidance of the procedure.",
"   </p>",
"   <p>",
"    Anxiety is characterized by the interaction of cognitive, physiological, and behavioral components [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/50\">",
"     50",
"    </a>",
"    ]. At the cognitive level, anxiety is a feeling of apprehension of possible future threat or danger to one's personal safety or security. Physiological manifestations include physical symptoms of arousal, such as elevated heart rate, palpitations, sweating, shortness of breath, or muscle tension. Behavioral features of anxiety may include avoidance or reassurance seeking, which usually has the goal of decreasing the anxiety or escaping from the perceived threatening stimulus. Anxiety exists on a continuum, with normal anxiety when the threat estimate is accurate, to &ldquo;pathological&rdquo; or clinical anxiety when the threat estimate is biased.",
"   </p>",
"   <p>",
"    When anxiety is acute and severe, it may take the form of a panic attack. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21422378\">",
"    <span class=\"h2\">",
"     Focus of fear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The focus of fear in acute procedure anxiety can vary dependent on procedural type; foci may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Concerns about the potential risks and complications of the procedure",
"     </li>",
"     <li>",
"      Perceptions of pain and discomfort during the procedure",
"     </li>",
"     <li>",
"      Fears about implications and outcomes of the procedure",
"     </li>",
"     <li>",
"      Uncertainty about illness, disability, and other factors related to the procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients undergoing oral and maxillary surgery, some of the fearful aspects of treatment included fears of complications (eg, getting an infection), pain during treatment and wait-time before treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In pregnant women undergoing invasive prenatal testing, acute procedure anxiety is related to potential complications of the procedure (eg, risk of miscarriage) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/25\">",
"       25",
"      </a>",
"      ]",
"      <strong>",
"      </strong>",
"      and concerns about an abnormal result [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/25,27\">",
"       25,27",
"      </a>",
"      ]. In one study in this population, 48 percent of the women studied reported being worried about having a miscarriage and 42 percent reported anxiety about the results [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In women undergoing colposcopy, the three most frequently endorsed concerns are about pain, discomfort, and uncertainty over what would happen during the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/35,48\">",
"       35,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients undergoing angiography, the most fearful aspects of the procedure are (in rank order) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/52\">",
"       52",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fears of coronary artery bypass surgery",
"     </li>",
"     <li>",
"      Uncertainty about the illness",
"     </li>",
"     <li>",
"      Death",
"     </li>",
"     <li>",
"      Pain",
"     </li>",
"     <li>",
"      Clinical findings",
"     </li>",
"     <li>",
"      Lying flat in bed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 831 patients in Sweden on a waiting list for angiography, angioplasty, or CABG, six percent of patients reported that the most distressing symptom was fear and 43 percent reported that uncertainty about the future [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/53\">",
"       53",
"      </a>",
"      ]. This uncertainty focused on concerns, eg, whether they would receive treatment in time (as median wait time was five to eight months), their financial situation, and future of their families.",
"     </li>",
"     <li>",
"      In patients undergoing cataract surgery, the most anxiety provoking aspects of the surgery were local anesthesia, the unknown, and possible failure of surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21422385\">",
"    <span class=\"h2\">",
"     Focus with specific phobias",
"    </span>",
"    &nbsp;&mdash;&nbsp;When acute procedure anxiety is a manifestation of a specific phobia, the focus of fear is specific to the procedure or its immediate effects. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In patients with claustrophobia, the main focus is fear of suffocation and fear of restriction while in an enclosed space [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the MRI setting, in addition to fear of suffocation and fear of restriction, patients may fear being harmed by the machine (ie, fear of having a stroke in a scanner) or fear of losing control [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with blood phobia, the fear at the sight of blood is typically concern about physical sensations, fear of fainting, and feelings of disgust [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Blood-injection-injury phobia is distinguished from other subtypes of specific phobia by the presence of a vasovagal fainting response, which occurs in the majority of individuals diagnosed with the subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/57\">",
"     57",
"    </a>",
"    ]. The fainting response in specific phobia appears to be unique to situations associated with blood and medical procedures. Disgust sensitivity may be a possible mediator of the fainting response [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21422400\">",
"    <span class=\"h2\">",
"     Avoidance or delay of procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoidance or delay of a necessary procedure is one of the main negative health consequences in patients with severe acute procedure anxiety. Rates of avoidant behavior have been documented mainly for the specific phobias [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/15,59\">",
"     15,59",
"    </a>",
"    ], but avoidance occurs in other manifestations of acute procedure anxiety as well. Avoidance of medical procedures can delay diagnosis and treatment, and adversely affect patient outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/59\">",
"     59",
"    </a>",
"    ], as illustrated in the studies below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant women with blood-injection-injury phobia have been found to be more fearful of childbirth and have a higher rate of elective cesarean sections, pregnancy complications (eg, preeclampsia and premature contractions), adverse obstetric outcomes (eg, premature delivery and longer hospital stays), and poorer neonatal morbidity (eg, small for gestational age) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study found that patients with dental anxiety were more likely to avoid dental visits; most had not seen a dentist for at least 18 months [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/10\">",
"       10",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"      Numerous studies have demonstrated that patients with dental anxiety have significantly worse oral health status compared to non-anxious individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/9,61\">",
"       9,61",
"      </a>",
"      ]. As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A community sample of 455 adults, individuals with dental anxiety were found to have a greater number of caries but half as many filled surfaces, and higher percentage of teeth with calculi and gingival bleeding, compared to individuals without dental anxiety [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 548 older adults, the presence of dental anxiety was associated with a greater number of missing teeth and root fragments [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies have reported mixed findings on the health effects of finger-stick and insulin-injection avoidance among patients with insulin-dependent diabetes and a fear of injection. As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A study of 115 patients reported that more patients with high injection-related anxiety avoided insulin injection because of anxiety compared to patients with low injection-related anxiety (9 versus 28 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/7\">",
"       7",
"      </a>",
"      ]. However, there was no correlation between fear of injection and glycemic control.",
"     </li>",
"     <li>",
"      A study of 1275 diabetic patients using retrospective self-report questionnaires found that extreme fear of injections was associated with less frequent self-monitoring of blood glucose, but not associated with the number of insulin injections per day, glycemic control, or diabetes complications [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A community survey of 1920 adults, eight individuals with diabetes and blood-injection-injury phobia experienced a higher rate of macrovascular complications (peripheral vascular disease and cardiovascular disease), compared to 138 individuals with diabetes alone (76 percent versus 18 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If avoidance is not possible or if a fear reaction was not anticipated prior to the procedure, then the patient may have to endure the procedure with great distress or may require treatment of the anxiety in order for the procedure to be completed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9849/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9512?source=see_link\">",
"     \"Treatment of acute procedure anxiety in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425218\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute procedure anxiety is an excessive fear",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anxiety about a medical procedure that results in acute distress in anticipation of the procedure or during the procedure, or avoidance of the procedure. The fears experienced are often rational (eg, concern that a breast biopsy may find a malignancy), but in some cases can be irrational (eg, fear of suffocation during an MRI).",
"     </li>",
"     <li>",
"      Studies have found acute procedure anxiety to occur among patients undergoing a wide range of screening, diagnostic, and treatment procedures, including (See",
"      <a class=\"local\" href=\"#H12823208\">",
"       'Epidemiology'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Non-invasive diagnostic procedures (See",
"      <a class=\"local\" href=\"#H1235078\">",
"       'Screening procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minimally invasive diagnostic procedures (See",
"      <a class=\"local\" href=\"#H1235127\">",
"       'Minimally invasive diagnostic procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minimally invasive treatment procedures (See",
"      <a class=\"local\" href=\"#H1235157\">",
"       'Minimally invasive treatment procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major surgery (See",
"      <a class=\"local\" href=\"#H1184805\">",
"       'Major surgeries'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The focus of fear in acute procedure anxiety varies among individuals and by the type of procedure; foci may include concerns about the procedure&rsquo;s potential risks and complications, perceptions of associated pain and discomfort, or fears of the implications and outcomes of a procedure. (See",
"      <a class=\"local\" href=\"#H21422378\">",
"       'Focus of fear'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute procedure anxiety is diagnosed as a specific phobia using DSM-IV-TR criteria when the focus of the patient&rsquo;s fear or anxiety is specific to the procedure or its effects (eg, a fear of seeing blood during venipuncture or suffocating during an MRI scan). A specific phobia would not be diagnosed when the patient&rsquo;s",
"      <span class=\"nowrap\">",
"       fear/anxiety",
"      </span>",
"      is not specific to the procedure itself, but about, for example, its outcome or implications (eg, a fear that a diagnostic procedure may detect a malignancy). (See",
"      <a class=\"local\" href=\"#H2928505\">",
"       'Specific phobias'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Examples of acute procedure anxiety that is diagnosed as a specific phobia include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with blood phobia, the fear at the sight of blood is typically concern about physical sensations, fear of fainting, and feelings of disgust.",
"     </li>",
"     <li>",
"      Dental phobia is the specific fear of going to the dentist and the fear may be triggered by multiple stimuli in the dental office, such as sound of the drill, receiving an intraoral injection or undergoing any dental treatment.",
"     </li>",
"     <li>",
"      In patients with MRI claustrophobia, the main focus is fear of suffocation and fear of restriction while in an enclosed space, though alternatively, patients may fear being harmed by the machine or losing control.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The epidemiology of the specific phobias has been studied with more rigorous methods than other manifestations of acute procedure anxiety. Community-based studies have estimated that 2 to 5 percent of the general population in the US has experienced blood-injection-injury phobia, dental phobia, or MRI claustrophobia. (See",
"      <a class=\"local\" href=\"#H12823208\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The avoidance or delay of clinical procedures resulting from acute procedure anxiety has been associated with poor health outcomes in a variety of patient samples. (See",
"      <a class=\"local\" href=\"#H12823250\">",
"       'Clinical Manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/2\">",
"      Curtis GC, Magee WJ, Eaton WW, et al. Specific fears and phobias. Epidemiology and classification. Br J Psychiatry 1998; 173:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/3\">",
"      Stinson FS, Dawson DA, Patricia Chou S, et al. The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2007; 37:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/4\">",
"      Bienvenu OJ, Eaton WW. The epidemiology of blood-injection-injury phobia. Psychol Med 1998; 28:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/5\">",
"      Deacon B, Abramowitz J. Fear of needles and vasovagal reactions among phlebotomy patients. J Anxiety Disord 2006; 20:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/6\">",
"      Mollema ED, Snoek FJ, Ad&egrave;r HJ, et al. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res 2001; 51:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/7\">",
"      Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999; 46:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/8\">",
"      Lilliecreutz C, Josefsson A. Prevalence of blood and injection phobia among pregnant women. Acta Obstet Gynecol Scand 2008; 87:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/9\">",
"      Doerr PA, Lang WP, Nyquist LV, Ronis DL. Factors associated with dental anxiety. J Am Dent Assoc 1998; 129:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/10\">",
"      Elter JR, Strauss RP, Beck JD. Assessing dental anxiety, dental care use and oral status in older adults. J Am Dent Assoc 1997; 128:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/11\">",
"      Kaakko T, Milgrom P, Coldwell SE, et al. Dental fear among university students: implications for pharmacological research. Anesth Prog 1998; 45:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/12\">",
"      Locker D, Poulton R, Thomson WM. Psychological disorders and dental anxiety in a young adult population. Community Dent Oral Epidemiol 2001; 29:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/13\">",
"      Weiner AA, Forgione AG, Weiner LK. Survey examines patients' fear of dental treatment. J Mass Dent Soc 1998; 47:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/14\">",
"      Dewey M, Schink T, Dewey CF. Claustrophobia during magnetic resonance imaging: cohort study in over 55,000 patients. J Magn Reson Imaging 2007; 26:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/15\">",
"      Berg WA, Blume JD, Adams AM, et al. Reasons women at elevated risk of breast cancer refuse breast MR imaging screening: ACRIN 6666. Radiology 2010; 254:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/16\">",
"      Eshed I, Althoff CE, Hamm B, Hermann KG. Claustrophobia and premature termination of magnetic resonance imaging examinations. J Magn Reson Imaging 2007; 26:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/17\">",
"      Hensley ML, Robson ME, Kauff ND, et al. Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. Gynecol Oncol 2003; 89:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/18\">",
"      Williams GL, Clarke P, Vellacott KD. Anxieties should not be forgotten when screening relatives of colorectal cancer patients by colonoscopy. Colorectal Dis 2006; 8:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/19\">",
"      Steinemann SK, Chun MB, Huynh DH, Loui K. Breast cancer worry among women awaiting mammography: is it unfounded? Does prior counseling help? Hawaii Med J 2011; 70:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/20\">",
"      B&ouml;l&uuml;kba N, Erbil N, Kahraman AN. Determination of the anxiety level of women who present for mammography. Asian Pac J Cancer Prev 2010; 11:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/21\">",
"      Reddy DM, Wasserman SA. Patient anxiety during gynecologic examinations. Behavioral indicators. J Reprod Med 1997; 42:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/22\">",
"      Carlsson S, Aus G, Wessman C, Hugosson J. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study. Eur J Cancer 2007; 43:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/23\">",
"      Jadhav SA, Sukumar S, Kumar G, Bhat SH. Prospective analysis of psychological distress in men being investigated for prostate cancer. Indian J Urol 2010; 26:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/24\">",
"      Awsare NS, Green JS, Aldwinckle B, et al. The measurement of psychological distress in men being investigated for the presence of prostate cancer. Prostate Cancer Prostatic Dis 2008; 11:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/25\">",
"      Cederholm M, Sj&ouml;d&eacute;n PO, Axelsson O. Psychological distress before and after prenatal invasive karyotyping. Acta Obstet Gynecol Scand 2001; 80:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/26\">",
"      Sarkar P, Bergman K, Fisk NM, Glover V. Maternal anxiety at amniocentesis and plasma cortisol. Prenat Diagn 2006; 26:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/27\">",
"      Marteau TM, Kidd J, Cook R, et al. Psychological effects of having amniocentesis: are these due to the procedure, the risk or the behaviour? J Psychosom Res 1992; 36:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/28\">",
"      Marteau TM, Johnston M, Shaw RW, et al. The impact of prenatal screening and diagnostic testing upon the cognitions, emotions and behaviour of pregnant women. J Psychosom Res 1989; 33:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/29\">",
"      Mitsonis C, Dimopoulos N, Zavrou M, et al. Panic Attack during Elective Gastrointestinal Endoscopy. Gastroenterol Res Pract 2011; 2011:162574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/30\">",
"      Felley C, Perneger TV, Goulet I, et al. Combined written and oral information prior to gastrointestinal endoscopy compared with oral information alone: a randomized trial. BMC Gastroenterol 2008; 8:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/31\">",
"      Stermer E, Levy N, Beny A, et al. Ambience in the endoscopy room has little effect on patients. J Clin Gastroenterol 1998; 26:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/32\">",
"      Uzbeck M, Quinn C, Saleem I, et al. Randomised controlled trial of the effect of standard and detailed risk disclosure prior to bronchoscopy on peri-procedure anxiety and satisfaction. Thorax 2009; 64:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/33\">",
"      Howells RE, Dunn PD, Isasi T, et al. Is the provision of information leaflets before colposcopy beneficial? A prospective randomised study. Br J Obstet Gynaecol 1999; 106:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/34\">",
"      Walsh JC, Curtis R, Mylotte M. Anxiety levels in women attending a colposcopy clinic: a randomised trial of an educational intervention using video colposcopy. Patient Educ Couns 2004; 55:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/35\">",
"      Chan YM, Lee PW, Ng TY, et al. The use of music to reduce anxiety for patients undergoing colposcopy: a randomized trial. Gynecol Oncol 2003; 91:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/36\">",
"      Flory N, Lang EV. Distress in the radiology waiting room. Radiology 2011; 260:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/37\">",
"      Lenzen MJ, Gamel CJ, Immink AW. Anxiety and well-being in first-time coronary angioplasty patients and repeaters. Eur J Cardiovasc Nurs 2002; 1:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/38\">",
"      Astin F, Jones K, Thompson DR. Prevalence and patterns of anxiety and depression in patients undergoing elective percutaneous transluminal coronary angioplasty. Heart Lung 2005; 34:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/39\">",
"      Trotter R, Gallagher R, Donoghue J. Anxiety in patients undergoing percutaneous coronary interventions. Heart Lung 2011; 40:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/40\">",
"      Uzun S, Vural H, Uzun M, Yokusoglu M. State and trait anxiety levels before coronary angiography. J Clin Nurs 2008; 17:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/41\">",
"      Maranets I, Kain ZN. Preoperative anxiety and intraoperative anesthetic requirements. Anesth Analg 1999; 89:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/42\">",
"      Vingerhoets G. Perioperative anxiety and depression in open-heart surgery. Psychosomatics 1998; 39:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/43\">",
"      Pringle AM, Taylor R, Whittle IR. Anxiety and depression in patients with an intracranial neoplasm before and after tumour surgery. Br J Neurosurg 1999; 13:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/44\">",
"      McCormick KM, Naimark BJ, Tate RB. Uncertainty, symptom distress, anxiety, and functional status in patients awaiting coronary artery bypass surgery. Heart Lung 2006; 35:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/45\">",
"      Foggitt PS. Anxiety in cataract surgery: pilot study. J Cataract Refract Surg 2001; 27:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/46\">",
"      Nijkamp MD, Kenens CA, Dijker AJ, et al. Determinants of surgery related anxiety in cataract patients. Br J Ophthalmol 2004; 88:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/47\">",
"      Oosterink FM, de Jongh A, Aartman IH. What are people afraid of during dental treatment? Anxiety-provoking capacity of 67 stimuli characteristic of the dental setting. Eur J Oral Sci 2008; 116:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/48\">",
"      Marteau TM, Walker P, Giles J, Smail M. Anxieties in women undergoing colposcopy. Br J Obstet Gynaecol 1990; 97:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/49\">",
"      Locker D, Liddell A, Dempster L, Shapiro D. Age of onset of dental anxiety. J Dent Res 1999; 78:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/50\">",
"      Beck AT, Clark DA. An information processing model of anxiety: automatic and strategic processes. Behav Res Ther 1997; 35:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/51\">",
"      Hermes D, Matthes M, Saka B. Treatment anxiety in oral and maxillofacial surgery. Results of a German multi-centre trial. J Craniomaxillofac Surg 2007; 35:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/52\">",
"      Heikkil&auml; J, Paunonen M, Laippala P, Virtanen V. Patients' fears in coronary arteriography. Scand J Caring Sci 1999; 13:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/53\">",
"      Bengtson A, Herlitz J, Karlsson T, Hjalmarson A. Distress correlates with the degree of chest pain: a description of patients awaiting revascularisation. Heart 1996; 75:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/54\">",
"      Rachman S, Taylor S. Analyses of claustrophobia. J Anxiety Disord 1993; 7:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/55\">",
"      Thorpe S, Salkovskis PM, Dittner A. Claustrophobia in MRI: the role of cognitions. Magn Reson Imaging 2008; 26:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/56\">",
"      Lipsitz JD, Barlow DH, Mannuzza S, et al. Clinical features of four DSM-IV-specific phobia subtypes. J Nerv Ment Dis 2002; 190:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/57\">",
"      Ost LG. Blood and injection phobia: background and cognitive, physiological, and behavioral variables. J Abnorm Psychol 1992; 101:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/58\">",
"      Exeter-Kent HA, Page AC. The role of cognitions, trait anxiety and disgust sensitivity in generating faintness around blood-injury phobic stimuli. J Behav Ther Exp Psychiatry 2006; 37:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/59\">",
"      Page AC. Blood-injury-injection fears in medical practice. Med J Aust 1996; 164:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/60\">",
"      Lilliecreutz C, Sydsj&ouml; G, Josefsson A. Obstetric and perinatal outcomes among women with blood- and injection phobia during pregnancy. J Affect Disord 2011; 129:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/61\">",
"      Poulton R, Thomson WM, Brown RH, Silva PA. Dental fear with and without blood-injection fear: implications for dental health and clinical practice. Behav Res Ther 1998; 36:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9849/abstract/62\">",
"      Murphy KJ, Brunberg JA. Adult claustrophobia, anxiety and sedation in MRI. Magn Reson Imaging 1997; 15:51.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16618 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9849=[""].join("\n");
var outline_f9_39_9849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H425218\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12823173\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12823180\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1235004\">",
"      Acute procedure anxiety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2928505\">",
"      - Specific phobias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H86700484\">",
"      Blood-injection-injury phobia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12823194\">",
"      Dental phobia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12823201\">",
"      MRI claustrophobia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12823208\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2928841\">",
"      Specific phobias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2928848\">",
"      - Blood-injection-injury phobia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2928855\">",
"      - Dental phobia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2928862\">",
"      - MRI claustrophobia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1235078\">",
"      Screening procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1235127\">",
"      Minimally invasive diagnostic procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1235157\">",
"      Minimally invasive treatment procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1184805\">",
"      Major surgeries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2929291\">",
"      Procedural risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H521715683\">",
"      Comorbidities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12823250\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21422378\">",
"      Focus of fear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21422385\">",
"      Focus with specific phobias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21422400\">",
"      Avoidance or delay of procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H425218\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11782?source=related_link\">",
"      Acute procedure anxiety in adults: Course, screening, assessment, and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/15/10488?source=related_link\">",
"      Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=related_link\">",
"      Overview of fears and specific phobias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=related_link\">",
"      Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6806?source=related_link\">",
"      Pharmacotherapy for specific phobia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25527?source=related_link\">",
"      Psychotherapy for specific phobia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=related_link\">",
"      Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=related_link\">",
"      Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9512?source=related_link\">",
"      Treatment of acute procedure anxiety in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_39_9850="Unipolar depression in adults: Continuation and maintenance treatment";
var content_f9_39_9850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unipolar depression in adults: Continuation and maintenance treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/39/9850/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/39/9850/contributors\">",
"     Robin B. Jarrett, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/39/9850/contributors\">",
"     Joanne Sanders, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/39/9850/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/39/9850/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/39/9850/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/39/9850/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/39/9850/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H173307799\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuation and maintenance treatment are generally indicated for patients with unipolar major depression because the illness is highly recurrent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Standard treatments include pharmacotherapy, psychotherapy, or pharmacotherapy plus psychotherapy.",
"   </p>",
"   <p>",
"    This topic reviews continuation and maintenance treatment for nonpsychotic, unipolar major depression. Choosing a regimen for the initial treatment of depression and treatment of resistant depression is discussed separately, as is maintenance treatment of psychotic depression and geriatric depression.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8055?source=see_link\">",
"       \"Unipolar major depression with psychotic features: Maintenance treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=see_link&amp;anchor=H28#H28\">",
"       \"Diagnosis and management of late-life depression\", section on 'Duration of treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14392038\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2080222\">",
"    <span class=\"h2\">",
"     Unipolar major depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode and have no history of mania, mixed mania, or hypomania [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/4\">",
"     4",
"    </a>",
"    ]. A major depressive episode is a period lasting at least two weeks, with five or more of the following symptoms: depressed mood, loss of interest or pleasure in most or all activities, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration, thoughts of worthlessness or guilt, and recurrent thoughts about death or suicide (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"     table 1",
"    </a>",
"    ). Additional information about the clinical presentation and diagnosis of major depressive disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2080251\">",
"    <span class=\"h2\">",
"     Continuation and maintenance treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuation treatment and maintenance treatment are distinguished from each other, as are remission and recovery, and relapse and recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Continuation treatment is administered after resolution of a major depressive episode to preserve and enhance remission, and prevent relapse of the presenting episode. Remission represents a period of time with minimal or no symptoms; the duration of this time period varies among different studies (eg, two to eight consecutive months) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. Continuation treatment is followed by maintenance treatment, which is provided after recovery from the presenting episode to prevent recurrence of new, subsequent episodes. Recovery is said to occur when patients remain well for a period of time exceeding the interval used to define remission.",
"   </p>",
"   <p>",
"    However, there is no established cutoff that separates the end of remission from the beginning of recovery; thus, the distinction between continuation and maintenance treatment is not standardized. Many studies therefore use the terms \"continuation treatment\" and \"maintenance treatment\" interchangeably to describe treatment that is provided after patients respond to acute therapy. Likewise, \"relapse\" and \"recurrence\" are used interchangeably because distinguishing relapse of the presenting episode from recurrence of a new episode is arbitrary. Continuation treatment has been studied more frequently than maintenance treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/9\">",
"     9",
"    </a>",
"    ], and systematic reviews of \"maintenance treatment\" typically include both continuation and maintenance trials [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional information about recovery from and recurrence of major depressive episodes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=see_link\">",
"     \"Unipolar depression in adults: Prognosis and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7164739\">",
"    <span class=\"h1\">",
"     RELAPSE/RECURRENCE IN THE ABSENCE OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse and recurrence are common in patients with unipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/13\">",
"     13",
"    </a>",
"    ], including acutely ill patients who",
"    <span class=\"nowrap\">",
"     remit/recover",
"    </span>",
"    with treatment and then discontinue it [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of 11 randomized trials that included 1019 patients who were successfully treated with acute pharmacotherapy and then assigned to placebo,",
"      <span class=\"nowrap\">",
"       relapse/recurrence",
"      </span>",
"      occurred within one year in 51 percent and within two years in 62 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of 13 randomized and observational studies that included 364 patients with major depression who were successfully treated with acute cognitive-behavioral therapy (CBT) and received no subsequent treatment, relapse and recurrence during follow-up (mean 74 weeks) occurred in 39 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/10\">",
"       10",
"      </a>",
"      ]. By two years, the estimated rate was 54 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients acutely ill with unipolar major depression who improve with pharmacotherapy and subsequently discontinue it appear to be at greater risk for",
"    <span class=\"nowrap\">",
"     relapse/recurrence",
"    </span>",
"    than patients who improve with and discontinue CBT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of seven randomized and observational studies (335 patients with major depression) with a mean follow-up of 68 weeks,",
"      <span class=\"nowrap\">",
"       relapse/recurrence",
"      </span>",
"      occurred in more patients who received acute pharmacotherapy than acute CBT (61 versus 39 percent).",
"     </li>",
"     <li>",
"      In a meta-analysis of six randomized and observational studies (285 patients with major depression) with a mean follow-up of 56 weeks,",
"      <span class=\"nowrap\">",
"       relapse/recurrence",
"      </span>",
"      occurred in more patients who received acute pharmacotherapy alone than acute pharmacotherapy plus CBT (65 versus 38 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One hypothesis for the decreased risk of",
"    <span class=\"nowrap\">",
"     relapse/recurrence",
"    </span>",
"    in patients treated with acute phase, depression-specific psychotherapy is that patients resolve maladaptive thought patterns, learn new skills, respond more adaptively to stressful life events, and reduce their problematic behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/15\">",
"     15",
"    </a>",
"    ]. After psychotherapy ceases, these changes may persist and forestall reemerging symptoms. By contrast, the neurochemical changes that occur with medications may dissipate if pharmacotherapy is stopped.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14391901\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuation treatment (lasting, for example, four to nine months) is generally indicated for patients who respond to acute treatment of unipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2,16-19\">",
"     1,2,16-19",
"    </a>",
"    ]. Additional maintenance treatment (lasting, for example, one to three years) is indicated for patients with an increased risk of recurrence due to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Childhood maltreatment (physical or sexual abuse, neglect, or family violence or conflict)",
"     </li>",
"     <li>",
"      Early age of onset of unipolar major depression (eg, &le;18 to 21 years of age)",
"     </li>",
"     <li>",
"      A lifetime history of at least two or three major depressive episodes",
"     </li>",
"     <li>",
"      Persistent residual depressive symptoms, especially sleep disturbances",
"     </li>",
"     <li>",
"      Comorbid psychiatric or general medical disorders",
"     </li>",
"     <li>",
"      Psychosocial stressors or impairment (eg, marital conflict or inability to work)",
"     </li>",
"     <li>",
"      Negative cognitive style (eg, \"I'm no good,\" \"The future is hopeless,\" or \"There&rsquo;s nothing I can do\")",
"     </li>",
"     <li>",
"      Family history of mood disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with unipolar major depression who respond to acute therapy,",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    treatment is consistent with practice guidelines from the American Psychiatric Association [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], United Kingdom National Institute of Health and Clinical Excellence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/3\">",
"     3",
"    </a>",
"    ], Canadian Network for Mood and Anxiety Treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], British Association for Psychopharmacology [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/22\">",
"     22",
"    </a>",
"    ], and World Federation of Societies of Biological Psychiatry [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, patients with unipolar major depression who respond to acute treatment with cognitive-behavioral therapy (CBT) and are not at increased risk of",
"    <span class=\"nowrap\">",
"     relapse/recurrence",
"    </span>",
"    may reasonably decline continuation treatment, provided the presenting episode was neither chronic nor severe. Acute CBT can provide enduring effects beyond the end of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. The efficacy of CBT is described elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H8038740\">",
"     'Cognitive-behavioral therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with unipolar major depression who respond to acute treatment with behavioral activation and are not at increased risk of",
"    <span class=\"nowrap\">",
"     relapse/recurrence",
"    </span>",
"    may also reasonably decline continuation treatment, provided the presenting episode was neither chronic nor severe. Behavioral activation focuses on increasing rewarding activities, promoting behaviors that decrease rumination, and improving problem solving skills [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A one year randomized trial found that relapse of major depression was comparable for patients who remitted with acute phase behavioral activation and received no further treatment (N = 27) and for patients who remitted with and continued",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    (maximum dose 50 mg per day; N = 28) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who recover from their first lifetime episode of unipolar major depression with acute and continuation pharmacotherapy may reasonably decline maintenance treatment, provided that the presenting episode was neither chronic nor severe, that remission was stable rather than marked by subsyndromal symptoms, and that patients are not at increased risk of",
"    <span class=\"nowrap\">",
"     relapse/recurrence",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, this approach is based upon limited evidence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86758411\">",
"    <span class=\"h1\">",
"     TREATMENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unipolar major depression who respond to acute phase therapy, standard continuation and maintenance treatments include pharmacotherapy, psychotherapy, or pharmacotherapy plus psychotherapy. The same treatment that was successfully used acutely is typically selected for",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2,28\">",
"     1,2,28",
"    </a>",
"    ]. Pharmacotherapy alone has been most widely studied and used for acute treatment and thus continuation and maintenance treatment as well because of convenience and availability [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2,29\">",
"     1,2,29",
"    </a>",
"    ]. Other factors to consider in choosing maintenance treatment include the patient's past response as well as that of family members, patient preference, and cost. The efficacy of standard",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    treatments is discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H8038540\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Continuation/maintenance",
"    </span>",
"    pharmacotherapy for unipolar major depression nearly always includes antidepressant medications, which should be used at the same dose that achieves remission (see",
"    <a class=\"local\" href=\"#H8038660\">",
"     'Dose'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2,28\">",
"     1,2,28",
"    </a>",
"    ]. Although selective serotonin reuptake inhibitors (SSRIs) and tricyclics have been most widely studied, other reasonable options include serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin modulators (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"     vilazodone",
"    </a>",
"    ), atypical antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    ), and monoamine oxidase inhibitors (MAOIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/11,12,30\">",
"     11,12,30",
"    </a>",
"    ]. Head-to-head randomized trials do not indicate that any one medication or medication class is superior [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients may want to discontinue the acute phase antidepressant and switch to a different drug for",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    treatment; indications for switching include adverse effects, specific residual depressive symptoms (eg, insomnia may respond to sedating medications), comorbid general medical conditions, and drug-drug interactions. Switching antidepressants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link&amp;anchor=H2#H2\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Switching antidepressant medication'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During acute treatment of unipolar major depression, antidepressants may be augmented with other medications such as second-generation antipsychotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , triiodothyronine, or a second antidepressant [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, there are no high quality",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    studies of medication combinations. Augmentation of antidepressants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31993?source=see_link\">",
"     \"Unipolar depression in adults: Treatment with second-generation antipsychotics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17192?source=see_link\">",
"     \"Unipolar depression in adults: Treatment with lithium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27175?source=see_link\">",
"     \"Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    treatment of major depression, psychotherapy alone is efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2,21\">",
"     1,2,21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8038682\">",
"     'Psychotherapy'",
"    </a>",
"    below.). However, the efficacy of pharmacotherapy may possibly exceed that of interpersonal psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8038653\">",
"     'Compared with interpersonal psychotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The most widely studied psychotherapy for continuation and maintenance treatment of unipolar major depression is cognitive-behavioral therapy (CBT) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/21\">",
"     21",
"    </a>",
"    ]. Other reasonable choices include interpersonal psychotherapy and mindfulness-based cognitive therapy. No head-to-head randomized trials have compared different psychotherapies; thus, the choice frequently depends upon availability and patient preference. (See",
"    <a class=\"local\" href=\"#H8038682\">",
"     'Psychotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Randomized trials indicate that continuation and maintenance treatment with pharmacotherapy plus interpersonal psychotherapy is superior to either pharmacotherapy alone or psychotherapy alone. (See",
"    <a class=\"local\" href=\"#H8038582\">",
"     'Antidepressant medications plus interpersonal psychotherapy'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86758477\">",
"    <span class=\"h2\">",
"     Sequential treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unipolar major depression who successfully complete acute phase pharmacotherapy may switch to or add psychotherapy (eg, CBT or mindfulness-based cognitive therapy) for",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    treatment; this strategy is called sequential treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/21\">",
"     21",
"    </a>",
"    ]. Switching from pharmacotherapy to psychotherapy can be used to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoid adverse medication side effects",
"     </li>",
"     <li>",
"      Avoid teratogenic and postnatal risks of antidepressants",
"     </li>",
"     <li>",
"      Manage poor adherence with pharmacotherapy",
"     </li>",
"     <li>",
"      Resolve residual symptoms (eg, hopelessness)",
"     </li>",
"     <li>",
"      Improve interpersonal or occupational functioning",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adding psychotherapy to pharmacotherapy can be used for poor adherence, residual symptoms, and impaired functioning.",
"   </p>",
"   <p>",
"    A meta-analysis of eight randomized trials compared sequential treatment (using CBT or mindfulness-based cognitive therapy) with a control treatment in 875 patients with major depression who responded to acute phase pharmacotherapy;",
"    <span class=\"nowrap\">",
"     relapse/recurrence",
"    </span>",
"    was reduced in patients who received sequential treatment (RR 0.80, 95% CI 0.66-0.96) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with major depression who remit after acute phase psychotherapy may reasonably choose to stop psychotherapy and initiate pharmacotherapy for",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    treatment; an ongoing trial is evaluating this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86757398\">",
"    <span class=\"h1\">",
"     DURATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86757420\">",
"    <span class=\"h2\">",
"     Continuation treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unipolar major depression who respond to acute therapy, multiple reviews and treatment guidelines recommend that clinicians administer continuation treatment for four to nine months to [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1-3,20,22,28\">",
"     1-3,20,22,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prevent relapse",
"     </li>",
"     <li>",
"      Eliminate residual symptoms (which are associated with relapse)",
"     </li>",
"     <li>",
"      Restore baseline psychosocial functioning",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence for the efficacy of continuation treatment includes a meta-analysis of five trials that compared antidepressants with placebo in 2000 patients who were treated with antidepressants for four to six months prior to random assignment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/11\">",
"     11",
"    </a>",
"    ]. Relapse occurred in fewer patients who received antidepressants than placebo (18 versus 35 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86757427\">",
"    <span class=\"h2\">",
"     Maintenance treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with risk factors for recurrence should receive at least one to three years of maintenance treatment following continuation treatment, as should patients who recover from a chronic (duration &ge;2 years) or severe episode (eg, the episode includes a suicide attempt) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/3,20,28\">",
"     3,20,28",
"    </a>",
"    ]. Risk factors for recurrence are discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H14391901\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Evidence supporting the use of maintenance treatment for three years comes from a two-part study; 20 patients who were initially randomized to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    and remained well for three years were then randomized again to imipramine or placebo for two more years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/35\">",
"     35",
"    </a>",
"    ]. The mean time to recurrence was significantly longer with imipramine than placebo (99 versus 54 weeks).",
"   </p>",
"   <p>",
"    In addition, randomized trials lasting up to three years have found that maintenance treatment is efficacious:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 10 randomized maintenance trials lasting 18 to 36 months (703 recovered patients) found that recurrence occurred in fewer patients who received antidepressants than placebo (24 versus 63 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A three-year randomized trial assigned 50 recovered patients to either monthly maintenance sessions of interpersonal psychotherapy plus pill placebo or to monthly medication clinic visits with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/31\">",
"       31",
"      </a>",
"      ]. Recurrence occurred in fewer patients who received psychotherapy plus placebo than placebo alone (64 versus 90 percent).",
"     </li>",
"     <li>",
"      A three-year randomized trial assigned 49 recovered patients to either monthly maintenance sessions of interpersonal psychotherapy plus pill placebo or to monthly medication clinic visits with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/32\">",
"       32",
"      </a>",
"      ]. The median time to recurrence was longer in patients who received psychotherapy plus placebo than placebo alone (61 versus 21 weeks).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with a history of multiple (eg, three) chronic or severe major depressive episodes, or with comorbid psychiatric and general medical disorders, are encouraged to maintain treatment indefinitely [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Such patients may be discouraged by the prospect of treatment that lasts \"forever.\" For these patients, it is important to emphasize the long-term nature of the relationship between the clinician and patient, and that the need for maintenance treatment will be reevaluated periodically (eg, annually) in light of the patient's progress in maintaining symptomatic and functional stability, as well as changes in risk factors for recurrence (eg, residual depressive symptoms or psychosocial stressors may resolve). It may be useful to help the patient conceptualize recurrent major depression as a chronic disease and to point out that other chronic illnesses such as hypertension, diabetes mellitus, and asthma often require life-time medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86757434\">",
"    <span class=\"h1\">",
"     MONITORING PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving continuation and maintenance treatment for unipolar major depression should be regularly monitored for reemerging symptoms, with particular emphasis upon suicidal ideation. Patients treated with pharmacotherapy are also evaluated for adverse side effects. For patients who remit and remain stable, monitoring can be tapered, with progressively longer intervals between assessments. As an example, a patient who is seen every two weeks at the beginning of remission can be seen every two weeks for one to three more visits, and then every month for one to three visits. Continuously stable patients receiving pharmacotherapy can eventually be seen every three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2,28\">",
"     1,2,28",
"    </a>",
"    ]. Stable patients receiving psychotherapy are typically seen once per month [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], following careful tapering from weekly to twice a month visits. More frequent visits should be scheduled for patients who develop symptoms or side effects; monitoring acutely ill patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link&amp;anchor=H26#H26\">",
"     \"Initial treatment of depression in adults\", section on 'Timing of response and follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with unipolar depression who receive maintenance treatment, we suggest measurement based care using a self-report instrument [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Measurement based care is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=see_link\">",
"     \"Using scales to monitor symptoms and treatment of depression (measurement based care)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286945\">",
"    <span class=\"h1\">",
"     ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients have difficulty adhering to (complying with) continuation and maintenance treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/36-41\">",
"     36-41",
"    </a>",
"    ]. Strategies that can improve adherence are discussed separately in the context of bipolar disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=see_link&amp;anchor=H1205113#H1205113\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Adherence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173034179\">",
"    <span class=\"h1\">",
"     REEMERGING SYMPTOMS DURING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;If symptoms of unipolar major depression reemerge during",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    pharmacotherapy, doses of medications should be optimized. If this does not control symptoms within four to eight weeks, or doses are already at the maximum of the therapeutic range, we suggest adding psychotherapy; this strategy is called sequential treatment. (See",
"    <a class=\"local\" href=\"#H86758477\">",
"     'Sequential treatment'",
"    </a>",
"    above.) If a full blown episode occurs despite optimizing medication doses and adding psychotherapy, the treatment regimen should be switched. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If symptoms reemerge during",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    psychotherapy, the frequency of sessions should be increased to that used during acute phase treatment. If a full blown episode occurs despite increasing the frequency of psychotherapy sessions, the treatment regimen should be switched. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87348931\">",
"    <span class=\"h1\">",
"     DISCONTINUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to discontinuing continuation and maintenance treatment for unipolar major depression, clinicians should discuss the potential for relapse and recurrence with patients, and the signs and symptoms that may arise [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These discussions often include family members and generate contingency plans for seeking treatment should the need arise. In addition, the date for termination of psychotherapy should be discussed at the outset of",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    treatment.",
"   </p>",
"   <p>",
"    We suggest tapering",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    medications over two to four weeks prior to discontinuation to minimize the discontinuation syndrome, which includes gastrointestinal distress, headache, myalgia, insomnia, anergia, and dysphoria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1-3,28\">",
"     1-3,28",
"    </a>",
"    ]. Medications with shorter half lives (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ) should be tapered over one month. The dose is generally reduced by the same amount for each step of the taper. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    200 mg per day is decreased by 50 mg every three to five days. Additional information about discontinuing antidepressants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link&amp;anchor=H12#H12\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Discontinuation of antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, tapering allows clinicians to detect recrudescent symptoms of major depression and reinstitute the full dose used initially to achieve remission. If a full-blown episode develops despite increasing the dose and does not improve within four to eight weeks, we suggest augmenting or switching treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following discontinuation of",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    pharmacotherapy or psychotherapy for unipolar major depression, it is prudent to monitor patients for several (eg, three to eight) months, because the risk of relapse or recurrence is greatest in the first several months after stopping treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. For patients who suffer a relapse or recurrence, we suggest restarting the same treatment that was discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8038540\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8038582\">",
"    <span class=\"h2\">",
"     Antidepressant medications plus interpersonal psychotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8038589\">",
"    <span class=\"h3\">",
"     Compared with antidepressants alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with acute unipolar major depression who respond to the combination of pharmacotherapy and interpersonal psychotherapy, randomized trials indicate that continuation and maintenance treatment with combination treatment is superior to pharmacotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/42\">",
"     42",
"    </a>",
"    ]. A meta-analysis of four randomized trials (282 patients who remitted from an episode of unipolar major depression with combination treatment) found that",
"    <span class=\"nowrap\">",
"     relapse/recurrence",
"    </span>",
"    was more likely in patients who received pharmacotherapy alone than combination treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/43\">",
"     43",
"    </a>",
"    ]. Additional information about the advantage of maintenance treatment with pharmacotherapy plus interpersonal psychotherapy over pharmacotherapy alone is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17674?source=see_link&amp;anchor=H2291374#H2291374\">",
"     \"Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy\", section on 'Recurrent unipolar major depression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8038596\">",
"    <span class=\"h3\">",
"     Compared with psychotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon randomized maintenance trials in patients with unipolar major depression, pharmacotherapy plus interpersonal psychotherapy is superior to psychotherapy alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A three-year randomized trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      (target serum concentration 80 to 100 ng per mL) plus interpersonal psychotherapy (one session per month) with placebo plus interpersonal psychotherapy in 50 patients who initially recovered with combination treatment; there were fewer recurrences in patients who received combination treatment than in patients who received psychotherapy alone (20 versus 64 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a three-year randomized trial that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      (mean dose 208 mg per day) plus monthly interpersonal psychotherapy with placebo plus interpersonal psychotherapy in 51 patients who initially recovered with combination treatment, the mean time to recurrence of depression was nearly twice as long for combination treatment compared with interpersonal psychotherapy alone (131 versus 74 weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8038603\">",
"    <span class=\"h2\">",
"     Antidepressant medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unipolar major depression who respond to antidepressant medications, continuation and maintenance treatment can delay or prevent reemerging episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2,28,30\">",
"     1,2,28,30",
"    </a>",
"    ]. However, the efficacy of different antidepressants appears to be comparable. In head-to-head randomized trials that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    with sertraline, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    , relapse or recurrence within each trial was comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8038646\">",
"    <span class=\"h3\">",
"     Compared with placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 31 randomized continuation and maintenance trials compared antidepressants with placebo in 4410 depressed patients who initially responded to acute treatment with antidepressants; the trials lasted for up to three years (most lasted 12 or fewer month). The primary findings were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapse and recurrence occurred in fewer patients who received antidepressants than placebo (18 versus 41 percent)",
"     </li>",
"     <li>",
"      Benefits appeared to be comparable for selective serotonin reuptake inhibitors (SSRIs) and tricyclics, based upon separate analyses for each medication class",
"     </li>",
"     <li>",
"      Discontinuation of treatment for any reason (eg, adverse effects or lack of efficacy) occurred in more patients who received antidepressants than placebo (18 versus 15 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent two year, randomized maintenance trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    extended release (mean dose 214 mg per day) with placebo in 258 patients with recurrent unipolar major depression who were successfully treated for an acute episode and remained well through 6 months of continuation treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/44\">",
"     44",
"    </a>",
"    ]. The estimated rate of recurrence was lower in patients treated with venlafaxine than placebo (29 versus 47 percent). Adverse effects in venlafaxine patients included weight gain, headache, and upper respiratory infection.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Continuation/maintenance",
"    </span>",
"    antidepressants may provide greater benefits in patients with one lifetime major depressive episode than patients with multiple lifetime episodes. In a meta-analysis of 30 randomized",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    trials (4890 patients) that compared antidepressants with placebo, antidepressants reduced the probability of",
"    <span class=\"nowrap\">",
"     relapse/recurrence",
"    </span>",
"    in patients with no episodes prior to the presenting episode (OR 0.12, 95% CI 0.06-0.26), as well as patients with a history of at least one depressive episode prior to the presenting episode (OR 0.37, 95% CI 0.31-0.44); however, the reduction was greater in patients with no prior episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8038653\">",
"    <span class=\"h3\">",
"     Compared with interpersonal psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon small randomized trials that compared pharmacotherapy with interpersonal psychotherapy for",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    treatment of unipolar major depression, the efficacy of pharmacotherapy may possibly exceed that of psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A two-year randomized",
"      <span class=\"nowrap\">",
"       continuation/maintenance",
"      </span>",
"      trial compared pharmacotherapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      monotherapy or paroxetine plus a second antidepressant) with monthly interpersonal psychotherapy plus pill placebo in 70 patients who recovered or partially recovered from an episode of major depression;",
"      <span class=\"nowrap\">",
"       relapse/recurrence",
"      </span>",
"      occurred in fewer patients who received pharmacotherapy than interpersonal psychotherapy (37 versus 68 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A three-year trial (N = 54 patients) found that the mean time to recurrence for patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      (mean dose 208 mg per day) and patients who received interpersonal psychotherapy (one session per month) was 124 and 82 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/32\">",
"       32",
"      </a>",
"      ]. Although the difference between treatments was not statistically significant, a difference of this magnitude, if real, would be clinically meaningful.",
"     </li>",
"     <li>",
"      In a three-year trial that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      (target serum concentration 80 to 100 ng per mL, N = 28) with monthly interpersonal psychotherapy (N = 25), recurrent episodes occurred in 12 (43 percent) patients treated with nortriptyline and 16 (64 percent) patients who received interpersonal psychotherapy plus placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/31\">",
"       31",
"      </a>",
"      ]. Although the difference between treatments was not statistically significant, a difference of this magnitude, if real, would be clinically meaningful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8038660\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same antidepressant dose that is used to acutely treat unipolar major depression is typically used for",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2,11,28\">",
"     1,2,11,28",
"    </a>",
"    ]. A meta-analysis of five randomized trials compared maintaining the full dose with reducing the dose in 1009 patients who had",
"    <span class=\"nowrap\">",
"     remitted/recovered",
"    </span>",
"    with acute pharmacotherapy.",
"    <span class=\"nowrap\">",
"     Relapse/recurrence",
"    </span>",
"    occurred in fewer patients who received the full dose (15 versus 25 percent). However, for patients who cannot tolerate the full dose, it is reasonable to attempt to decrease the dose. Persistent side effects or loss of efficacy at lower doses is managed by switching treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link&amp;anchor=H2#H2\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Switching antidepressant medication'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8038682\">",
"    <span class=\"h2\">",
"     Psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unipolar major depression who respond to psychotherapy, continuation and maintenance psychotherapy can delay or prevent reemerging episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/1,2,21\">",
"     1,2,21",
"    </a>",
"    ] and may be especially beneficial for patients with a lifetime history of multiple unipolar major depressive episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8038740\">",
"    <span class=\"h3\">",
"     Cognitive-behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT is a time-limited, structured therapy that combines cognitive therapy and behavior therapy to help depressed patients change dysfunctional cognitions (distorted thoughts and beliefs about oneself, the world, and future) and problematic behaviors (eg, inactivity) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Additional information about CBT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link&amp;anchor=H432862147#H432862147\">",
"     \"Overview of psychotherapies\", section on 'Cognitive and behavioral therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Continuation CBT reduces relapse of unipolar major depression. A meta-analysis of four randomized trials compared continuation CBT with no continuation treatment in 234 patients who initially remitted with acute CBT; over a mean follow-up of 41 weeks, relapse occurred in fewer patients who received CBT (12 versus 38 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/10\">",
"     10",
"    </a>",
"    ]. Continuation CBT also appears to benefit patients at increased risk for relapse, including patients with an early age of onset (eg, age &le;18 years) of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/50\">",
"     50",
"    </a>",
"    ] and residual symptoms following response to acute phase CBT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, acute phase CBT may prevent relapse in the absence of continuation CBT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/10\">",
"     10",
"    </a>",
"    ]. In a randomized trial, depressed patients were treated with pharmacotherapy or CBT; patients who responded to pharmacotherapy (N = 69) were then randomly assigned to continuation medication or placebo for one year, and patients who responded to CBT (N = 35) were withdrawn from treatment except for three booster sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/24\">",
"     24",
"    </a>",
"    ]. Relapse over 12 months occurred in fewer patients withdrawn from CBT compared with patients who discontinued pharmacotherapy (31 versus 76 percent). In addition, relapse occurred in fewer patients who received prior CBT compared with patients who received continuation pharmacotherapy (31 and 47 percent); although the difference between treatments was not statistically significant, a difference of this magnitude, if real, would be clinically meaningful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8038762\">",
"    <span class=\"h3\">",
"     Interpersonal psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpersonal psychotherapy is a time-limited, structured, manual-based therapy that emphasizes current relationships and the connection between recent adverse life events and major depression. Treatment focuses upon resolving interpersonal problems that are due to [",
"    <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grief &ndash; complicated bereavement",
"     </li>",
"     <li>",
"      Role disputes &ndash; conflicts with spouses, family members, close friends, or coworkers over different expectations about the relationship",
"     </li>",
"     <li>",
"      Role transition &ndash; major changes in life circumstances such as divorce or retirement",
"     </li>",
"     <li>",
"      Interpersonal deficits &ndash; poor social skills that result in loneliness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence for the efficacy of maintenance interpersonal psychotherapy for unipolar major depression includes randomized trials showing recurrence is decreased in patients who receive interpersonal psychotherapy plus placebo compared with patients who receive placebo alone. The efficacy of maintenance interpersonal psychotherapy is discussed separately, as are the specific interventions that therapists use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17674?source=see_link&amp;anchor=H2291374#H2291374\">",
"     \"Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy\", section on 'Recurrent unipolar major depression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4425?source=see_link\">",
"     \"Interpersonal Psychotherapy (IPT) for depressed adults: Specific interventions and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8038769\">",
"    <span class=\"h3\">",
"     Mindfulness-based cognitive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mindfulness-based cognitive therapy is a skills-training group program that combines the clinical application of mindfulness meditation with elements of CBT to delay or prevent recurrence in patients with unipolar major depression who have responded to acute phase treatment (typically with pharmacotherapy) and have a history of at least three lifetime episodes. Mindfulness is purposeful, nonjudgmental attention to the present moment, which is developed through meditation and other practices. CBT is based upon the theory that maladaptive thoughts and behaviors lead to psychopathology such as major depression; the clinician addresses these dysfunctional cognitions, and the patient tries to change the resulting problematic behaviors.",
"   </p>",
"   <p>",
"    Evidence for the efficacy of mindfulness-based cognitive therapy in patients with unipolar major depression includes randomized trials that compared",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    mindfulness-based cognitive therapy with",
"    <span class=\"nowrap\">",
"     continuation/maintenance",
"    </span>",
"    pharmacotherapy and found that",
"    <span class=\"nowrap\">",
"     relapse/recurrence",
"    </span>",
"    may possibly occur less often with psychotherapy. The efficacy of maintenance mindfulness-based cognitive therapy is discussed separately, as are the specific interventions that therapists use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8584?source=see_link\">",
"     \"Mindfulness based cognitive therapy as maintenance treatment for unipolar major depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8038776\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unipolar major depression may benefit from maintenance treatment with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; Monotherapy with the second generation antipsychotic quetiapine may prevent relapse of major depression. A one-year randomized trial compared quetiapine extended release (mean dose 177 mg per day) with placebo in 776 patients with unipolar major depression who were stabilized for at least 12 weeks with open label quetiapine [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/54\">",
"       54",
"      </a>",
"      ]. Relapse occurred in fewer patients treated with quetiapine than placebo (14 versus 34 percent). Adverse effects of quetiapine included sedation, dry mouth, dizziness, increased appetite and weight, and extrapyramidal side effects.",
"     </li>",
"     <li>",
"      <strong>",
"       Electroconvulsive therapy",
"      </strong>",
"      &ndash; For patients with unipolar major depression who respond with electroconvulsive therapy (ECT),",
"      <span class=\"nowrap\">",
"       continuation/maintenance",
"      </span>",
"      treatment generally consists of pharmacotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/55\">",
"       55",
"      </a>",
"      ] or pharmacotherapy plus psychotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/56\">",
"       56",
"      </a>",
"      ]. However,",
"      <span class=\"nowrap\">",
"       continuation/maintenance",
"      </span>",
"      ECT should be considered for patients who repeatedly (eg, two to three times) respond to acute ECT and then fail standard maintenance treatment.",
"      <span class=\"nowrap\">",
"       Continuation/maintenance",
"      </span>",
"      ECT is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link&amp;anchor=H24#H24\">",
"       \"Overview of electroconvulsive therapy (ECT) for adults\", section on 'Continuation and maintenance ECT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Repetitive transcranial magnetic stimulation",
"      </strong>",
"      &ndash; For patients with unipolar major depression who respond to repetitive transcranial magnetic stimulation (TMS),",
"      <span class=\"nowrap\">",
"       continuation/maintenance",
"      </span>",
"      treatment generally consists of pharmacotherapy or pharmacotherapy plus psychotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/57\">",
"       57",
"      </a>",
"      ]. However,",
"      <span class=\"nowrap\">",
"       continuation/maintenance",
"      </span>",
"      repetitive TMS may possibly help patients who repeatedly fail standard treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16682?source=see_link&amp;anchor=H259860078#H259860078\">",
"       \"Unipolar depression in adults: Treatment with transcranial magnetic stimulation (TMS)\", section on 'Maintenance transcranial magnetic stimulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Exercise",
"      </strong>",
"      &ndash; Exercise alone or combined with pharmacotherapy, psychotherapy, or pharmacotherapy plus psychotherapy may possibly delay or prevent recurrence of depression. In a prospective observational study, 172 patients with unipolar major depression received pharmacotherapy, psychotherapy, or no treatment; at the one-year assessment, 66 percent were euthymic [",
"      <a class=\"abstract\" href=\"UTD.htm?9/39/9850/abstract/58\">",
"       58",
"      </a>",
"      ]. Fewer depressive symptoms were found in patients who exercised (moderate to vigorous intensity) for three hours per week compared with patients who did not exercise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7164921\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unipolar major depression is diagnosed in patients who have suffered at least one major depressive episode and have no history of mania, mixed mania, or hypomania. A major depressive episode is a period lasting at least two weeks, with five or more of the following symptoms: dysphoria, anhedonia, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, anergia, poor concentration, thoughts of worthlessness or guilt, and recurrent thoughts about death or suicide (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Continuation treatment is administered to preserve and enhance remission and to prevent relapse of the presenting episode. Remission represents a period of time (eg, two to eight months) with minimal or no symptoms. Continuation treatment is followed by maintenance treatment, which is used after recovery from the presenting episode to prevent recurrence of new episodes. Recovery occurs when patients remain well for a period of time exceeding the interval used to define remission. However, it is not clear when remission ends and recovery begins, and thus the cutoff between continuation and maintenance treatment is not standardized. (See",
"      <a class=\"local\" href=\"#H2080251\">",
"       'Continuation and maintenance treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relapse and recurrence are common in patients with unipolar major depression who improve with treatment and then discontinue it. (See",
"      <a class=\"local\" href=\"#H7164739\">",
"       'Relapse/recurrence in the absence of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Continuation treatment is generally indicated for patients with unipolar major depression who respond to acute treatment; additional maintenance treatment is indicated for patients with an increased risk of recurrence due to:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Childhood maltreatment",
"     </li>",
"     <li>",
"      Early age of onset of unipolar major depression",
"     </li>",
"     <li>",
"      A lifetime history of at least two or three major depressive episodes",
"     </li>",
"     <li>",
"      Persistent residual depressive symptoms",
"     </li>",
"     <li>",
"      Comorbid psychiatric or general medical disorders",
"     </li>",
"     <li>",
"      Psychosocial stressors or impairment",
"     </li>",
"     <li>",
"      Negative cognitive style",
"     </li>",
"     <li>",
"      Family history of mood disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H14391901\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who respond to acute cognitive-behavioral therapy (CBT) or behavioral activation may reasonably decline continuation treatment, provided they are not at increased risk of relapse, the presenting episode was neither chronic nor severe, and that remission was stable. (See",
"      <a class=\"local\" href=\"#H14391901\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard continuation and maintenance treatments include pharmacotherapy, psychotherapy, and pharmacotherapy plus psychotherapy. Randomized trials indicate that pharmacotherapy plus interpersonal psychotherapy is more efficacious than pharmacotherapy alone or psychotherapy alone. The efficacy of monotherapy with either pharmacotherapy or psychotherapy is superior to no treatment. Pharmacotherapy alone may possibly be more effective than interpersonal psychotherapy alone. (See",
"      <a class=\"local\" href=\"#H8038540\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with unipolar major depression who respond to acute therapy, we recommend continuation treatment rather than no treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest continuation treatment with the same regimen that was used acutely. (See",
"      <a class=\"local\" href=\"#H86758411\">",
"       'Treatment selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unipolar major depression who respond to acute phase and continuation phase therapy and are at risk of recurrence, we recommend maintenance therapy rather than discontinuing treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Maintenance treatment typically consists of the same regimen used during the acute and continuation phases. (See",
"      <a class=\"local\" href=\"#H86758411\">",
"       'Treatment selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unipolar major depression who respond to acute phase and continuation phase therapy and are at low risk of recurrence, we suggest discontinuing treatment rather than administering maintenance therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, it is reasonable to provide maintenance treatment for patients concerned about recurrence. (See",
"      <a class=\"local\" href=\"#H86758411\">",
"       'Treatment selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Continuation/maintenance",
"      </span>",
"      pharmacotherapy for unipolar major depression nearly always includes antidepressant medications. For patients treated with",
"      <span class=\"nowrap\">",
"       continuation/maintenance",
"      </span>",
"      antidepressants, we suggest maintaining the same dose that achieved remission rather than decreasing the dose (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Patients with substantial side effects can reasonably choose to decrease the dose. Head to head trials do not indicate that any one medication or medication class is superior. Indications for discontinuing the acute phase antidepressant and switching to a different drug for",
"      <span class=\"nowrap\">",
"       continuation/maintenance",
"      </span>",
"      treatment include intolerable adverse effects, specific residual depressive symptoms, comorbid general medical conditions, and drug-drug interactions. (See",
"      <a class=\"local\" href=\"#H86758411\">",
"       'Treatment selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8038603\">",
"       'Antidepressant medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most widely studied psychotherapy for",
"      <span class=\"nowrap\">",
"       continuation/maintenance",
"      </span>",
"      treatment of unipolar major depression is cognitive-behavioral therapy (CBT); other reasonable choices include interpersonal psychotherapy and mindfulness-based cognitive therapy. No head to head trials have compared different psychotherapies. (See",
"      <a class=\"local\" href=\"#H86758411\">",
"       'Treatment selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8038682\">",
"       'Psychotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with unipolar major depression who successfully complete acute pharmacotherapy may switch to or add on psychotherapy for",
"      <span class=\"nowrap\">",
"       continuation/maintenance",
"      </span>",
"      treatment (called sequential treatment). Switching can be used to avoid adverse medication side effects, conceive and breastfeed children, manage poor adherence with pharmacotherapy, resolve residual symptoms, or improve psychosocial functioning. Adding psychotherapy can be used for poor adherence, residual symptoms, and impaired functioning. (See",
"      <a class=\"local\" href=\"#H86758477\">",
"       'Sequential treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of continuation treatment typically ranges from four to nine months. Patients with risk factors for recurrence should receive at least one to three years of maintenance treatment following continuation treatment, as should patients who recover from a chronic or severe episode. Patients with a history of multiple chronic or severe major depressive episodes, or comorbid psychiatric and general medical disorders, are encouraged to maintain treatment indefinitely. (See",
"      <a class=\"local\" href=\"#H86757398\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other options for",
"      <span class=\"nowrap\">",
"       continuation/maintenance",
"      </span>",
"      treatment of patients with unipolar major depression include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      , exercise, electroconvulsive therapy, and repetitive transcranial magnetic stimulation. (See",
"      <a class=\"local\" href=\"#H8038776\">",
"       'Other approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/1\">",
"      American Psychiatric Association. Practice Guideline for the treatment of patients with major depressive disorder, third edition. Am J Psychiatry 2010; 167:1.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. file://psychiatryonline.org/guidelines.aspx (Accessed on April 17, 2012).",
"    </li>",
"    <li>",
"     National Institute of Health and Clinical Excellence. Depression: The treatment and management of depression in adults (updated version). National Clinical Practice Guideline 90. file://www.nice.org.uk/ (Accessed on May 19, 2012).",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/5\">",
"      Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/6\">",
"      Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006; 31:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/7\">",
"      Dunlop BW, Holland P, Bao W, et al. Recovery and subsequent recurrence in patients with recurrent major depressive disorder. J Psychiatr Res 2012; 46:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/8\">",
"      Jarrett RB, Thase ME. Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up. Contemp Clin Trials 2010; 31:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/9\">",
"      Deshauer D, Moher D, Fergusson D, et al. Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. CMAJ 2008; 178:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/10\">",
"      Vittengl JR, Clark LA, Dunn TW, Jarrett RB. Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects. J Consult Clin Psychol 2007; 75:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/11\">",
"      Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/12\">",
"      Kaymaz N, van Os J, Loonen AJ, Nolen WA. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 2008; 69:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/13\">",
"      Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature 2011; 475:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/14\">",
"      Williams N, Simpson AN, Simpson K, Nahas Z. Relapse rates with long-term antidepressant drug therapy: a meta-analysis. Hum Psychopharmacol 2009; 24:401.",
"     </a>",
"    </li>",
"    <li>",
"     Jarrett RB, Vittengl JR, Clark LA. Preventing recurrent depression. In: Adapting Cognitive Therapy for Depression: Managing Complexity and Comorbidity, Whisman MA.  (Ed), Guilford Publications, New York 2008. p.132.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/16\">",
"      Hirschfeld RM. Clinical importance of long-term antidepressant treatment. Br J Psychiatry Suppl 2001; 42:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/17\">",
"      Preventing recurrent depression: long-term treatment for major depressive disorder. Prim Care Companion J Clin Psychiatry 2007; 9:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/18\">",
"      Bockting CL, Spinhoven P, Koeter MW, et al. Prediction of recurrence in recurrent depression and the influence of consecutive episodes on vulnerability for depression: a 2-year prospective study. J Clin Psychiatry 2006; 67:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/19\">",
"      Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry 2012; 169:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/20\">",
"      Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117 Suppl 1:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/21\">",
"      Parikh SV, Segal ZV, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord 2009; 117 Suppl 1:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/22\">",
"      Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/23\">",
"      Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 2002; 3:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/24\">",
"      Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005; 62:417.",
"     </a>",
"    </li>",
"    <li>",
"     Martell, CR, Addis, et al. Depression in Context: Strategies for Guided Action, W.W. Norton &amp; Company, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/26\">",
"      Dimidjian S, Davis KJ. Newer variations of cognitive-behavioral therapy: behavioral activation and mindfulness-based cognitive therapy. Curr Psychiatry Rep 2009; 11:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/27\">",
"      Dobson KS, Hollon SD, Dimidjian S, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. J Consult Clin Psychol 2008; 76:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/28\">",
"      Mann JJ. The medical management of depression. N Engl J Med 2005; 353:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/29\">",
"      Williams JM, Kuyken W. Mindfulness-based cognitive therapy: a promising new approach to preventing depressive relapse. Br J Psychiatry 2012; 200:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/30\">",
"      Hansen R, Gaynes B, Thieda P, et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 2008; 59:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/31\">",
"      Reynolds CF 3rd, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999; 281:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/32\">",
"      Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/33\">",
"      Reynolds CF 3rd, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med 2006; 354:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/34\">",
"      Guidi J, Fava GA, Fava M, Papakostas GI. Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis. Psychol Med 2011; 41:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/35\">",
"      Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/36\">",
"      Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995; 310:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/37\">",
"      Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998; 7 Suppl 1:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/38\">",
"      Demyttenaere K, Adelin A, Patrick M, et al. Six-month compliance with antidepressant medication in the treatment of major depressive disorder. Int Clin Psychopharmacol 2008; 23:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/39\">",
"      Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006; 163:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/40\">",
"      Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009; 70 Suppl 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/41\">",
"      Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/42\">",
"      Cuijpers P, Geraedts AS, van Oppen P, et al. Interpersonal psychotherapy for depression: a meta-analysis. Am J Psychiatry 2011; 168:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/43\">",
"      Oestergaard S, M&oslash;ldrup C. Optimal duration of combined psychotherapy and pharmacotherapy for patients with moderate and severe depression: a meta-analysis. J Affect Disord 2011; 131:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/44\">",
"      Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 2007; 68:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/45\">",
"      Blackburn IM, Moore RG. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br J Psychiatry 1997; 171:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/46\">",
"      Bockting CL, Spinhoven P, Wouters LF, et al. Long-term effects of preventive cognitive therapy in recurrent depression: a 5.5-year follow-up study. J Clin Psychiatry 2009; 70:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/47\">",
"      Chiesa A, Serretti A. Mindfulness based cognitive therapy for psychiatric disorders: a systematic review and meta-analysis. Psychiatry Res 2011; 187:441.",
"     </a>",
"    </li>",
"    <li>",
"     Beck, AT, et al. Cognitive Therapy of Depression, Guilford Press, New York 1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/49\">",
"      Beck AT, Dozois DJ. Cognitive therapy: current status and future directions. Annu Rev Med 2011; 62:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/50\">",
"      Jarrett RB, Kraft D, Doyle J, et al. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry 2001; 58:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/51\">",
"      Jarrett RB, Vittengl JR, Clark LA. How much cognitive therapy, for which patients, will prevent depressive relapse? J Affect Disord 2008; 111:185.",
"     </a>",
"    </li>",
"    <li>",
"     Klerman, G, et al. Interpersonal psychotherapy of depression, Basic Books, New York 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/53\">",
"      Markowitz JC, Weissman MM. Interpersonal psychotherapy: past, present and future. Clin Psychol Psychother 2012; 19:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/54\">",
"      Liebowitz M, Lam RW, Lepola U, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety 2010; 27:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/55\">",
"      Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001; 285:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/56\">",
"      McClintock SM, Brandon AR, Husain MM, Jarrett RB. A systematic review of the combined use of electroconvulsive therapy and psychotherapy for depression. J ECT 2011; 27:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/57\">",
"      George MS, Post RM. Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression. Am J Psychiatry 2011; 168:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/39/9850/abstract/58\">",
"      Hoffman BM, Babyak MA, Craighead WE, et al. Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. Psychosom Med 2011; 73:127.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14674 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9850=[""].join("\n");
var outline_f9_39_9850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7164921\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H173307799\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14392038\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2080222\">",
"      Unipolar major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2080251\">",
"      Continuation and maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7164739\">",
"      RELAPSE/RECURRENCE IN THE ABSENCE OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14391901\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86758411\">",
"      TREATMENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86758477\">",
"      Sequential treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86757398\">",
"      DURATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86757420\">",
"      Continuation treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86757427\">",
"      Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86757434\">",
"      MONITORING PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8286945\">",
"      ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H173034179\">",
"      REEMERGING SYMPTOMS DURING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87348931\">",
"      DISCONTINUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8038540\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8038582\">",
"      Antidepressant medications plus interpersonal psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8038589\">",
"      - Compared with antidepressants alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8038596\">",
"      - Compared with psychotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8038603\">",
"      Antidepressant medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8038646\">",
"      - Compared with placebo",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8038653\">",
"      - Compared with interpersonal psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8038660\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8038682\">",
"      Psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8038740\">",
"      - Cognitive-behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8038762\">",
"      - Interpersonal psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8038769\">",
"      - Mindfulness-based cognitive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8038776\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7164921\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14674\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14674|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17756\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17674?source=related_link\">",
"      Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4425?source=related_link\">",
"      Interpersonal Psychotherapy (IPT) for depressed adults: Specific interventions and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8584?source=related_link\">",
"      Mindfulness based cognitive therapy as maintenance treatment for unipolar major depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27175?source=related_link\">",
"      Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=related_link\">",
"      Unipolar depression in adults: Prognosis and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17192?source=related_link\">",
"      Unipolar depression in adults: Treatment with lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31993?source=related_link\">",
"      Unipolar depression in adults: Treatment with second-generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16682?source=related_link\">",
"      Unipolar depression in adults: Treatment with transcranial magnetic stimulation (TMS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8055?source=related_link\">",
"      Unipolar major depression with psychotic features: Maintenance treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=related_link\">",
"      Using scales to monitor symptoms and treatment of depression (measurement based care)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_39_9851="Clinical situations associated with vitamin deficiency";
var content_f9_39_9851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=19\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=19\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical situations in which vitamin deficiency syndromes occur",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor intake",
"       </td>",
"       <td>",
"        Poverty, elderly, alcoholics, restrictive diets (eg, vegan)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malabsorption",
"       </td>",
"       <td>",
"        Celiac disease, Crohn's disease, short bowel, gastric bypass, elderly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal losses",
"       </td>",
"       <td>",
"        Hemodialysis, chronic diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal metabolism",
"       </td>",
"       <td>",
"        Genetic polymorphisms, alcoholism (increases folate metabolism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inadequate synthesis",
"       </td>",
"       <td>",
"        Vitamin D (Northern climates, homebound, little exposed skin)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9851=[""].join("\n");
var outline_f9_39_9851=null;
var title_f9_39_9852="Causes of hypoaldosteronism";
var content_f9_39_9852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F74155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F74155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of hypoaldosteronism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Aldosterone deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Primary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Primary adrenal insufficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Congenital adrenal hyperplasia, particularly 21-hydroxylase deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Isolated aldosterone synthase deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Heparin and low molecular weight heparin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Hyporeninemic hypoaldosteronism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Renal disease, most often diabetic nephropathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Volume expansion, as in acute glomerulonephritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Angiotensin inhibition, as with angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, or direct renin inhibitors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Nonsteroidal antiinflammatory drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cyclosporine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       HIV infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Some cases of obstructive uropathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Aldosterone resistance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Drugs which close the collecting tubule sodium channel",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Amiloride",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Spironolactone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Triamterene",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Trimethoprim (usually in high doses)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Pentamidine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tubulointerstitial disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pseudohypoaldosteronism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Distal chloride shunt",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9852=[""].join("\n");
var outline_f9_39_9852=null;
var title_f9_39_9853="Food-borne diseases II";
var content_f9_39_9853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for confirmation of food-borne disease outbreaks-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Bacterial (cont.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Clostridium perfringens",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        6-24 hrs",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea, abdominal cramps; vomiting and fever are uncommon",
"       </td>",
"       <td>",
"        Isolation of &ge;10",
"        <sup>",
"         6",
"        </sup>",
"        organisms/g in stool of two or more ill persons, provided specimen properly handled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demonstration of enterotoxin in the stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        <em>",
"         Escherichia coli",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Enterohemorrhagic (EHEC -",
"        <em>",
"         E. coli",
"        </em>",
"        0157:H7 and others)",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        1-10 days, usually 3-4 days",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Diarrhea (often bloody), abdominal cramps (often severe), little or no fever",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of",
"        <em>",
"         E. coli",
"        </em>",
"        O157:H7 or other Shiga toxin-producing",
"        <em>",
"         E. coli",
"        </em>",
"        from clinical specimen of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Isolation of",
"        <em>",
"         E. coli",
"        </em>",
"        O157 or other Shiga toxin-producing",
"        <em>",
"         E. coli",
"        </em>",
"        from epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Enterotoxigenic (ETEC)",
"       </td>",
"       <td class=\"sublist_other\">",
"        6-48 hrs",
"       </td>",
"       <td class=\"sublist_other\">",
"        Diarrhea, abdominal cramps, nausea; vomiting and fever are less common",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of organism of same serotype, which are demonstrated to produce heat-stable (ST) and/or heat-liable (LT) enterotoxin, from stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Enteropathogenic (EPEC)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Variable",
"       </td>",
"       <td class=\"sublist_other\">",
"        Diarrhea, fever, abdominal cramps",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of same enteropathogenic serotype from stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Enteroinvasive variable (EIEC)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Variable",
"       </td>",
"       <td class=\"sublist_other\">",
"        Diarrhea (may be bloody), fever, abdominal cramps",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of same enteroinvasive serotype from stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        <em>",
"         Listeria monocytogenes",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Invasive disease",
"       </td>",
"       <td class=\"sublist_other\">",
"        2-6 weeks",
"       </td>",
"       <td class=\"sublist_other\">",
"        Meningitis, neonatal sepsis, fever",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of organism from normally sterile site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Diarrheal disease",
"       </td>",
"       <td class=\"sublist_other\">",
"        Unknown",
"       </td>",
"       <td class=\"sublist_other\">",
"        Diarrhea, abdominal cramps, fever",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of organism of same serotype from stool of two or more ill persons exposed to food that is epidemiologically implicated or from which organism of same serotype has been isolated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.cdc.gov/mmwr//mmwr.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9853=[""].join("\n");
var outline_f9_39_9853=null;
var title_f9_39_9854="Pelagia noctiluca print";
var content_f9_39_9854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelagia noctiluca print",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 287px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEfANgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDziW5kUkljUP2x2HytUd4u6UnPFVvuH39aALT3UvqaBdS46moCWKjpSeYRxQBYN1Lj7xpBdS/3qrtKSCMVHlvWgC8t1IR94077RJ/eNUVLckGnZf1oJZbS6kDH5jVuy1CS2kYBuJOM1kANtIyMk09c+WFz8w70AjpNEupBqUjZ57VvWqXE1wky5LRmuW0Ft1+jL0HBHrXf6dMYJwqbWSQ/MMcikzKe5U1jxLCFW3vLYsem6qdnd2TsrQFlxziqnjaP7PeI8eNrdQRWVpU37yQjDFuw7VlI2pn1D8OrpbjQd+8kjAFdXFLzgmuA+Ezt/wAI6wcDcGBruolLHOQK5H8R120uXQ9QXUpA9aV32jpmq0zBh6Vq3ZChHUiaTjPSnJMMcg1XnOB1qur5YDnnvXLJ3Z0cuhswOpWkuMbSRVSHMectmnzSZUilZGTjZlS4kAQ81zlzK/mOQeM1sXjfKR3Nc/dqyljvFTPuddNWRVuLht2Caq3txjbg1VumbzR8wxUFzIpGSelC7mhia1cM85welFUNYmBmbaelFdUFoYVHqeU3KZJw2KqMAp65qxMMsc1Ayiu88sQNz+FMbBNPwKYeKACikJ4pMmgTZKnSlqJWINP3GgW4bsU5XAIOajPWgAEjNCCxv+DnQazGkp4Y13mqxGwv4WHKueK848PhTrVuxHyhh3rv/EOpwzXsccYx5Y45pMiUW9SDxpbedaRzHrisPQ4YIITIzgs3Y1d1TVheWjQPyVHasfT7ZnhLgkfNWT7lwlZ2Po34SP5mkNx8uRXfBSDxXC/CRNuggD1Ga71gccVyr3mdu2gjsMdcmqk2SMinyHA96rvJgcmlKVzSESCYkVAr4479qmncbQTzVZPmcEA8GuZ7m+yNCFuMHrQ5KZJ79KSFcrmnXIDALVcxk9WZd5IAc5zXM37M00hGcZror9Ao6GsO7jKjLd6UtTpWxhTAknPFZd9IqRsS3ata+Vl59a5vWQywOcmlF3dg6XOT1W+C3BAbOTRWFq8hFycHvRXoUo+6cVWsuaxiv94/WoW5qZ/vN9aiI5rqOEjPpTD1pzdaVaAZGRxTamYcZqM9aCRB1p1JS0XKSDBpQDkU8dBQDzQgsaehssM8bnGQ1bOp4+3rMCMEc1zEPBwD1q7LMRAqZpS0EXJpEDs6/wAVXNLnCW4Tux6VXgtQ1ujSdKfpMMdxrtvADxvGKyfUaV2j6X+Go8rw+hAwTiu0D/J1rA8O2q2mnQRrxlQf0rVlyE71yQO9xIZ3Bbg1nXMpGeeKfcSlG4XNZt1Mpzk7fapkdCiW1uMABhkVYjdZF+UVl2soIOSCKuWzDdketYyK5TSgYouDxUrKD81QK+/rVnI28GpMXuZd+gb5iOlc/evvGB2NdJejcprnL4EFsCnY6IbGXeRiUDjpXLeI0xaSHtiuxRC6kEVzniWD/RJBjtU09yvss8U1pyLkD3op2uqUvCGHeivVpfCjx6vxszpFO4/WoyDzzUz/AHjUZ6VuZkDDmlxilak7UCEbpTNtSUUCsR7aXBp9FUkrBqgHSg0tHvUXFdixN++WprtXUbwRtqupw2avwSxGJ1m5yeKT8ykrly0vA9qiux47Vs+D9Okv/FNn9mx98E+1c0bZp5I47VWcnsBX0B8GfCZsLM3l5F++f5lDDkVlOStZG1KGt2eq2MHlxQI3JCDp06VYuE+WpLXIXnvT7hfl/CsUrGnM+Y568byskLnNcvqrFmbJIrrryPcp9q5DVIyXYLWE9D0IWsNsJSiAZJGK1Le5VWAOeTWJaxsAc9qlSfLFc4rBvU25VZnW28qudq5qxG5Qvu5Fcxb3TQng1qWl00+c0HG4mi4Eo4rIuYAHYsRir0rGIfWsu7fdnnmrZom0VZAqtlSOK5zXiDG+QcGrd/M0cgO7ArE1rUI1tHJPNZxXvaGtvd1PJvFkOL7I4y1FL4ilE06ketFenSfunkV7c7sYb9TUTHFTSDDGoHrpMhCKb0p5qM9emaBBRRRg+hoAKa5IPFObinIjPwqk/QZqZOxSjcYnz8Dk05lPQg1s6P4a1HUX/wBGtHXP8TDGa7jQ/hddTIXv7lU7kc5rJztqPkvoeYwQmZwsaksewFdRofgbVdUk+SHYgIyTXsvh3wPplgEJiWVh0JFdzp1gsKkKiIPRRUyqXNo0ranC+DPhlb6W0V1cMZJRztzXqljGIgoVQoAxiksoV6Hj3q7sCDjn3rGKe5q5K1iWP5W9jTpVDL1qOPJ9aWSTHy96sxs7mVcgZNc3dxbpmwK6PUDs5HeshFDzZxXPUO6D0MuaHyoyRxnrWQxAckda6LVOFxiufkj+83aud7nQmEMrMcHpW3p0wTHoa5+I4PFaETErkdqofLc1dSvWBAjIrOkkVhkn5j1qvNNluTWde3Jh+Y9KGTKFtivrbqGHXNcN4qufLgIz2rqb2/jmXP8AFXF+KgZIGII6VrRV2XWXLA5C4cPgse9FU53wwU9jRXdytbHhTfM7hKPmNQMKsuu5jyKrOOvcg9K0asFg49KZCQ5dQCuDjJrS0zRr/U2xaW7N7niu50X4X3E6K2pyCNTztHNRKoolxouR5rsIJBO8+3NaGmaHqWouFt4X2njLKa9z0jwZo2kqoFuJZF5Bat2AxQZWGJEHsorF4g2jhmeT6V8LrqZVa/uFVTztru9F8CaTpS7liEr469a6FbkKTsXPrmpIpQxznb9KzdTmNVS5dCWGJIo0EcaqoGAAOlWol3kccU1sNEpQ5OKmsyCOc5FZ21G7WLcKbDV2KXhhiqg460qyDPFURY0opspirMc7KqjsKxElIlyfu1NJerG3Xr0qkxctzbimJcelLIwD561kLdYKgkfN0xRd3YVQpPNU5B7Mfevlxz96o1gCpu71XRjMyn+71qW5ukAKqTkVnI0UrKxn6wDJGAB0rmNQDqygdPaukubjeuF5NZzpvOGAzWEjSnOy1MdAUGTUxufLQ4HNSzxhCQazbokFQvTvUHVTLMZR0MhPI7ViatcNIhq9OfLt2aMiufvbr91ub609zp0sZlzKyHI4FYOuzebEw9RWleXaycCue1SQBSM1vQic+JqLlsc1OgE2aKWXLSZFFeitDwZ/E7HpFj8M7qQh7/zIeeQB2rprHwFotiVkYvcOOcMelejahLwcHI965a+fD5Q49QK45VWz0IUUhILi2skEdrbwxYGM4pj6udxHGfasu8lJHOKzppSBxWPM3udKprodGb4t826h7zKjB5rnreUkjJNXLdt0hFQ0Wo2NVbzauCeWq/aPjBJzWEyHdkVesH2MN35U43M5xudRp/zZyePSr0YUMQo61h2M/wC8yTgGtmKZMDng961TRzOnK9ySRjHnJzUK3IZWwMGoLubDHBBX3rOlvhGDnAzTLUG9jQa8IcgmoZrsSZBYZFYk2oDf2rOu78hicnHtU3NI0mtTp7O+ZLhQzZGc1burliwbORXJ6fOtzwpPvmtq2c42NyPWi4mlHc6OxuFaPPcis+6uNk0hJ4pkVwIOuMdqpahOrRu/rSbM1FN3IRelpSM1cSUGMt3ArnYnXcTuq6lwBhc8Gs5I0duhfuCrw7v4qwrl97gA8g81tIh8ok/dxXKanMbeZiDkNWdrHTSXNqhL+4IOwNxWBqEwCuoOcUy+vstlWyazbidjCW/ibrWkYtamlSSiih5+6Rh6Vl6pJlTzUpJRywzzVC7Oc5rroxs7nl16lzPZsNRTZaK62efLV3Ppu9vSoKk81h3cneodSusyHnFZ7Tbhycj615dj2YobeTc1XVdwzSy881Nax/jmixomRAEdDV22OzB9aZKAPQYqLzdvBoHzG3G4MY6VFNLsUkVk/agvfiq8t4G4zQQ9WdLZXjOwHpW9ayMAM9K4mzuG3IcYUCuz0grcwrz81NLUl7CXbOW+XlaytSBKqV7da6R7UhtuKbPpe5QSKtsKckefXEjoxGTVF7iYs4K5Xsa7S+01Qeg/KqB0rJyKzudOjWhkaPNPHJtxw3pXZWUypDl8bqwPswg+YjkdKikujAd5J+ho5jOVO50Ukhdtx+7UV26tbFaxYNXVgcng9KsfbkaMjjmkZOm07Ge8jI7BTU8ErHBzVC8lLOdoqW0kIiIPWmL2bOrtbrdbbD1rkfEcTEH1Ga1LaZoyhPeqfiBjLGxHHBpSjqawfLHQ8rvr14Lk7jxmkTUfM6Gq2tja75Gee9ZMc3FdUYXRwTqvmaZvSygr15qhctxVdJzxzmklkycZrWKsYt3K7nmipSM4wKK1Ri1qeyXj7pCKrqdwOw9OtT3QXzmqpu2vgd686x6qdiTax4q2uVjH0qmzkLkVG1y+MUcpXMWnlySM81TmlC5BNRtcY+Y44qnPNu54o5Q5ieSYYxnmoYNzyYNUZJyXXFX9OBeYc0coJ30Ol01VMBDDGBW9oTmBtxJC54rI0qHKyDmt22i2xp9aLBJW0OhSbeQ3arayiQFc4rIt5DtCgVZR2RhnoabM1GxJcWiPzxVFrZVb5sAdq1tnnRgA4NZ8vMnlnqveocUaxm4mXeWefugEVz+oWjMxXbxiuxutsaY71h36ggletS4nTTk3ucVOjRy7U4x1pwuGDcGrOo27Ekr1NZkdu4kG48UkzVpF0z92NT29yvADCs24QgcGq4ZlOQcEVSkS0rHUT3K7VCEZFU9QuA8D5PQVj280kknLVDrN2YI9qnlutPm1IjBKJyetqGLEH1rm8cn61t3c5csDWPIuCa7ab0PJxC1HxA59qm8vJ6c1Bbtzir8a1pcwSFiiyMYoqxEvziip5rFcilqepXkPzk5qkybGyM1tahHgnFZki5PSuRHciF2LKAQKgkIwR3q2VB4rOnyHYAd6BlS4kwSKoyzHgVLc53Ek1UPzNigB0S5cE10+j24yGArCtoiziuw0aMKoBFBUdzasIRFgjndyfatxYcxKc1n6fGHfnoK24kwuO1A5jbKIIwZuTVq6ZXXd0IqNfu8VDLuCkmggasjpyGNRTzrIRztbuaa8gMRA61RkG/aAdp9aTLpq7LcpdQM8j1rOkfbMc9KsNI0QAfLKe/pTJ/LZMjFZyNb22MPVFX7ynmsKZmlyMY9xXTTxI8bHrXM6kDCrFKg3g7oieLMY3Oaz5VIbCmp4pmlUAg5xTJl29+aaKZD53kr2zWRfStMSWP0rRmTcvzdayLkEPz0p9TnqT5TJu4tpyDVGRS/ata6TIxVYRDFdsdjzanvMz0i2sDWlbgNimGMAE4pYjtFO5nYuoFBH1oqqJOR1opMpI901ODk8dqwZkKhs12WpQ5LcVzV9FhTgc+lcp1IyWGxCWNV3wVz61PcB9pBFQDlQD1FFy3sULiMNngVQW33PxWzJGGGO5qe107IywNBJX0+2PHeun0+EjAqKws9o+Vc5ratYQvVeapDvoaOnoFReOcVobgqE1ThGwDPFOmbCEk8GmyGm2SbieQcClaZXjYdxVMSEphTnFVPNKyYPFRqbxiTOxXOBmoUlDBgRzmklvFVgBgmq1wcN5y/dPJpNm0IWJbl8RiqU1yNoAHSkkd3RiQduOKy5ZCJPmOKhsvkNMzps6Vk6syPbsABmobiZ1+6cg1DO4NuTnmkWlYyRA7DKHGKlt2VpUV+cHnNJBdbAynHNVXAVncHGaaGy1qse7PlgAVzt2pQPk5Naou3EeGGazrgeYHNaRRy1TE3k5zTcmp1jBJqIoQenFbxPOkNycdaSjB9KKskdHjdzRTMgMKKLks+oL+D53rltRi2v9a7rUUySR3rldVgOVJOOvFch1RZyt2hzVPystW1cwHPXNU/LPmAAUk7mjeg23sd5DYrZtbUMMYOatWFriME9/ata0tVVskcU9SbmdDbYxgYqz5bBhWmkC7iQPwprR4fOKpXJb1GBQYx6gVSumLcdhV0BhuJ6HpVWXGWHc0bm8EirC+GIziql04RuT71aNuyNu3Vm6oC4ypxgVDlbc64pFSWX59wpTI/lDJO1j0qpG6/dJBNNaTYpZ3yvYelK9zblVjoJmjfT1VDyOcCubvhiTJ/WrenzM7FskoOoqDVcSnK4FSxGddygRptNZlxOdpXOasy5PfpWZcZ80nPFAmrEZLBuehqeV12hSOTVYlmfg8VOF8zAyAaEZua6lWYkcDpVWViiNt71emXa208n1qsYchua1RzVJJ7Ga0fykjrUe0lcnNWWkCfKVzTH+5nHFaxZxSRVK4qPbVjGRUbqR9K0uZ2IXXkUU/OSOKKNSWfW15CAhI5rmtQjMjewrsryIAEAcVi3Nv1+WsHE0jI5CeAZNOs7BZWzWtcW2WIC5q1p1sFGNtKMTTmG2tkMAA9Kvx2wQYzUgiKsCoqxFluoquUOYqpCMnmmtCK0XjCgFQOetN8tT1FHKLm1MyWFQozxTUs4mUtnkVfnhUoWOMCqcCiSQhDgA8gGjlOmMjJ1ICNWNctfXOcj8K67Wo9qNnpXBXAPnkt68Vz1Tsox5ilIzLL7VYjRLgbGODViSFTBvKjisu3lCXWTwM0kb36Gw6fY4GC8gism6uc1p37CWJdh+XvWBegg8cUyWQGUnPFUpDls1I7lQeap+YWk60WIlLoWYk3GpPKKyKeozUlig5J71OzbpMYpozkroqSRhmJqi52swrTkARzmqE6fPn1rSJzSiZ0qck1HIvy1dZBnpUDgZI7VoYyViqq8Ed6ZKvy1O+BnFV5WyK0ic7IsdKKYW5FFaIzZ9pXEeRWdPB1xzW26ZJqtLD14rNxIjIwGtQTyp/Klig2NwK12iNPS2wMnjiiMLM157FNIcoWKnj2qPZnkAj8K0jxxTGGetXyi9oyrEu3duGahlHXtV9Uzn1qtPHxUtWBSuzOuEYRMM8H1rKh3wXA285PNbrj5SG6Vk3KFXylQ2dMWw1WETwFgOfSuI1i1ESbgpzXVxzOZCCTjmsrUI/MEu/qOlc81c9DD1WtDm4tzWpDDA7VgzrtmYHgiu2ktFNoCnWuR1mIxSsfeoOqybuOhuMxlD+dQXC7147UyzO9STVeW4McrKOlBL0M68JBIHWqkI+cEmr06GRiwpkUYB5q1qYS3uWYOFJzxUsDgEgjJqELxx0ppcjkUWGpWLVymUBPBqk4yBwTSNI7nJJprylMZNVHQxdiF1x1qo4+Y4qzPJuGarM3ynFapXOeoQOKoyE4q47Z69arS1olY5miqeCOKKeeo+tFVzWMmfc23nmkkTdipMUYrXlOdMpvGBTGRieDxVqQe1MApWLTuQeQT1IpkkJHTGKuEfKfWo3IA5pDKTAqKqT9OKuP0PNUJcqeelRJFxM92Ic+ZyM8VTveCCp61oXy7oSVPIrGO5s5zxWLOuJVu2Ijypwaz53Bt2V/vHpV+8/1fWs2dQwXnpWTOiGhnPJJGgUEnFYusL5i7j1roZCE96x9WAdcpyx6isjrhO5z1sdhNVruPMu4Gr6RPhtwwahkQ5560DkzPyQcZxTlwCCTmp5IwzD1prwDb2q4mDYrFfLDDpVVxnJB/Cpipxj0qvMCoPNUS5DGcqtUpJC7nnpT5H7GoG45rSMTnlMSR6jMnHSmStTc5FapWMpTuNZ+fSo5BkZpzdajZjjimYSlYiYYKg9zRTvvHPpRSFHU+6sCmtTqQ11s5iJskUADGaeaYVrNjQ0nmo5FU9acy45qJzUlEcqrg4HNZ94v7v3q3ITuHFVrgZOB3qZGkGZsoIj55BFZk+1N2B1rYuDxj0rNuI8ndWMjojIyJl3r7VRkCnjZ0rWuIDkkEY9Kpsigcjms3E25mZksAfkDBrNuLMBicHP1rcmjyfl4qjPgfKe3epcSo1GupgzQDsOaqSW2RyOa3pYgQWqjItTym8Z3MY2q8lhUXkqTjHFazqCKqsuDVxQmzKmiKvx0qvdRkrn1FaeoYCrjmqDvximZORjzRHj1qswb+I1qz/dqjIM55rSJjJlJwD1qNmx0p9wRVUtya1iYTYrPzTSQaYzc0mauyMiQYyMetFR56UUmio7H3bSUtGK3ZzjaQ0pFAGahq40RPyagcbassuOarTdKh6FLUrSP1FUmYhuatlcMSar3BBHFQ2OzKdz+85GOKqyHA6dKtDgtnnmqdxkFves2rmsZFG6XcSQKo7GHStCRwPk6mq0iPwV6U7I05ipOBj5+tUbhMrx0rQmXIw1VnVduPSpkkkHMZZyFYHpVK4FaEsZ3DHSqtylRY1jNmS6kE1FOm1M5q68RGS1VZeVOelBpzaGXKwI7VQmxzzzU91kSNjpVJ1ZicHikZu5BKQVrNnYZNXbk+WuCaypZQxNXEykyCd6qO1TTg9aqOa2iYybEZqaW+YU0kE00rk5BqybllTnb9aKbFzj1BooKTPvSiko5rcwFHFFHNJ9aAGv3qnKeKukZqrKgNYzLiym3fmqsvINXGUA471WkWsmUUW6mqV2SFb6VoShVyecmqcoDfWkNbmasZ4JpWAIwKuomAd449qgMZyccClcuzM+dcEVTuYwBkda0rhBg461Tki4zg5+tRJjXmZwOFYEVQulPFbHlde1Z9whLkH6VNzWJmyDKVmT/KjVsypwQelY16pG4AcUGqMi5wRWbJu5rTlQEY5zWZcb0JGOKQmZt0WYGstlIYk1qXDN6Cqcibhkg8VpExkU5+lUJPvVoTc9Koy5AzitomMiu/WgNgU2Qt6VHub04q7GdieN8MTRUSlsjiigpH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Junghanss, T, Bodio, M. Medically important venomous animals: Biology, prevention, first aid, and clinical management. CID 2006; 32:1309. Copyright &copy; 2006 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9854=[""].join("\n");
var outline_f9_39_9854=null;
var title_f9_39_9855="Trans-urethral bladder catheterization labial traction";
var content_f9_39_9855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gentle traction of the labia majora in females to visualize the urethra",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gentle traction of the labia majora in girls facilitates the visualization of the urethra for transurethral bladder catheterizaton.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from King C, Henreting FM. Pocket Atlas of Pediatric Emergency Procedures, Lippincott Williams and Wilkins, Philadelphia 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_39_9855=[""].join("\n");
var outline_f9_39_9855=null;
